Filed Pursuant to Rule 424(b)(3)
Registration
No. 333-235915
Prospectus
Beyond
Air, Inc.
4,157,006
shares of Common Stock
This
prospectus relates to the offer and sale by the selling stockholders identified in this prospectus of up to 532,786 shares of
our common stock, par value $0.0001 per share, issued and outstanding, and 3,624,220 shares of our common stock, par value $0.0001
per share, issuable upon the exercise of warrants. These securities were acquired by the selling stockholders either in our January
2017 merger with Beyond Air Ltd., or in private placements in 2017 and 2019. See “Description of the Merger and the Private
Placements” on page 91 of this prospectus.
The
selling stockholders may sell or otherwise dispose of the shares of common stock covered by this prospectus in a number of different
ways and at varying prices. The prices at which the selling stockholders may sell the shares will be determined by prevailing
market prices for the shares or in negotiated transactions. We provide more information about how the selling stockholders may
sell or otherwise dispose of their shares of common stock in the section titled “Plan of Distribution.” The selling
stockholders will pay all brokerage fees and commissions and similar expenses. We will pay all expenses (except brokerage fees
and commissions and similar expenses) relating to the registration of the shares with the Securities and Exchange Commission.
We
may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the
entire prospectus and any amendments or supplements carefully before you make your investment decision.
Our
common stock is quoted on the Nasdaq Capital Market under the symbol “XAIR.” The last reported sale price of our common
stock on the Nasdaq Capital Market on January 22, 2020 was $6.78 per share.
Investing
in our securities involves certain risks. See “Risk Factors” beginning on page 10 of this prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this Prospectus is January 23, 2020.
table
of contents
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions
for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. All statements other than statements of historical facts contained in this prospectus, including statements regarding
our future results of operations and financial position, business strategy, prospective products, product approvals, research
and development costs, timing and likelihood of success, and the plans and objectives of management for future operations and
future results of anticipated products are forward-looking statements. These statements involve known and unknown risks, uncertainties
and other important factors that may cause our actual results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the forward-looking statements.
In
some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “expect,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential”, or “continue” or the negative of these terms or other similar conditional expressions. The
forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements largely on
our current expectations and projections about future events and financial trends that we believe may affect our business, financial
condition and results of operations. These forward-looking statements speak only as of the date of this prospectus and are subject
to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements,
including the factors described under the sections in this prospectus titled “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” as well as the following:
-
our status as a development-stage
company and our expectation to incur losses in the future;
-
our future capital needs and our need to raise additional funds;
-
our ability to build a pipeline of product candidates and develop and commercialize products;
-
our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary regulatory
approvals;
-
our ability to maintain our existing or future collaborations or licenses;
-
our ability to protect and enforce our intellectual property rights;
-
federal, state, and foreign regulatory requirements, including the U.S. Food and Drug Administration or the FDA regulation of
our product candidates;
-
our ability to obtain and retain key executives and attract and retain qualified personnel;
-
our ability to successfully manage our growth; and
You
should read this prospectus and the documents that we reference in this prospectus completely and with the understanding that
our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by
these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Beyond
Air, Inc. the Beyond Air logo, and other trademarks or service marks of Beyond Air, Inc. appearing in this prospectus are the
property of Beyond Air, Inc. This prospectus also includes trademarks, tradenames and service marks that are the property of other
organizations. Solely for convenience, trademarks and tradenames referred to in this prospectus appear without the ® and ™
symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.
PROSPECTUS
SUMMARY
This
summary highlights the more detailed information contained elsewhere in this prospectus, and does not contain all of the information
that you should consider before deciding to invest in our shares of common stock. You should read the entire prospectus carefully,
including the documents incorporated by reference herein. Unless the context otherwise requires, the terms “we,” “us,”
“our,” “Beyond Air” or the “Company” refer to the business of Beyond Air, Inc. and its consolidated
subsidiaries.
Corporate
Information
Beyond
Air, Inc. was incorporated on April 24, 2015 as KokiCare, Inc. under the laws of the State of Delaware. On June 25, 2019, the
Company changed its name from AIT Therapeutics, Inc. to Beyond Air, Inc., effective June 26, 2019.
Advanced
Inhalation Therapies Ltd. (“AIT Ltd.”) was incorporated in Israel on May 1, 2011 and commenced its operations in May
2012 and is a wholly-owned subsidiary of the Company. On August 29, 2014, AIT Ltd. established a wholly-owned subsidiary, Advanced
Inhalation Therapies Inc., a Delaware corporation. Effective July 4, 2019, AIT Ltd. changed its name to Beyond Air Ltd.
Our
principal executive offices are located at 825 East Gate Boulevard, Suite 320 Garden City, New York 11530, and our telephone number
is (516) 665-8200. Our website address is www.beyondair.net. Our website and the information contained on our website, or linked
through our website, are not part of this prospectus, and you should not rely on our website or such information in making a decision
to invest in our common stock.
Business
Overview
We
are an emerging medical device company developing a nitric oxide (“NO”) generator and delivery system (the “LungFit™
system”) that is capable of generating NO from ambient air. LungFit™ can generate NO up to 400 parts per million (“ppm”)
for delivery to a patient’s lungs. LungFit™ can deliver NO either continuously or for a fixed amount of time at various
flow rates and has the ability to either titrate dose on demand or maintain a constant dose. We believe that LungFit™ can
be used to treat patients on ventilators that require NO, as well as patients with chronic lung disease or acute severe lung infections
via delivery through a breathing mask or similar apparatus. Furthermore, we believe that there is a high unmet medical need for
patients suffering from certain severe lung infections that LungFit™ can potentially address. Our current areas of focus
are persistent pulmonary hypertension of the newborn (“PPHN”), bronchiolitis (“BRO”) and nontuberculous
mycobacteria (“NTM”). Our current product candidates will be subject to premarket reviews and approvals by
the U.S. Food and Drug Administration, or the FDA, as well as similar regulatory agencies in other countries or regions. If approved,
our system will be marketed as a medical device in the U.S.
With
respect to PPHN, our novel LungFit™ is designed to deliver a dosage of NO to the lungs that is consistent with current guidelines
for delivery of 20 ppm NO with a range of 0.5 ppm – 80 ppm (low-concentration NO). We believe LungFit™ has many competitive
advantages over the current approved NO delivery systems in the U.S., European Union, Japan and other markets. For example, LungFit™
does not require the use of a high-pressure cylinder, utilizes less space than other similar devices, does not require cumbersome
purging procedures and places less burden on hospital staff in carrying out safety procedures.
Our
novel LungFit™ can also deliver a high concentration of NO to the lungs, which we believe has the potential to eliminate
microbial infections, including bacteria, fungi and viruses, among other benefits. We believe current FDA-approved NO vasodilation
treatments would have limited success in treating microbial infections given the low concentrations of NO being delivered. Given
that NO is produced naturally by the body as an innate immunity mechanism at a concentration of 200 ppm, supplemental high dose
NO should aid in the body’s fight against infection. Based on our clinical studies, we believe that 160 ppm is the minimum
therapeutic dose to achieve the desired pulmonary antimicrobial effect of NO. To date, neither the FDA nor equivalent regulatory
agencies in other countries or regions have approved any NO formulation and/or delivery system for the delivery of a dosage of
NO at 160 ppm or higher to the lungs.
To
date, we have conducted the following studies:
Study
|
|
Indication
|
|
Primary
|
|
|
Results
|
Phase 1 Safety (n=10)
|
|
All comers
|
|
Safety
|
|
●
|
No SAEs
|
|
|
|
|
|
|
|
|
Phase
2 double blind randomized
(n=43)
|
|
Bronchiolitis
(all
causes)
|
|
Safety
&
Efficacy
|
|
●
●
|
No
SAEs
24-hour
reduction in hospital length of stay
|
|
|
|
|
|
|
|
|
Pilot open label
(n=9)
|
|
Cystic Fibrosis (CF)
|
|
Safe & Eff
|
|
●
|
No SAEs; Lowered bacterial load
|
|
|
|
|
|
|
|
|
Compassionate use
ISR (n=2)
|
|
NTM
abscessus
(CF)
|
|
Safe & Eff
|
|
●
|
No SAEs; clinical & surrogate endpoints
improved
|
|
|
|
|
|
|
|
|
Compassionate
use National
Institute
of Health, US (n=1)
|
|
NTM
abscessus
(CF)
|
|
Safe & Eff
|
|
●
|
No SAEs; Improvements in clinical endpoints
|
|
|
|
|
|
|
|
|
Pilot open label
(N=9)
|
|
NTM abscessus
|
|
Safe & Eff
|
|
●
|
No SAEs; clinical & surrogate endpoints
improved
|
|
|
|
|
|
|
|
|
Pilot
study: double blind
randomized
(n=67)
|
|
Bronchiolitis
(all
causes)
|
|
Safe & Eff
|
|
●
|
No SAEs; 23hr reduction in hospital length
of stay
|
|
|
|
|
|
|
|
|
Compassionate use
ISR (n=1)
|
|
NTM
abscessus
(CF)
|
|
Safety
|
|
●
|
No
SAEs at 250 ppm NO
dose
|
Our
active pipeline of product candidates is shown in the table below:
Product
|
|
Indication
|
|
Development
Status
|
|
Further
Information
|
The
LungFit™ PH
(Pulmonary
Hypertension)
|
|
In-Hospital Use
|
|
Commercial system in development
|
|
Regulatory
filings expected
first
quarter of 2020.
Commercial
launch in the U.S. and Israel expected in 2020.
|
|
|
|
|
|
|
|
The
LungFit™ -BRO
(Bronchiolitis)
|
|
Bronchiolitis
Infants
(elderly
patients to follow)
|
|
Randomized 67 patient study completed
|
|
Next
study to be completed Spring 2020.
Commercial
launch expected in 2022.
|
|
|
|
|
|
|
|
The
LungFit™ -NTM
(Nontuberculous
Mycobacteria)
|
|
Mycobacterium
Abscessus Complex
(MABSC)
|
|
9 patient pilot study dosing complete
|
|
Preparations
ongoing for At-Home self-administered study to begin in 2020.
Commercial
launch expected in 2024.
|
|
|
|
|
|
|
|
The
LungFit™ PA
(Pseudomonas
Aeruginosa)
|
|
Pseudomonas Aeruginosa
|
|
In vitro testing
ongoing
|
|
Pilot study anticipated
in 2021. *
|
|
|
|
|
|
|
|
The
LungFit™ COPD
(Chronic
Obstructive Pulmonary Disease)
|
|
Exacerbation caused by any type of infection
|
|
In vitro testing expected to begin first half
of 2020*
|
|
Proof of concept initiation
anticipated in 2021. *
|
*Subject
to our obtaining additional funding.
We
plan to submit for premarket approval or (“PMA”) to the FDA late in the first quarter of 2020 for the use of the LungFit™
in PPHN. We also expect to make certain regulatory filings outside of the U.S. first half of 2020. According to the 2018 yearend
report from Mallinckrodt Pharmaceuticals, aggregate sales of low concentration NO in the U.S. were in excess of $500 million in
2018, while sales outside of the U.S., where there are multiple market participants, sales were considerably lower than in the
U.S. We believe the U.S. sales potential of LungFit™ in PPHN to be greater than $300 million and worldwide sales potential
to be greater than $600 million. If regulatory approval is obtained, we anticipate a product launch in both the U.S. and Israel
in 2020 and will continue to launch globally throughout 2021 and beyond.
With
respect to bronchiolitis, we initiated a trial for infants hospitalized due to bronchiolitis in the fourth quarter of 2019. The
trial will last approximately 6 months after initiation. We anticipate data for this study to be available during the first half
of 2020. If the trial is successful, we would perform another study over the 2020/21 winter in the United States and then submit
a PMA to the FDA about 6 months after trial completion. Regulatory filings outside of the U.S., as long as no additional trials
are required, would begin after our review process is completed in the U.S. For this indication, we believe U.S. sales potential
to be greater than $500 million and worldwide sales potential to be greater than $1.2 billion.
Our
nontuberculous mycobacteria (NTM) program has produced data from four compassionate use subjects and nine patients from a multi-center
pilot study completed in 2018. All patients suffered from NTM abscessus infection and had underlying cystic fibrosis. One
compassion patient was treated with our nitric oxide generator at the National Heart, Lung and Blood Institute (“NHLBI”).
The rest were treated with our NO cylinder-based delivery system. All patients were treated with 160 ppm NO at intermittent 30-minute
dosing over 21 days, except one patient who was treated over 26 days and another patient who was treated with 250 ppm NO over
28 days. We expect to begin a study by the middle of 2020 where patients will self-administer high concentration NO at home over
a period of 12 weeks with LungFit™. We anticipate preliminary data for this study will be available during the second half
of 2020 and that a full dataset will be available in the first half of 2021. If the trial is successful, we would commence a pivotal
study towards the end of 2021. For this indication, we believe U.S. sales potential to be greater than $1 billion and worldwide
sales potential to be greater than $2.5 billion.
Our
programs in pseudomonas aeruginosa and chronic obstructive pulmonary disease are both in the pre-clinical stage are will remain
there subject to our obtaining additional financing.
For
our high concentration platform, as mentioned above, the initial target is lower respiratory tract infections (“LRTI”).
Our initial two target indications are infants hospitalized due to bronchiolitis (mainly caused by respiratory syncytial virus
“RSV”) and patients suffering from NTM and other severe, chronic, refractory lung infections. There are over 1.5 million
hospitalizations related to LRTI annually in the U.S., and LRTI is the third leading cause of death worldwide.
NTM
lung infection is a rare and serious pulmonary disease associated with increased morbidity and mortality. There is an increasing
rate of lung disease caused by NTM, which is an emerging public health concern worldwide. There are approximately 50,000 patients
diagnosed with NTM in the U.S., and there are an estimated additional 100,000 patients in the U.S. that have not yet been diagnosed.
In Asia, the number of patients suffering from NTM surpasses what is seen in the U.S. To date we have treated only the abscessus
form of NTM which comprises approximately 20-25% of all NTM. We will be treating both the abscessus and mycobacterium avium
complex (MAC) forms of NTM.
Patients
with NTM lung disease may experience a multitude of symptoms such as fever, weight loss, cough, lack of appetite, night sweats,
blood in the sputum and fatigue. Patients with NTM lung disease, specifically abscessus and other forms of NTM that are
refractory to antibiotic therapy, frequently require lengthy and repeated hospital stays to manage their condition. There
are no treatments specifically indicated for the treatment of NTM abscessus lung disease in North America, Europe or Japan.
There is one inhaled antibiotic approved in the U.S. for the treatment of refractory NTM MAC. Current guideline-based approaches
to treat NTM lung disease involve multi-drug regimens of anti-biotics that may cause severe, long lasting side effects, and treatment
can be as long as 18 months or more. Median survival for NTM MAC patients is approximately 13 years while median survival for
patients with other variations of NTM is typically 4.6 years. The prevalence of human disease attributable to NTM has increased
over the past two decades. In a study conducted between 1997 and 2007, researchers found that the prevalence of NTM in the U.S.
is increasing at approximately 8% per year and that NTM patients on Medicare over the age of 65 are 40% more likely to die over
the period of the study than those who did not have the disease (Adjemian et al., 2012). NTM abscessus treatment costs
are estimated to be more than double that of NTM MAC. In total, a 2015 publication from co-authors from several U.S. government
departments stated that prior year statistics led to a projected 181,037 national annual cases in 2014 costing the U.S. healthcare
system approximately $1.7 billion (Strollo et al., 2015).
Over
3 million new cases of bronchiolitis are reported worldwide each year. In the U.S., there are more than 125,000 annual bronchiolitis
hospitalizations among children two years of age or younger and approximately 177,000 annual hospitalizations among the elderly
population related to viral infections similar to those that cause bronchiolitis in very young children.
Currently,
there is no approved treatment for bronchiolitis. The treatment for acute viral lung infections that cause bronchiolitis in infants
is largely supportive care and is based primarily on prolonged hospitalization during which the infant receives a constant flow
of oxygen to treat hypoxemia, a reduced concentration of oxygen in the blood. In addition, systemic steroids and inhalation with
bronchodilators are sometimes utilized until recovery, but we believe these treatments do not successfully reduce hospital length
of stay.
We
believe, based on the currently understood mechanisms of action of NO, that our LungFit™ can deliver NO at 150 ppm and higher
to potentially eliminate bacteria, viruses, fungi and other microbes from the lungs and may also be effective against antibiotic-resistant
bacteria. Because our product candidates are not antibiotics, we believe there is a reduced risk of the development of resistant
bacteria and there could be synergy with co-administration of antibiotics.
In
addition, our LungFit™ can deliver NO at concentrations of 0.5 – 80 ppm consistent with currently approved NO delivery
systems for the treatment of PPHN while providing significant advantages associated with the elimination of the use of high-pressure
cylinders.
We
have a global, exclusive, perpetual license agreement with NitricGen, Inc. for the eNOGenerator and all associated patents and
know how related thereto. Additionally, we have a broad intellectual property portfolio directed to our product candidates and
mode of delivery, monitoring parameters and methods of treating specific disease indications. Our intellectual property portfolio
consists of issued patents and pending applications, which includes patents we acquired pursuant to the exercise of an option
in 2017 granted to us by Pulmonox Technologies Corporation.
As
of September 30, 2019, we had approximately $19.5 million in cash and marketable securities after giving pro forma effect
to the net proceeds of our December 2019 offerings excluding restricted cash of approximately $459,000.
Recent
Events
On
May 7, 2019, the Company’s common stock commenced trading on the Nasdaq Capital Market under the symbol “AITB”.
The changed its ticker symbol to “XAIR” effective July 15, 2019.
On
June 3, 2019, the Company entered into agreements with investors for the issuance of 1,394,997 shares of common stock at $5.00
per share and the issuance of 188,746 shares of common stock to insiders at $5.15 per share.
On
December 10, 2019, the Company entered into an underwriting agreement with SunTrust Robinson Humphrey, Inc. as representative
of the several underwriters named therein, relating to the issuance and sale of 2,325,000 shares of common stock. The price to
the public in the offering was $3.66 per share, and the underwriters agreed to purchase the shares from the Company pursuant to
the underwriting agreement at a price of $3.4038 per share. The underwriters had a 30-day option to purchase up to an additional
348,750 shares of common stock, which option was partially exercised on December 12, 2019 for 295,199 shares. The offering, including
the issuance and sale of shares pursuant to the underwriters’ partial exercise of their option to purchase additional shares,
closed on December 12, 2019.
Also
on December 10, 2019, the Company and certain existing U.S. and foreign investors entered into common stock purchase agreements
for the issue and sale of an aggregate of 532,786 unregistered shares of common stock at $3.66 per share. The concurrent private
placement closed on December 12, 2019. The Underwriters served as placement agents and received a placement agent fee equal to
a percentage of the total purchase price of the private placement shares, which percentage was equal to the percentage discount
the underwriters received on shares sold in the public offering.
On
December 18, 2019, the Company terminated the License, Development and Commercialization Agreement (the “Agreement”)
with Circassia Limited (“Circassia”) entered into on January 23, 2019 pursuant to which the Company had granted Circassia
an exclusive royalty-bearing license to distribute, market and sell the Company’s nitric oxide generator and delivery system
in the United States and China. As previously described in the Company’s Form 8-K filed with the Securities and Exchange
Commission on January 29, 2019, Circassia had agreed to pay the Company certain milestone and royalty payments, with the remaining
milestone and royalty payments payable in cash or ordinary shares of Circassia at Circassia’s option. The Company terminated
the Agreement pursuant to section 13.3(b) of the Agreement, termination by either party for material breach or default. The Company
is evaluating other options for the commercialization of its generator and delivery system. In connection the termination of the
license with Circassia, we may be subject to a variety of claims. Adverse outcomes in some or all of these claims may adversely
affect our ability to conduct our business.
Emerging
Growth Company Status
We
are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act enacted on April 5, 2012, referred
to as the JOBS Act. For as long as we are an emerging growth company, we may take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not
limited to, not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding advisory “say-on-pay” and “say-when-on-pay” votes on executive
compensation and shareholder advisory votes on golden parachute compensation.
Under
the JOBS Act, we will remain an emerging growth company until the earliest of:
●
|
December
31, 2021;
|
|
|
●
|
the
last day of the fiscal year during which we have total annual gross revenues of $1 billion or more;
|
|
|
●
|
the
date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt; and
|
|
|
●
|
the
date on which we are deemed to be a “large accelerated filer” under the Securities Exchange Act of 1934, as amended,
referred to as the Exchange Act (we would qualify as a large accelerated filer as of the first day of the first fiscal year
after we (i) have more than $700 million in aggregate market value of outstanding common equity held by our non-affiliates
as of the last day of our second fiscal quarter of our prior fiscal year and (ii) have been public for at least 12 months).
|
We
have taken advantage of reduced disclosure requirements in this prospectus by providing reduced disclosure regarding executive
compensation arrangements. We may choose to take advantage of some, but not all, of these reduced disclosure obligations in future
filings. If we do, the information that we provide stockholders may be different than the information you might get from other
public companies in which you hold stock.
The
JOBS Act also provides that an emerging growth company may utilize the extended transition period provided for complying with
new or revised accounting standards. We have irrevocably elected to take advantage of this extended transition period. Because
we will not be required to comply with new or revised accounting standards on the relevant dates on which adoption of such standards
is required for other public companies, our financial statements may not be comparable to the financial statements of companies
that comply with the effective dates of those accounting standards.
The
Offering
Common stock offered by the
selling stockholders:
|
4,157,006
shares, consisting of 532,786 shares and 3,624,220 shares issuable upon the exercise of the warrants.
|
|
|
Common stock outstanding prior to the offering:
|
14,137,675
shares as of the date of this prospectus, excluding:
|
|
|
|
6,006,459
shares issuable upon the exercise of warrants;
|
|
|
|
2,286,049
shares issuable upon the exercise of stock options;
|
|
|
|
651,800
shares issuable upon the vesting of restricted stock; and
|
|
|
|
5,047
shares of our common stock reserved for future grants under our equity incentive plan.
|
|
|
Common stock outstanding following the offering:
|
17,761,895
shares as of the date of
this prospectus, assuming the exercise of warrants to purchase the 3,624,220 shares registered
herein, and excluding:
|
|
|
|
2,382,239
shares issuable upon the exercise of warrants;
|
|
|
|
2,286,049
shares issuable upon the exercise of stock options;
|
|
651,800
shares issuable upon the vesting of restricted stock; and
|
|
|
|
5,047
shares of our common stock reserved for future grants under our equity incentive plan.
|
|
|
Use of proceeds:
|
The
selling stockholders will receive the proceeds from the sale of shares of common stock offered
hereby. We will not receive any proceeds from the sale of the shares of common stock, but
will pay the offering expenses (other than any underwriting discounts and broker’s commissions
and similar expenses) of this offering. Assuming that the selling stockholders exercise all
of their respective warrants in cash exercises, we would receive gross proceeds of $13,264,600
which we presently intend to use for working capital and general corporate purposes, which
may include, without limitation, clinical studies required to gain regulatory approvals, implementation
of adequate systems and controls to allow for regulatory approvals, further development of
the LungFit™ for use in the home, investing in or acquiring companies that are synergistic
with or complimentary to our technologies, and licensing activities related to our current
and future product candidates. See “Use of Proceeds.”
|
RISK
FACTORS
Investing
in our common stock involves a high degree of risk. You should consider carefully the risks described below, together with the
other information included in this prospectus. If any of the following risks occur, our business, financial condition, results
of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price
of our common stock could decline. Other events that we do not currently anticipate or that we currently deem immaterial may also
affect our business, prospects, financial condition and results of operations.
Risks
Related to This Offering
Risks
Related to Our Financial Position and Capital Requirements
We
have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable
future. We are a clinical-stage company. We have no approved products and have generated no revenue to date and may never generate
revenue or achieve profitability.
Our
ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment
decision. These are not the only risks we face. These risks include, among others, that:
|
●
|
we are a development-stage
medical device and biopharmaceutical company and have a limited operating history on which to assess our business, have incurred
significant losses since our inception, including a net loss of $10,278,561 for the six months ended September 30, 2019,
and an accumulated deficit of approximately $47,923,133 as of September 30, 2019, and anticipate that we will continue to
incur significant losses for the foreseeable future
|
|
|
|
|
●
|
we are unable to
predict the extent of future losses or when we will become profitable based on the sale of any product, if at all. Even if
we succeed in developing and commercializing our product candidates, we may never generate revenue to sustain profitability;
|
|
|
|
|
●
|
we
do not have an approved FDA product in the market, and we expect that we will need to raise additional funding before
we can expect to become profitable from sales of our products;
|
|
|
|
|
●
|
we are heavily dependent
upon the success of our product candidates, which are in various stages of clinical development, and we cannot provide any
assurance that the FDA or other regulatory agencies will allow us to conduct further clinical trials;
|
|
|
|
|
●
|
we are in the process
of developing our proprietary NO delivery system, and unexpected delays will adversely impact the timing of our U.S.-based
clinical trials and approvals;
|
|
|
|
|
●
|
we
might be unable to develop product candidates that will achieve commercial success in a timely and cost-effective manner,
or ever;
|
|
|
|
|
●
|
our competitors
may develop or commercialize products faster or more successfully than us;
|
|
|
|
|
●
|
because
some of the target patient populations of our product candidates are small, we must be able to successfully identify patients
and achieve a significant market share to maintain profitability and growth;
|
|
|
|
|
●
|
our reliance on
third parties to help conduct our pre-clinical studies, clinical trials and commercial scale manufacturing;
|
|
|
|
|
●
|
we do not have any
products approved for sale by the FDA or any other regulatory agencies, and we cannot provide any assurance that any of our
product candidates will receive regulatory approval;
|
|
●
|
if we are unable
to obtain and maintain effective intellectual property rights for our technologies, product candidates or any future product
candidates, we may not be able to compete effectively in our markets; and
|
|
|
|
|
●
|
our future success
depends in part upon our ability to retain our executive and scientific teams, and to attract, retain and motivate other qualified
personnel.
|
It
is highly likely that we will need to raise additional capital to meet our business requirements in the future, and such capital
raising may be costly or difficult to obtain, and could dilute current stockholders’ ownership interests.
Our
future capital requirements will depend on many factors, including the progress and results of our clinical trials, the timing
and outcome of regulatory review of our product candidates, commercial manufacturing success, the number and development requirements
of other product candidates that we pursue, and the costs of commercialization activities, including product marketing, sales,
and distribution. Because of the numerous risks and uncertainties associated with the development and commercialization of our
product candidates, we are unable to reasonably estimate the amounts of additional capital outlays and operating expenditures
that our business will require. It is likely that we will need to raise additional funds through public or private debt or equity
financings to meet various objectives including, but not limited to:
|
●
|
clinical
trials for our product candidates;
|
|
|
|
|
●
|
researching
and developing new products;
|
|
|
|
|
●
|
pursuing
growth opportunities, including more rapid expansion;
|
|
●
|
acquiring
complementary businesses or technologies;
|
|
|
|
|
●
|
making
capital improvements to improve our infrastructure;
|
|
|
|
|
●
|
hiring
qualified management and key employees;
|
|
|
|
|
●
|
responding
to competitive pressures;
|
|
|
|
|
●
|
complying
with regulatory requirements; and
|
|
|
|
|
●
|
maintaining
compliance with applicable laws.
|
Any
additional capital raised through the sale of equity or equity-linked securities may dilute our current stockholders’ ownership
in us and could also result in a decrease in the market price of our common stock. The terms of those securities issued by us
in future capital transactions may be more favorable to new investors and may include preferences, superior voting rights and
the issuance of warrants or other derivative securities, which may have a further dilutive effect.
Furthermore,
any debt or equity financing that we may need may not be available on terms favorable to us, or at all.
Additionally,
we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting
fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize
non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely
impact our financial condition.
If
we are unable to obtain required additional capital, we may have to curtail our growth plans or cut back on existing business,
and we may not be able to continue operating if we do not generate sufficient revenues from operations needed to stay in business.
Risks
Related to the Discovery and Development of Our Product Candidates
We
are heavily dependent on the success of our product candidates, which are in the early stages of clinical development. We cannot
give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be
commercialized.
To
date, we have invested substantially all of our efforts and financial resources to design and develop our product candidates,
including conducting clinical studies and providing general and administrative support for these operations. Our future success
is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize one or
more product candidates. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize
a marketable product.
Two
of our product candidates are in the early stages of development and will require additional clinical development (and in some
cases additional preclinical development), management of nonclinical, clinical and manufacturing activities, regulatory approval,
obtaining adequate manufacturing supply, building of a commercial organization and significant marketing efforts before we generate
any revenue from product sales. To date, we have conducted two pilot clinical trials involving 110 patients with bronchiolitis
and a pilot clinical trial in nine patients with NTM abscessus lung infection with underlying CF. In addition, Rambam healthcare
campus in Israel conducted a compassionate treatment for two patients with CF who suffer from NTM infections (specifically M.
Abscessus), the National Heart, Lung and Blood Institute (NHLBI) conducted a compassion treatment in a CF patient with an NTM
lung infection and an NTM abscessus patient was treated at Soroka Medical Center in Israel under compassion. All of these studies,
except the one at the NHLBI, were conducted outside the U.S. and were not conducted pursuant to an FDA IND or IDE. The results
of these studies showed improvements in various endpoints and clinical outcomes. The trials were small, however, and it is likely
that the FDA will view them as not significant because of their size and scope. In addition, the delivery systems were different
from the one that we intend to test and market, subject to FDA approval, in the U.S., further reducing the likelihood that FDA
would view these test results as adequate or sufficient to support marketing applications. We therefore intend to conduct larger
clinical trials aiming for statistically and clinically significant favorable results, or we will not be able to obtain regulatory
approval to market our product candidates. It may be years before a pivotal study is initiated, if at all. Before a medical device
clinical trial can be undertaken in the U.S., the sponsor of the trial must submit an IDE application for a medical device and
the FDA must permit the trial to go forward. We cannot assure that we will obtain such agency acquiescence in a timely manner,
or at all.
In
addition, we cannot be sure that we will be successful in completing the development of our NO Delivery System to the satisfaction
of the FDA, which could lead to material delays in our ability to commence U.S.-based clinical trials, if at all. We are not permitted
to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory
authorities, and we may never receive such regulatory approval for any of our product candidates.
We
as a company have never submitted marketing applications for approval of our product candidates to the FDA or comparable foreign
regulatory authorities; although in 2014 the FDA granted the Company orphan drug designation for the use of NO in the treatment
of CF and in 2015, the EU also granted the Company orphan drug designation for the use of NO in the treatment of CF. We are no
longer pursuing the drug regulatory pathway so the orphan drug designation may have no application. We cannot be certain that
any of our product candidates will be successful in clinical studies or receive regulatory approval. Further, our product candidates
may not receive regulatory approval even if they are successful in clinical studies. If we do not receive regulatory approvals
for our product candidates, we may not be able to continue our operations. Even if we do receive FDA approval for our drug, the
indications for which we are initially seeking approval are very narrow and this, as a result, may limit their commercial viability.
We
generally plan to seek regulatory approval to commercialize our product candidates in the U.S., the EU and in additional foreign
countries. To obtain regulatory approvals we must comply with the numerous and varying regulatory requirements of such countries
regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing and distribution
of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will
obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions,
our revenue and results of operations would be negatively affected.
The
regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable.
If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
The
time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following
the commencement of clinical studies and depends upon numerous factors. In addition, approval policies, regulations or the type
and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development
and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have
not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or
any product candidates we may seek to develop in the future will ever obtain regulatory approval.
The
process required by the FDA before a new medical device may be marketed in the U.S. generally involves the following:
|
●
|
completion
of or reference to extensive preclinical laboratory tests and preclinical animal studies,
all performed in accordance with the FDA’s Good Laboratory Practice (“GLP”);
|
|
|
|
|
●
|
submission
to the FDA of a pre-IDE application, which the FDA authorizes before we may begin conducting
human clinical trials, provided that the FDA does not object; the IDE must be updated annually;
|
|
|
|
|
●
|
performance
of adequate and well-controlled human clinical trials to establish the safety and efficacy
of the medical device candidate for each proposed indication; and
|
|
|
|
|
●
|
submission
to the FDA of a 510(k) or PMA, after completion of all pivotal clinical trials.
|
An
IDE application is a request for authorization from the FDA to administer an investigational medical device to humans. We currently
do not have any IDEs in effect.
Clinical
trials involve the administration of the medical device to human subjects under the supervision of qualified investigators in
accordance with current Good Clinical Practices (“cGCPs”) which include the requirement that all research subjects
provide their informed consent for participation in any clinical trial. A protocol for each clinical trial and any subsequent
protocol amendments must be submitted to the FDA as part of the IDE. Additionally, approval must also be obtained from each clinical
trial site’s Institutional Review Board (“IRB”) before the trials may be initiated, and the IRB must monitor
the study until completed and re-assess and approve the study at least annually. There are also requirements governing the reporting
of ongoing clinical trials and clinical trial results to public registries.
Clinical
trials for medical devices are usually conducted in two phases. Pilot clinical trials are normally conducted in small groups of
patients to assess safety, find the optimal dosing range and assess potential efficacy. After a successful pilot study or studies,
the device is administered to a population of patients large enough to meet the requirements for regulatory approval. This size
of trial is usually multi-center, controlled and potentially double-blind.
During
the course of a clinical trial, we are required to inform the FDA and the IRB about adverse events associated with our product
candidate. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials
are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring
board or committee, or DSMB. This group reviews unblinded data from clinical trials and provides authorization for whether a trial
may move forward at designated check points based on access to certain data from the study. We may also suspend or terminate a
clinical trial based on evolving business objectives or competitive climates.
Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational
medical device information is submitted to the FDA in the form of an PMA requesting approval to market the product for one or
more indications. The application includes all relevant data available from pertinent preclinical and clinical trials, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s
chemistry, manufacturing, controls and proposed labeling, among other things.
Once
the PMA submission has been accepted for filing, the FDA’s goal is to review applications within ten months of filing. However,
the review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer
the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved.
The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.
An
IDE is a request for authorization from the FDA to administer an investigational medical device to humans. We currently do not
have any IDEs in effect.
Applications
for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:
|
●
|
the
FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;
|
|
|
|
|
●
|
we
may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that
a product candidate’s risk-benefit ratio for its proposed indication is acceptable;
|
|
|
|
|
●
|
the
FDA may determine that the population studied in the clinical program was not sufficiently
broad or representative to assure safety in the full population for which we seek approval;
|
|
●
|
the
FDA or comparable foreign regulatory authorities may disagree with our interpretation
of data from preclinical studies or clinical studies;
|
|
|
|
|
●
|
the
data collected from clinical studies of our product candidates may not be sufficient
to support the submission of a PMA in the U.S. or elsewhere;
|
|
|
|
|
●
|
the
FDA or comparable foreign regulatory authorities may fail to approve the manufacturing
processes, test procedures and specifications or facilities of third-party manufacturers
with which we contract for clinical and commercial supplies;
|
|
|
|
|
●
|
the
approval policies or regulations of the FDA or comparable foreign regulatory authorities
may significantly change in a manner rendering our clinical data insufficient for approval;
and
|
This
lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain
regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations
and prospects.
Medical
device development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not
be predictive of future study results.
Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may
not be predictive of the results of later-stage clinical studies. Product candidates that have shown promising results in early-stage
clinical studies may still suffer significant setbacks in subsequent advanced clinical studies. There is a high failure rate for
medical devices proceeding through clinical studies, and product candidates in later stages of clinical studies may fail to show
the desired safety and efficacy traits despite having progressed satisfactorily through preclinical studies and initial clinical
studies. A number of companies in the medical device and biopharmaceutical industry have suffered significant setbacks in advanced
clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies. Moreover,
preclinical and clinical data are often susceptible to varying interpretations and analyses. We do not know whether any pivotal
studies we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain regulatory approval to
market our product candidates. Nor do we know whether the FDA will permit us to proceed directly to pivotal trials without performing
pilot trials in the U.S. using the same delivery system that we will seek approval by the agency.
We
are working on NTM Abscessus which is very rare.
NTM
Abscessus is a very rare disease and only a small number of people suffer from this condition. As a result of these small
numbers, we may not be able to complete the study related to NTM Abscessus or, even if approved, the device for that indication
may never be profitable. In addition, there are many strains of NTM but our study is only on one of them, Abscessus. Therefore,
we may face a situation that this strain will disappear or there will be no candidates with this strain, so the FDA may not grant
us approval to treat other NTM strains without further validation and trials, or possibly ever, and/or the FDA may not allow us
to work on NTM in patients who do not have CF.
We
are working on bronchiolitis in infants that usually is caused by the RSV virus.
RSV
is a seasonal virus (only in the winter). In our trial, we are heavily dependent on the occurrence and the severity of this virus.
Treating for bronchiolitis is highly reliant on the weather conditions in winter. The weather in the winter is not predictable.
For example, if the winter is warm or short, or the viral infection was not severe enough when we conducted our trial, or the
length of stay in the hospital at the year that trial was conducted was different from previous seasons, then we might miss the
season or the results can be significantly different between two seasons or between different countries or even between different
sites.
We
are working on PPHN which is a highly competitive market and regulatory approval may not be easily obtained.
Our
NO Delivery System has not yet been manufactured at commercial scale for use with a ventilator and this process has significant
risks. Additionally, a delivery system with a generator of NO has never been approved anywhere in the world and this may cause
significant delays in the approval process.
We
may find it difficult to enroll patients in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical
studies of our product candidates.
Identifying
and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of
our clinical studies depends in part on the speed at which we can recruit patients to participate in testing our product candidates,
and we may experience delays in our clinical studies if we encounter difficulties in enrollment.
Some
of the conditions for which we plan to evaluate our current product candidates are for rare diseases. For example, we estimate
that 10,000 patients suffer from NTM abscessus and refractory NTM MAC in the U.S. Accordingly, there is a limited patient
pool from which to draw for clinical studies. Further, the eligibility criteria of our clinical studies will further limit the
pool of available study participants as we will require that patients have specific characteristics that we can measure or to
assure their disease is either severe enough or not too advanced to include them in a study.
Additionally,
the process of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number
of patients to complete our clinical studies because of the perceived risks and benefits of the product candidate under study,
particularly the toxicity of NO in certain doses, the availability and efficacy of competing therapies and clinical studies, the
proximity and availability of clinical study sites for prospective patients and the patient referral practices of physicians.
If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies
and obtaining regulatory approval of potential products will be delayed.
If
we experience delays in the completion or termination of any clinical study of our product candidates, the commercial prospects
of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could
be delayed or prevented. In addition, any delays in completing our clinical studies will increase our costs, slow down our product
candidate development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these
occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause,
or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory
approval of our product candidates.
We
may encounter substantial delays in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction
of applicable regulatory authorities.
Before
obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical
studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time consuming
and uncertain as to outcome. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule,
if at all. Our clinical studies involve infants, children, and adults and, before we are permitted to enroll them in clinical
trials, we must demonstrate that although the research may pose a risk to the subjects, there is a prospect of direct benefit
to each patient. We must do so to the satisfaction of each research site’s IRB. If we fail to adequately demonstrate this
to the satisfaction of the relevant IRB, it will decline to approve the research, which could have significant adverse consequences
for the Company.
A
failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful.
Events that may prevent successful or timely completion of clinical development include but are not limited to:
|
●
|
inability
to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support
the initiation of human
clinical studies;
|
|
|
|
|
●
|
delays
in reaching a consensus with regulatory agencies on study design;
|
|
●
|
delays
in reaching agreement on acceptable terms with prospective contract research organizations
(“CROs”) and clinical
study sites, the terms of which can be subject to extensive negotiation and may vary
significantly among different CROs and clinical study sites;
|
|
|
|
|
●
|
delays
in obtaining required IRB approval at each clinical study site;
|
|
|
|
|
●
|
imposition
of a clinical hold by regulatory agencies, after review of an IDE application, or equivalent
application, or an inspection of our clinical study operations or study sites;
|
|
|
|
|
●
|
delays
in recruiting suitable patients to participate in our clinical studies;
|
|
|
|
|
●
|
difficulty
collaborating with patient groups and investigators;
|
|
|
|
|
●
|
failure
by our CROs, other third parties or us to adhere to clinical study requirements;
|
|
|
|
|
●
|
failure
to perform in accordance with the FDA’s GPC requirements, or applicable regulatory
guidelines in other countries;
|
|
|
|
|
●
|
delays
in having patients complete participation in a study or return for post-treatment follow-up;
|
|
|
|
|
●
|
patients
dropping out of a study;
|
|
|
|
|
●
|
occurrence
of serious adverse events associated with the product candidate that are viewed to outweigh
its potential benefits;
|
|
|
|
|
●
|
changes
in regulatory requirements and guidance that require amending or submitting new clinical protocols;
|
|
|
|
|
●
|
the
cost of clinical studies of our product candidates being greater than we anticipate;
|
|
|
|
|
●
|
clinical
studies of our product candidates producing negative or inconclusive results, which may
result in us deciding, or regulators requiring us, to conduct additional clinical studies
or abandon product development programs; and
|
|
|
|
|
●
|
delays
in manufacturing, testing, releasing, validating or importing/exporting sufficient stable
quantities of our product candidates for use in clinical studies or the inability to
do any of the foregoing.
|
Any
inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability
to generate revenue. We may also be required to conduct additional safety, efficacy and comparability studies before we will be
allowed to start clinical studies. Clinical study delays could also shorten any periods during which our products have patent
protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully
commercialize our product candidates and may harm our business and results of operations.
Our
product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label or result in significant negative consequences following marketing approval,
if any.
Undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies
and could result in a more restrictive marketing label or the delay or denial of regulatory approval by the FDA or other comparable
foreign authorities. There is currently limited data regarding possible side effects for an antimicrobial dosage of NO treatments,
such as our product candidates. Potential side effects of NO treatments may include high methemoglobin, nitrogen dioxide (“NO2”)
toxicity, nose bleeding or low blood pressure. Results of our studies may identify unacceptable severity and prevalence of these
or other side effects. In such an event, our studies could be suspended or terminated, and the FDA or comparable foreign regulatory
authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted
indications.
NO-related
side effects could affect patient recruitment, the ability of enrolled patients to complete the study or result in potential product
liability claims.
Additionally,
if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects
caused by such products, a number of potentially significant negative consequences could result, including but not limited to:
|
●
|
regulatory
authorities may withdraw approvals of such product;
|
|
|
|
|
●
|
regulatory
authorities may require additional warnings on the label;
|
|
|
|
|
●
|
as
a condition of approval, we may be required to create a Risk Evaluation and Mitigation Strategy
(“REMS”) plan, which could include a medication guide outlining the risks of such
side effects for distribution to patients, a communication plan for healthcare providers and/or
other elements to assure safe use;
|
|
|
|
|
●
|
we
could be sued and held liable for harm caused to patients; and
|
|
|
|
|
●
|
our
reputation may suffer.
|
Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved,
and could significantly harm our business, results of operations and prospects.
Even
if we obtain regulatory approval for our product candidates, we will still face extensive, ongoing regulatory requirements and
review, and our products may face future development and regulatory difficulties.
Even
if we obtain regulatory approval for one or more of our product candidates in the U.S., the FDA may still impose significant restrictions
on the indicated uses or marketing or to the conditions for approval, or impose ongoing requirements for potentially costly post-approval
studies, including post-market surveillance. As a condition to granting marketing approval of a product, the FDA may require a
company to conduct additional clinical trials. The results generated in these post-approval clinical trials could result in loss
of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product.
For example, the labeling for our product candidates, if approved, may include restrictions on use or warnings. The Food and Drug
Administration Amendments Act of 2007 (“FDAAA”) gives the FDA enhanced post-market authority, including the explicit
authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance
with FDA-approved REMS programs. If approved, our product candidates will also be subject to ongoing FDA requirements governing
the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record keeping, and
reporting of safety and other post-market information. The FDA’s exercise of its authority could result in delays or increased
costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval
regulatory requirements, and potential restrictions on sales of approved products. Foreign regulatory agencies often have similar
authority and may impose comparable costs. Post-marketing studies, whether conducted by us or by others and whether mandated by
regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely
affect sales of our product candidates once approved, and potentially our other marketed products. Further, the discovery of significant
problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products
could have an adverse effect on sales of our approved products. Accordingly, new data about our products could negatively affect
demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product
withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government agencies,
professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or
recommendations related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines
or recommendations may lead to lower sales of our products.
The
holder of an approved PMA or cleared 510(k) also is subject to obligations to monitor and report adverse events and instances
of the failure of a product to meet the specifications in the marketing application. Application holders must submit new or supplemental
applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process.
Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials.
Legal requirements have also been enacted to require disclosure of clinical trial results on publicly available databases.
In
addition, manufacturers of FDA regulated products and their facilities are subject to continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with the FDA’s cGMPs regulations. If we or a regulatory agency
discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency or problems
with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing
facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring
new warnings or other labeling changes to limit use of the product, requiring that we conduct additional clinical trials, imposing
new monitoring requirements, or requiring that we establish a REMS program for our approved products. Advertising and promotional
materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The distribution of product
samples to physicians must comply with the requirements of the Prescription Drug Marketing Act. Sales, marketing, and scientific/educational
grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the False Claims Act, and similar
state laws. We would also be required under the Sunshine provision of the Affordable Care Act (“ACA”) to report annually
to the Centers for Medicare & Medicaid Services on payments that we make to physicians and teaching hospitals and ownerships
interests in the company held by physicians. Pricing and rebate programs must comply with the Medicaid rebate requirements of
the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. If products are made available to authorized
users of the Federal Supply Schedule of the General Services Administration and to low income patients of certain hospitals, additional
laws and requirements apply. Our activities are also potentially subject to federal and state consumer protection and unfair competition
laws. If we or our third-party collaborators fail to comply with applicable regulatory requirements, a regulatory agency may take
any of the following actions:
|
●
|
conduct
an investigation into our practices and any alleged violation of law;
|
|
|
|
|
●
|
issue
warning letters or untitled letters asserting that we are in violation of the law;
|
|
|
|
|
●
|
seek
an injunction or impose civil or criminal penalties or monetary fines;
|
|
|
|
|
●
|
suspend
or withdraw regulatory approval;
|
|
|
|
|
●
|
require
that we suspend or terminate any ongoing clinical trials;
|
|
|
|
|
●
|
refuse
to approve pending applications or supplements to applications filed by us;
|
|
|
|
|
●
|
suspend
or impose restrictions on operations, including costly new manufacturing requirements;
|
|
|
|
|
●
|
seize
or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or
|
|
|
|
|
●
|
exclude
us from providing our products to those participating in government health care programs,
such as Medicare and Medicaid, and refuse to allow us to enter into supply contracts,
including government contracts.
|
The
occurrence of any of the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly
inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign
jurisdictions.
Risks
Related to our Reliance on Third Parties
We
rely on third parties to conduct our preclinical and clinical studies and perform other tasks for us. If these third parties do
not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not
be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
We
have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing preclinical and
clinical programs. We rely on these parties for execution of our preclinical and clinical studies, and we directly control only
certain aspects of their activities, although from a regulatory perspective we are responsible for their actions. We are responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific
standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors
are required to comply with Good Clinical Practice (“GCP”), QSR and GLP, which are regulations and guidelines enforced
by the FDA, the Competent Authorities of the Member States of the European Economic Area (“EEA”), and comparable foreign
regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these regulations
through periodic inspections of study sponsors, principal investigators, study sites and other contractors. If we or any of our
CROs or vendors fail to comply with applicable regulations, the clinical data generated in our clinical studies may be deemed
unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical studies
before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical studies comply with GCP regulations. In addition, our clinical studies must
be conducted with products that are produced under QSR regulations. Our failure to comply with these regulations may require us
to repeat clinical studies, which would delay the regulatory approval process, or have other adverse consequences.
If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative
CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available
to us under our agreements with such CROs, we cannot control whether they devote sufficient time and resources to our on-going
clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations
or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical studies may
be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our
product candidates. CROs may also generate higher costs than anticipated. As a consequence, our results of operations and the
commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue
could be delayed.
Switching
or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays may occur, which could materially impact our ability to meet our desired
clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we
will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse
impact on our business, financial condition and prospects.
We
will rely on third parties to manufacture our NO generator and delivery system. Our business could be harmed if those third parties
fail to provide us with sufficient quantities of our needed supplies, or fail to do so at acceptable quality levels or prices.
We
do not currently have the infrastructure or capability internally to manufacture the components of our NO generator and delivery
system, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial
scale. We plan to rely on third parties for such supplies. There are a limited number of manufacturers who have the ability to
produce our delivery system, and there may be a need to identify alternate manufacturers to prevent a possible disruption of our
clinical studies. Any significant delay or discontinuity in the supply of these components could considerably delay completion
of our clinical studies, product testing and potential regulatory approval of our product candidates, which could harm our business
and results of operations.
We
and our collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product
candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.
All
entities involved in the preparation of medical devices for clinical studies or commercial sale, including our existing contract
manufacturers for our product candidates, are subject to extensive regulation. Components of a finished medical device product
approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with QSR. These regulations
govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems
to control and assure the quality of investigational products and products approved for sale. Poor control of production processes
can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates
that may not be detectable in final product testing. We, our collaborators or our contract manufacturers must supply all necessary
documentation in support of any marketing application on a timely basis and must adhere to GLP and QSR regulations enforced by
the FDA and other regulatory agencies through their facilities inspection program. The facilities and quality systems of some
or all of our collaborators and third-party contractors must pass a pre-approval inspection for compliance with the applicable
regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition,
the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product
candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to
the activities being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection,
regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the
satisfaction of the regulatory authority, if ever.
The
regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our
collaborators and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations
or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we
or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third
party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales, or the
temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract
could materially harm our business.
If
we, our collaborators, or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable
regulatory authorities can impose regulatory sanctions including, among other things, refuse to approve a pending application
for a new drug product, withdrawal of an approval, suspend production, suspend clinical studies, require a recall or suspension
of production. As a result, our business, financial condition and results of operations may be materially harmed.
Additionally,
if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an PMA
or Marketing Authorization Application amendment, or equivalent foreign regulatory filing, which could result in further delay.
The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching
manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.
These
factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions,
required approvals or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements
and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical
studies may be delayed or we could lose potential revenue.
Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover
them or that our trade secrets will be misappropriated or disclosed.
Because
we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them.
We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material
transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators,
advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically
limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual
provisions employed when working with third parties, the need to share trade secrets and other confidential information increases
the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others,
or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how
and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our
competitive position and may have a material adverse effect on our business.
Risks
Related to Commercialization of Our Product Candidates
If
the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected,
and our business may suffer.
Our
projections of both the number of people who have our target diseases, as well as the subset of people with these diseases who
have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates
have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market
research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases.
The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat
is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally,
the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment
with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely
affect our results of operations and our business.
We
intend to rely on third-party manufacturers to produce our product candidates, but we have not entered into binding agreements
with any such manufacturers to support commercialization.
We
have not yet secured manufacturing capabilities for commercial quantities of our product candidates. We intend to rely on third-party
manufacturers for commercialization. We may be unable to negotiate binding agreements with the manufacturers to support our commercialization
activities on commercially reasonable terms, or at all. See “Risk Related to our Reliance on Third Parties—We and
our collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates.
The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.”
We
face intense competition and rapid technological change and the possibility that our competitors may discover, develop or commercialize
therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and
our ability to successfully commercialize our product candidates.
The
medical device, biotechnology and pharmaceutical industries are highly competitive. There are many medical device companies, pharmaceutical
companies, biotechnology companies, public and private universities and research organizations actively engaged in the research
and development of products that may be similar to our products. We are aware of several companies currently developing and/or
selling NO therapies for various indications such as PPHN. For example, Mallinckrodt commercializes INOMAX® (nitric
oxide) for inhalation, which is approved for use to treat newborns suffering from HRF-PPHN, in the U.S., Canada, Australia, Mexico
and Japan. Praxair markets the NOxBOX cylinder based system in the US. The Linde Group has marketing rights to INOMAX®
in Europe. Air Liquide sells a similar product in Europe, called VasoKINOX™, together with their delivery platform
called OptiKINOX™, for the treatment of pulmonary hypertension that occurs during or after heart surgery. In Europe, Praxair
has a delivery system called NOxBOX® and Air Products PLC has a gas product called NOXAP®, each
used in delivering inhaled NO formulations. Bellepheron Therapeutics is developing NO-based products for persistent arterial hypertension
and pulmonary hypertension associated with chronic obstructive pulmonary disease. Geno LLC is developing NO-based products for
the treatment of a variety of pulmonary and cardiac diseases such as acute vasoreactivity testing, pulmonary arterial hypertension
and pulmonary hypertension associated with idiopathic pulmonary fibrosis. In addition, other companies may be developing generic
NO formulation delivery systems for various dosages. Ceretec, Inc., a company affiliated with 12th Man Technologies Inc., recently
obtained clearance from the FDA to market a NO gas product for use in membrane diffusing capacity testing in pulmonary function
laboratories in the U.S. Novoteris, LLC previously received orphan drug designation from the FDA and EMA for the use of inhaled
NO-based treatments in treating CF. In January 2015, Mallinckrodt entered into an agreement with Novoteris to collaborate on the
development of an outpatient program for treating bacterial infections associated with CF.
In
addition to NO treatments currently available or under development, we also face competition from non-NO-based drugs and therapies.
For example, the successful development of immunizations for bronchiolitis may render useless any product we develop for that
indication. Also, antibiotic treatments for infections associated with CF, and inhaled short-acting beta-2 agonist and oral corticosteroids
for the treatment of asthma may be preferred over any product that we develop. Even if we successfully develop our product candidates,
and obtain approval for them, other treatments may be preferred and we may not be successful in commercializing our product candidates.
Many
of our competitors have substantially greater financial, technical and other resources, such as larger research and development
staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and
pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies
may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products
as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large, established companies. Competition may increase further as a result of advances in the commercial applicability of
technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing,
acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that
we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than
we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete,
and we may not be successful in marketing our product candidates against competitors.
We
currently have no marketing and sales organization. If we are unable to establish sales and marketing capabilities or enter into
agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.
Although
our employees may have sold other similar products in the past while employed at other companies, we as a company have no experience
selling and marketing our product candidates and we currently have no marketing or sales organization. To successfully commercialize
any products that may result from our development programs, we will need to develop these capabilities, either on our own or with
others. If our product candidates receive regulatory approval, we intend to establish a sales and marketing organization with
technical expertise and supporting distribution capabilities to commercialize our product candidates in major markets, which will
be expensive, difficult and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution
capabilities would adversely impact the commercialization of our products.
Further,
given our lack of prior experience in marketing and selling medical device products, our initial estimate of the size of the required
sales force may be materially more or less than the size of the sales force actually required to effectively commercialize our
product candidates. As such, we may be required to hire substantially more sales representatives to adequately support the commercialization
of our product candidates or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect
to certain geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution
capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do
not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing
capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We may be competing
with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support
of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established
companies.
The
commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians,
patients, third-party payors and others in the medical community.
Even
with the requisite approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our product
candidates will depend in part on the medical community, patients and third-party payors accepting our product candidates as medically
useful, cost-effective and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients,
third-party payors and others in the medical community. The degree of market acceptance of any of our product candidates, if approved
for commercial sale, will depend on a number of factors, including:
|
●
|
the
safety and efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments;
|
|
|
|
|
●
|
the
prevalence and severity of any side effects, including any limitations or warnings contained in a product’s approved
labeling;
|
|
|
|
|
●
|
the
clinical indications for which approval is granted;
|
|
|
|
|
●
|
relative
convenience and ease of administration;
|
|
|
|
|
●
|
the
cost of treatment, particularly in relation to competing treatments;
|
|
|
|
|
●
|
the
willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
|
|
|
|
|
●
|
the
strength of marketing and distribution support and timing of market introduction of competitive products;
|
|
|
|
|
●
|
publicity
concerning our products or competing products and treatments; and
|
|
|
|
|
●
|
sufficient
third-party insurance coverage and reimbursement.
|
Even
if a potential product displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance
of the product will not be fully known until after it is launched. Our efforts to educate the medical community and third-party
payors on the benefits of the product candidates may require significant resources and may never be successful. If our product
candidates are approved but fail to achieve an adequate level of acceptance by physicians, patients, third-party payors and others
in the medical community, we will not be able to generate sufficient revenue to become or remain profitable.
The
insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage
and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate
revenue.
The
pricing, coverage and reimbursement of our product candidates, if approved, must be adequate to support our commercial infrastructure.
Our per-patient prices must be sufficient to recover our development and manufacturing costs and potentially achieve profitability.
Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors are essential for
most patients to be able to afford expensive treatments such as ours, assuming approval. Sales of our product candidates will
depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid for
by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government
authorities, private health insurers and other third-party payors. If coverage and reimbursement are not available, or are available
only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided,
the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a
return on our investment.
There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the U.S., the principal
decisions about coverage and reimbursement for new medical devices are typically made by the Centers for Medicare & Medicaid
Services (“CMS”), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to
what extent a new device will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement
policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement
for products such as ours.
Outside
the U.S., international operations are generally subject to extensive governmental price controls and other market regulations,
and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue
to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject
to varying price control mechanisms as part of national health systems. In general, the prices of medical devices under such systems
are substantially lower than in the U.S. Other countries allow companies to fix their own prices for medical products, but monitor
and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount
that we are able to charge for our product candidates. Accordingly, in markets outside the U.S., the reimbursement for our products
may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.
Moreover,
increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such
organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover
or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale
of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations
and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and
surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to
the entry of new products.
Healthcare
legislative reform measures may have a material adverse effect on our business and results of operations.
In
the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in
March 2010, the Patient Protection and American Care Act (“ACA”) as amended by the ACA was passed, which substantially
changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. medical
device industry. We cannot predict how our product candidates may be impacted.
Future
legislation or regulations may adversely affect reimbursement from government programs.
In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, President Obama
signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction
to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve targeted deficit reductions,
triggering the legislation’s automatic reduction of several government programs. This includes aggregate reductions to Medicare
payments to healthcare providers of up to 2.0% per fiscal year, starting in 2013. In January 2013, President Obama signed into
law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare
providers and increased the statute of limitations period for the government to recover overpayments to providers from three to
five years. On December 13, 2016, the President signed into law the 21st Century Cures Act, which, among other things, may increase
the types of clinical trial designs that would be acceptable to support a PMA. It is unclear, at this time, how these provisions
will be implemented or whether they would have any effect on our company.
Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
medical device products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations,
guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates
may be. In that regard, Congress has taken the first step in repealing the funding mechanism for certain aspects of the ACA. If
the ACA or parts of it are repealed, it is unclear what impact that would have on reimbursements or coverage and it is equally
unclear what programs, if any, Congress and the Trump Administration might enact and sign into law to replace the repealed portions
of the ACA.
We
are subject to additional federal and state laws and regulations relating to our business, and our failure to comply with those
laws could have a material adverse effect on our results of operations and financial conditions
We
are subject to additional health care regulation and enforcement by the federal government and the states in which we conduct
our business. The laws that may affect our ability to operate include the following:
|
●
|
the
federal health care program Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering, or paying remuneration, directly or indirectly, in exchange for or to induce either the referral
of an individual for, or the purchase, order, or recommendation of, any good or service for which payment may be made under
government health care programs such as the Medicare and Medicaid programs;
|
|
●
|
federal
false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented,
claims for payment from Medicare, Medicaid or other government health care programs that are false or fraudulent;
|
|
|
|
|
●
|
federal
criminal laws that prohibit executing a scheme to defraud any health care benefit program or making false statements relating
to health care matters; and
|
|
|
|
|
●
|
state
law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or
services reimbursed by any third-party payor, including commercial insurers.
|
Further,
the ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes.
A person or entity can now be found guilty of fraud or false claims under the ACA without actual knowledge of the statute or specific
intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims
statutes. Possible sanctions for violation of these anti-kickback laws include monetary fines, civil and criminal penalties, exclusion
from Medicare, Medicaid and other government programs and forfeiture of amounts collected in violation of such prohibitions. Any
violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could
result in a material adverse effect on our reputation, business, results of operations, and financial condition.
The
ACA also imposes new reporting requirements on device and pharmaceutical manufacturers to make annual public disclosures of payments
to certain health care providers and physician ownership of their stock by health care providers. Failure to submit required information
may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year
for “knowing failures”), for all payments, transfers of value, or ownership or investment interests that are not reported.
Manufacturers were required to begin data collection on August 1, 2013 and were required to report such data to CMS by March 31,
2014.
In
addition, there has been a recent trend of increased federal and state regulation of payments made to physicians for marketing.
Some states, such as California, Massachusetts and Vermont mandate implementation of corporate compliance programs, along with
the tracking and reporting of gifts, compensation, and other remuneration to physicians.
The
scope and enforcement of these laws is uncertain and subject to change in the current environment of health care reform, especially
in light of the lack of applicable precedent and regulations. We cannot predict the impact on our business of any changes in these
laws. Federal or state regulatory authorities may challenge our current or future activities under these laws. Any such challenge
could have a material adverse effect on our reputation, business, results of operations, and financial condition. Any state or
federal regulatory review of us, regardless of the outcome, would be costly and time-consuming.
Risks
Related to Our Intellectual Property
If
we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may
not be able to compete effectively in our markets.
We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property
related to our technologies and product candidates. Our success depends in large part on our and our licensors’ ability
to obtain and maintain intellectual property protection in the U.S. and in other countries with respect to our proprietary technology
and products.
We
have sought to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel technologies
and products that are important to our business. This process is expensive and time consuming, and we may not be able to file
and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also fail to identify
patentable aspects of our research and development output before it is too late to obtain patent protection.
The
patent position of medical device, biotechnology and pharmaceutical companies generally is highly uncertain and involves complex
legal and factual questions for which legal principles remain unsolved. The patent applications that we own or in-license may
fail to result in issued patents with claims that cover our product candidates in the U.S. or in other foreign countries. There
is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which
can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue,
and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which
may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our
patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates
or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from
third parties, which may have an adverse impact on our business.
We
have filed several patent applications directed to various aspects of our product candidates. We cannot offer any assurances about
which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable
or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to
us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that
we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product
candidate under patent protection could be reduced. In addition, some or all of our patent applications may not result in issued
patents.
If
we cannot obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively and
our business and results of operations would be harmed.
We
have a non-exclusive license to certain patents owned by CareFusion that relate to methods and devices for delivering 80-400 PPM
NO formulations to patients. CareFusion may grant additional non-exclusive licenses to third parties.
Absent
any agreement with CareFusion to the contrary, each of the joint owners may make, use, offer to sell, or sell the patented invention
within the U.S., or import the patented invention into the U.S., without the consent of and without accounting to the other owner.
While we are unaware of any other licenses issued by CareFusion to third parties granting rights in the patents CareFusion licensed
to us, we cannot be sure other licenses have not already been granted, or will not be granted in the future, by CareFusion to
third parties.
Any
such licenses may enable third parties to develop and market products competitive with ours, provided that they do not infringe
our other intellectual property rights. The terms of our non-exclusive license with CareFusion leaves full control of any and
all enforcement of the licensed patents with CareFusion. If CareFusion elects to not enforce any or all of the licensed patents
it could significantly undercut the value of any of our product candidates, which would materially adversely affect our revenue,
financial condition and results of operations.
Intellectual
property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our product candidate. Such litigation or licenses
could be costly or not available on commercially reasonable terms.
Given
the number of companies developing various types of NO devices, it is difficult to conclusively assess our freedom to operate
without infringing on third party rights. There are numerous companies that have pending patent applications and issued patents
in the field of therapeutic NO delivery. Our competitive position may suffer if patents issued to third parties or other third-party
intellectual property rights cover our products or elements thereof, or our manufacture or uses relevant to our development plans.
In such cases, we may not be in a position to develop or commercialize products or our product candidates unless we successfully
pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement
with the intellectual property right holder, if available on commercially reasonable terms. There may be pending patent applications
of which we are not aware, that if they result in issued patents, could be alleged to be infringed by our product candidates.
If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to
abandon our product candidates or seek a license from any patent holders. No assurances can be given that a license will be available
on commercially reasonable terms, if at all.
It
is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications
filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain
confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the
earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date.
Therefore, patent applications covering our product candidate or platform technology could have been filed by others without our
knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended
in a manner that could cover our platform technologies, our product candidate or the use of our product candidate. Third party
intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be
able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims
on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and
may be prevented from or experience substantial delays in pursuing the development of and/or marketing our product candidate.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from
commercializing our product candidate that is held to be infringing. We might, if possible, also be forced to redesign our product
candidate so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately
to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote
to our business.
Patent
terms are limited and we may not be able to effectively protect our products and business.
Patents
have a limited lifespan. In the U.S., the natural expiration of a patent is generally 20 years after it is filed. Although various
extensions may be available, the life of a patent, and the protection it affords, is limited.
In
addition, upon issuance in the U.S., the patent term may be extended based on certain delays caused by the applicant(s) or the
U.S. Patent and Trademark Office (“USPTO”). Even if we obtain effective patent rights for our product candidates,
we may not have sufficient patent terms or regulatory exclusivity to protect our products, and our business and results of operations
would be adversely affected.
Patent
policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and
the enforcement or defense of our issued patents.
Changes
in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents
or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the
laws of the U.S. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent
applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not
at all. We therefore cannot be certain that we or our licensor were the first to make the invention claimed in our owned and licensed
patents or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming
the other requirements for patentability are met, in the U.S. prior to March 15, 2013, the first to invent the claimed invention
is entitled to the patent, while outside the U.S., the first to file a patent application is entitled to the patent. After March
15, 2013, under the Leahy-Smith America Invents Act (“Leahy-Smith Act”), enacted on September 16, 2011, the U.S. has
moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent
applications will be prosecuted and may also affect patent litigation. The effects of these changes are currently unclear as the
USPTO must still implement various regulations, the courts have yet to address these provisions and the applicability of the act
and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the
Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial
condition.
If
we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not
be able to compete effectively in our markets.
In
addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other
elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology
that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology
and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors.
We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our
premises and physical and electronic security of our information technology systems. While we have confidence in these individuals,
organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.
In addition, our trade secrets may otherwise become known or be independently discovered by competitors.
All
of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology
enter into confidentiality agreements and we expect they will assign all rights in their inventions to us pursuant to the terms
of such agreements; however, we cannot provide any assurances that all such agreements have been duly executed or that our trade
secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access
to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized
disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business.
Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against
third parties for misappropriating the trade secret.
Third-party
claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
Our
commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There
have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and
pharmaceutical industries, including with respect to NO delivery systems and formulations, including patent infringement lawsuits,
interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S.
and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we
are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the
risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.
Third
parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents
or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the
use or manufacture of our product candidates. We do not know whether there are any third-party patents that would impair our ability
to commercialize these product candidates. We also cannot be sure that we have identified each and every patent and pending patent
application in the U.S. and abroad that is relevant or necessary to the commercialization of our product candidates. Because patent
applications can take many years to issue, there may be currently pending patent applications that may later result in issued
patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use
of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to
cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any
final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate
unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid
or unenforceable.
Similarly,
if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for
manufacture or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize the
applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid
or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all.
Parties
making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a
successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’
fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties,
which may be impossible or require substantial time and monetary expenditure.
We
may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
We
currently own and have in-licensed rights to intellectual property through licenses from third parties and under patents that
we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties,
the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In
addition, our product candidates may require specific formulations to work effectively and efficiently and the rights to these
formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other
third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing
and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies
are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These
established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development
and commercialization capabilities.
For
example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development
underwritten agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license
to any of the institution’s rights in technology resulting from the collaboration. Regardless of such option, we may be
unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do
so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our
program.
In
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable
to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our
investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, we may have to
abandon development of that program and our business and financial condition could suffer.
If
we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third
parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that
are important to our business.
We
are currently a party to intellectual property license agreements that are important to our business, and we expect to enter into
additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements
will impose, various diligence, milestone payment, royalty and other obligations on us. For example, our existing license agreement
with CareFusion imposes the following milestones, which comport with the plans we discuss under “Business—Our Strategy”:
completion of a Phase II study by September 2017; completion of a Phase III study by September 2018; FDA approval for a licensed
product by September 2020; and the first sale of a licensed product by September 2021. We have completed the Phase II, double
blind, randomized study conducted in Israel in infants with bronchiolitis discussed under “Business—Our Strategy”,
and we have commenced the “Phase III” study referenced under “Business—Our Strategy”. Obtaining
FDA approval by September 2020 of a licensed product will most likely not occur. If we fail to comply with our obligations under
the CareFusion agreement or other agreements, or we are subject to a bankruptcy, we may be required to make certain payments to
the licensor, we may lose our license or the licensor may have the right to terminate the license, in which event we would not
be able to develop or market products covered by the license.
Licensing
of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues.
Disputes may arise regarding intellectual property subject to a licensing agreement, including but not limited to:
|
●
|
the
scope of rights granted under the license agreement and other interpretation-related issues;
|
|
|
|
|
●
|
the
extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the
licensing agreement;
|
|
|
|
|
●
|
the
sublicensing of patent and other rights;
|
|
|
|
|
●
|
our
diligence obligations under the license agreement and what activities satisfy those diligence obligations;
|
|
|
|
|
●
|
the
ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and
us and our collaborators; and
|
|
|
|
|
●
|
the
priority of invention of patented technology.
|
If
disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current
licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.
We
may be involved in lawsuits or post-grant proceedings to protect or enforce our patents or the patents of our licensor, which
could be expensive, time consuming and unsuccessful.
Competitors
may infringe the patents of our licensor. If our licensing partner were to initiate legal proceedings against a third party to
enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product
candidate is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or
unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an
allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading
statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
Pending
patent applications may be subject to third-party pre-issuance submission of prior art to the USPTO, and any patents issuing thereon
may become involved in derivation, reexamination, inter partes review, post grant review, interference proceedings or other patent
office proceedings in the U.S. challenging our patent rights.
Proceedings
provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with
respect to our patents or patent applications or those of our licensor. An unfavorable outcome could require us to cease using
the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing
party does not offer us a license on commercially reasonable terms. Our defense of litigation or proceedings may fail and, even
if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties
associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical
trials, continue our research programs, license necessary technology from third parties or enter into development partnerships
that would help us bring our product candidates to market.
Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors
perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares.
We
may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential
information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
We
employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including
our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors
do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our
employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including
trade secrets or other proprietary information, of any of our employee’s former employer or other third parties. Litigation
may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
We
may be subject to claims challenging the inventorship of our patents and other intellectual property.
We
may be subject to claims that former employees, collaborators or other third parties have an interest in or right to compensation
with respect to our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship
disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation
may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If we
fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights,
such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse
effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. To the extent that our employees have not effectively waived the right
to compensation with respect to inventions that they helped create, they may be able to assert claims for compensation with respect
to our future revenue may be successful. As a result, we may receive less revenue from future products if such claims are successful
which in turn could impact our future profitability.
Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
As
is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity. Therefore, obtaining
and enforcing biotechnology patents is costly, time consuming and inherently uncertain. In addition, the U.S. has recently enacted
and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope
of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition
to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the value of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and
the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain
new patents or to enforce our existing patents and patents that we might obtain in the future.
We
may not be able to protect our intellectual property rights throughout the world.
Filing,
prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition,
the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in
the U.S.
Competitors
may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also
export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that
in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing.
Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade
secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it
difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights
generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated
or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against
us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain
a significant commercial advantage from the intellectual property that we develop or license.
Under
applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our
competitors from benefiting from the expertise of some of our former employees.
We
generally enter into non-competition agreements with our employees and certain key consultants. These agreements prohibit our
employees and certain key consultants, if they cease working for us, from competing directly with us or working for our competitors
or clients for a limited period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which
our employees work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees
or consultants developed while working for us. For example, Israeli courts have required employers seeking to enforce non-compete
undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited
number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company’s
confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that such interests
will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees or consultants
and our ability to remain competitive may be diminished.
Risks
Relating to Our Business Operations
We
manage our business through a small number of employees and key consultants. We depend on them even more than similarly-situated
companies.
We
have a total of 19 full-time employees and a number of dedicated consultants. In addition, any of our employees and consultants
may leave our company at any time, subject to certain notice periods. The loss of the services of any of our executive officers
or any key employees or consultants would adversely affect our ability to execute our business plan and harm our operating results.
We
do not currently carry “key person” insurance on the lives of members of management.
We
will need to expand our organization and we may experience difficulties in recruiting needed additional employees and consultants,
which could disrupt our operations.
As
our development and commercialization plans and strategies develop and because we are so leanly staffed, we will need additional
managerial, operational, sales, marketing, financial, legal and other resources. The competition for qualified personnel in the
pharmaceutical field is intense. Due to this intense competition, we may be unable to attract and retain qualified personnel necessary
for the development of our business or to recruit suitable replacement personnel.
Our
management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial
amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations,
which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees
and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may
divert financial resources from other projects, such as the development of additional product candidates. If our management is
unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue
could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to
commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future
growth.
Although
a substantial amount of our effort will focus on the continued clinical testing, potential approval and commercialization of our
existing product candidates, the success of our business also depends upon our ability to identify, license or discover additional
product candidates. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development
for a number of reasons, including but not limited to the following:
|
●
|
our
research or business development methodology or search criteria and process may be unsuccessful in identifying potential product
candidates;
|
|
|
|
|
●
|
we
may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;
|
|
|
|
|
●
|
our
product candidates may not succeed in preclinical or clinical testing;
|
|
|
|
|
●
|
our
potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the
products unmarketable or unlikely to receive marketing approval;
|
|
|
|
|
●
|
competitors
may develop alternatives that render our product candidates obsolete or less attractive;
|
|
|
|
|
●
|
product
candidates we develop may be covered by third parties’ patents or other exclusive rights;
|
|
|
|
|
●
|
the
market for a product candidate may change during our program so that such a product may become unreasonable to continue to
develop;
|
|
|
|
|
●
|
a
product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
|
|
|
|
|
●
|
a
product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.
|
If
any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able
to identify, license or discover additional product candidates, which would have a material adverse effect on our business and
could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical,
financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately
prove to be unsuccessful.
We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the U.S., our operations
may directly, or indirectly through our customers, subject us to various federal and state fraud and abuse laws, including, without
limitation, the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These
laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient
privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our
ability to operate include:
|
●
|
the
federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving,
offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an
item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;
|
|
|
|
|
●
|
federal
civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities
from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors
that are false or fraudulent;
|
|
|
|
|
●
|
the
federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created new federal criminal
statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to
healthcare matters;
|
|
●
|
HIPAA,
as amended by the Health Information Technology and Clinical Health Act (“HITECH”), and its implementing regulations,
which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health
information;
|
|
●
|
the
federal physician sunshine requirements under the Health Care Reform Laws requires manufacturers of drugs, devices and medical
supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other
transfers of value to physicians, other healthcare providers and teaching hospitals and ownership and investment interests
held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;
and
|
|
|
|
|
●
|
state
law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or
services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies
to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral
sources; state laws that require manufacturers to report information related to payments and other transfers of value to physicians
and other healthcare providers or marketing expenditures and state laws governing the privacy and security of health information
in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus
complicating compliance efforts.
|
Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some
of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform
legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends the intent requirement
of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge
of this statute or specific intent to violate it. Moreover, the Health Care Reform Law provides that the government may assert
that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or
fraudulent claim for purposes of the False Claims Act.
If
our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply
to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in
government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of our operations,
any of which could adversely affect our ability to operate our business and our results of operations.
International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated
with doing business outside of the U.S. or Israel.
Other
than our operations that are located in Israel (as further described below), we currently have limited international operations,
but our business strategy incorporates potentially significant international expansion, particularly in anticipation of approval
of our product candidates. We plan to maintain sales representatives and conduct physician and patient association outreach activities,
as well as clinical trials, outside of the U.S. and Israel. Doing business internationally involves a number of risks, including
but not limited to:
|
●
|
multiple,
conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment
laws, regulatory requirements and other governmental approvals, permits and licenses;
|
|
|
|
|
●
|
failure
by us to obtain regulatory approvals for the use of our products in various countries;
|
|
●
|
additional
potentially relevant third-party patent rights;
|
|
|
|
|
●
|
complexities
and difficulties in obtaining protection and enforcing our intellectual property;
|
|
|
|
|
●
|
difficulties
in staffing and managing foreign operations;
|
|
|
|
|
●
|
complexities
associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;
|
|
●
|
limits
on our ability to penetrate international markets;
|
|
|
|
|
●
|
financial
risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial
crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;
|
|
|
|
|
●
|
natural
disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts,
curtailment of trade and other business restrictions;
|
|
|
|
|
●
|
certain
expenses including, among others, expenses for travel, translation and insurance; and
|
|
|
|
|
●
|
regulatory
and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within
the purview of the FCPA, its books and records provisions or its anti-bribery provisions.
|
Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of
operations.
If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or
incur costs that could have a material adverse effect on the success of our business.
Our
research and development activities and our third-party manufacturers’ and suppliers’ activities involve the controlled
storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds.
We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and
disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are
stored at our and our manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of contamination,
which could cause an interruption of our commercialization efforts, research and development efforts, business operations and
environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage,
handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized
by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed
by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or
injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed
our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our
business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become
more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently
carry biological or hazardous waste insurance coverage.
The
use of any of our product candidates could result in product liability or similar claims that could be expensive, damage our reputation
and harm our business.
Our
business exposes us to an inherent risk of potential product liability or similar claims. The medical device industry has historically
been litigious, and we face financial exposure to product liability or similar claims if the use of any of our products were to
cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our
products might necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of
these policies may not be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance
on acceptable terms or at reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities.
A product liability claim, regardless of merit or ultimate outcome, or any product recall could result in substantial costs to
us, damage to our reputation, customer dissatisfaction and frustration and a substantial diversion of management attention. A
successful claim brought against us in excess of, or outside of, our insurance coverage could have a material adverse effect on
our business, financial condition and results of operations.
Our
business and operations would suffer in the event of system failures.
Despite
the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable
to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.
While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the
loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval
efforts and we may incur substantial costs to attempt to recover or reproduce the data. If any disruption or security breach resulted
in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we
could incur liability and/or the further development of our product candidates could be delayed.
We
may be subject to certain claims by Circassia.
In
connection the termination of our license agreement with Circassia, we may be subject to certain claims by Circassia. Adverse
outcomes in some or all of these claims may negatively affect our ability to conduct our business. However, as of the date of
this prospectus, we cannot estimate the likelihood that we will be subject to any claims or the effects thereof on our business
and operations.
Risks
Related to this Offering
Our
management will have broad discretion over the use of any net proceeds from this offering and the, you may not agree with how
we use the proceeds, and the proceeds may not be invested successfully.
Our
management will have broad discretion as to the use of any net proceeds from this offering and the Concurrent Private Placement
and could use them for purposes other than those contemplated at the time of this offering. Accordingly, you will be relying on
the judgment of our management with regard to the use of any proceeds from the exercise of warrants on a cash basis in this offering
and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return for you.
Investors
in this offering may experience future dilution as a result of this and future equity offerings.
In
order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible
into or exchangeable for our common stock. Investors purchasing our shares or other securities in the future could have rights
superior to existing common stockholders, and the price per share at which we sell additional shares of our common stock or other
securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price
per share in this offering.
Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could
depress the market price of our common stock.
Sales
of a substantial number of shares of our common stock in the public markets could depress the market price of our common stock
and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future
sales of our common stock would have on the market price of our common stock.
Our
share price is volatile and may be influenced by numerous factors, some of which may be beyond our control.
The
trading price of our common stock is likely to be highly volatile, and could be subject to wide fluctuations in response to various
factors, some of which are beyond our control. In addition to the factors discussed in this “Risk Factors” section
and elsewhere in this prospectus, these factors include:
|
●
|
the
product candidates we seek to pursue, and our ability to obtain rights to develop, commercialize and market those product
candidates;
|
|
|
|
|
●
|
our
decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;
|
|
|
|
|
●
|
actual
or anticipated adverse results or delays in our clinical trials;
|
|
|
|
|
●
|
our
failure to commercialize our product candidates, if approved;
|
|
|
|
|
●
|
unanticipated
serious safety concerns related to the use of any of our product candidates;
|
|
|
|
|
●
|
adverse
regulatory decisions;
|
|
|
|
|
●
|
additions
or departures of key scientific or management personnel;
|
|
|
|
|
●
|
changes
in laws or regulations applicable to our product candidates, including without limitation clinical trial requirements for
approvals;
|
|
|
|
|
●
|
disputes
or other developments relating to patents and other proprietary rights and our ability to obtain patent protection for our
product candidates;
|
|
|
|
|
●
|
our
dependence on third parties, including CROs as well as our potential partners that provide us with companion diagnostic products;
failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the
public;
|
|
|
|
|
●
|
actual
or anticipated variations in quarterly operating results;
|
|
|
|
|
●
|
failure
to meet or exceed the estimates and projections of the investment community;
|
|
|
|
|
●
|
overall
performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance
of our competitors, including changes in market valuations of similar companies;
|
|
|
|
|
●
|
conditions
or trends in the biotechnology and biopharmaceutical industries;
|
|
|
|
|
●
|
introduction
of new products offered by us or our competitors;
|
|
|
|
|
●
|
announcements
of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;
|
|
|
|
|
●
|
our
ability to maintain an adequate rate of growth and manage such growth;
|
|
|
|
|
●
|
issuances
of debt or equity securities;
|
|
|
|
|
●
|
sales
of our common stock by us or our stockholders in the future, or the perception that such sales could occur;
|
|
|
|
|
●
|
trading
volume of our common stock; ineffectiveness of our internal control over financial reporting or disclosure controls and procedures;
|
|
|
|
|
●
|
general
political and economic conditions;
|
|
|
|
|
●
|
effects
of natural or man- made catastrophic events; and
|
|
|
|
|
●
|
the
market value of the Circassia shares; and
|
|
|
|
|
●
|
other
events or factors, many of which are beyond our control.
|
In
addition, the stock market in general, and the stocks of small-cap biotechnology companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.
Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these
“Risk Factors,” could have a dramatic and material adverse impact on the market price of our common stock.
If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our
stock price and trading volume could decline.
The
trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish
about us or our business. Several analysts cover our stock. If one or more of those analysts downgrade our stock or publish inaccurate
or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage
of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price
and trading volume to decline.
We
incur increased costs associated with, and our management currently do and, in the future, will need to devote substantial time
and effort to, compliance with public company reporting and other requirements.
As
a public company, and particularly if and after we cease to be an “emerging growth company” or a “smaller reporting
company,” we incur significant legal, accounting and other expenses that Beyond Air Ltd. did not incur as a private company.
In addition, the rules and regulations of the SEC and national securities exchanges impose numerous requirements on public companies,
including requirements relating to our corporate governance practices, with which we now need to comply. Since becoming subject
to the Exchange Act, we have been required to, among other things, file annual, quarterly and current reports with respect to
our business and operating results. Our management and other personnel currently do and, in the future, will need to devote substantial
time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations, and our
efforts and initiatives to comply with those requirements could be expensive.
We
are an emerging growth company and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies
will make our common stock less attractive to investors.
We
are an emerging growth company as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may
choose to take advantage of certain exemptions from various reporting requirements applicable to other public companies, including,
among other things:
|
●
|
exemption
from the auditor attestation requirements under Section 404 of the Sarbanes-Oxley Act of 2002;
|
|
|
|
|
●
|
reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements;
|
|
|
|
|
●
|
exemption
from the requirements of holding non-binding stockholder votes on executive compensation arrangements; and
|
|
|
|
|
●
|
exemption
from any rules requiring mandatory audit firm rotation and auditor discussion and analysis and, unless the SEC otherwise determines,
any future audit rules that may be adopted by the Public Company Accounting Oversight Board.
|
We
will be an emerging growth company until the earliest of (i) December 31, 2021, (ii) the last day of the fiscal year during which
we have total annual gross revenues of $1 billion or more, (iii) the date on which we have, during the previous three-year period,
issued more than $1 billion in non-convertible debt and (iv) the date on which we are deemed to be a large accelerated filer under
the federal securities laws. We will qualify as a large accelerated filer as of the first day of the first fiscal year after we
(i) have more than $700 million in aggregate market value of outstanding common equity held by our non-affiliates as of the last
day of our second fiscal quarter, (ii) have been public for at least 12 months and (iii) have filed at least one annual report
pursuant to the Exchange Act.
We
cannot predict if investors will find our common stock less attractive if we rely on these exemptions. If some investors find
our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price
may be more volatile.
If
we issue additional shares of our capital stock in the future, our existing stockholders will be diluted.
Our
amended and restated certificate of incorporation authorize the issuance of up to 100,000,000 shares of our common stock and up
to 10,000,000 shares of preferred stock with the rights, preferences and privileges that our Board of Directors may determine
from time to time. In addition to capital raising activities, which we expect to pursue in order to raise the funding we will
need in order to continue our operations, other possible business and financial uses for our authorized capital stock include,
without limitation, future stock splits, acquiring other companies, businesses or products in exchange for shares of our capital
stock, issuing shares of our capital stock to partners or other collaborators in connection with strategic alliances, attracting
and retaining employees by the issuance of additional securities under our equity compensation plans, or other transactions and
corporate purposes that our Board of Directors deems are in the best interest of our company. Additionally, shares of our capital
stock could be used for anti-takeover purposes or to delay or prevent changes in control or our management. Any future issuances
of shares of our capital stock may not be made on favorable terms or at all, they may not enhance stockholder value, they may
have rights, preferences and privileges that are superior to those of our common stock, and they may have an adverse effect on
our business or the trading price of our common stock. The issuance of any additional shares of our common stock will reduce the
book value per share and may contribute to a reduction in the market price of the outstanding shares of our common stock. Additionally,
any such issuance will reduce the proportionate ownership and voting power of all of our current stockholders.
Future
sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans or
otherwise, could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
We
expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital,
we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner
we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction,
investors in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales may result in material
dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders
of our common stock.
Anti-takeover
provisions in our amended and restated certificate of incorporation and our amended and restated bylaws, as well as provisions
of Delaware law, might discourage, delay or prevent a change in control of our company or changes in our Board of Directors or
management and, therefore, depress the trading price of our common stock.
Our
amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may depress
the market price of our common stock by acting to discourage, delay or prevent a merger, acquisition or other change in control
that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares
of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove members
of our Board of Directors or our management. Our corporate governance documents include provisions:
|
●
|
providing
that directors may be removed by stockholders with or without cause;
|
|
●
|
limiting
the ability of our stockholders to call and bring business before special meetings and to take action by written consent in
lieu of a meeting;
|
|
|
|
|
●
|
requiring
advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of
candidates for election to our Board of Directors;
|
|
|
|
|
●
|
authorizing
blank check preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common
stock; and
|
|
|
|
|
●
|
limiting
the liability of, and providing indemnification to, our directors and officers.
|
As
a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation
Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock from engaging in certain
business combinations with us. Any provision of our amended and restated certificate of incorporation, amended and restated bylaws
or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders
to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to
pay for our common stock.
The
existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay
in the future for shares of our common stock. They could also deter potential acquirers of our company, thereby reducing the likelihood
that you could receive a premium for your common stock in an acquisition.
The
elimination of personal liability against our directors and officers under Delaware law and the existence of indemnification rights
held by our directors, officers and employees may result in substantial expenses.
Our
amended and restated certificate of incorporation and our Bylaws eliminate the personal liability of our directors and officers
to us and our stockholders for damages for breach of fiduciary duty as a director or officer to the extent permissible under Delaware
law. Further, our amended and restated certificate of incorporation and our Bylaws and individual indemnification agreements we
have entered with each of our directors and executive officers provide that we are obligated to indemnify each of our directors
or officers to the fullest extent authorized by the Delaware law and, subject to certain conditions, advance the expenses incurred
by any director or officer in defending any action, suit or proceeding prior to its final disposition. Those indemnification obligations
could expose us to substantial expenditures to cover the cost of settlement or damage awards against our directors or officers,
which we may be unable to afford. Further, those provisions and resulting costs may discourage us or our stockholders from bringing
a lawsuit against any of our current or former directors or officers for breaches of their fiduciary duties, even if such actions
might otherwise benefit our stockholders.
Our
amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive
forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain
a favorable judicial forum for disputes with us or our directors, officers or employees.
Our
certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for (A) any derivative
action or proceeding brought on behalf of us; (B) any action asserting a claim of breach of a fiduciary duty owed by any of our
directors, officers or other employees to us or our stockholders; (C) any action asserting a claim against us arising pursuant
to any provision of the Delaware General Corporation Law, our Amended and Restated Certificate of Incorporation or our Bylaws;
or (D) any action asserting a claim against us governed by the internal affairs doctrine. Section 27 of the Exchange Act creates
exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules
and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or
liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition,
Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce
any duty or liability created by the Securities Act or the rules and regulations thereunder. As a result, the exclusive forum
provision will not apply to suits brought to enforce any duty or liability created by the Securities Act or any other claim for
which the federal and state courts have concurrent jurisdiction.
The
choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors,
officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate
of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such
action in other jurisdictions, which could adversely affect our business and financial condition.
We
do not intend to pay cash dividends on our capital stock in the foreseeable future.
Other
than the cash dividend paid in connection with our reverse merger in 2017, we have never declared or paid any dividends on our
common stock and do not anticipate paying any dividends in the foreseeable future. Any future payment of cash dividends in the
future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate laws,
results of operations, anticipated cash requirements and other factors and will be at the discretion of our Board of Directors.
Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock.
We
could be subject to securities class action litigation.
In
the past, securities class action litigation has often been brought against a company following a decline in the market price
of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock
price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s
attention and resources, which could harm our business.
The
number of shares being registered for resale is significant in relation to the number of our outstanding shares of common stock.
We
have filed a registration statement of which this prospectus is a part to register the shares offered hereunder for sale into
the public market by the selling stockholders. These shares represent a large number of shares of our common stock, and if sold
in the market all at once or at about the same time, could depress the market price of our common stock during the period the
registration statement remains effective and could also affect our ability to raise equity capital.
Antidilution
provisions in certain of our outstanding warrants may affect the interests of our common stockholders.
The
warrants we issued in our January 2017 and March 2017 financing transactions, or the 2017 Warrants, which underlying shares of
common stock are being registered for resale herein, contain price protection provisions that could be triggered by our issuance
of common stock in the future, if the offering price for any such future issuance is less than the then-applicable warrant exercise
price. The 2017 Warrants had an original exercise price of $6.90 per share, which was adjusted to $4.25 as a result of our February
2018 financing and further adjusted to $3.66 as a result of our December 2019 financings.
USE
OF PROCEEDS
The
shares of our common stock offered by this prospectus are being registered solely for the account of the selling stockholders.
We will not receive any proceeds from the sale of the shares of Common Stock but will pay the expenses (other than any underwriting
discounts and brokers’ commissions and similar expenses) of this offering.
The
selling stockholders hold warrants to purchase an aggregate of 3,624,220 shares of common stock at an exercise price of
$3.66 per share. 1,701,616 and 1,701,616 of the warrants are exercisable at any time prior to their expiration on January
13, 2022 and February 27, 2022, respectively, by paying to us the exercise price in cash. In addition, 220,988 of
the warrants are exercisable at any time prior to their expiration on March 31, 2022 by paying to us the exercise price in cash.
However, if at any time during the term of the warrants a registration statement covering the resale of the shares of common stock
issuable upon exercise of the warrants is not currently effective and available for the resale of all of such shares, then the
holders of the warrants may exercise all or any part of the warrant in a “cashless” or “net-issue” exercise,
in which case we would receive no cash proceeds upon such exercise.
Assuming
that the selling stockholders exercise all of their respective warrants in cash exercises, we would receive gross proceeds of
approximately $13 million, which we presently intend to use for working capital and general corporate purposes, which may include,
without limitation, clinical studies required to gain regulatory approvals, implementation of adequate systems and controls to
allow for regulatory approvals, commercialization of LungFit, further development of the LungFit™ for use in the home, investing
in or acquiring companies that are synergistic with or complimentary to our technologies, and licensing activities related to
our current and future product candidates. We can provide no assurance that any of the selling stockholders will exercise any
of the warrants, whether in cash or cashless exercises.
DIVIDENDS
On
January 9, 2017, our Board of Directors declared a $2.50 per share cash dividend to its stockholders of record as of January 9,
2017 in connection with our merger with Beyond Air Ltd. (the “Merger”). Other than the cash dividend paid in connection
with the Merger, we have never declared or paid any dividends on our common stock and do not anticipate paying any dividends in
the foreseeable future.
Management’s
Discussion and Analysis of Financial Condition and Results of Operations
Prospective
investors should read the following discussion and analysis of our financial condition and results of operations together with
our financial statements and the related notes and other financial information contained in this prospectus. Some of the information
contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our
plans and strategy for our business, includes forward-looking statements
For
the Three and Six Months Ended September 30, 2019
Introduction
We
are an emerging medical device and biopharmaceutical company developing a nitric oxide (“NO”) generator and delivery
system (the “LungFit™”) that is capable of generating NO from ambient air. The LungFit™ can generate NO
up to 400 parts per million (“ppm”) for delivery to a patient’s lungs. The LungFit™ can deliver NO either
continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain
a constant dose. We believe that the LungFit™ can be used to treat patients on ventilators that require NO, as well as patients
with chronic lung disease or acute severe lung infections via delivery through a breathing mask or similar apparatus. Furthermore,
we believe that there is a high unmet medical need for patients suffering from certain severe lung infections that our Beyond
Air LungFit™ can potentially address. Our initial areas of focus are persistent pulmonary hypertension of the newborn (“PPHN”),
bronchiolitis (“BRO”) and nontuberculous mycobacteria (“NTM”). Our current product candidates will be
subject to premarket reviews and approvals by the U.S. Food and Drug Administration, or the FDA, as well as similar regulatory
agencies in other countries or regions. If approved, our system will be marketed as a medical device in the U.S. The Company is
expected to file a Premarketing (“PMA”) Approval application before the end of its fiscal year end on March 31, 2020
for its first product.
With
respect to PPHN, our novel LungFit™ is designed to deliver a dosage of NO to the lungs that is consistent with current guidelines
for delivery of 20 ppm NO with a range of 0.5 ppm – 80 ppm (low-concentration NO). We believe our Beyond Air LungFit™
has many competitive advantages over the current approved NO delivery systems in the U.S., European Union, Japan and other markets.
For example, our Beyond Air LungFit™ does not require the use of a high-pressure cylinder, utilizes less space than other
similar devices, does not require cumbersome purging procedures and places less burden on hospital staff in carrying out safety
procedures.
Our
novel LungFit™ can also deliver a high concentration of NO to the lungs, which we believe has the potential to eliminate
microbial infections, including bacteria, fungi and viruses, among other benefits. We believe current FDA approved NO vasodilation
treatments would have limited success in treating microbial infections given the low concentrations of NO being delivered. Given
that NO is produced naturally by the body as an innate immunity mechanism at a concentration of 200 ppm, supplemental high dose
NO should aid in the body’s fight against infection. Based on our clinical studies, we believe that 160 ppm is the minimum
therapeutic dose to achieve the desired pulmonary antimicrobial effect of NO. To date, neither the FDA nor equivalent regulatory
agencies in other countries or regions have approved any NO formulation and/or delivery system for the delivery of a dosage of
NO at 160 ppm or higher to the lungs.
To
date, we have not generated revenue from the sale of any product, and we do not expect to generate revenue unless and until we
obtain marketing approval of, and commercialize, our product candidates. As of September 30, 2019, we had an accumulated deficit
of $47,923,133. Our financing activities are described below under “Liquidity and Capital Resources.”
Critical
Accounting Policies
The
accounting policies followed in the preparation of our condensed consolidated financial statements appearing at the beginning
of this Quarterly Report on Form 10-Q are consistent in all material respects with those included in Note 2 of our Annual Report
on the Form 10-K for the year ended March 31, 2019. The unaudited condensed consolidated financial statements have been prepared
in accordance with generally accepted accounting principles in the United States (“US GAAP”) for interim financial
information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required
to be presented for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments
(consisting only of normal recurring items) which are, in the opinion of management, necessary for a fair presentation of the
results for the interim periods presented. The accompanying condensed consolidated Balance Sheet as of March 31, 2019 has been
derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended March
31, 2019. The condensed consolidated financial statements and related disclosures have been prepared with the assumption that
users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding
fiscal year. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements
and the related notes thereto included in the Annual Report on Form 10-K for the year ended March 31, 2019 which was filed with
the United States Securities and Exchange Commission, (“SEC”), on June 28, 2019.
Off-Balance
Sheet Arrangements
As
of September 30, 2019, we did not have any off-balance sheet arrangements as defined in the rules and regulations of the Securities
and Exchange Commission.
Contractual
Obligation
Please
refer to Note 12 in our Annual Report on Form 10-K for the year ended March 31, 2019 under the heading Commitments and Contingencies.
To our knowledge there have been no material changes to the risk factors that were previously disclosed in the Company’s
Annual Report on Form 10-K for the year ended March 31, 2019. Additional risks and uncertainties not currently known to us or
that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating
results.
Results
of Operations
Below
are the results of operations for the three months ended September 30, 2019 and September 30, 2018:
|
|
For
the Three Months
Ended September 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
License
revenues
|
|
$
|
645,602
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
(2,849,990
|
)
|
|
|
(647,866
|
)
|
General
and administrative
|
|
|
(2,064,872
|
)
|
|
|
(1,765,489
|
)
|
Total
operating expenses
|
|
|
(4,914,862
|
)
|
|
|
(2,413,355
|
)
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(4,269,260
|
)
|
|
|
(2,413,355
|
)
|
|
|
|
|
|
|
|
|
|
Other
income (loss)
|
|
|
|
|
|
|
|
|
Realized
and unrealized gain on marketable securities
|
|
|
142,806
|
|
|
|
2,805
|
|
Dividend
income
|
|
|
30,691
|
|
|
|
31,085
|
|
Foreign
exchange loss
|
|
|
(1,977
|
)
|
|
|
(4,167
|
)
|
Other
expenses
|
|
|
-
|
|
|
|
(5,587
|
)
|
Total
other income
|
|
|
171,520
|
|
|
|
24,136
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(4,097,740
|
)
|
|
$
|
(2,389,219
|
)
|
|
|
|
|
|
|
|
|
|
Net
loss per share – basic and diluted
|
|
$
|
(0.38
|
)
|
|
$
|
(0.28
|
)
|
|
|
|
|
|
|
|
|
|
Weighted
average number of common shares outstanding – basic and diluted
|
|
|
10,699,370
|
|
|
|
8,400,327
|
|
Comparison
of Three Months Ended September 30, 2019 with the Three Months Ended September 30, 2018
Revenue
License
revenue for the three months ended September 30, 2019 was $646,000 and $0 for the three months ended September 30, 2018.
On
January 23, 2019, the Company entered into an agreement for commercial rights (“the License Agreement”) with Circassia
Pharmaceuticals plc, (“Circassia”) (located in the United Kingdom) for PPHN and future related indications at concentrations
of < 80 ppm in the hospital setting in the United States and China. The Company may receive payments up to $32.55 million
in up front and regulatory milestones, of which $31.5 million is associated with the U.S. market. All such payments are payable
in cash or ordinary shares of Circassia Pharmaceuticals plc, at the discretion of Circassia Pharmaceuticals, Inc., with payments
in cash discounted by approximately 5%. During the three months ended March 31, 2019, the Company met the first two milestones
under the license agreement and received 17,572,815 ordinary shares valued at $9,987,295. This consideration was allocated to
two separate identified performance obligations, one being the non-exclusive transfer of the intellectual property to Circassia,
which was recognized at a point in time and was valued at $9,987,295, and the other being the ongoing support associated with
the PMA submission and regulatory approval by the FDA, which was initially valued at $2.9 million and recorded as deferred revenue
to be recognized over a period of time from the commencement of the agreement to when management expects to submit the PMA. During
the three months ended September 30, 2019, $646,000 of such deferred revenue associated with this second performance obligation
has been recognized with $1,881,000 being cumulatively recognized through September 30, 2019.
Research
and development expenses
Research
and development expenses for the three months ended September 30, 2019 was $2,845,000 as compared to $648,000 for the three
months ended September 30, 2018. The increase of $2,202,000 was primarily attributed to $931,000 of development of LungFit™
for PPHN and pre-clinical studies increase of $1,153,000 for other indications, an increase in salaries and benefits for new hires
and an increase of $157,000 in non-cash stock-based compensation.
General
and administrative expenses
General
and administrative expense for the three months ended September 30, 2019, was $2,065,000 as compared to the three months September
30, 2018 of $1,765,000. The difference of 300,000 was primarily attributed to an increase in professional fees of $218,000, an
increase of $65,000 in salary and benefits due to the hiring of employees, an increase of $95,000 in insurance, which was offset
by a decrease of $76,000 in non-cash stock-based compensation expense.
Comparison
of Six Months Ended September 30, 2019 with the Six Months Ended September 30, 2018
Below
are the results of operations for the six months ended September 30, 2019 and September 30, 2018:
|
|
For
the Six Months
Ended September 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
License
revenues
|
|
$
|
1,273,071
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
(5,173,503
|
)
|
|
|
(1,711,011
|
)
|
General
and administrative
|
|
|
(4,247,430
|
)
|
|
|
(2,458,494
|
)
|
Total
operating expenses
|
|
|
(9,420,933
|
)
|
|
|
(4,169,505
|
)
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(8,147,862
|
)
|
|
|
(4,169,505
|
)
|
|
|
|
|
|
|
|
|
|
Other
income (loss)
|
|
|
|
|
|
|
|
|
Realized
and unrealized (loss) gain on marketable securities
|
|
|
(2,164,513
|
)
|
|
|
8,208
|
|
Dividend
income
|
|
|
34,067
|
|
|
|
63,986
|
|
Foreign
exchange loss
|
|
|
(253
|
)
|
|
|
(966
|
)
|
Other
expenses
|
|
|
-
|
|
|
|
(9,289
|
)
|
Total
other income
|
|
|
(2,130,699
|
)
|
|
|
61,939
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(10,278,561
|
)
|
|
$
|
(4,115,774
|
)
|
|
|
|
|
|
|
|
|
|
Net
loss per share – basic and diluted
|
|
$
|
(1.03
|
)
|
|
$
|
(0.49
|
)
|
|
|
|
|
|
|
|
|
|
Weighted
average number of common shares outstanding – basic and diluted
|
|
|
9,935,444
|
|
|
|
8,420,281
|
|
Revenue
License
revenue for the six months ended September 30, 2019 was $1,273,000 and $0 for the six months ended September 30, 2018.
On
January 23, 2019, the Company entered into an agreement for commercial rights (“the License Agreement”) with Circassia
Pharmaceuticals plc, (“Circassia”) (located in the United Kingdom) for PPHN and future related indications at concentrations
of < 80 ppm in the hospital setting in the United States and China. The Company may receive payments up to $32.55 million
in up front and regulatory milestones, of which $31.5 million is associated with the U.S. market. All such payments are payable
in cash or ordinary shares of Circassia, at the discretion of Circassia Pharmaceuticals, Inc., with payments in cash discounted
by approximately 5%. During the three months ended March 31, 2019, the Company met the first two milestones under the license
agreement and received 17,572,815 ordinary shares valued at $9,987,295. This consideration was allocated to two separate identified
performance obligations, one being the non-exclusive transfer of the intellectual property to Circassia, which was recognized
at a point in time and was valued at $9,987,295, and the other being the ongoing support associated with the PMA submission and
regulatory approval by the FDA, which was initially valued at $2.9 million and recorded as deferred revenue to be recognized over
a period of time from the commencement of the agreement to when management expects to submit the PMA. During the six months ended
September 2019, $1,273,000 of such deferred revenue associated with this second performance obligation has been recognized with
$1,881,000 being cumulatively recognized through September 30, 2019.
Research
and development expenses
Research
and development expenses for the six months ended September 30, 2019 was $5,174,000 as compared to $1,711,000 for the six months
ended September 30, 2018. The increase of $3,463,000 was primarily attributed to $1,601,000 of development of the LungFit System
for PPHN and pre-clinical studies of $1,773,000 for other indications and an increase in stock-based compensation of $277,000.
General
and administrative expenses
General
and administrative expense for the six months ended September 30, 2019, was $4,247,000 as compared to the six months September
30, 2018 of 2,458,000. The difference of $1,789,000 was primarily attributed to an increase of $695,000 of non-cash stock-based
compensation expense, an increase in professional fees of $444,000, an increase of $227,000 in salary and benefits due to the
hiring of employees and an increase of insurance expense of $136,000.
Other
income (loss)
Other
loss for the six months ended September 30, 2019 was $2,131,000 and as compared to $62,000 for the six months ended September
30, 2018. Other loss for the six months ended September 30 2019 was primarily from realized and unrealized loss of marketable
securities of $2,165,000.
Cash
Flows
Below
is a summary of the Company’s cash flows activities for the six months ended September 30, 2019 and for the six months ended
September 30, 2018:
|
|
Six
Months Ended
|
|
|
|
September
30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Net
cash provided by (used in):
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
$
|
(5,633,362
|
)
|
|
$
|
(4,107,031
|
)
|
Investing
activities
|
|
|
(3,125,401
|
)
|
|
|
3,718,626
|
|
Financing
activities
|
|
|
9,756,249
|
|
|
|
(18,500
|
)
|
Net
increase (decrease) in cash, cash equivalents and restricted cash
|
|
$
|
997,506
|
|
|
$
|
(406,905
|
)
|
Operating
Activities
For
the six months ended September 30, 2019, the net cash used in operating activities was $5,633,000 which was primarily due to our
net loss of $10,279,000 and an increase in deferred revenue of $1,273,000 which was offset by an increase in realized and unrealized
loss in marketable securities of $2,165,000 and non-cash stock-based compensation expense of $1,836,000 and an increase in accounts
payable and accrued expenses of $1,440,000. For the six months ended September 30, 2018 net cash used in operating activities
was $4,107,000 which was primarily due to the net loss of $4,116,000 and an increase in accrued expenses of $895,000 which was
offset by an increase in non-cash stock-based compensation expense of $922,000.
Investing
Activities
For
the six months ended September 30, 2019 net cash used in investing activities was $3,125,000 and for the six months ended September
30, 2018 net cash provided by investing activities was $3,719,000. The primary use of cash for the six months September 30, 2019
was from the net investment of marketable securities of $3,108,000. The primary source of cash for the six months September 30,
2018 was from the net sale of marketable securities of $3,682,000.
Financing
Activities
Net
cash provided by financing activities for the six months ended September 30, 2019 was $9,757,000 and was primarily from the net
proceeds of a private placement of $7,839,000, and the issuance and sales of $1,982,000 of common stock to Lincoln Park Financial
Corporation (“LPC”). Net cash used by financing activities for the six months ended September 30, 2018 was $19,000
which was from the issuance and sale of common stock, net of offering cost to LPC.
Liquidity
and Capital Resources
Overview
We
have incurred losses and generated negative cash flows from operations since inception. To date, we have not generated any revenue
from the sale of products, and we do not expect to generate revenue from sale of our products in the next several years. Since
the time the Company became public through September 30, 2019, we have funded our operations principally through the issuance
of equity securities. As shown in the accompanying financial statements, the Company has used cash from operating activities of
$5.6 million for the six months ended September 30, 2019 and has accumulated losses of $47.9 million through September 30, 2019.
The Company has cash equivalent and marketable securities, excluding restricted cash of $9.4 million as of September 30, 2019.
Included in marketable securities is Circassia Pharmaceuticals plc of $1.9 million. Based upon the Company’s business plan
and expected burn utilization including proceeds from the sale of all its marketable securities, the Company estimates that it
will have enough cash to operate its business for at least one year from filing Beyond Air September 30, 2019 10-Q. Insufficient
funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs.
On
July 2, 2019, the SEC declared effective the Company’s Form S-3 shelf registration statement which allows the Company to
sell up to $100 million of equity securities.
In
addition, the Company has a $20 million purchase agreement (“Purchase Agreement”) and a registration rights agreement
with Lincoln Park Capital Fund, LLC (“LPC”), providing for the issuance of up to $20 million of the Company’s
common stock through August 2021 at the Company’s discretion. There is approximately $16,674,000 remaining on the Purchase
Agreement.
Our
ability to continue to operate is dependent upon the filing of our PMA, regulatory approval of the PMA, expected timing of the
Company’s launch of our product, obtaining partners in other parts of the world, timing of future milestones, royalties
and, raising additional funds to finance our activities. There are no assurances that we will be successful in obtaining an adequate
level of financing for the development and commercialization of our product candidates. The Company’s ability to continue
to operate is dependent upon raising additional funds to finance its activities.
There
are numerous risks and uncertainties associated with the development of our LungFit™ NO generator and delivery system, we
are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research
and development of our product candidate.
Our
future capital requirements will depend on many factors, including:
|
●
|
the
progress and costs of our preclinical studies, clinical trials and other research and development activities;
|
|
|
|
|
●
|
the
scope, prioritization and number of our clinical trials and other research and development programs;
|
|
|
|
|
●
|
the
costs and timing of obtaining regulatory approval for our product candidates;
|
|
|
|
|
●
|
the
costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
|
|
|
|
|
●
|
the
costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical quantities of our
product candidate;
|
|
●
|
the
potential costs of contracting with third parties to provide marketing and distribution services for us or for building such
capacities internally;
|
|
|
|
|
●
|
the
costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications
of our product candidate;
|
|
|
|
|
●
|
the
magnitude of our general and administrative expenses; and
|
|
|
|
|
●
|
any
cost that we may incur under current and future in-and out-licensing arrangements relating to our product candidate.
|
Foreign
Currency Exchange Risk
Our
results of operations and cash flow are subject to fluctuations due to changes in foreign currency exchange rates. Certain of
our expenses are denominated in New Israeli Shekels (“NIS”). Our results of operations and cash flow are, therefore,
subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes
in foreign exchange rates. We do not hedge our foreign currency exchange risk. In the future, we may enter into formal currency
hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating
currencies. These measures, however, may not adequately protect us from significant changes in such fluctuations.
We
have received Circassia Shares as payment, the price will be converted into US dollars for purposes of calculating our payment.
As a result, our payment will be exposed to currency exchange rate risk with respect to British Pounds. Our net payment will depend
on the extent to which British Pounds strengthens or weakens against the U.S. dollar and the relative weight of Circassia Shares
we receive as payment. If, taking into account such weighting, the U.S. dollar strengthens against British Pounds, the price of
Circassia Shares will be adversely affected and our payment may be reduced.
Financial
Operations Overview For The Year Ended March 31, 2019, the Three Months Ended March 31, 2018 And The Year Ended March 31, 2018
Critical
Accounting Estimates and Policies
We
describe our significant accounting policies more fully in Note 2 to our consolidated financial statements for the year ended
March 31, 2019, three months ended March 31, 2018 and for the year ended December 31, 2017.
Stock-Based
Compensation
The
Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date
fair value of the award. Fair value for restricted stock awards is valued using the closing price of the Company’s stock
on the date of grant. That cost is recognized over the period during which an employee is required to provide service in exchange
for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes
option pricing model adjusted for the unique characteristics of those instruments. The risk-free interest rate assumptions were
based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield
was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends
in the foreseeable future. The Company does not have enough history to establish volatility based upon its own stock trading.
Therefore, the expected volatility was based upon similar publicly traded peer companies. The Company routinely reviews its calculation
of volatility changes in future volatility, the Company’s life cycle, its peer group, and other factors. The Company uses
the simplified method for share-based compensation to estimate the expected term Compensation expense for options and warrants
granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments
issued, whichever is more reliably measured, and is recognized over the service period. The expense was previously adjusted to
fair value at the end of each reporting period until such awards vested, and the fair value of such instruments, as adjusted,
is expensed over the related vesting period. Adjustments to fair value at each reporting date resulted in income or expense, depending
upon the estimate of fair value and the amount of expense recorded prior to the adjustment. In June 2018, the FASB issued ASU
No. 2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting, which amends the existing accounting
standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee
awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the
grant date.
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those
estimates. The Company’s significant estimates are accrual of expenses under consulting and licensing agreements, stock-based
compensation, and warrant liabilities valuation assumptions used in revenue recognition, and the determination of deferred tax
attributes and the valuation of allowance thereon.
Licensing
Right to Use Technology
Licensing
right to use technology is an intangible asset resulting from the NitricGen transaction. The intangible asset was valued based
upon the fair value of the options issued to NitricGen and the cash paid for this transaction. The Company reversed a prior period
expense of $200,000 and recorded a licensing right to use asset related to acquired technology. This adjustment was due to the
Company’s re-assessment of the acquired technology and the conclusion that it has alternative future use. The license contains
two milestone payments aggregating $1,800,000.
Impairment
of Long-Lived Assets
The
Company assess the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate
that the carrying value may not be recoverable. The Company’s impairment review process is based upon an estimate of future
undiscounted cash flow. Factors we consider that could trigger an impairment review include the following:
●
|
significant
underperformance relative to expected historical or projected future operating results,
|
|
|
●
|
significant
changes in the manner of our use of the acquired assets or the strategy for our overall business,
|
|
|
●
|
significant
negative industry or economic trends, and
|
|
|
●
|
significant
technological changes, which would render equipment and manufacturing processes obsolete.
|
Recoverability
of assets that will continue to be used in our operations is measured by comparing the carrying value to the future net undiscounted
cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues,
driven by market growth rates, and estimated future costs.
Revenue
Recognition
During
the year ended March 31, 2019, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts
with Customers (Topic 606) (“Topic 606”) using the modified retrospective method which consisted of applying and recognizing
the cumulative effect of Topic 606 at the date of initial application. Topic 606 supersedes the revenue recognition requirements
in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition (“Topic 605”). There was no
impact on adoption to the Company’s consolidated financial statements related to the adoption of ASC 606 since there was
no historical revenue at such time.
We
recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which
we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers
we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s)
in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in
the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess
the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those
that are performance obligations.
The
Company must use significant judgment to determine: a) the number of performance obligations based on the determination under
step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b)
the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified
in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones
or other variable consideration, except for royalties, should be included in the transaction price. The transaction price is allocated
to each performance obligation on an estimated stand-alone selling price basis, for which the Company recognizes revenue as or
when the performance obligations under the contract are satisfied.
Where
a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under
the terms of a license arrangement, they are recorded as contract liabilities or deferred revenue and recognized as revenue when
(or as) the underlying performance obligation is satisfied.
Income
Taxes
The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change
is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established
when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to
realize the benefit, or that future deductibility is uncertain. As of March 31, 2019, and March 31, 2018, the Company recorded
a valuation allowance to the full extent of our net deferred tax assets since the likelihood of realization of the benefit does
not meet the more likely than not threshold.
The
Company files a U.S. Federal, various state, and International income tax returns. Uncertain tax positions are reviewed on an
ongoing basis and are adjusted in light of changing facts and circumstances. Such adjustment is reflected in the tax provision
when appropriate. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in income
taxes in the statements of operations and comprehensive loss. The Company has recorded a liability in accrued expenses of $154,300
for certain tax position as of March 31, 2019 and 2018. Tax returns that are open for examination for the Company is since 2015
for AIT is from 2013 to 2017.
Investment
in Marketable Securities
Investments
in marketable securities classified available for sale are carried at fair value with the changes in unrealized gains and losses
recognized in the Company’s results in income or (loss). Realized gains and (loss) from the sale of marketable securities
are recognized in the statement of operations. using the specific identification method on a trade date basis. Additionally,
we assess our marketable equity securities for potential other-than-temporary impairment. The Company employ a methodology that
considers available evidence in evaluating potential other-than-temporary impairment of our marketable equity securities classified
as available-for-sale. If the cost of an investment exceeds its fair value, we evaluate, among other factors, the magnitude and
duration of the decline in fair value. We also evaluate the financial health of and business outlook for the issuer, the performance
of the underlying assets for interests in securitized assets, and, for securities classified as available-for-sale, our intent
and ability to hold the investment.
Derivative
Instrument Liabilities
The
Company had measured the warrants that had down round protection at fair value in each reporting period until they are exercised
or expired, with changes in the fair value being recognized in the Company’s statements of loss and comprehensive loss.
During the fiscal third quarter of 2018, the Company adopted ASU 2017-11 retrospectively to outstanding financial instruments
with a down round feature by means of cumulative-effect adjustment. The balance as of April 1, 2018 for additional paid-in capital
was increased by $6,194,292 and accumulated deficit was decreased by $516,358 and therefore are classified in stockholders’
equity.
Commitment
and Contingencies
On
October 22, 2013, The Company entered into a patent license agreement with a third party, pursuant to which Beyond Air agreed
to pay to the third party a non-refundable upfront fee of $150,000 and is obligated to pay 5% royalties of any licensed product
revenues, but at least $50,000 per annum through the term of the agreement and the advance is credited against future royalties
payments. As of March 31, 2019, the Company did not pay any royalties since the Company did not have any revenues from this license.
The term of the agreement extends through the life of applicable patents and may be terminated by either party with 60 days’
prior written notice in the event of a breach of the agreement, and may be terminated unilaterally by CareFusion with 30 days’
prior written notice in the event that we do not meet certain milestones.
In
August 2015, Beyond Air entered into an Option Agreement (the “Option Agreement”) with a third party whereby Beyond
Air acquired the Option to purchase certain intellectual property assets and rights (the “Option”) on September 7,
2016 for $25,000. On January 13, 2017 we exercised the Option and paid $500,000. Upon exercise of the Option, we became obligated
to make certain one-time development and sales milestone payments to Pulmonox, commencing with the date on which we receive regulatory
approval for the commercial sale of the first product candidate qualifying under the agreement. These milestone payments are almost
entirely sales related and are capped at a total of $87 million across three separate and distinct indications that fall under
the agreement with the majority of them, approximately $83 million, being sales related based on cumulative sales milestones for
each of the three products. Beyond Air exercised the Option in January 2017. Beyond Air issued to the third party a warrant (the
“Third Party Warrant”) to purchase up to 178,570 ordinary shares of Beyond Air at an exercise price of $4.80 for each
share. This warrant was exchanged for a warrant to acquire the same number of shares of the Company’s common stock upon
consummation of the merger. The shares exchange was at 1:1 ratio. The Company recorded stock-based compensation expense of $479,700
to research and development based upon the fair value using the Black-Scholes option pricing model. On May 10, 2018, the Company
issued to the third-party additional warrants to purchase up to 29,763 shares of the Company at an exercise price of $4.80 per
share for each share of common stock. The Company recorded stock-based compensation expense of $55,900 to research and development
based upon the fair value using the Black-Scholes option pricing model. The warrants expire in January 2024.
On
January 31, 2018 the Company entered into an agreement (“Agreement”) with NitricGen, Inc. (“NitricGen”)
and acquired a global, exclusive, transferable license and associated assets including intellectual property, know-how, trade
secrets and confidential information from NitricGen related to NO delivery systems (“Delivery System”). The Company
acquired the licensing right to use the technology and agreed to pay NitricGen a total of $2,000,000 in future payments based
upon achieving certain milestones, as defined in the Agreement, and royalties on sales of the Delivery System. The Company paid
NitricGen $100,000 upon the execution agreement, $100,000 upon achieving the next milestone and has an obligation to issue 100,000
options to purchase the Company’s stock upon executing the agreement. The remaining future milestone payments is $1,800,000
of which $1,500,000 in six months after the first approval of the eNOGenorator by the FDA or EMEA. The term of the options
is five year and has an exercise price of $6.90 per share. On June 19, 2019, the 100,000 options to purchase common stock were
issued. The Company recorded stock-based compensation of $295,000 which was the fair market value of the options Black-Scholes
option pricing model. The Company used a volatility rate of 79.9%, risk-free interest rate of 2.5%, an expected term of five years
and a dividend rate of 0%. The Company recorded the milestone payments and the fair market value of the options as a licensing
right to use the technology which is an intangible asset, aggregating $495,000. The Company reversed a prior period expense of
$200,000 and recorded a licensing right to use asset related to acquired technology. This adjustment was due to the Company’s
re-assessment of the acquired technology and the conclusion that it has alternative future use.
On
March 16, 2018, Empery Asset Master, Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (collectively, “Empery”),
filed a complaint in the Supreme Court of the State of New York, relating to the notice of adjustment of both the exercise price
of and the number of warrant shares issuable under warrants issued to Empery in January 2017. The Empery Suit alleges that, as
a result of certain circumstances in connection with the February 2018 Offering, the January 2017 Warrants issued to Empery provide
for adjustments to both the exercise price of the warrants and the number of warrant shares issuable upon such exercise. Empery
seeks monetary damages and declaratory relief under theories of breach of contract or contract reformation predicated on mutual
mistake. The Company intends to vigorously defend all claims. Given the early stage of the litigation, it is not possible to determine
or assess the probability of any particular outcome. The Company believes they met the contractual requirements of the contract
and properly adjusted the applicable warrants in accordance with the protection features.
Results
of Operations
We
have changed our fiscal year end from December 31 to March 31 effective for our fiscal year 2018. Accordingly, we have reported
our results for the year ended March 31, 2019, for the three months ended March 31, 2018 and for the year ended December 31, 2017.
To
facilitate comparisons to our Management’s Discussion and Analysis, we have presented similar audited and unaudited periods,
including the audited results for the year ended March 31, 2019 as compared to the unaudited results for the year ended March
31, 2018. The following discussion should be read in conjunction with the Selected Historical Consolidated Financial Data presented
above, our Consolidated Financial Statements, the notes to those statements and other financial information appearing elsewhere
in this Form 10-K.
Comparison
of the year ended March 31, 2019 to the year ended March 31, 2018
|
|
Year
Ended
March 31, 2019
|
|
|
Year
Ended
March 31, 2018
|
|
|
|
|
|
|
(Unaudited)
|
|
License
revenue
|
|
$
|
7,724,001
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
(3,929,558
|
)
|
|
|
(4,636,287
|
)
|
General
and administrative
|
|
|
(6,852,988
|
)
|
|
|
(5,306,884
|
)
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(3,058,545
|
)
|
|
|
(9,943,171
|
)
|
|
|
|
|
|
|
|
|
|
Other
income (loss)
|
|
|
|
|
|
|
|
|
Change
in fair value of warrant liabilities
|
|
|
-
|
|
|
|
(794,093
|
)
|
Unrealized
loss on available for sale marketable securities
|
|
|
(3,581,193
|
)
|
|
|
-
|
|
Dividend
income
|
|
|
85,242
|
|
|
|
-
|
|
Imputed
interest income with respect to loans from related parties and others and loans from bank
|
|
|
|
|
|
|
3,495
|
|
Foreign
exchange (loss) gain
|
|
|
(920
|
)
|
|
|
21,524
|
|
Other
(expenses) income
|
|
|
(3,034
|
)
|
|
|
(3,610
|
)
|
Total
other loss
|
|
|
(3,499,905
|
)
|
|
|
(772,684
|
)
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(6,558,450
|
)
|
|
$
|
(10,715,855
|
)
|
|
|
|
|
|
|
|
|
|
Net
loss per share – basic and diluted
|
|
$
|
(0.77
|
)
|
|
$
|
(1.68
|
)
|
|
|
|
|
|
|
|
|
|
Weighted
average number of common shares outstanding – basic and diluted
|
|
|
8,498,525
|
|
|
|
6,391,218
|
|
License
Revenue
License
revenue for the year ended March 31, 2019 was $7,724,001 and $0 for the year ended March 31, 2018.
On
January 23, 2019, the Company entered into an agreement for commercial rights (“the License Agreement”) with Circassia
Pharmaceuticals plc, (“Circassia”) (located in the United Kingdom) for PPHN and future related indications at concentrations
of < 80 ppm in the hospital setting in the United States and China. The Company may receive payments up to $32.5 million
in up front and regulatory milestones, of which $31.5 million is associated with the U.S. market. All such payments are payable
in cash or ordinary shares of Circassia Pharmaceuticals plc, at the discretion of Circassia Pharmaceuticals, Inc., with payments
in cash discounted by approximately 5%. During the fourth quarter 2019, the Company met the first two milestones under the license
agreement and received 17,572,815 ordinary shares valued at $9,987,295. This consideration was allocated to two separate identified
performance obligations, one being the transfer of the intellectual property to Circassia, which was recognized at a point in
time and was valued at $9,987,295, and the other being the ongoing support associated with the PMA submission and regulatory approval
by the FDA, which was valued at $2,263,394 and recorded as deferred revenue to be recognized over a period of time from the commencement
of the agreement to when management expects to submit the PMA. Through March 31, 2019, $607,769 of such deferred revenue associated
with this second performance obligation has been recognized.
Research
and Development
Research
and development for the year ended March 31, 2019 was $3,929,558, as compared to $4,636,287 for the year ended March 31, 2018.
The decrease of $706,729 was primarily attributed to clinical trial expenses for the year ended March 31, 2018 of $1,370,481,
offset by an increase in non-cash stock-based compensation expense of $405,946 and $313,557 for the development of NO Generator
and Delivery System. The Company reversed a prior period expense of $200,000 and recorded a licensing right to use asset related
to acquired technology. This adjustment was due to the Company’s re-assessment of the acquired technology and the conclusion
that it has alternative future use.
General
and Administrative Expenses
General
and administrative expense for the year ended March 31, 2019 was $6,852,988, as compared to $5,312,884 for the year ended March
31, 2018. The increase of $1,540,104 was primarily attributed to increases in salaries and benefits of $641,957 and professional
fees of $990,083 for the for the year ended March 31, 2019 as compared to the year ended March 31, 2018. This was due to the hiring
of additional employees and professional fees related to the Circassia agreement and filing and maintenance of patents. This was
offset by a decrease in non-cash stock-based compensation of $510,810 for the year ended March 31, 2019. In August 2018 and November
2018, the Board of Directors granted to the Directors and Officers, 810,000 options to purchase common stock. Non-cash stock-based
compensation for the year ended March 31, 2019 was $1,977,403, of which $1,476,524 related to aforementioned August 2018 and November
2018 option grants.
Other
Income (Loss)
Other
loss for the year ended March 31, 2019 was $3,499,905, as compared to $772,684 for the year ended March 31, 2018. For the year
ended March 31, 2019, $3,581,193 was primarily from for the unrealized loss on available for sale securities and realized loss
on related to Circassia Pharmaceuticals plc stock. For the year ended March 31, 2018, a non-cash expense of $794,093 was due to
the change in fair market value of the warrant liabilities.
Net
Loss
As
a result of the foregoing, our net loss for the year ended March 31, 2019, was $6,558,450 or $0.77 per share, basic and diluted,
as compared to a net loss for the year ended March 31, 2018 was $10,715,855 or 1.68 per share, basic and diluted.
Liquidity
and Capital Resources
Overview
We
have incurred losses and generated negative cash flows from operations since inception. To date, we have not generated any revenue
from the sale of products, and we do not expect to generate revenue from sale of our products in the next several years. Since
the time the Company became public through March 31, 2019, we have funded our operations principally through the issuance of equity
securities. As shown in the accompanying financial statements, the Company has incurred cash provided from operating cash flows
of $1,341,052 for the year March 31, 2019 and has accumulated losses of $37,644,572 since inception through March 31, 2019. The
Company has cash equivalent and marketable securities of $7,899,804 as of March 31, 2019. Included in marketable securities is
Circassia Pharmaceuticals plc of $5,649,486, see (Note 9) to the consolidated financial statements and notes thereto. This stock
has declined in value $3,733,437 for the year ended March 31, 2019. Based upon the Company’s business plan assumption and
expected cash burn rate, including net proceeds received through June 26, 2019, from common stock sales discussed below, and excluding
any proceeds from the sale of Circassia stock, the Company estimates that it has enough cash to operate its business into the
third calendar quarter of 2020. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our
development programs.
In
August 2018, the Company entered into a Stock Purchase Agreement with Lincoln Park Corporation for $20 million. The Company may
sell and issue LPC and LPC is obligated to purchase up to $20 million in value of shares of common stock from time to time over
three years. The Company may direct LPC, at its sole discretion, and subject to certain conditions, to purchase up to 10,000 to
30,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase.
The amount of a purchase may be increased under certain circumstances provided, however that LPC cannot make any single purchase
that exceeds $750,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing
market prices of such shares at the time of sales as described in the Stock Purchase Agreement. From the execution of the Purchase
Agreement on August 10, 2018 to March 31 2019, the Company issued and sold to LPC 297,000 shares of common stock at an average
price of $4.53 per shares for gross of $1,344,185 and incurred offering costs of $545,000 that was charged to additional paid
in capital. Net proceeds for these transactions were $799,185. Subsequent to March 31, 2019, through May 23, 2019, the Company
issued and sold to LPC 250,000 shares of common stock for proceeds of $1,173,810 at an average price of $4.70 per share. There
is $17,482,005 remaining under the Purchase Agreement
On
January 23, 2019, the Company entered into an agreement for commercial rights (“the License Agreement”) with Circassia
(located in the United Kingdom) for persistent pulmonary hypertension of the newborn (PPHN) and future related indications at
concentrations of < 80 ppm in the hospital setting in the United States and China. The Company may receive payments
up to $32.5 million in up front and regulatory milestones, of which $31.5 million is associated with the U.S. market. The Company
met the first two milestones which resulted in the payment of $10.5 million in Circassia’s ordinary shares. The ordinary
share price was predetermined as subject to a volume weighted average price that was defined in the Licensing Agreement. The Company
will receive future royalties from 15-20% based upon gross profit, which is defined in the License Agreement. We received 17,572,815
ordinary shares of ordinary shares of Circassia stock and as of March 31, 2018, the Company had 16,267,815 shares. The Company
incurred an unrealized and realized loss of $3,733,437 and $82,310 respectively, resulting from the decline in the market value
of Circassia ordinary shares through March 31, 2019. The fair market value of the Circassia ordinary shares was discounted by
approximately 4.8% based upon management’s assessment of a variety of factors including the estimated time the Company plans
on selling these shares, its trading volume, the arm’s length negotiations if such shares were paid in cash by Circassia
and if a large block of shares were sold at one time.
On
June 3, 2019, the Company entered into subscription agreements with several accredited investors for the sale of an aggregate
of 1,583,743 shares of common stock at a $5.00 per share and $5.15 per share to employees, directors and officers. The Company
raised gross proceeds of $7,960,635 The Offering closed on June 3, 2019. The Offering was made directly by the Company without
an underwriter or placement agent.
Our
ability to continue to operate is dependent upon the filing of our PMA, expected timing of the Company’s launch of our product,
obtaining Partners in other parts of the world, timing of future milestones and royalties, raising additional funds to finance
our activities. There are no assurances that we will be successful in obtaining an adequate level of financing for the development
and commercialization of our product candidates. The Company’s ability to continue to operate is dependent upon raising
additional funds to finance its activities.
There
are numerous risks and uncertainties associated with the development of our NO delivery system, we are unable to estimate the
amounts of increased capital outlays and operating expenses associated with completing the research and development of our product
candidate.
Our
future capital requirements will depend on many factors, including:
|
●
|
the
progress and costs of our preclinical studies, clinical trials and other research and development activities;
|
|
|
|
|
●
|
the
scope, prioritization and number of our clinical trials and other research and development programs;
|
|
|
|
|
●
|
the
costs and timing of obtaining regulatory approval for our product candidates;
|
|
|
|
|
●
|
the
costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
|
|
|
|
|
●
|
the
costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical quantities of our
product candidate;
|
|
|
|
|
●
|
the
potential costs of contracting with third parties to provide marketing and distribution services for us or for building such
capacities internally;
|
|
|
|
|
●
|
the
costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications
of our product candidate;
|
|
|
|
|
●
|
the
magnitude of our general and administrative expenses; and
|
|
|
|
|
●
|
any
cost that we may incur under current and future in-and out-licensing arrangements relating to our product candidate.
|
Cash
Flows
For
the Year Ended March 31, 2019 as compared to the Year Ended March 31, 2018 is as follows:
|
|
For
The Year Ended
March 31, 2019
|
|
|
For
The Year Ended
March 31, 2018
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
Net
cash provided by (used in):
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
$
|
1,341,052
|
|
|
$
|
(8,692,450
|
)
|
Investing
activities
|
|
$
|
(1,793,639
|
)
|
|
$
|
(8,523,987
|
)
|
Financing
activities
|
|
$
|
1,071,490
|
|
|
$
|
10,813,767
|
|
Net
increase (decrease) in cash, cash equivalents and restricted stock
|
|
$
|
618,903
|
|
|
$
|
(6,402,670
|
)
|
Operating
Activities
For
the year ended March 31, 2019, the net cash provided by operating activities was $1,341,052 which was primarily due to our net
loss of $6,558,440, a decrease in prepaid expenses of $729,159 and was offset by an increase in unrealized loss in available for
sale securities of $3,498,883, deferred revenue of 2,263,494, accrued expenses of $322,633,contingent liability of $250,000 and
non-cash stock-based compensation expense of $2,399,321. For the year ended March 31, 2018, net cash used in operating activities
$8,692,450 was primarily due to the net loss of $10,715,855, which was offset by a non-cash expense for the change in fair value
of derivative liabilities of $793,956 and non-cash stock-based compensation expense of $574,395.
Investing
Activities
For
the year ended March 31, 2019, cash used in investing activities was $1,793,639 which was from the net purchases of available
for sale marketable securities of $1,737,164 and $56,475 purchase of property and equipment. For the year ended March 31, 2018,
the Company used in activities $8,523,987 which was from the net purchases of available for sales marketable of $8,304,092 and
$219,595 of property and equipment.
Financing
Activities
For
the year ended March 31, 2019, net cash provided by financing activities was $1,071,490 which was primarily from the net proceeds
of $799,156 from the sale of stock to Lincoln Park Financial Corporation and a bank loan of $292,250. For the year ended March
31, 2018, net cash provided by financing activities was $10,813,767 which was from the sale of common stock and warrants.
Contractual
Obligations
The
following tables sets forth our contractual obligations for the next five years and thereafter for the year ended March 31:
|
|
2020
|
|
|
2021
|
|
|
2022
|
|
|
2023
|
|
|
2024
|
|
|
2025
|
|
|
Total
|
|
Rent
|
|
$
|
129,100
|
|
|
$
|
90,100
|
|
|
$
|
65,400
|
|
|
$
|
64,700
|
|
|
$
|
16,300
|
|
|
$
|
-
|
|
|
$
|
365,600
|
|
Note
|
|
|
263,604
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
263,604
|
|
Total
|
|
$
|
392,704
|
|
|
$
|
90,100
|
|
|
$
|
65,400
|
|
|
$
|
64,700
|
|
|
$
|
16,300
|
|
|
$
|
-
|
|
|
$
|
629,204
|
|
Off-Balance
Sheet Arrangements
We
currently do not have any off-balance sheet arrangements.
Quantitative
and Qualitative Disclosure about Market Risk
We
are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our
financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result
of foreign currency exchange rates.
Foreign
Currency Exchange Risk
Our
results of operations and cash flow are subject to fluctuations due to changes in foreign currency exchange rates. Certain of
our expenses are denominated in New Israeli Shekels (“NIS”). Our results of operations and cash flow are, therefore,
subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes
in foreign exchange rates. We do not hedge our foreign currency exchange risk. In the future, we may enter into formal currency
hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating
currencies. These measures, however, may not adequately protect us from significant changes in such fluctuations.
We
have received Circassia Shares as payment, the price will be converted into US dollars for purposes of calculating our payment.
As a result, our payment will be exposed to currency exchange rate risk with respect to British Pounds. Our net payment will depend
on the extent to which British Pounds strengthens or weakens against the U.S. dollar and the relative weight of Circassia Shares
we receive as payment. If, taking into account such weighting, the U.S. dollar strengthens against British Pounds, the price of
Circassia Shares will be adversely affected and our payment may be reduced.
BUSINESS
History
Beyond
Air, Inc. (“Beyond Air” or the “Company”) was incorporated on April 24, 2015 as KokiCare, Inc. under the
laws of the State of Delaware. On January 9, 2017, the name of the Company was changed to AIT Therapeutics, Inc. On June 25, 2019,
the Company filed an Amendment to its Certificate of Incorporation to change its name from AIT Therapeutics, Inc. to Beyond Air,
Inc., effective June 26, 2019.
Advanced
Inhalation Therapies Ltd. (“AIT Ltd.”) was incorporated in Israel on May 1, 2011 and commenced its operations in May
2012 and is a wholly-owned subsidiary of the Company. On August 29, 2014, AIT Ltd. established a wholly-owned subsidiary, Advanced
Inhalation Therapies Inc., a Delaware corporation. Effective July 4, 2019, AIT Ltd. changed its name to Beyond Air Ltd.
Overview
We
are an emerging medical device and biopharmaceutical company developing a nitric oxide (“NO”) generator and delivery
system (the “LungFit™ system”) that is capable of generating NO
from ambient air. LungFit™ can generate NO up to 400 parts per million (“ppm”)
for delivery to a patient’s lungs. LungFit™ can deliver NO either continuously
or for a fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain a constant
dose. We believe that LungFit™ can be used to treat patients on ventilators
that require NO, as well as patients with chronic lung disease or acute severe lung infections via delivery through a breathing
mask or similar apparatus. Furthermore, we believe that there is a high unmet medical need for patients suffering from certain
severe lung infections that LungFit™ can potentially address. Our current areas
of focus are persistent pulmonary hypertension of the newborn (“PPHN”), bronchiolitis (“BRO”) and nontuberculous
mycobacteria (“NTM”). Our current product candidates will be subject to premarket reviews and approvals by
the U.S. Food and Drug Administration, or the FDA, as well as similar regulatory agencies in other countries or regions. If approved,
our system will be marketed as a medical device in the U.S.
With
respect to PPHN, our novel LungFit™ is designed to deliver a dosage of NO to
the lungs that is consistent with current guidelines for delivery of 20 ppm NO with a range of 0.5 ppm – 80 ppm (low-concentration
NO). We believe LungFit™ has many competitive advantages over the current approved
NO delivery systems in the U.S., European Union, Japan and other markets. For example, LungFit™
does not require the use of a high-pressure cylinder, utilizes less space than other similar devices, does not require
cumbersome purging procedures and places less burden on hospital staff in carrying out safety procedures.
Our
novel LungFit™ can also deliver a high concentration of NO to the lungs, which
we believe has the potential to eliminate microbial infections, including bacteria, fungi and viruses, among other benefits. We
believe current FDA-approved NO vasodilation treatments would have limited success in treating microbial infections given the
low concentrations of NO being delivered. Given that NO is produced naturally by the body as an innate immunity mechanism at a
concentration of 200 ppm, supplemental high dose NO should aid in the body’s fight against infection. Based on our clinical
studies, we believe that 160 ppm is the minimum therapeutic dose to achieve the desired pulmonary antimicrobial effect of NO.
To date, neither the FDA nor equivalent regulatory agencies in other countries or regions have approved any NO formulation and/or
delivery system for the delivery of a dosage of NO at 160 ppm or higher to the lungs.
To
date, we have conducted the following studies:
Study
|
|
Indication
|
|
Primary
|
|
|
Results
|
Phase
1 Safety (n=10)
|
|
All
comers
|
|
Safety
|
|
●
|
No
SAEs
|
|
|
|
|
|
|
|
|
Phase
2 double blind randomized
(n=43)
|
|
Bronchiolitis
(all
causes)
|
|
Safety
&
Efficacy
|
|
●
●
|
No
SAEs
24
hour reduction in hospital length of stay
|
|
|
|
|
|
|
|
|
Pilot
open label (n=9)
|
|
Cystic
Fibrosis (CF)
|
|
Safe
& Eff
|
|
●
|
No
SAEs; Lowered bacterial load
|
|
|
|
|
|
|
|
|
Compassionate
use ISR (n=2)
|
|
NTM
abscessus
(CF)
|
|
Safe
& Eff
|
|
●
|
No
SAEs; clinical & surrogate endpoints improved
|
|
|
|
|
|
|
|
|
Compassionate
use National
Institute
of Health, US (n=1)
|
|
NTM
abscessus
(CF)
|
|
Safe
& Eff
|
|
●
|
No
SAEs; Improvements in clinical endpoints
|
|
|
|
|
|
|
|
|
Pilot
open label (N=9)
|
|
NTM
abscessus
|
|
Safe
& Eff
|
|
●
|
No
SAEs; clinical & surrogate endpoints improved
|
|
|
|
|
|
|
|
|
Pilot
study: double blind
randomized
(n=67)
|
|
Bronchiolitis
(all
causes)
|
|
Safe
& Eff
|
|
●
|
No
SAEs; 23hr reduction in hospital length of stay
|
|
|
|
|
|
|
|
|
Compassionate
use ISR (n=1)
|
|
NTM
abscessus
(CF)
|
|
Safety
|
|
●
|
No
SAEs at 250 ppm NO
dose
|
Our
active pipeline of product candidates is shown in the table below:
Product
|
|
Indication
|
|
Development
Status
|
|
Further
Information
|
The
LungFit™ PH
(Pulmonary
Hypertension)
|
|
In-Hospital
Use
|
|
Commercial
system in development
|
|
Regulatory
filings expected
first
quarter of 2020.
Commercial
launch in the U.S. and Israel expected in 2020.
|
|
|
|
|
|
|
|
The
LungFit™ -BRO
(Bronchiolitis)
|
|
Bronchiolitis
Infants
(elderly
patients to follow)
|
|
Randomized
67 patient study completed
|
|
Next
study to be completed Spring 2020.
Commercial
launch expected in 2022.
|
|
|
|
|
|
|
|
The
LungFit™ -NTM
(Nontuberculous
Mycobacteria)
|
|
Mycobacterium
Abscessus Complex
(MABSC)
|
|
9
patient pilot study dosing complete
|
|
Preparations
ongoing for At-Home self-administered study to begin in 2020.
Commercial
launch expected in 2024.
|
|
|
|
|
|
|
|
The
LungFit™ PA
(Pseudomonas
Aeruginosa)
|
|
Pseudomonas
Aeruginosa
|
|
In
vitro testing ongoing
|
|
Pilot
study anticipated in 2021.*
|
|
|
|
|
|
|
|
The
LungFit™ COPD
(Chronic
Obstructive Pulmonary Disease)
|
|
Exacerbation
caused by any type of infection
|
|
In
vitro testing expected to begin first half of 2020*
|
|
Proof
of concept initiation anticipated in 2021.*
|
*Subject
to our obtaining additional funding.
We
plan to submit for premarket approval or (“PMA”) to the FDA late in the first quarter of 2020 for the use of the LungFit™
in PPHN. We also expect to make certain regulatory filings outside of the U.S. first half of 2020. According to the 2018
yearend report from Mallinckrodt Pharmaceuticals, aggregate sales of low concentration NO in the U.S. were in excess of $500 million
in 2018, while sales outside of the U.S., where there are multiple market participants, sales were considerably lower than in
the U.S. We believe the U.S. sales potential of LungFit™ in PPHN to be greater
than $300 million and worldwide sales potential to be greater than $600 million. If regulatory approval is obtained, we anticipate
a product launch in both the U.S. and Israel in 2020 and will continue to launch globally throughout 2021 and beyond.
With
respect to bronchiolitis, we initiated a trial for infants hospitalized due to bronchiolitis in the fourth quarter of 2019. The
trial will last approximately 6 months after initiation. We anticipate data for this study to be available during the first half
of 2020. If the trial is successful, we would perform another study over the 2020/21 winter in the United States and then submit
a PMA to the FDA about 6 months after trial completion. Regulatory filings outside of the U.S., as long as no additional trials
are required, would begin after our review process is completed in the U.S. For this indication, we believe U.S. sales potential
to be greater than $500 million and worldwide sales potential to be greater than $1.2 billion.
Our
nontuberculous mycobacteria (NTM) program has produced data from four compassionate use subjects and nine patients from a multi-center
pilot study completed in 2018. All patients suffered from NTM abscessus infection and had underlying cystic fibrosis. One
compassion patient was treated with our nitric oxide generator at the National Heart, Lung and Blood Institute (“NHLBI”).
The rest were treated with our NO cylinder-based delivery system. All patients were treated with 160 ppm NO at intermittent 30-minute
dosing over 21 days, except one patient who was treated over 26 days and another patient who was treated with 250 ppm NO over
28 days. We expect to begin a study by the middle of 2020 where patients will self-administer high concentration NO at home over
a period of 12 weeks with LungFit™. We anticipate preliminary data for this
study will be available during the second half of 2020 and that a full dataset will be available in the first half of 2021. If
the trial is successful, we would commence a pivotal study towards the end of 2021. For this indication, we believe U.S. sales
potential to be greater than $1 billion and worldwide sales potential to be greater than $2.5 billion.
Our
programs in pseudomonas aeruginosa and chronic obstructive pulmonary disease are both in the pre-clinical stage are will remain
there subject to our obtaining additional financing.
For
our high concentration platform, as mentioned above, the initial target is lower respiratory tract infections (“LRTI”).
Our initial two target indications are infants hospitalized due to bronchiolitis (mainly caused by respiratory syncytial virus
“RSV”) and patients suffering from NTM and other severe, chronic, refractory lung infections. There are over 1.5 million
hospitalizations related to LRTI annually in the U.S., and LRTI is the third leading cause of death worldwide.
NTM
lung infection is a rare and serious pulmonary disease associated with increased morbidity and mortality. There is an increasing
rate of lung disease caused by NTM, which is an emerging public health concern worldwide. There are approximately 50,000 patients
diagnosed with NTM in the U.S., and there are an estimated additional 100,000 patients in the U.S. that have not yet been diagnosed.
In Asia, the number of patients suffering from NTM surpasses what is seen in the U.S. To date we have treated only the abscessus
form of NTM which comprises approximately 20-25% of all NTM. We will be treating both the abscessus and mycobacterium avium
complex (MAC) forms of NTM.
Patients
with NTM lung disease may experience a multitude of symptoms such as fever, weight loss, cough, lack of appetite, night sweats,
blood in the sputum and fatigue. Patients with NTM lung disease, specifically abscessus and other forms of NTM that are
refractory to antibiotic therapy, frequently require lengthy and repeated hospital stays to manage their condition. There
are no treatments specifically indicated for the treatment of NTM abscessus lung disease in North America, Europe or Japan.
There is one inhaled antibiotic approved in the U.S. for the treatment of refractory NTM MAC. Current guideline-based approaches
to treat NTM lung disease involve multi-drug regimens of anti-biotics that may cause severe, long lasting side effects, and treatment
can be as long as 18 months or more. Median survival for NTM MAC patients is approximately 13 years while median survival for
patients with other variations of NTM is typically 4.6 years. The prevalence of human disease attributable to NTM has increased
over the past two decades. In a study conducted between 1997 and 2007, researchers found that the prevalence of NTM in the U.S.
is increasing at approximately 8% per year and that NTM patients on Medicare over the age of 65 are 40% more likely to die over
the period of the study than those who did not have the disease (Adjemian et al., 2012). NTM abscessus treatment costs
are estimated to be more than double that of NTM MAC. In total, a 2015 publication from co-authors from several U.S. government
departments stated that prior year statistics led to a projected 181,037 national annual cases in 2014 costing the U.S. healthcare
system approximately $1.7 billion (Strollo et al., 2015).
Over
3 million new cases of bronchiolitis are reported worldwide each year. In the U.S., there are more than 125,000 annual bronchiolitis
hospitalizations among children two years of age or younger and approximately 177,000 annual hospitalizations among the elderly
population related to viral infections similar to those that cause bronchiolitis in very young children.
Currently,
there is no approved treatment for bronchiolitis. The treatment for acute viral lung infections that cause bronchiolitis in infants
is largely supportive care and is based primarily on prolonged hospitalization during which the infant receives a constant flow
of oxygen to treat hypoxemia, a reduced concentration of oxygen in the blood. In addition, systemic steroids and inhalation with
bronchodilators are sometimes utilized until recovery, but we believe these treatments do not successfully reduce hospital length
of stay.
We
believe, based on the currently understood mechanisms of action of NO, that our LungFit™
can deliver NO at 150 ppm and higher to potentially eliminate bacteria, viruses, fungi and other microbes from the lungs
and may also be effective against antibiotic-resistant bacteria. Because our product candidates are not antibiotics, we believe
there is a reduced risk of the development of resistant bacteria and there could be synergy with co-administration of antibiotics.
In
addition, our LungFit™ can deliver NO at concentrations of 0.5 – 80 ppm
consistent with currently approved NO delivery systems for the treatment of PPHN while providing significant advantages associated
with the elimination of the use of high-pressure cylinders.
We
have a global, exclusive, perpetual license agreement with NitricGen, Inc. for the eNOGenerator and all associated
patents and know how related thereto. Additionally, we have a broad intellectual property portfolio directed to our product candidates
and mode of delivery, monitoring parameters and methods of treating specific disease indications. Our intellectual property portfolio
consists of issued patents and pending applications, which includes patents we acquired pursuant to the exercise of an option
in 2017 granted to us by Pulmonox Technologies Corporation.
Recent Events
On
May 7, 2019, the Company’s common stock commenced trading on the Nasdaq Capital Market under the symbol “AITB”.
The changed its ticker symbol to “XAIR” effective July 15, 2019.
On
June 3, 2019, the Company entered into agreements with investors for the issuance of 1,394,997 shares of common stock at $5.00
per share and the issuance of 188,746 shares of common stock to insiders at $5.15 per share.
On
December 10, 2019, the Company entered into an underwriting agreement with SunTrust Robinson Humphrey, Inc. as representative
of the several underwriters named therein, relating to the issuance and sale of 2,325,000 shares of common stock. The price to
the public in the offering was $3.66 per share, and the underwriters agreed to purchase the shares from the Company pursuant to
the underwriting agreement at a price of $3.4038 per share. The underwriters had a 30-day option to purchase up to an additional
348,750 shares of common stock, which option was partially exercised on December 12, 2019 for 295,199 shares. The offering, including
the issuance and sale of shares pursuant to the underwriters’ partial exercise of their option to purchase additional shares,
closed on December 12, 2019.
Also
on December 10, 2019, the Company and certain existing U.S. and foreign investors entered into common stock purchase agreements
for the issue and sale of an aggregate of 532,786 unregistered shares of common stock at $3.66 per share. The concurrent private
placement closed on December 12, 2019. The Underwriters served as placement agents and received a placement agent fee equal to
a percentage of the total purchase price of the private placement shares, which percentage was equal to the percentage discount
the underwriters received on shares sold in the public offering.
On
December 18, 2019, the Company terminated the License, Development and Commercialization Agreement (the “Agreement”)
with Circassia Limited (“Circassia”) entered into on January 23, 2019 pursuant to which the Company had granted Circassia
an exclusive royalty-bearing license to distribute, market and sell the Company’s nitric oxide generator and delivery system
in the United States and China. As previously described in the Company’s Form 8-K filed with the Securities and Exchange
Commission on January 29, 2019, Circassia had agreed to pay the Company certain milestone and royalty payments, with the remaining
milestone and royalty payments payable in cash or ordinary shares of Circassia at Circassia’s option. The Company terminated
the Agreement pursuant to section 13.3(b) of the Agreement, termination by either party for material breach or default. The Company
is evaluating other options for the commercialization of its generator and delivery system. In connection the termination of the
license with Circassia, we may be subject to a variety of claims. Adverse outcomes in some or all of these claims may adversely
affect our ability to conduct our business.
Background
and Mechanism of Action
NO
is recognized as a vital molecule involved in many physiological and pathological processes. NO is naturally produced by the body’s
immune system to provide a first line of defense against invading pathogens. It is a powerful molecule with a short half-life
of a few seconds in the blood, enabling it to be cleared rapidly from the body. NO has been shown to play a critical role in the
function of several body systems. For example, as vasodilator of smooth muscles, NO enhances blood flow and circulation. In addition,
NO is involved in regulation of a wound healing and immune responses to infection. The pharmacology, toxicity and other data for
NO in humans is generally well known, and its use has been approved by the FDA as a vasodilator. The precise effect of inhaled
NO is dependent on concentration, oxidation state and type of pathogen.
NO
has multiple immunoregulatory and antimicrobial functions that are likely to be of relevance to inhaled NO therapy. In vitro
studies suggest that NO possesses anti-microbial activity against common bacteria, gram positive and gram negative, as well
as mycobacteria, fungi, yeast, parasites and helminthes. It has the potential to eliminate multi-drug resistant strains of the
above. Anti-viral activity covers respiratory viruses such as influenza, corona viruses, RSV and others. In healthy humans, NO
has been shown to stimulate mucocilary clearance, and low levels of nasal NO correlate with impaired mucociliary function in the
human upper airway. Unlike other inhaled drugs, NO is also a smooth muscle relaxant and avoids the concomitant bronchial constriction
often associated with inhaled antibiotics and mucolytics. In addition to treating CF infections, this suggests that NO may be
useful in directly treating the mucus caused by CF, which is the principal manifestation of the disease.
Nitric
Oxide and Infection
NO
possesses broad-spectrum anti-microbial activity acting against bacteria, fungi and viruses. NO is produced at high output as
part of the innate immune response. NO and its by-products (for example, reactive nitrogen species, or RNS) are responsible for
the process of killing microorganisms within white blood cells called macrophages and in organs such as the lungs and other mucolytic
tissues.
More
than a decade ago, several research groups showed that NO and RNS possess anti-viral activity and affect several viruses including
coxsackievirus, or CVB, RSV, influenza, severe acute respiratory syndrome, or SARS, coronavirus, rhinovirus, herpes simplex virus,
or HSV, Epstein-Barr virus, or EBV, and others. NO has also been shown to be useful in preventing bacterial growth on surfaces.
Continuous
exposure to 160 ppm NO and above, especially in the lungs, may have side effects and cause damage to host cells. Intermittent
exposure to NO in cycles retains NO anti-microbial activity both in vitro and in animal model of infection. Exposure of bacteria
to concomitant 30-minute treatments with 160 ppm NO resulted in a significant reduction in bacterial load. A similar dose has
been shown to reduce viruses (common influenza) by 30-100% in a canine kidney infection model. In vivo, in a pneumonia model in
rats, inhaled 160 ppm NO, for 30 minutes, every 4 hours, resulted in significant reduction in bacteria counts in the lungs, without
affecting the body’s defense mechanisms, and without any other adverse effect. In addition, we believe a daily dose of 160
ppm of NO can treat bovine respiratory disease (“BRD”) in cattle.
Importantly,
several studies report synergy between NO and antibiotic drugs. Adjunctive treatment combining NO together with inhaled tobramycin
antibiotics or other anti-microbial agents has been shown to greatly enhance the efficacy of the antibiotics in dispersing P.
aeruginosa biofilms and to increase their ability to elicit anti-microbial activity. These studies suggest that adjuvant treatment
combining NO with antibiotics might have a beneficial role by reducing bacterial infectivity, and therefore reduce the dependency
on antibiotics.
Beyond
Air Technology
We
have developed the LungFit™ system, a novel and precise delivery system that uses NO generated from ambient air with a novel
NO generator. We believe our system provides continuous monitoring and control of the gaseous content administered during intermittent
and continuous NO inhalation treatments, as well as a precise and reliable monitoring system that is able to monitor patient status
and alert medical staff to any adverse effects.
Our
innovative novel LungFit™ system is designed to provide patients with a gaseous dose of NO (ranging from 0.5 ppm up to 400
ppm) combined with ambient air. The gaseous blend is supplied to the patient via a ventilator for concentrations up to 80 ppm
and a face mask, or similar apparatus, for concentrations of above 80 ppm. Our LungFit™ system is designed to minimize the
time that NO is mixed with oxygen and air. The system is also designed to continuously monitor inhaled NO concentration, NO2
concentration, methemoglobin and the fraction of inspired oxygen, or FiO2, blood oxygen saturation and heart
rate, all of which are important parameters. A dedicated screen allows for monitoring of the gas mixture and the patient’s
vital signs. Further, our product candidates resemble other inhalation systems, making it user friendly, with operation and maintenance
that we believe will be familiar to medical staff. Our novel delivery system for use with a mask has been manufactured at commercial
scale with a contract manufacturer.
Our
novel LungFit™, when programmed for lung infections, is designed to specifically
deliver a NO dosage of 160 ppm and higher, and we believe that it has a number of advantages over other NO formulation delivery
systems. For example, it is:
|
●
|
optimized
to deliver 160 ppm and higher of NO, whereas existing formulations of NO currently on the market consist of a maximum deliverable
NO concentration of 80 ppm;
|
|
|
|
|
●
|
equipped
with a monitoring system that continuously monitors system parameters (e.g., NO, NO2 and FiO2 concentrations)
as well as patient parameters (e.g. vital signs, MetHemoglobin and OxyHemoglobin percentages);
|
|
|
|
|
●
|
capable
of providing constant flow of our NO formulation, which we believe allows it to adequately cover the surface area of the lung
to eliminate bacteria, viruses, fungi and other microbes;
|
|
|
|
|
●
|
programmable
and able to deliver different dosage regimens for a wide range of lung infections;
|
|
|
|
|
●
|
able
to generate NO from ambient air, eliminating the need for the use of high-pressure cylinders;
|
|
●
|
designed
to be used by the patient, thus convenient and portable; and
|
|
|
|
|
●
|
administered
non-invasively through a facial mask, which has the potential to address large, underserved chronic-care markets, such as
CF and chronic obstructive pulmonary disease (COPD).
|
We
believe that our solution has the potential for a number of additional benefits and opportunities, as follows:
●
The antimicrobial and multiple other properties of the NO molecule delivered to the lungs suggest the potential for application
in a wide range of respiratory diseases. In contrast to the often arduous and slow drug discovery process for small molecules,
proteins, peptides, etc., the use of NO in medicine is well-known, and therefore the identification of conditions where NO provides
benefits has been, and we expect will continue to be, much simpler, quicker and less costly.
●
The FDA approved the use of NO as an inhaled drug for the treatment of Fnary hypertension in newborns in 1999. More than 18 years
of clinical experience in the delivery, monitoring and understanding of NO in the clinical environment for vascular uses has been
documented.
●
NO is naturally produced by the immune system and acts as a first line of defense against infectious diseases. We believe therapeutic
use of NO for viral and bacterial co-infections would potentially improve the success of antimicrobial and anti-viral treatments
by mimicking the body’s natural defense mechanism and thereby directly reduce viral infectivity, as well as antibiotic drug
resistant bacteria.
●
NO is used naturally by the body for vasodilation and we believe that the benefits to patients with various medical conditions
will be seen via vasodilation when delivered with our system.
NitricGen
License
On
January 31, 2018, we announced that we entered into a definitive agreement to acquire a global, exclusive, perpetual, transferable
license to the eNOGenerator and associated critical assets including intellectual property, know-how, trade secrets and confidential
information (the “License”) from NitricGen. The eNOGenerator is a novel and precise delivery system that uses NO generated
from ambient air with a novel NO generator.
The
LungFit™ system, which incorporates the eNOGenerator, has been designated as a medical device by the U.S. Food and Drug
Administration. The eNOGenerator can generate NO on demand for delivery to the lungs at concentrations ranging from 0.5 to 400
ppm. With the License, we expect that we will be able to target all conditions requiring NO at any concentration, regardless of
the need for intermittent or continuous dosing.
Under
the terms of the License, we agree to pay NitricGen an aggregate of $2 million in up-front, clinical, and regulatory milestone
payments, with the majority pertaining to regulatory milestones, as well as royalties on net sales of the delivery system containing
the eNOGenerator at a percentage in the low-single digits. As partial consideration for the License, we issued to
NitricGen options to purchase 100,000 shares of our common stock at an exercise price of $6.90 per share. To date, $200,000 was
paid for milestone that were earned.
Strategies
Our
objective is to build a leading medical device company that will develop and commercialize patented and proprietary products for
the treatment of respiratory infections and diseases, with an initial focus on the treatment of PPHN, bronchiolitis, severe lung
infections such as NTM, chronic obstructive pulmonary disease, or COPD, and CF. If our clinical trials for our product candidates
are successful, we expect to seek marketing approval from the FDA and other worldwide regulatory bodies.
Our
completed clinical trials and plans for future clinical trials are as follows:
●
We licensed Phase 1 study results in healthy volunteers from University of British Columbia Hospital, or UBC. Results showed safe
delivery of 160 ppm NO to the lung.
●
Bronchiolitis. We completed a double blind, randomized, placebo controlled pilot study conducted in Israel in infants with
bronchiolitis. We completed a second Israeli-based clinical trial in the second quarter of 2018 which serves as another pilot
study. We expect to gather further supportive data in Israel in 2019/20 and we intend to submit an Investigational Device Exemption
(“IDE”) to the FDA in 2020 and expect to commence a pivotal clinical trial in 2020 in the United States which will
complete in 2021.
●
NTM. Four patients with CF who suffer from NTM infections (specifically, M. Abscessus) have been treated under compassionate
use, comprising two patients at the Rambam healthcare campus in Israel, one at Soroka Medical Center in Israel and one patient
in the United States, treated with our Beyond Air NO GDS, at the National Heart, Lung and Blood Institute (NHLBI). A pilot study
of nine CF patients infected with NTM Abscessus in Israel were treated with our LungFit™ system using cylinder gas was completed
in the fourth quarter of 2017. In addition, we intend to perform all tasked needed, based on discussion with the FDA in 2018,
to begin an at-home self-administration study. We expect that the study will use our generator based NO delivery system and treat
patients infected with NTM and other severe, refractory lung infections with and without CF. Endpoints are expected to include
physical function, bacterial load, forced expiratory volume in one second (FEV1), quality of life and safety. The study is anticipated
to commence in 2020.
●
CF-Related Lung Infections. We completed a pilot open label, multi-center study in Israel of CF patients who are over 10
years old. Results showed a reduction in bacterial load in multiple infections.
Our
Initial Disease Targets and Market Opportunity
Our
initial targets are PPHN, infants suffering from bronchiolitis and patients infected by NTM.
PPHN
is a condition at birth that requires mechanical ventilation. NO is added as a vasodilator to improve oxygenation and reduce the
need for ventilation in neonates with hypoxic respiratory failure. The use of NO in the hospital setting had associated net sales
of greater than $500m in 2018 in the United States alone according to published reports.
According
to the World Health Organization, bronchiolitis is the most common acute lower respiratory infection in infants, and is the leading
cause of the hospitalization of infants during the first year of life. Bronchiolitis is an acute inflammatory injury of the bronchioles
that is usually caused by viruses, most commonly by RSV. While bronchiolitis may affect persons of any age, severe symptoms are
usually evident only in young infants. The initial symptoms of bronchiolitis are similar to that of a common cold, but the illness
sometimes leads to fast and troubled breathing due to spread of the infection to the lower respiratory system. To date, the standard
treatment has been supportive care consisting of assisted feeding and hydration, minimal handling, nasal suctioning and oxygen
administration. In addition, better airway cleaning, which improves the respiratory function, has been achieved using nebulized
hypertonic saline. We believe that many pharmacological therapies, ranging from bronchodilators to corticosteroids, have been
found to offer either no or short-term benefits.
Each
year, according to the World Health Organization, over 3 million new cases of bronchiolitis are reported worldwide in infants.
In the U.S., there are greater than 150,000 annual bronchiolitis hospitalizations among children younger than five years, of which
greater than 125,000 hospitalizations are among children younger than two years old. These hospital visits resulted in total hospital
charges of $1.7 billion in 2009 according to a study published in 2013. For infants, bronchiolitis accounts for 20% of annual
hospitalizations and 18% of emergency department visits.
Clinical
practice in the management of acute bronchiolitis varies widely even among medical centers in the same country, and there is much
controversy, confusion and lack of evidence concerning the best treatment option. Disease management mainly consists of supportive
care by means of oxygen supplementation, but also includes inhalations of hypertonic saline or steroids with or without beta agonist
drugs, anti-viral therapy and chest physiotherapy.
We
believe that none of the specified treatments has been proven to have a positive outcome on the course of the disease or a reduction
in the length of hospitalization. In addition, some treatment strategies have been subject to debate regarding whether they work.
For example, the anti-viral drug, Ribavirin, a broad-spectrum antiviral agent approved for treatment of RSV infections, is controversial
due to questions regarding its high cost and uncertain treatment effect.
NTM
infection of the lungs is a chronic, as well as progressive lung condition. NTM exhibits across a variety of lung diseases such
as bronchiectasis, COPD, Asthma, CF and Cancer. In certain severe NTM cases, life expectancy is under five years, for which we
believe there are no successful treatments available.
There
are an estimated 50,000-86,000 cases of NTM lung infections in the U.S. with an annual 8% increase. More than 70% of NTM cases
are underreported, and therefore the projected number of NTM cases could be as high as 181,000 in the U.S. alone. With the rise
of NTM infections, NTM is currently more prevalent than tuberculosis in the U.S. NTM mostly affects adults middle-aged to elderly,
with increasing infection in patients aged 65 and over, a population that is expected to double by the year 2030.
NTM
lung infections also pose a substantial financial burden on the U.S. healthcare system. In 2010, the annual cost was over $800
million, and the same study estimated the cost for 2014 to be $1.7 billion in the U.S.
There
are no approved products in the U.S. and Europe to treat NTM abscessus infections, but there is one product approved for
refractory NTM MAC infections.
For
NTM patients, prolonged treatment is necessary and varies among different types of NTM species, severity of the disease and drug-susceptibility.
As NTM are typically antibiotic-resistant, treatment requires a combination of two, three or more different drugs. Therefore,
current treatment includes a mixture of IV antibiotics as well as steroids.
Our
Clinical Results to Date
We
have conducted several clinical trials to assess our >150 ppm NO inhalation-treatment in various indications. These
trials include:
A
prospective, open label, controlled, single-center Phase 1 study was conducted on ten healthy adults between 20 and 62 years of
age. Subjects received our proprietary 160 ppm NO formulation for 30 minutes, five times a day, for five consecutive days by direct
inhalation to the lungs via a prototype delivery system
The
primary objective of the study was to determine the effect of the inhaled NO formulation treatment, to determine the effect of
the treatment based on pulmonary function test results, to determine the met hemoglobin (MetHb - a form of hemoglobin that cannot
bind oxygen, a bi-product of NO and hemoglobin) level associated with the inhaled NO formulation treatment and to assess adverse
events associated with the treatment. Secondary objectives of the study were to assess the changes in cytokine levels. NO and
NO2 concentrations (a gaseous substance that is a bi-product of NO and O2, that can be toxic at high concentrations),
inhaled fraction of inspired oxygen (FiO2), as well as. MetHb and oxygen saturation (SaO2) were continuously monitored,
as elevation of MetHb or reduction in SaO2 levels may be harmful. Vital signs, lung function, blood chemistry (including
nitrite/nitrates), hematology, prothrombin time, inflammatory cytokine/chemokines levels and endothelial activation (angiopoietin
ratio) were also closely monitored.
All
individuals tolerated the NO formulation treatment courses well. No significant adverse events occurred. The maximal amount of
air one can forcefully exhale in one second, known as forced expiratory volume in one second (“FEV1”) and other lung
function parameters, serum nitrites/nitrates, prothrombin, pro-inflammatory cytokine and chemokine levels did not differ between
baseline and day five, while MetHb increased during the study period to a level of 0.9%, as expected. These data suggest that
inhalation of 160 ppm NO for 30 minutes, five times a day, for five consecutive days is well tolerated in healthy individuals.
Rambam
healthcare campus in Israel conducted a compassionate use treatment for two patients with CF who suffer from NTM Abscessus
infections. The data were published in the Pediatric Infectious Disease Journal in 2017. The NO treatment regime, as well
as the device for this treatment, was supplied by AIT Ltd. Patients received intermittent 30-minute treatments of 160 ppm NO,
with two different regimes including hospitalization (5 times a day) and ambulatory treatment (2-3 inhalations a day).
Treatment
was well tolerated with no evidence of any serious side effects. We observed significant improvement in sputum production (up
to 5-10 time more sputum), and subjective improvement in the well-being of both patients.
Significant
reduction in systemic inflammation was observed in the first patient, as observed by reduction of CRP (C-reactive protein, a systemic
inflammation marker that rises in response to inflammation) levels during treatment. In addition, the first patient had a 2 log
(100-fold) reduction in NTM Abscessus during treatment (an effect that was lost after the treatment regime changed to ambulatory).
The second patient showed a significant increase in the 6-minute walk test and the sputum culture became negative, which is consistent
with eradication of the NTM Abscessus.
Further
information is needed, but we believe these results suggest that the treatment of NTM Abcsessus with high dose inhaled NO is effective.
Further,
one patient with CF who suffers from NTM infections (specifically, M. abscessus) has been treated under compassionate use
in the United Sates at the National Heart, Lung and Blood Institute with our generator based NO delivery system. The patient saw
improvements in 6-minute walk, FEV1, most Quality of Life measures and had no SAEs. The bacteria was not eradicated. The patient
requested to be treated again and this treatment was commenced in February 2018. A total of 38 treatments were administered over
8 days, 29 of them at a concentration of 240 ppm, with no SAEs believed to be related to NO reported.
An
additional CF patient infected with M. abscessus was treated over a 4 week period with 76 of 84 treatments at 250 ppm NO
in Israel at Soroka Medical Center. The patient saw improvements in 6-minute walk, FEV1 and most Quality of Life measures. The
bacteria was not eradicated. Importantly, there were no SAE’s reported and all treatments were completed without incident.
We
have completed a Phase 2 open label, multi-center study in nine CF patients (≥10 years old). Patients received intermittent
(30 minutes, three times a day) inhalation of 160 ppm NO formulation, five days a week, over a two-week period. The study was
performed in two centers, Soroka Medical Center and Schneider Children’s Medical Center of Israel.
The
primary endpoints of the study were to determine the MetHb percentage, adverse events associated with inhaled NO and the percentage
of subjects who prematurely discontinued the study due to adverse events, or AEs, and/or SAEs, or for any other reason.
AEs
were reported by five (55.5%) subjects. There were no SAEs or AEs, no treatment withdrawals due to AEs, and no deaths. AEs considered
by the investigator as possibly or probably related to treatment were reported for two (22.2%) subjects. There were no AEs of
MetHb elevation >5% or NO 2 elevation >5 ppm (study safety threshold of MetHb and NO 2, respectively).
In total, seven cases of haemoptysis were reported in two subjects and all events were mild in severity.
There
were no subjects with MetHb >5% at any point during the study and there was no cumulative effect of MetHb exposure during the
study. The maximum MetHb level reported was 4.6%.
Several
secondary efficacy analyses were conducted in this study, and though the study was not powered for efficacy, results show various
positive effects of the treatment regime. Bacterial and fungal sputum load analysis results were highly variable, though marked
reductions of MSSA, Achromabacter, P. aeruginosa, and Asperigillus were seen in several subjects. These results suggest non-specific
targeting of bacteria and fungi that commonly manifest in CF patients. In subjects with systemic inflammation (CRP >5 mg/mL)
at baseline, CRP levels decreased over the treatment period, showing the effect of NO in the reduction of systemic inflammation.
There were no statistically significant or clinically relevant changes in FEV1 over time, and lung function indices also remained
relatively constant throughout the study duration.
We
completed a double blind, randomized Pilot study for infants with bronchiolitis for which the data were published in the Pediatric
Pulmonology Journal in 2017. The study was performed at Soroka University Medical Center in Israel. Forty-three infants between
the ages of two to 12 months diagnosed with bronchiolitis were randomly assigned to either the treatment group or the control
group. The treatment group comprised 21 subjects who received intermittent (30 minutes, five times a day) inhalation of 160 ppm
NO formulation, in addition to supportive O2 treatment for up to five days. The control group, 22 subjects, received
ongoing inhalation of the supportive O2 treatment.
Primary
endpoints included determination of the MetHb levels, adverse events associated with the inhaled NO formulation and proportion
of subjects who prematurely discontinued the study. Baseline clinical score, indicating disease severity at screening, was similar
between treatment groups (~8).
Results
were encouraging, with similar overall incidence of AEs between the treatment groups. Out of 43 patients, 39 (~90%) completed
the study per protocol (“PP”), with similar percentages (90%) for both the control and the treatment groups, individually.
Only one subject from the treatment group discontinued treatment due to an adverse event, namely – repeated MetHb levels
above 5%. Adverse events were reported by 23 (53.5%) subjects overall, with ten (47.6%) subjects in the NO group reporting a total
of 22 AEs, and 13 (59.1%) subjects in the control group reporting a total of 22 AEs. Serious adverse events were reported by four
(19.0%) subjects in the NO group and four (18.2%) in the standard treatment group. There were no deaths during the study. There
were no treatment-related SAEs in the NO treatment group.
In
the NO group, six (28.6%) subjects had any MetHb measurement >5% during the study treatment period, and three of these subjects
had more than one MetHb >5%. The maximum MetHb level was 5.6% in one subject in the NO group. There was no cumulative effect
of MetHb exposure during the study. It should be noted that MetHb levels in this study were defined to <5% as a safety measure,
though previous findings have shown that higher levels (6.4%) are non-toxic in children.
Secondary
and exploratory analyses were performed, and results show positive impact of the treatment regime. In a subgroup of subjects that
stayed at the hospital at least 24 hours (Length of Stay (“LOS”) >24 hours), a statistically significant treatment
benefit of NO versus standard treatment was demonstrated. Mean results for subjects with LOS > 24 hours show that LOS was shortened
by approximately 34% in the NO group compared to the standard treatment group, with a one-day difference between the groups (PP,
N=24). Time to normal oxygenation ((SaO2 of 92%) was shortened by approximately 44% (27.75 hours) in the NO group compared to
the standard treatment group (PP, N=24). An 80% improvement in time to clinical score (indicating improvement in disease severity)
and time to normal oxygenation (92%) was observed in favor of the NO group (PP, N=24).The results of preclinical studies and early
clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies.
Furthermore,
the FDA or other regulatory agencies may not concur with our assessment of safety and efficacy. Product candidates that have shown
promising results in early-stage clinical studies may still suffer significant setbacks in subsequent advanced clinical studies.
We do not know whether any Phase 2, Phase 3 or other clinical studies we may conduct will demonstrate consistent or adequate efficacy
and safety sufficient to obtain regulatory approval to market our product candidates. While we believe the results of our Phase
2 trials in bronchiolitis and CF demonstrated improvements in various endpoints and clinical outcomes, the trials were small,
and it is likely that the FDA will view them as not statistically or clinically significant because of their size and scope. We
must conduct larger clinical trials with statistically significant favorable results or we will not be able to obtain regulatory
approval to market our product candidates.
We
have completed a single-arm, open-label Pilot trial in nine patients with MABSC, who were refractory to standard-of-care. The
patients were treated with inhaled NO at a concentration of 160 ppm for 30 minutes, in addition to treatment with standard-of-care.
Our inhaled NO treatment was administered intermittently five times per day over a 14-day period, followed by a seven-day period
with three treatments per day. The primary endpoint of safety, as measured by NO-related SAEs, over the 21-day treatment period
was met with no SAEs reported. Secondary endpoints of a 6-minute walk test, FEV1, Quality of Life and Mycobacterium abscessus
load in sputum all trended positively. 6MW showed an increase of >40 meters at the end of treatment at day 21 versus baseline
and an increase of >25 meters on day 81 (60 days after the cessation of therapy). The mean percentage change in FEV1 at day
21 and day 51 (30 days after the cessation of treatment) was > 3.5% with FEV1 returning to baseline at day 81 (60 days after
the cessation of therapy). At day 81 (60 days after the cessation of therapy) bacterial load was 65% lower than baseline. 1 of
9 patients saw culture conversion. This study was published in the Journal of Cystic Fibrosis in 2019.
We
have completed a second pilot study in bronchiolitis in 6 centers in Israel. The prospective, randomized, double-blind, controlled
pilot study enroll 67 patients, aged 0-12 months, who were hospitalized due to bronchiolitis. The patients received either standard-of-care
(typically oxygen and hydration) or standard-of-care plus inhaled NO at a concentration of 160 ppm for 30 minutes 5 times per
day for up to 5 days. The primary endpoint of hospital length-of-stay (LOS) was met with a 23 hour reduction in hospital length
of stay demonstrated (p=0.085). Secondary endpoints of time required to achieve a clinical score of 5 or less on the modified
Tal score and time required to achieve oxygen saturation (SaO2) of 92% or greater showed improvement versus the standard-of-care.
There were no issues with NO2 or metHb and no SAEs were recorded.
We
plan to seek regulatory approval for our current product candidates and, if approved, we expect they will be marketed as medical
devices.
If
we reach the commercialization stage, we expect that we will collaborate with companies outside the U.S. for all indications and
inside the U.S. for PPHN, specifically. We are still determining whether to attempt to collaborate for bronchiolitis and/or NTM
in the U.S.
The
medical device, biotechnology and pharmaceutical industries are highly competitive. There are many medical device companies, pharmaceutical
companies, biotechnology companies, public and private universities and research organizations actively engaged in the research
and development of products that may be similar to our products. We are aware of several companies currently developing and/or
selling NO therapies for various indications such as PPHN. For example, Mallinckrodt commercializes INOMAX® (nitric oxide)
for inhalation, which is approved for use to treat newborns suffering from HRF-PPHN, in the U.S., Canada, Australia, Mexico and
Japan. Praxair markets the NOxBOX cylinder based system in the US. The Linde Group has marketing rights to INOMAX® in Europe.
Air Liquide sells a similar product in Europe, called VasoKINOX™, together with their delivery platform called OptiKINOX™,
for the treatment of pulmonary hypertension that occurs during or after heart surgery. In Europe, Praxair has a delivery system
called NOxBOX® and Air Products PLC has a gas product called NOXAP®, each used in delivering inhaled NO formulations.
Bellepheron Therapeutics is developing NO-based products for persistent arterial hypertension and pulmonary hypertension associated
with chronic obstructive pulmonary disease. Geno LLC is developing NO-based products for the treatment of a variety of pulmonary
and cardiac diseases such as acute vasoreactivity testing, pulmonary arterial hypertension and pulmonary hypertension associated
with idiopathic pulmonary fibrosis. In addition, other companies may be developing generic NO formulation delivery systems for
various dosages. Ceretec, Inc., a company affiliated with 12th Man Technologies Inc., recently obtained clearance from the FDA
to market a NO gas product for use in membrane diffusing capacity testing in pulmonary function laboratories in the U.S. Novoteris,
LLC previously received orphan drug designation from the FDA and EMA for the use of inhaled NO-based treatments in treating CF.
In January 2015, Mallinckrodt entered into an agreement with Novoteris to collaborate on the development of an outpatient program
for treating bacterial infections associated with CF.
Our
competitors, either alone or through their strategic partners, might have substantially greater name recognition and financial,
technical, manufacturing, marketing and human resources than we do and greater experience and infrastructure in the research and
clinical development of pharmaceutical products, obtaining FDA and other regulatory approvals of those products and commercializing
those products around the world.
We
have contracted with a third-party contract manufacturer, Sparton Corporation, who has completed a substantial portion of the
commercial manufacturing process for our generator based NO delivery system. We will be reliant on our partner for commercial
manufacture of our systems for both clinical studies and commercial supply, if regulatory approval is received.
We
own or have exclusively licensed patents, pending patent applications, know how and trade secrets that relate to our NO generator,
NO2 filtration, delivery systems, devices configured for delivering NO to patients by inhalation, methods of exposing patients
to inhalation of NO, and methods for treating subjects in need of NO inhalation.
In
particular, we are party to a global, exclusive, transferable license agreement with NitricGen, Inc. for the eNOGenerator ,
its components, and all associated patents and know how related thereto. Additionally, we have a broad intellectual property portfolio
directed to our product candidates and mode of delivery, monitoring parameters and methods of treating specific disease indications.
Our intellectual property portfolio consists of issued patents and pending applications, which includes patents we acquired pursuant
to the exercise of an option in 2017 granted to us by Pulmonox Technologies Corporation (“Pulmonox”).
CareFusion
Non-Exclusive License Agreement. In October 2013, we entered into a non-exclusive worldwide license agreement with CareFusion,
whereby we licensed seven issued U.S. patents and corresponding foreign counterparts. Our intellectual property licensed from
CareFusion, for which the earliest expiring patent term is 2019 and the last to expire is 2025. The term of the agreement extends
through the life of the patents and may be terminated by either party with 60 days’ prior written notice in the event of
a breach of the agreement, and may be terminated unilaterally by CareFusion with 30 days’ prior written notice in the event
that we do not meet certain milestones. Pursuant to the agreement, we are required to pay CareFusion royalty payments of 5% of
the net sales of a licensed product by the Company and an annual fee of $50,000, which is creditable against the royalty payments
for the respective year.
Pulmonox
Patents and Assets - Option to Acquire. On August 31, 2015, we entered into an agreement with Pulmonox whereby we acquired
the option, referred to as the Option, to purchase certain intellectual property assets, including Pulmonox’s rights in
17 issued U.S. patents, including eight patents jointly owned with CareFusion which are directed to:
|
●
|
devices
and methods for delivering NO formulations to a patient at steady and alternating concentrations (80-400 ppm), including intermittent
delivery of NO;
|
|
|
|
|
●
|
a
device and methods for treatment of surface infections; and
|
|
|
|
|
●
|
use
of NO as a mucolytic agent and for treatment and disinfection of biofilms.
|
We
exercised the Option in January 2017, acquired Pulmonox’s rights in the patents described above. Upon exercise of the Option,
we became obligated to make certain one-time development and sales milestone payments to Pulmonox, commencing with the date on
which we receive regulatory approval for the commercial sale of the first product candidate qualifying under the agreement. These
milestone payments are almost entirely sales related and are capped at a total of $87 million across three separate and distinct
indications that fall under the agreement with the majority of them, approximately $83 million, being sales related based on cumulative
sales milestones for each of the three products. In addition, the Company issued a fully vested warrant to purchase up to 178,570
common stock of the Company at an exercise price of $4.80 per share for each share of common stock. On May 10, 2018, the Company
issued to the same third-party additional fully vested warrants to purchase up to 29,763 common stock of the Company at an exercise
price of $4.80 per share.
Patent
Applications. We have filed over 20 US and foreign patents and patent applications, PCT patent applications.
A
PCT patent application is a filing under the Patent Cooperation Treaty to which the U.S. and a number of other countries are a
party. It provides a unified procedure for filing a single patent application to protect inventions in those countries. A search
with respect to the application is conducted by the International Searching Authority, accompanied by a written opinion regarding
the patentability of the invention. A PCT application does not itself result in the grant of a patent, and the grant of patent
is a prerogative of each national or regional authority where the PCT application is filed during national phase filings.
Government
Regulations
U.S.
Regulation. In the U.S., the FDA regulates drug and medical device products under the Federal Food, Drug, and Cosmetic Act
(“FFDCA”), and its implementing regulations. Our products have been designated as devices by the FDA and will be regulated
by the Center for Devices and Radiological Health (CDRH). Given that currently approved NO products and delivery systems were
approved in the Unites States as drug-device combinations, we expect our device to not only be reviewed by CDRH, but also have
input from the Center for Drug Evaluation and research (CDER).
Among
other things, we will have to demonstrate compliance with applicable QSRs, to ensure that the device is in compliance with applicable
performance standards.
Orphan
Drug Designation and Exclusivity. Under the Orphan Drug Act, the FDA may grant orphan drug designation to products that are
intended to treat rare diseases or conditions (i.e., those affecting fewer than 200,000 patients in the U.S.). Although orphan
drug designation does not convey any advantage in the regulatory review and approval process, it can provide certain tax benefits
and access to grants. Additionally, FDA user fees, which can be substantial, are waived for products that obtain orphan drug designation.
Further, if a product with orphan drug designation subsequently receives FDA approval for the designated disease or condition,
the product is entitled to orphan product exclusivity, which (with certain limited exceptions) blocks for seven years FDA approval
of another product with the same active ingredient for the same indication.
Approval
or Clearance of Medical Devices. To varying degrees, each of the regulatory agencies having oversight over medical devices,
including the FDA and comparable foreign regulators, has laws and regulations governing the development, testing, manufacturing,
labeling, marketing and distribution of medical devices. In the U.S., medical device products are subject to regulation that is
intended to ensure that the device is either safe and effective or is substantially equivalent to a previously marketed device.
Medical devices are classified into one of three classes based on the level of control necessary to assure the safety and effectiveness
of the device. The three classes and the requirements that apply to them are: (i) Class I General Controls, with exemptions and
without exemptions, (ii) Class II General Controls and Special Controls, with exemptions and without exemptions and (iii) Class
III General Controls and Premarket Marketing authorization. The class to which a device is assigned determines the process that
applies for gaining marketing authorization. Most Class I devices are exempt from Premarket Notification 510(k); most Class II
devices require Premarket Notification clearance under section 510(k) of the Food, Drug, and Cosmetic Act; and most Class III
devices require Premarket Approval.
A
brief summary overview of the three classifications is set forth below.
Exempt
Class I Medical Device: Prior to marketing an exempt Class I medical device, the manufacturer must register its establishment,
list the generic category or classification name of the medical device being marketed and pay a registration fee.
510(k)
Clearance Process: A Class II medical device normally requires FDA clearance in the U.S. pursuant to the 510(k) clearance
process. The 510(k) clearance process is available to medical device developers that can demonstrate that their device is substantially
equivalent to a legally marketed medical device. In this process, the developer would be required to submit data that supports
the equivalence claim and wait for an order from the FDA finding substantial equivalence to another legally marketed medical device
before distributing the device for commercial sale. Modifications to cleared medical devices can be made without using the 510(k)
process if the changes do not significantly affect safety or effectiveness.
Premarket
Approval: A more rigorous and time-consuming process applicable to Class III medical devices, known as pre-market approval
(“PMA”) which would require the developer to independently demonstrate that a medical device is safe and effective.
This is done by submitting data regarding design, materials, bench and animal testing and human clinical data for the medical
device. The FDA will authorize commercial release of a Class III medical device if it determines there is reasonable assurance
that the medical device is safe and effective. This determination is based on benefit outweighing risk for the population intended
to be treated with the device. This process is much more detailed, time-consuming and expensive than the 510(k) clearance process.
The
basic design of our delivery system will be similar to those functions used in current predicate devices. However, our therapy
requires the administration of a higher concentration of NO than is currently approved by the FDA. Therefore, the FDA could reject
a Class II-510(k) and declare it not substantially equivalent to a legally marketed device, and set it on the regulatory path
of Class III-PMA.
Continuing
Regulation of Approved or Cleared Drugs and Medical Devices. Products manufactured or distributed pursuant to FDA approval
or clearance are subject to continuing regulation by the FDA, including requirements for ongoing recordkeeping, annual product
quality review, annual reporting, post-market surveillance requirements, post-market study commitments, drug adverse experience
reporting in a timely fashion, maintenance of pharmacovigilance program to proactively monitor for adverse events and medical
device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have
caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to a death
or serious injury if the malfunction of the device or a similar device were to recur.
Quality
System Regulation. Companies engaged in the manufacture of medical devices or their components are required to register their
establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain
state agencies for compliance with ongoing regulatory requirements. Medical devices must comply with QSR requirements. These requirements
impose certain procedural and documentation requirements upon us and our third-party manufacturers related to the methods used
in and the facilities and controls used for designing, manufacturing, packaging, labeling, storing, medical devices. Following
these inspections, the FDA may assert noncompliance with QSR requirements on a Form 483, which is a report of observations from
an inspection, or by way of “untitled letters” or “warning letters” that could cause us or any third-party
manufacturers to modify certain activities. A Form 483 notice, if issued at the conclusion of an FDA inspection, can list conditions
the FDA investigators believe may have violated QSR or other FDA requirements. We cannot be certain that we or our present or
any future third-party manufacturers or suppliers will be able to comply with QSR or other FDA regulatory requirements to the
agency’s satisfaction. Failure to comply with these obligations may lead to possible legal or regulatory enforcement action
by the FDA, such as suspension of manufacturing, operating restrictions, seizure or recall of product, injunctive action, withdrawal
of approval or clearance, import detention, refusal or delay in approving or clearing new products or supplemental applications,
fines, civil penalties and criminal prosecution.
Advertising
and Promotion. The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of medical
devices, including standards and regulations for direct-to-consumer advertising, communications about unapproved uses, industry-
sponsored scientific and educational activities and promotional activities involving the internet. Devices may be marketed only
for the approved or cleared indications and in accordance with the provisions of the approved or cleared label.
Healthcare
providers are permitted to prescribe approved devices for “off-label” uses—that is, uses not approved by the
FDA and therefore not described in the product’s labeling. These off-label uses are common across medical specialties. Physicians
may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate
the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers’
communications regarding off-label use. Thus, we may market our products, if approved by the FDA, only for their approved indications,
but under certain conditions may engage in non-promotional, balanced communication regarding off-label uses. Failure to comply
with applicable FDA requirements and restrictions in this area may subject us to adverse publicity and a variety of sanctions,
which could harm our business and financial condition.
Anti-Kickback,
False Claims Act and Other Laws. In addition to the FDA’s ongoing post-approval regulation of devices discussed above,
several other types of laws and regulations, subject to differing enforcement regimes, govern advertising and promotion. In recent
years, promotional activities regarding FDA-regulated products have come under intense scrutiny and have been the subject of enforcement
action brought by the Department of Justice and the Office of Inspector General of the Department of Health and Human Services,
as well as state authorities and even private individuals.
A
development affecting the healthcare industry is the increased use of the federal civil False Claims Act to impose liability on
any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for
payment by a federal healthcare program. In addition, many states have enacted false claim laws similar to the federal False Claims
Act. If certain conditions are met, the False Claims Act allows a private individual (typically a “whistleblower”)
to bring a civil action on behalf of the federal government and to share in any monetary recovery. Engaging in impermissible promotion
of our products for off-label uses can subject us to false claims litigation under federal and state statutes, which can lead
to civil money penalties, restitution, criminal fines and imprisonment and exclusion from participation in Medicare, Medicaid
and other federal and state health care programs In recent years, the number of suits brought by private individuals against pharmaceutical
and device companies for off-label promotion has increased dramatically.
The
federal Anti-Kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving
remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare
item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted
to apply to arrangements between pharmaceutical or device manufacturers, on the one hand, and prescribers, purchasers and formulary
managers on the other. Violations are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from
participation in federal healthcare programs. Any sales or marketing practices that involve remuneration intended to induce prescribing,
purchases or recommendations may be subject to scrutiny under the Anti-Kickback statute. Many states have likewise adopted state
anti-kickback statutes and enforcement has been significant.
A
host of other laws and regulations govern the advertising and promotion of devices. The federal Sunshine Law, which is part of
the Health Care Reform Law, each enacted in March 2010, imposes federal “sunshine” provisions, requiring annual reporting
of various types of payments to physicians and teaching hospitals. CMS published the first set of data about these financial relationships
on its website on September 30, 2014. Inaccurate or incomplete reports may be subject to enforcement. Like the federal Sunshine
Law, several states have existing laws that require manufacturers to report transfers of value to select healthcare providers
licensed within the state. Additionally, other laws such as the federal Lanham Act and similar state laws allow competitors and
others to initiate litigation relating to advertising claims. If the Company sells its device outside the United States, it must
comply with the Foreign Corrupt Practices Act (“FCPA”) and local laws of other countries. FCPA is a complex patchwork
of laws can change rapidly with relatively short notice.
Environmental
Laws. Elements of our potential products may be classified as hazardous materials, subject to regulation by the Department
of Transportation, the International Air Transportation Association, the International Maritime Organization, the Environmental
Protection Agency and the Occupational Safety and Health Administration, which may impose various requirements pertaining to the
way we manufacture, transport, store, handle and dispose of our products.
European
Regulation. In order for our products to be marketed and sold in the EEA, we must obtain the required regulatory approvals
and comply with the extensive regulations regarding safety, manufacturing processes and quality requirements of the respective
countries. These regulations, including the requirements for approvals to market, and the various regulatory frameworks may differ.
In addition, there may be foreign regulatory barriers other than approval or clearance.
Medicinal
Product Approval. In the EEA, we expect our products to be regulated as a combination drug-delivery device product falling
within the scope of Directive 2001/83/EC, commonly known as the Community Code on medicinal products. Under this Directive, we
are required to obtain a marketing authorization for our products before they are placed on the market. Medicinal products must
be authorized in one of two ways, either through the decentralized procedure or mutual recognition procedure by the competent
authorities of the EEA Member States, or through the centralized procedure by the European Commission following a positive opinion
by the EMA. The authorization process is essentially the same irrespective of which route is used, and requires us to demonstrate
the quality, safety and efficacy of the NO delivered to the patient by our product. We are also required to demonstrate that the
drug delivery component of our products complies with the relevant Essential Requirements contained in Annex I to the Medical
Devices Directive.
Innovative
medicinal products are authorized in the EEA on the basis of a full marketing authorization application that must contain the
results of pharmaceutical tests, pre-clinical tests and clinical trials conducted with the medicinal product for which marketing
authorization is sought, and demonstrating the product’s quality, safety and efficacy. Once approved, an innovative medicinal
product is entitled to eight years of data exclusivity. During this period, no application for approval of a generic version of
the innovative product relying on data contained in the marketing authorization dossier for the innovative product may be submitted.
Innovative medicinal products are also entitled to ten years of market exclusivity. During this 10-year period, no generic medicinal
product can be placed on the EU market. The 10-year period of market exclusivity can be extended to a maximum of 11 years if,
during the first eight years of those ten years, the holder of the marketing authorization for the innovative product obtains
an authorization for one or more new therapeutic indications that are held to bring a significant clinical benefit in comparison
with existing therapies.
After
expiration of the data exclusivity period, an application for marketing authorization for a generic version of an approved innovative
medicinal product may be submitted. Such an application does not contain data demonstrating the proposed product’s quality,
safety and efficacy, but instead relies on the data in the dossier for the related innovative product, and a demonstration that
the two products are the same and bioequivalent. If approved, the generic product may not be placed on the market until expiration
of the 10-year marketing exclusivity period for the innovative medicinal product.
A
marketing application for a product that, although similar to an approved medicinal product does not qualify as a generic, may
also seek to rely to some degree on the data in the dossier for the approved product. As with a generic product, the application
may not be submitted until expiration of the data exclusivity period, and the product, if approved, may not be placed on the market
until expiration of the market exclusivity period. Such an application must also contain data specific to the proposed product,
however. The extent to which such a “hybrid” application requires new data is determined on a case-by-case basis by
the competent authorities, based on the differences between the innovative medicinal product and the medicinal product subject
to the hybrid application for marketing authorization. The purpose of the pre-clinical tests and clinical trials is to generate
additional data that complement the data relating to the innovative medicinal product and to demonstrate the quality, safety and
efficacy of the medicinal product for which authorization is sought.
Because
a NO formulation is already authorized in the EEA for treating pulmonary hypertension, we expect to be able to seek marketing
authorization for our products under the “hybrid” approach described in the previous paragraph. We anticipate that
the hybrid application for marketing authorization will require the successful completion of limited studies confirming the quality,
safety and efficacy of the NO formulation delivered using our proprietary delivery technology.
Continuing
Regulation. As in the U.S., marketing authorization holders and manufacturers of medicinal products are subject to comprehensive
regulatory oversight by the EMA and/or the competent authorities of the EEA Member States. This oversight applies both before
and after grant of manufacturing and marketing authorizations. It includes control of compliance with EU GMP rules and pharmacovigilance
rules.
In
the EEA, the advertising and promotion of our products will also be subject to EEA Member States’ laws concerning promotion
of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices, as
well as other EEA Member State legislation that may apply to the advertising and promotion of medicinal products. These laws require
that promotional materials and advertising in relation to medicinal products comply with the product’s Summary of Product
Characteristics (“SmPC”), as approved by the competent authorities. The SmPC is the document that provides information
to physicians concerning the safe and effective use of the medicinal product. Promotion of a medicinal product that does not comply
with the SmPC is considered to constitute off-label promotion, which is prohibited. The applicable laws at the EU level and in
the individual EEA Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations
of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative measures, fines and
imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and
may also impose limitations on our promotional activities with health care professionals.
Interactions
between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes
of conduct and physicians’ codes of professional conduct in the individual EEA Member States. The provision of benefits
or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use
of medicinal products is prohibited. The provision of benefits or advantages to physicians is also governed by the national anti-bribery
laws of the EEA Members states, including the UK Bribery Act 2010. Payments made to physicians in certain EEA Member States must
be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the
physician’s employer, his/her competent professional organization and/or the competent authorities of the individual EEA
Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable
in the EEA Member States.
Pricing
and Reimbursement. Each EEA Member State is free to restrict the range of medicinal products for which their national health
insurance systems provide reimbursement and to control the prices and/or reimbursement levels of medicinal products for human
use. An EEA Member State may approve a specific price or level of reimbursement for the medicinal product, or alternatively adopt
a system of direct or indirect controls on the profitability of the company responsible for placing the medicinal product on the
market, including volume-based arrangements and reference pricing mechanisms.
Health
technology assessment (“HTA”) of medicinal products is becoming an increasingly common part of the pricing and reimbursement
procedures in some EEA Member States, particularly the United Kingdom, France, Germany and Sweden. The HTA process in each EEA
Member State is governed by the national laws of the country. HTA is the procedure according to which an assessment is conducted
of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the
national healthcare systems of the individual country. HTA generally focuses on the clinical efficacy and effectiveness, safety,
cost and cost-effectiveness of individual medicinal products, as well as their potential implications for the healthcare system.
Those elements of medicinal products are compared with other treatment options available on the market. The outcome of HTA regarding
specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the
competent authorities of individual EEA Member States. The extents to which pricing and reimbursement decisions are influenced
by the HTA of the specific medicinal product vary between EEA Member States.
Data
Privacy Regulation. The collection and use of personal health data in the EEA is governed by the provisions of the Data Protection
Directive. This Directive imposes a number of requirements relating to the consent of the individuals to whom the personal data
relates, the information provided to the individuals, notification of data processing obligations to the competent national data
protection authorities and the security and confidentiality of the personal data. The Data Protection Directive also imposes strict
rules on the transfer of personal data out of the EEA to the U.S. Failure to comply with the requirements of the Data Protection
Directive and the related national data protection laws of the EEA Member States may result in fines.
Orphan
Designation and Exclusivity. In the European Union, the Committee for Medicinal Products for Human Use grants orphan drug
designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening
or chronically debilitating conditions affecting not more than five in 10,000 persons in the European Union Community and for
which no satisfactory method of diagnosis, prevention or treatment has been authorized (or the product would be a significant
benefit to those affected). Additionally, designation is granted for products intended for the diagnosis, prevention or treatment
of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that
sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the medicinal product.
In
the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers
and ten years of market exclusivity is granted following medicinal product approval. This period may be reduced to six years if
the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable
not to justify maintenance of market exclusivity.
Orphan
drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey
any advantage in, or shorten the duration of, the regulatory review and approval process.
Exceptional
Circumstances/Conditional Approval. Orphan medicinal product or products for unmet medical needs may be eligible for EU approval
under exceptional circumstances or with conditional approval. Approval under exceptional circumstances is applicable to orphan
products and is used when an applicant is unable to provide comprehensive data on the efficacy and safety under normal conditions
of use because the indication for which the product is intended is encountered so rarely that the applicant cannot reasonably
be expected to provide comprehensive evidence, when the present state of scientific knowledge does not allow comprehensive information
to be provided, or when it is medically unethical to collect such information. Conditional marketing authorization is applicable
to orphan medicinal products, medicinal products for seriously debilitating or life- threatening diseases or medicinal products
to be used in emergency situations in response to recognized public threats. Conditional marketing authorization can be granted
on the basis of less complete data than is normally required in order to meet unmet medical needs and in the interest of public
health, provided the risk-benefit balance is positive, it is likely that the applicant will be able to provide the comprehensive
clinical data, and unmet medical needs will be fulfilled.
Conditional
marketing authorization is subject to certain specific obligations to be reviewed annually.
Other
Regulations. We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions,
manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances.
We may incur significant costs to comply with such laws and regulations now or in the future.
Regulation
in Israel. In order to conduct clinical testing on humans in the State of Israel, special authorization must first be obtained
from the ethics committee and general manager of the institution in which the clinical studies are scheduled to be conducted,
as required under the Guidelines for Clinical Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations
(Clinical Trials in Human Subjects), as amended from time to time, and other applicable legislation. These regulations require
authorization by the institutional ethics committee and general manager as well as from the Israeli Ministry of Health, except
in certain circumstances, and in the case of genetic trials, special fertility trials and complex clinical trials, an additional
authorization of the Ministry of Health’s overseeing ethics committee. The institutional ethics committee must, among other
things, evaluate the anticipated benefits that are likely to be derived from the project to determine if it justifies the risks
and inconvenience to be inflicted on the human subjects, and the committee must ensure that adequate protection exists for the
rights and safety of the participants as well as the accuracy of the information gathered in the course of the clinical testing.
Since we perform a portion of the clinical studies on certain of our therapeutic candidates in Israel, we are required to obtain
authorization from the ethics committee and general manager of each institution in which we intend to conduct our clinical trials,
and in most cases, from the Israeli Ministry of Health.
Emerging
Growth Company Status
We
are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act enacted on April 5, 2012, referred
to as the JOBS Act. For as long as we are an emerging growth company, we may take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not
limited to, not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding advisory “say-on-pay” and “say-when-on-pay” votes on executive
compensation and shareholder advisory votes on golden parachute compensation.
Under
the JOBS Act, we will remain an emerging growth company until the earliest of:
●
|
December 31, 2021;
|
|
|
●
|
the last day
of the fiscal year during which we have total annual gross revenues of $1 billion or more;
|
|
|
●
|
the date on which
we have, during the previous three-year period, issued more than $1 billion in non-convertible debt; and
|
|
|
●
|
the date on which
we are deemed to be a “large accelerated filer” under the Securities Exchange Act of 1934, as amended, referred
to as the Exchange Act (we would qualify as a large accelerated filer as of the first day of the first fiscal year after we
(i) have more than $700 million in aggregate market value of outstanding common equity held by our non-affiliates as of the
last day of our second fiscal quarter of our prior fiscal year and (ii) have been public for at least 12 months).
|
We
have taken advantage of reduced disclosure requirements in this prospectus by providing reduced disclosure regarding executive
compensation arrangements. We may choose to take advantage of some, but not all, of these reduced disclosure obligations in future
filings. If we do, the information that we provide stockholders may be different than the information you might get from other
public companies in which you hold stock.
The
JOBS Act also provides that an emerging growth company may utilize the extended transition period provided for complying with
new or revised accounting standards. We have irrevocably elected to take advantage of this extended transition period. Because
we will not be required to comply with new or revised accounting standards on the relevant dates on which adoption of such standards
is required for other public companies, our financial statements may not be comparable to the financial statements of companies
that comply with the effective dates of those accounting standards.
Properties
Our
executive office is located at 825 East Gate Boulevard, Suite 320, Garden City, New York 11530 under a lease that expires in June
2023. We also lease office space at 12 Eli Horovitz Street, Rehovot, 7414002 Israel and that lease expires on March 31, 2020.
The Company has a research and development facility in Madison, Wisconsin under a lease that expires on April 2021.
Legal
Proceedings
On
March 16, 2018, Empery Asset Master, Ltd. (“Empery Master”), Empery Tax Efficient, LP (“Empery I) and Empery
Tax Efficient II, LP (“Empery II), (collectively, “Empery”), filed a complaint in the Supreme Court of the State
of New York, relating to the notice of adjustment of both the exercise price of and the number of warrant shares issuable under
warrants issued to Empery in January 2017. Empery alleges that, as a result of certain circumstances in connection with the February
2018 financing transaction, the 166,672 warrants issued to Empery in January 2017 provide for adjustments to both the exercise
price of the warrants and the number of warrant shares issuable upon such exercise. While we believe that we complied with the
applicable protective features of the 2017 Warrants and properly adjusted the exercise price, if Empery were to prevail on all
claims in their action against us, the new adjusted total number of warrant shares would be as follows: 319,967 warrant shares
for Empery Master, 159,869 warrant shares for Empery I and 252,672 warrant shares for Empery II and the exercise price could be
reduced to $1.57 per share. We believe that Empery’s claims have no merit and we shall continue to vigorously defend such
lawsuit.
In
addition to Empery, there are 1,139,220 warrants outstanding held by investors in the 2017 Warrants who did not participate in
the February 2018 financing transaction. Any further adjustments to these 2017 Warrants pursuant to the antidilution provisions
may result in additional dilution to the interests of our stockholders and may adversely affect the market price of our common
stock. The antidilution provisions may also limit our ability to obtain additional financing on terms favorable to us.
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The
following table sets forth information with respect to the beneficial ownership of our common stock by each person known by us
to beneficially own more than 5.0% of any class of our voting securities together with:
|
●
|
each
of our directors;
|
|
|
|
|
●
|
each
of our named executive officers; and
|
|
|
|
|
●
|
all
of our directors and executive officers as a group.
|
The
percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination
of beneficial ownership of securities. Except as indicated in the footnotes to this table, each beneficial owner named in the
table below has sole voting and sole investment power with respect to all shares beneficially owned. Percentage computations are
based on 14,137,675 shares of our common stock outstanding as of January 22, 2020.
Under
the terms of the warrants issued by the Company to the holders listed below, no holder may exercise a warrant to the extent such
exercise would cause such holder, together with its affiliates and any other persons acting as a group with such holder or any
of its affiliates, to have acquired a number of shares of common stock which would exceed 4.99%, or, in the case of certain holders
indicated below, 9.985%, (subject to an increase of such percentage to 9.99% on 61 days’ notice by the holder to the Company)
of our then outstanding common stock, excluding for purposes of such determination shares of common stock issuable upon exercise
of warrants that have not been exercised. We refer to the foregoing limitation applicable to each individual holder or group as
the “Ownership Cap.” The share numbers in the table below do not reflect the Ownership Cap, but the figures contained
in the “Percentage of Outstanding Shares” column reflect the Ownership Cap applicable to each holder.
Name
and Address of Beneficial Owner (1)
|
|
Number
of
Shares
|
|
|
Percentage
of Outstanding
Shares
(2)
|
|
5%
Owners
|
|
|
|
|
|
|
Deerfield
Partners, L.P.
|
|
|
856,863
|
(3)
|
|
|
5.71
|
%(4)
|
Pulmonox
Technologies Corporation
|
|
|
1,012,496
|
(5)
|
|
|
6.82
|
%(4)
|
Allianz
Global Investor U.S Holdings LLC
|
|
|
889,863
|
(6)
|
|
|
6.05
|
%(4)
|
Executive
Officers and Directors
|
|
|
|
|
|
|
|
|
Steven
A. Lisi
|
|
|
1,398,709
|
(7)
|
|
|
9.51
|
%(4)
|
Amir
Avniel
|
|
|
820,218
|
(8)
|
|
|
5.68
|
%(4)
|
Ron
Bentsur
|
|
|
362,918
|
(9)
|
|
|
2.55
|
%
|
Dr.
William Forbes
|
|
|
13,105
|
(10)
|
|
|
*
|
|
Robert
F, Carey
|
|
|
25,918
|
(11)
|
|
|
*
|
|
Erick
Lucera
|
|
|
19,842
|
(12)
|
|
|
*
|
|
Yoori
Lee
|
|
|
25,918
|
(13)
|
|
|
*
|
|
Douglas
Beck, CPA
|
|
|
40,460
|
(14)
|
|
|
*
|
|
Executive
Officers and Directors as a Group (Eight persons)
|
|
|
2,706,959
|
|
|
|
17.85
|
%
|
*
|
Less
than one percent (1.0%).
|
(1)
|
The
address of these persons, unless otherwise noted, is c/o Beyond Air, Inc., 825 East Gate Boulevard, Suite 320 Garden City,
New York, 11530.
|
(2)
|
Shares
of common stock beneficially owned and, except as limited by the Ownership Cap, the respective percentages of beneficial ownership
of common stock includes for each person or entity shares issuable on the exercise of all options and warrants and the conversion
of other convertible securities beneficially owned by such person or entity that are currently exercisable or will become
exercisable or convertible within 60 days following January 22, 2020. Such shares, however, are not included for the
purpose of computing the percentage ownership of any other person.
|
|
(3)
|
Based
upon an assignment of warrants to Deerfield Partners, L.P from Special Situations Fund, L.P. date and James E. Flynn. Includes
856,863 shares of common stock issuable upon exercise of the warrants originally issued to Deerfield Special Situations Fund,
L.P. in the Company’s 2017 and 2018 offerings. James E. Flynn is the President of J.E. Flynn Capital, LLC, which is
the general partner of Deerfield Mgmt, L.P., which is the general partner of Deerfield Special Situations Fund, L.P. Flynn
Management LLC is the general partner of Deerfield Management Company, L.P., which is the investment advisor to Deerfield
Special Situation Fund, L.P. The reporting persons’ business address is 780 Third Avenue, 37th Floor, New York, NY 10017.
|
|
|
(4)
|
The
provisions of the warrants beneficially owned by the holder restrict the exercise of such warrants to the extent that, upon
such exercise, the number of shares then beneficially owned by the holder and any other person or entities with which such
holder would constitute a Section 13(d) “group” would exceed 4.99% (subject to an increase of such percentage
to 9.99%) of the total number of our then-outstanding shares of common stock
|
|
|
(5)
|
Includes
705,415 shares of common stock issuable upon exercise of the warrants issued to Pulmonox Technologies Corporation in the Company’s
2017 and 2018 offerings.
|
|
|
(6)
|
Based,
in part, on information provided on Schedule 13G filed with the SEC on December 31, 2018 by Allianz Global Investors U.S.
Holdings LLC and Allianz Global Investors GmbH. Includes 560,723 shares of common stock issuable upon exercise of the warrants
issued to Allianz Global Investor U.S Holdings LLC in the Company’s 2017 and 2018 offerings. Allianz Global Investors
U.S. Holdings LLC and Allianz Global Investors GmbH are investment advisors to Allianz Biotechnologie. The business address
for Allianz Global Investors U.S. Holdings LLC is 1633 Broadway, New York, NY 10019. The business address for Allianz Global
Investors GmbH is Bockenheimer Landstrasse 42-44, Frankfurt, 2M 60323 Germany.
|
|
|
(7)
|
Includes
Excludes 200,446 shares of common stock issuable upon exercise of the warrants issued to Mr. Lisi in the Company’s 2017
and 2018 offerings, see footnote 4. Includes 362,500 vested options to purchase shares of common stock.
|
|
|
(8)
|
Includes
45,676 shares of common stock issuable upon exercise of the warrants issued to Mr. Avniel in the Company’s 2017 and
2018 offerings, see footnote 4. Includes 260,000 vested options to purchase common stock and 32,666 shares of common stock
held by Dandelion Investments Ltd., over which Mr. Avniel has sole voting and dispositive power.
|
|
|
(9)
|
Includes
73,419 shares of common stock issuable upon exercise of the warrants issued to Mr. Bentsur in the Company’s 2017 and
2018 offerings. Includes 6,000 vested options to purchase common stock
|
|
|
(10)
|
Includes
1,171 shares of common stock issuable upon exercise of the warrants issued to Mr. Lucera
in the Company’s 2018 offering, and 17,500 vested options to purchase common stock.
|
|
|
(11)
|
Includes
17,500 vested options to purchase common stock.
|
|
|
(12)
|
Includes
6,500 vested options to purchase common stock
|
|
|
(13)
|
Includes
2,342 shares of common stock issuable upon exercise of the warrants issued to Mr. Lee in the Company’s 2018 offering
and 16,250 vested options to purchase common stock.
|
|
|
(14)
|
Includes
25,000 vested options to purchase common stock.
|
MANAGEMENT
Directors
and Executive Officers
The
table below sets forth the name, age and position of each of our directors and executive officers and as of the date of this prospectus.
Name
|
|
Age
|
|
Position
|
Steven
A. Lisi
|
|
49
|
|
Chief
Executive Officer and Chairman of the Board of Directors
|
Amir
Avniel
|
|
46
|
|
President,
Chief Operating Officer and Director
|
Douglas
Beck, CPA
|
|
58
|
|
Chief
Financial Officer
|
Ron
Bentsur
|
|
51
|
|
Director
|
Erick
J. Lucera
|
|
51
|
|
Director
|
Yoori
Lee
|
|
46
|
|
Director
|
Dr.
William Forbes
|
|
57
|
|
Director
|
Robert
F. Carey
|
|
60
|
|
Director
|
Steven
A. Lisi, Chief Executive Officer and Chairman of the Board
Steven
Lisi has served on our Board since January 13, 2017, and has served on the Board of AIT Ltd., our wholly-owned subsidiary, since
June 2016. Mr. Lisi has served as our Chief Executive Officer since June 14, 2017. Mr. Lisi was previously Senior Vice President
of Business and Corporate Development at Avadel Technologies (AVDL), where he was instrumental in restructuring the company and
transforming it from $100,000,000 in enterprise value to $1 billion in three years. Mr. Lisi raised $121 million in equity, led
the sale of Flamel’s contract manufacturing facility, rationalized the product pipeline, refocused the business development
effort, transformed the investor base and established Flamel’s presence in Ireland. Prior to his position with Flamel, Mr.
Lisi spent 18 years investing in healthcare companies on a global basis at Mehta and Isaly (now OrbiMed), SAC Capital (portfolio
manager), Millennium Partners (portfolio manager), Panacea Asset Management (co-owner) and Deerfield Management (Partner). Mr.
Lisi serves on the Board of Mico Innovations, a next generation coronary and neurovascular stent company and the Board of Incysus
Ltd, a transformational cell therapy company targeting solid tumors. Mr. Lisi received his Masters in International Business from
Pepperdine University.
Amir
Avniel, President, Chief Operating Officer and Director
Amir
Avniel has served on AIT Ltd.’s Board since 2011 and became AIT Ltd.’s Chief Executive Officer in August 2014. He
has served on our Board and served as our Chief Executive Officer from January 13, 2017 to June 14, 2017. He has more than ten
years of management experience in the biotechnology industry. From 2013 through 2014, Mr. Avniel served as Strategy and Business
Development of A.B. Seeds, a wholly owned subsidiary of Monsanto Company. Mr. Avniel served as the Chief Executive Officer of
Rosetta Green Ltd. from 2010 through 2013 and led Rosetta Green in its acquisition by Monsanto. He also served as the president
and the Chief Executive Officer of Rosetta Genomics from 2006 to 2009, and Mr. Avniel is a named inventor in over 20 patent applications.
He studied computer science at the Academic College of Tel Aviv - Jaffa Israel and earned a Bachelor’s degree in Social
Sciences and Humanities - from Open University in Israel. Prior to his academic studies, he served as an officer in the Israel
Defense Force, where he was awarded four commendations for excellence.
Douglas
Beck, CPA, Chief Financial Officer
Douglas
Beck has been our Chief Financial Officer since November 1, 2018. He was the Chief Financial officer of JLM Couture Inc, from
February 16 until October 31, 2018, the Chief Financial Officer of Relmada Therapeutics, Inc. from December 2013 and was the Chief
Financial Officer for iBio, Inc. from January 2011 to March 2013. In addition, Mr. Beck serves on the New York State Society of
CPAs Chief Financial Officer and SEC committee. Mr. Beck is a graduate of Fairleigh
Dickinson University and is a licensed certified public accountant in New York.
Ron
Bentsur, Director
Ron
Bentsur joined AIT Ltd. in August 2015 and serves as a director. Mr. Bentsur has served as Chief Executive Officer and Director
of UroGen Pharma, Ltd. since August 2015. From 2009 through April 2015, Mr. Bentsur served as Chief Executive Officer and Director
of Keryx Biopharmaceuticals, Inc. Mr. Bentsur’s tenure as CEO of Keryx Biopharmaceuticals culminated in the September 2014
FDA approval of Auryxia TM (ferric citrate) and its December 2014 U.S. launch. Prior to joining Keryx Biopharmaceuticals,
Inc., from 2006 to 2009, Mr. Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals, Ltd. Prior to that, Mr. Bentsur
served as Vice President Finance and Chief Financial Officer of Keryx Biopharmaceuticals, Inc., as Director of Technology Investment
Banking at Leumi Underwriters, where he was responsible for all technology and biotechnology private placement and advisory transactions,
and as a New York City-based investment banker, primarily at ING Barings Furman Selz. Mr. Bentsur holds a B.A. in Economics and
Business Administration with distinction from the Hebrew University of Jerusalem and an M.B.A., magna cum laude, from New York
University’s Stern Graduate School of Business. Mr. Bentsur also serves as Director of Stemline Therapeutics, Inc. Ron’s
vast industry experience is invaluable to our Board.
Yoori
Lee, Director
Ms.
Yoori Lee joined Beyond Air’s Board of Directors in January 2018. She has served as Co-founder and President of Trio Health
Advisory Group, Inc. since 2013. Trio Health’s mission is to improve the quality of care in patient outcomes through coordinating
the efforts of all patient care stakeholders. Prior to Trio Health, Ms. Lee spent over 15 years at Leerink Partners LLC, a leading
healthcare investment bank, where she was Managing Director, and Director of MEDACorp Services. Additionally, she helped found
the MEDACorp network, a cadre of experts including more than 35,000 healthcare professionals in diverse areas of practice such
as clinical medicine, biomedical research, regulatory affairs, public policy, healthcare administration and healthcare information
technology. Yoori’s perspective on the industry is unique and provides Beyond Air with a distinct advantage over other companies
of our size and stage of development.
Dr.
William Forbes, Director
Dr.
William Forbes joined Beyond Air’s board of Director in August 2018. He brings to the Beyond Air Board more than 30 years
of pharmaceutical product development experience and, working with health authorities in the US and Europe, has contributed to
numerous marketing approvals spanning a diverse range of therapeutic areas. Dr. Forbes currently serves as the founder, President
and Chief Executive Officer of Vivelix Pharmaceuticals, Ltd., a clinical-stage pharmaceutical company focused on gastrointestinal
diseases since 2016. Prior to founding Vivelix, Dr. Forbes was at Salix Pharmaceuticals as the Chief Development Officer and also
Head of Medical and R&D. Prior to Salix, Dr. Forbes spent 15 years in Clinical Development & Regulatory Affairs and Clinical
Research at a number of global pharmaceutical companies.
Robert
F. Carey
Mr.
Carey joined Beyond Air’s Board of Directors in February 2019. He has an extensive track record of accomplishment within
the healthcare investment banking industry. He has assisted biotech and specialty pharma companies raise more than $10 billion
in initial public offerings, follow-on offerings, debt offerings, and private placements. He has served as a financial advisor
on mergers, acquisitions, and strategic alliance transactions with a total deal value of more than $10 billion. Mr. Carey continues
to serve as executive vice president and chief business officer at Horizon Pharma since 2014, during which Horizon Pharma deployed
in excess of $3 billion to acquire or license eight commercial products and three products in development and grew net sales from
$74 million in 2013 to approximately $1.2 billion* in 2018, a compound annual growth rate of 75%. Before Horizon, he spent more
than 11 years as managing director and head of the life sciences investment banking group at JMP Securities. Mr. Carey was a managing
director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities for a total of 14 years. He received
his B.B.A. in Accounting from the University of Notre Dame. Mr. Carey currently serves on the board of Sangamo Therapeutics, Inc.
Erick
J. Lucera, Director
Erick
J. Lucera joined Beyond Air’s Board of Directors in August 2017 and serves on our Audit Committee. He is the Chief Financial
Officer of Valeritas, a U.S. NASDAQ traded commercial stage company developing new technology for diabetes. Mr. Lucera served
as Chief Financial Officer, Treasurer and Secretary of Viventia Bio. From 2012 to 2015, he was Vice President, Corporate Development
at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company’s product
pipeline through a series of acquisitions and in licensing transactions financed through five public and private offerings of
nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management
as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head
of the healthcare research team at Independence Investments. He holds a Certificate in Public Health from Harvard University,
an MS in quantitative finance from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the
University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations. Erick’s financial and industry background
serve us well on many fronts, including our audit committee.
Term
of Office of Directors
Our
directors are elected at each annual meeting of stockholders for a term of one year. Each director shall serve until his successor
is duly elected and qualified or until his earlier death, resignation or removal.
Family
Relationships
There
are no family relationships among any of our current or former directors or executive officers.
Involvement
in Certain Legal Proceedings
None
of our directors, executive officers, significant employees, promoters or control persons has been involved in any legal proceeding
in the past ten years that would require disclosure under Item 401(f) of Regulation S-K promulgated under the Securities Act.
Board
Committees
Our
Board of Directors has established three standing committees: the audit committee, the compensation committee and the nominating
committee. The current members of our audit committee are Erick Lucera, Ron Bentsur and Robert F. Carey with Erick Lucera serving
as chairperson. The current members of our compensation committee are Yoori Lee, Erick J. Lucera, and Ron Bentsur with Yoori Lee
serving as chairperson. The current members of our nominating committee are Erick Lucera, Yoori Lee and Dr. William Forbes.
Our
Board of Directors has determined that Erick Lucera, Ron Bentsur and Robert F. Carey meet the additional test for independence
for audit committee members imposed by Securities and Exchange Commission (“SEC”) regulations and Section 5605(c)(2)(A)
of the NASDAQ Stock Market listing rules and that Erick J. Lucera, Yoori Lee and Ron Bentsur meet the additional test for independence
for compensation committee members imposed by Section 5605(d)(2)(A) of the NASDAQ Stock Market listing rules.
Audit
Committee
The
primary purpose of our audit committee is to assist the Board of Directors in the oversight of the integrity of our accounting
and financial reporting process, the audits of our consolidated financial statements, and our compliance with legal and regulatory
requirements. Our audit committee met four times during the year period ended March 31, 2019. The functions of our audit committee
include, among other things:
|
●
|
hiring
the independent registered public accounting firm to conduct the annual audit of our consolidated financial statements and
monitoring its independence and performance;
|
|
●
|
reviewing
and approving the planned scope of the annual audit and the results of the annual audit;
|
|
●
|
pre-approving
all audit services and permissible non-audit services provided by our independent registered public accounting firm;
|
|
●
|
reviewing
the significant accounting and reporting principles to understand their impact on our consolidated financial statements;
|
|
●
|
reviewing
our internal financial, operating and accounting controls with management, our independent registered public accounting firm
and our internal audit provider;
|
|
●
|
reviewing
with management and our independent registered public accounting firm, as appropriate, our financial reports, earnings announcements
and our compliance with legal and regulatory requirements;
|
|
●
|
periodically
reviewing and discussing with management the effectiveness and adequacy of our system of internal controls;
|
|
●
|
in
consultation with management and the independent auditors, reviewing the integrity of our financial reporting process and
adequacy of disclosure controls;
|
|
●
|
reviewing
potential conflicts of interest under and violations of our code of conduct;
|
|
●
|
establishing
procedures for the treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters
and confidential submissions by our employees of concerns regarding questionable accounting or auditing matters;
|
|
●
|
reviewing
and approving related-party transactions; and
|
|
●
|
reviewing
and evaluating, at least annually, our audit committee’s charter.
|
With
respect to reviewing and approving related-party transactions, our audit committee will review related-party transactions for
potential conflicts of interests or other improprieties. Under SEC rules, related-party transactions are those transactions to
which we are or may be a party in which the amount involved exceeds the lesser of $120,000 or 1% of total assets, and in which
any of our directors or executive officers or any other related person had or will have a direct or indirect material interest,
excluding, among other things, compensation arrangements with respect to employment and Board of Directors membership. Our audit
committee could approve a related-party transaction if it determines that the transaction is in our best interests. Our directors
are required to disclose to this committee or the full Board of Directors any potential conflict of interest, or personal interest
in a transaction that our Board of Directors is considering. Our executive officers are required to disclose any related-party
transaction to the audit committee. We also poll our directors on an annual basis with respect to related-party transactions and
their service as an officer or director of other entities. Any director involved in a related-party transaction that is being
reviewed or approved must recuse himself or herself from participation in any related deliberation or decision. Whenever possible,
the transaction should be approved in advance and if not approved in advance, must be submitted for ratification as promptly as
practical.
The
financial literacy requirements of the SEC require that each member of our audit committee be able to read and understand fundamental
financial statements. In addition, at least one member of our audit committee must qualify as an audit committee financial expert,
as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act, and have financial sophistication in accordance
with the NASDAQ Stock Market listing rules. Our Board of Directors has determined that Erick Lucera qualifies as an audit committee
financial expert.
Both
our independent registered public accounting firm and management periodically will meet privately with our audit committee.
Compensation
Committee
The
primary purpose of our compensation committee is to assist our Board of Directors in exercising its responsibilities relating
to compensation of our executive officers and employees and to administer our equity compensation and other benefit plans. In
carrying out these responsibilities, this committee reviews all components of executive officer and employee compensation for
consistency with its compensation philosophy, as in effect from time to time. The functions of our compensation committee include,
among other things:
|
●
|
designing
and implementing competitive compensation, retention and severance policies to attract and retain key personnel;
|
|
●
|
reviewing
and formulating policy and determining the compensation of our Chief Executive Officer, our other executive officers and employees;
|
|
●
|
reviewing
and recommending to our Board of Directors the compensation of our non-employee directors;
|
|
●
|
reviewing
and evaluating our compensation risk policies and procedures;
|
|
●
|
administering
our equity incentive plans and granting equity awards to our employees, consultants and directors under these plans;
|
|
●
|
administering
our performance bonus plans and granting bonus opportunities to our employees, consultants and non-employee directors under
these plans;
|
|
●
|
if
required from time to time, preparing the analysis or reports on executive officer compensation required to be included in
our annual proxy statement;
|
|
●
|
engaging
compensation consultants or other advisors it deems appropriate to assist with its duties; and
|
|
●
|
reviewing
and evaluating, at least annually, our compensation committee’s charter.
|
The
compensation committee retains sole authority to hire any compensation consultant, approve such consultant’s compensation,
determine the nature and scope of its services, evaluate its performance, and terminate its engagement.
The
compensation committee will review our compensation policies and practices for all employees, including our named executive officers,
as they relate to risk management practices and risk-taking incentives to assess and determine that there are no risks arising
from these policies and practices that are reasonably likely to have a material adverse effect on us.
Nominating
committee
The
primary purpose of our nominating committee is to assist our Board of Directors in promoting the best interest of our company
and our stockholders through the implementation of sound corporate governance principles and practices. The functions of our nominating
committee include, among other things:
|
●
|
identifying,
reviewing and evaluating candidates to serve on our Board of Directors;
|
|
●
|
determining
the minimum qualifications for service on our Board of Directors;
|
|
●
|
developing
and recommending to our Board of Directors an annual self-evaluation process for our Board of Directors and overseeing the
annual self-evaluation process;
|
|
●
|
developing,
as appropriate, a set of corporate governance principles, and reviewing and recommending to our Board of Directors any changes
to such principles; and
|
|
●
|
periodically
reviewing and evaluating our nominating committee’s charter.
|
Director
Candidates
Our
Board of Directors has a critical role in guiding our strategic direction and overseeing the management of our business, and accordingly,
we seek to attract and retain highly qualified directors who have sufficient time to engage in the activities of our Board of
Directors and to understand and enhance their knowledge of our industry and business plans. In evaluating the suitability of individual
candidates, the Board, in approving (and, in the case of vacancies, appointing) such candidates, may take into account many factors,
including: personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer
or former officer of a publicly held company; strong finance experience; experience relevant to our industry; experience as a
board member or executive officer of another publicly held company; relevant academic expertise or other proficiency in an area
of our operations; diversity of expertise and experience in substantive matters pertaining to our business relative to other board
members; diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence
and specialized experience; practical and mature business judgment, including, but not limited to, the ability to make independent
analytical inquiries; and any other relevant qualifications, attributes or skills. The Board evaluates each individual in the
context of the Board as a whole, with the objective of assembling a group that can best perpetuate the success of the business
and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various
areas.
Stockholder
Communications
Although
we do not have a formal policy regarding stockholder communications with our Board of Directors, stockholders may communicate
with our Board of Directors, or any individual director on our Board of Directors, by writing to us at the address of our principal
executive offices, addressing the communication to the attention of our Chief Executive Officer, and specifying the Board of Directors
or, if applicable, the individual member thereof as the intended recipient of the communication.
Board
Leadership Structure and Role in Risk Oversight
The
Board does not have a formal policy on whether or not the roles of Chairman of the Board and Chief Executive Officer should be
separate and believes that it should retain the flexibility to make this determination in the manner it believes will provide
the most appropriate leadership for our company from time to time. Currently, Steven A. Lisi serves as Chairman of the Board and
Chief Executive Officer, working closely with former CEO and present COO and President, Amir Avniel. Mr. Lisi sets the strategic
direction for the company and provides day-to-day leadership. As Chairman of the board of directors, Mr. Lisi further oversees
the agenda for board meetings in collaboration with the other board members
The
board of directors oversees our exposure to risk through its interaction with management and receipt from management of periodic
reports outlining matters related to financial, operational, regulatory, legal and strategic risks. Risk assessment and oversight
are an integral part of our governance and management processes. Our board of directors encourages management to promote a culture
that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic
and operational risks at regular management meetings, and conducts specific strategic planning and review sessions during the
year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these
risks with the board of directors at regular board meetings as part of management presentations that focus on particular business
functions, operations or strategies and presents the steps taken by management to mitigate or eliminate such risks.
Executive
Compensation
The
following table provides information regarding the compensation earned by our named executive officers for the year ended March
31, 2019, three months ended March 31, 2018 and for the year ended December 31, 2017.
Name
and
Principal
Position
|
|
Year
|
|
|
Salary
Cost
|
|
|
Restricted
Stock Awards (A)
|
|
|
Option
Awards (A)
|
|
|
Bonus
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Steven
A. Lisi. (1)
|
|
|
2019
|
|
|
$
|
450,000
|
|
|
$
|
462,007
|
|
|
$
|
1,927,657
|
|
|
$
|
|
|
|
$
|
2,839,657
|
Chief
Executive Officer and Chairman of the Board
|
|
|
2018
|
|
|
$
|
130,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
130,000
|
|
|
|
2017
|
|
|
$
|
163,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
163,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amir
Avniel (2)
|
|
|
2019
|
|
|
$
|
400,000
|
|
|
$
|
220,200
|
|
|
$
|
727,790
|
|
|
$
|
-
|
|
|
$
|
1,347,990
|
President,
Chief Operating Officer and Director
|
|
|
2018
|
|
|
$
|
85,000
|
|
|
$
|
27,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
112,000
|
|
|
|
2017
|
|
|
$
|
286,000
|
|
|
$
|
89,000
|
|
|
$
|
-
|
|
|
$
|
50,000
|
|
|
$
|
425,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Douglas
Beck, CPA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief
Financial Officer (3)
|
|
|
2019
|
|
|
$
|
104,167
|
|
|
$
|
-
|
|
|
$
|
300,012
|
|
|
$
|
-
|
|
|
$
|
404,179
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hai
Aviv
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief
Financial Officer (4)
|
|
|
2017
|
|
|
$
|
160,000
|
|
|
$
|
-
|
|
|
$
|
39,000
|
|
|
|
|
|
|
$
|
199,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam
Newman
Inhouse Counsel (5)
|
|
|
2019
|
|
|
$
|
250,000
|
|
|
$
|
229,500
|
|
|
$
|
492,493
|
|
|
|
|
|
|
$
|
971,993
|
|
|
|
2018
|
|
|
$
|
62,500
|
|
|
$
|
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
62,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Duncan
Fatkin (6)
|
|
|
2019
|
|
|
$
|
104,167
|
|
|
|
|
|
|
$
|
312,934
|
|
|
$
|
|
|
|
$
|
417,101
|
(A)
|
This
column represents the grant date fair value of the award in accordance with stock-based
compensation rules under Accounting Standards Codification Topic 718
|
(1)
|
Mr.
Lisi was appointed as the Company’s CEO on June 14, 2017. Presented in the above table include payments which were paid
to Mr. Lisi since his appointment as the Company’s CEO.
|
|
|
(2)
|
In
February, 2017, the Board of Directors approved a salary to Mr. Avniel of $260,000 per annum, which was thereafter confirmed
by the Board of Directors in June 2017 when Mr. Avniel resigned from the position of CEO and assumed the position of COO.
In March 2018, the board of directors increased Mr. Avniel’s annual salary to $400,000.
|
|
|
(3)
|
Mr.
Beck was appointed as the Company’s Chief Financial Officer on November 1, 2018.
|
|
|
(4)
|
Mr.
Aviv resigned as Chief Financial Officer on April 30, 2018. Mr. Steve DiPalma replaced Mr. Aviv as Chief Financial Officer
until the hiring of Mr. Beck.
|
|
|
(5)
|
Mr.
Newman was appointed as the Company’s Chief Legal Officer and General Counsel effective March 1, 2018. Prior to this
date, Mr. Newman was engaged by Beyond Air for attorney services through his Company.
|
|
|
(6)
|
Mr.
Fatkin was appointed as the Company’s Chief Commercial Officer on January 14, 2019.
|
Employment
and Service Agreements with Executive Officers; Consulting and Directorship Services with Directors
Our
employment and service agreements with our Executive Officers and Directors contain provisions standard for a company in our industry
regarding non-competition, confidentiality of information and assignment of inventions.
Directors
Agreement with Steven A. Lisi
On
June 24, 2016, the board of directors of AIT Ltd., appointed Steven Lisi to serve as a Member of its Board of Directors, effective
as of June 24, 2016, and concurrently entered into an agreement with Mr. Lisi to serve as a member of the Board of Directors pursuant
to which, among other things, the Company agreed to pay as compensation and benefits upon consummation of a financing round in
the United States (“Financing Round”) (i) an annual retainer of $40,000 to be paid on equal monthly installments;
(ii) one-time bonus amounted to $150,000 with 30 days from completion of the Financing Round (“One-Time Bonus”) and
(iii) restricted shares equal to 3% of all issued and outstanding fully diluted shares of the Company after the completion of
the Financing Round (including any green shoe or similar) with vesting schedule of 33.33% of such shares to be vested immediately
upon the completion of a Financing Round, 33.33% of such shares to be vested after 6 month anniversary of the completion of a
Financing Round and the remaining 33.33% of such shares after 12 month anniversary of the completion of a Financing Round. Upon
the closing of a change of control transaction, as defined in the agreement, the unvested options shall be accelerated and vested
immediately. The One-Time Payment was paid on January 27, 2017. The Board of AIT Ltd. determined to issue to Mr. Lisi an aggregate
of 364,286 ordinary shares issuable under this agreement in connection with financing transactions contemplated immediately prior
to the Merger. The shares were exchanged for shares of our Common Stock in connection with the Merger.
In
January 2017, the board of directors approved a consulting fee payable to Mr. Lisi in an amount equal to $18,000 per month which
terminated upon his acceptance of the CEO position in June, 2017 at which time, the Board of Directors approved a salary of $260,000
per annum to Mr. Lisi. In March 2018, the board of directors approved a salary of $450,000 per annum to Mr. Lisi pursuant to an
employment agreement.
Effective
March 1, 2018, we entered into an employment agreement with Mr. Lisi with an annual salary of $450,000. Pursuant to the terms
and conditions of employment, Mr. Lisi will receive 400,000 options to purchase common stock vesting over a period of three years.
In the event of termination without cause, Mr. Lisi will be entitled to severance equal to twenty-four months of base salary,
a lump sum payment 1.5 times that of the most recent earned short term incentive award and all outstanding options would automatically
vest.
Employment
Agreement with Amir Avniel
On
October 1, 2014, we entered into a service agreement with Amir Avniel, employing him to provide the Company with professional
Chief Executive Officer services, effective as of October 1, 2014. As thereafter amended in September, 2015, Mr. Avniel was entitled
to a base salary of $15,800 per month. If Mr. Avniel is terminated without cause, he shall be entitled to a salary continuation
at the rate then in effect for a period of 90 days from the effective date of termination. In the event Mr. Avniel is terminated
within two (2) years following the closing of a change of control of the Company, he shall
be entitled to a salary continuation at the rate then in effect for a period of seven (7) months following the effective date
of termination.
On
October 31, 2016, Mr. Avniel waived the accrued but unpaid salary owed by the Company to him in the total aggregate amount of
$304,000.
In
February, 2017, the Board of Directors approved a salary to Mr. Avniel of $260,000 per annum, which was thereafter confirmed by
the Board of Directors in June 2017 when Mr. Avniel resigned from the position of CEO and assumed the position of COO. In March
2018, the board of directors increased Mr. Avniel’s annual salary to $400,000.
Effective
March 1, 2018, we entered into an employment agreement with Mr. Avniel with an annual salary of $400,000. Pursuant to the terms
and conditions of employment, Mr. Avniel will receive 250,000 options to purchase common stock vesting over a period of three
years. In the event of termination without cause, Mr. Avniel will be entitled to severance equal to twenty-four months of base
salary, a lump sum payment equal to 1.5 times that of the most recent earned short-term incentive award and all outstanding options
would automatically vest.
Offer
Letter Agreement with Douglas Beck
Pursuant
to the terms of an employment offer letter agreement between the Company and Mr. Beck dated October 17, 2018. Mr. Beck will be
paid an annual salary of $250,000 per year. The Company issued Mr. Beck options to purchase 85,000 shares of common stock of the
Company at an exercise price of $4.25 per share. Under Mr. Beck’s offer letter his employment is at will. In the event of
termination without cause he will be entitled to a severance equal to one month’s base salary for every six months employed
by the Company not to exceed six months of base salary and the options will automatically vest.
Employment
Agreement with Adam Newman
Effective
March 1, 2018 we entered into an employment agreement with Mr. Newman with an annual salary of $450,000. Pursuant to the terms
and conditions of employment, Mr. Newman will receive 150,000 options to purchase common stock vesting over a period of three
years. In the event of termination without cause, Mr. Newman will be entitled to severance equal to twenty-four months of base
salary, a lump sum payment equal to 1.5 times that of the most recent earned short-term incentive award and all outstanding options
would automatically vest.
Offer
Letter Agreement with Duncan Fatkin
Pursuant
to the terms of an employment offer letter agreement between the Company and Mr. Fatkin December 20, 2018, Mr. Fatkin will be
paid an annual salary of $250,000 per year. The Company issued Mr. Fatkin options to purchase 85,000 shares of common stock of
the Company at an exercise price of $4.25 per share. Under Mr. Fatkin’s offer letter his employment is at will. In the event
of termination without cause he will be entitled to a severance equal to one month’s base salary for every six months employed
by the Company not to exceed six months of base salary. In the event of a change of control of the Company, he will receive severance
payments equal to six (6) months’ base salary and the options will automatically vest.
Equity
Compensation Plan Information
On
August 13, 2018, the Board approved the Amended and Restated 2013 Equity Incentive Plan (the “2013 Plan”). The
2013 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock
unit awards, stock appreciation rights, performance share awards, and other stock-based awards (collectively, the “stock
awards”). Stock awards may be granted under the 2013 Plan to our employees, directors and consultants, other than incentive
stock options which may only be granted to employees of the Company.
The
maximum number of shares of common stock available for issuance under the 2013 Plan is 3,100,000 shares.
The
2013 Plan is scheduled to terminate on August 13, 2028. No stock awards shall be granted pursuant to the 2013 Plan after such
date, but Awards theretofore granted may extend beyond that date. The Board may suspend or terminate the Plan at any earlier date
pursuant to the 2013 Plan. No stock awards may be granted under the Plan while the Plan is suspended or after it is terminated.
The
following table summarizes the total number of outstanding options and shares available for other future issuances of options
under the 2013 Plan as of March 31, 2019.
Plan
Category
|
|
Number
of Shares to be Issued Upon
Exercise of
Outstanding
Options, Warrants
and Rights
|
|
|
Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights
|
|
|
Number
of Shares
Remaining Available for Future Issuance
Under the Equity
Compensation Plan
(Excluding Shares
in First Column)
|
|
Equity
compensation plans approved by stockholders -
|
|
-
|
|
|
$
|
|
|
|
-
|
|
Equity
compensation plans not approved by stockholders
|
|
|
2,715,812
|
|
|
$
|
4.48
|
|
|
|
310,525
|
|
Total
|
|
|
2,715,812
|
|
|
$
|
4.48
|
|
|
|
310,525
|
|
Outstanding
Equity Awards as of March 31, 2019
|
|
Equity
awards
|
Name
|
|
Date
of Grant
|
|
Number
of securities underlying unexercised options (#) exercisable
|
|
|
Number
of securities underlying unexercised options (#)
unexcercisable
|
|
|
Equity
incentive plan awards: Number of securities underlying unexercised unearned
options (#)
|
|
|
Option
exercise
price ($)
|
|
|
Option
expiration
date
|
|
Number
of
shares or
units of
stock that
have not
vested (#)
|
|
Steven
A. Lisi
|
|
08/31/2018
|
|
|
200,000
|
|
|
|
200,000
|
|
|
|
-
|
|
|
|
4.25
|
|
|
08/13/2029
|
|
|
-
|
|
|
|
03/31/2019
|
|
|
-
|
|
|
|
250,000
|
|
|
|
|
|
|
|
4.80
|
|
|
03/31/2029
|
|
|
|
|
|
|
12/31/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
88,000
|
|
|
|
01/01/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,000
|
|
Amir
Avniel
|
|
08/31/2018
|
|
|
125,000
|
|
|
|
125,000
|
|
|
|
-
|
|
|
|
4.25
|
|
|
08/13/2029
|
|
|
-
|
|
|
|
03/31/2019
|
|
|
-
|
|
|
|
140,000
|
|
|
|
|
|
|
|
4.80
|
|
|
03/31/2029
|
|
|
|
|
|
|
12/31/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45,000
|
|
|
|
01/01/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,000
|
|
|
|
02/20/2017
|
|
|
66,667
|
|
|
|
33,333
|
|
|
|
|
|
|
|
4.25
|
|
|
02/20/2027
|
|
|
|
|
Douglas
Beck, CPA
|
|
11/01/2018
|
|
|
-
|
|
|
|
85,000
|
|
|
|
|
|
|
|
4.25
|
|
|
11/01/2028
|
|
|
|
|
|
|
03/31/2019
|
|
|
-
|
|
|
|
15,000
|
|
|
|
|
|
|
|
4.80
|
|
|
03/31/2029
|
|
|
|
|
Adam
Newman (1)
|
|
08/31/2018
|
|
|
75,000
|
|
|
|
75,000
|
|
|
|
-
|
|
|
|
4.25
|
|
|
08/13/2029
|
|
|
-
|
|
|
|
03/31/2019
|
|
|
-
|
|
|
|
140,000
|
|
|
|
|
|
|
|
4.80
|
|
|
03/31/2029
|
|
|
|
|
|
|
12/31/2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,000
|
|
|
|
01/01/2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,000
|
|
|
|
06/30/2017
(1)
|
|
|
66,667
|
|
|
|
33,333
|
|
|
|
|
|
|
|
4.25
|
|
|
02/20/2027
|
|
|
|
|
Duncan
Fatkin
|
|
02/14/2019
|
|
|
-
|
|
|
|
85,000
|
|
|
|
|
|
|
|
5.05
|
|
|
02/14/2029
|
|
|
|
|
(1)
|
Received
for performing legal services for the Company.
|
Director
Compensation
Persons
serving as both an Officer and a Director of the Company are only included in the Executive Compensation Table above for the year
ended March 31, 2019.
Name
|
|
Fees
earned or paid in cash
($)
|
|
|
Stock
awards
($)
|
|
|
Option
awards
($)
|
|
|
Non-equity
incentive plan compensation ($)
|
|
|
Nonqualified
deferred compensation earnings
($)
|
|
|
All
Other Compensation
($)
|
|
|
Total
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr,
William Forbes (1)
|
|
|
-
|
|
|
|
-
|
|
|
|
99,190
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
99,190
|
|
Ron
Bentsur (3)
|
|
|
-
|
|
|
|
-
|
|
|
|
83,730
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
83,730
|
|
David
Grossman (1)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Erick
J. Lucera (4)
|
|
|
-
|
|
|
|
-
|
|
|
|
95,380
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
95,380
|
|
Ari
Raved (2) (5)
|
|
|
-
|
|
|
|
-
|
|
|
|
83,730
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
83,730
|
|
Yoori
Lee (6)
|
|
|
-
|
|
|
|
-
|
|
|
|
83,730
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
83,730
|
|
Robert
F. Carey (2)
|
|
|
-
|
|
|
|
-
|
|
|
|
90,271
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
90,271
|
|
(1)
|
Dr.
Forbes was appointed to the Board on August 13, 2018 effective upon Mr. Grossman’s resignation on such date. During
the year ended March 31, 2019, Dr. Forbes received options to purchase 25,000 and 8,000 shares of stock at $4.25 and $4.80
per share, respectively and which option expire in ten years.
|
|
|
(2)
|
Mr.
Carey was appointed to the Board on February 13, 2019 effective upon Mr. Raved’s resignation on such date. During the
year ended March 31, 2019, Mr. Carey received options to purchase 25,000 and 1,000 shares of stock at $4.95 and $4.80 per
share, respectively and which option expire in ten years.
|
|
|
(3)
|
During
the year ended March 31, 2019, Mr. Benstur received options to purchase 24,000 shares of stock at $4.80 per share, respectively
and which option expire in ten years.
|
|
|
(4)
|
During
the year ended March 31, 2019, Mr. Lucera received options to purchase 25,000 and 20,000 shares of stock at $4.25 and $4.80
per share, respectively and which option expire in ten years.
|
|
|
(5)
|
During
the year ended March 31, 2019, Mr. Raved received options to purchase 24,000 shares of stock at $4.80 per share, respectively
and which option expire in ten years. This option grant was issued after his resignation from the Board of Directors.
|
|
|
(6)
|
During
the year ended March 31, 2019, Ms. Lee received options to purchase 25,000 and 15,000 shares of stock at $4.25 and $4.80 per
share, respectively and which option expire in ten years.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Transactions
with Related Persons
With
respect to reviewing and approving related-party transactions, our audit committee will review related-party transactions for
potential conflicts of interests or other improprieties. Under SEC rules, related-party transactions are those transactions to
which we are or may be a party in which the amount involved exceeds the lesser of $120,000 or 1% of total assets, and in which
any of our directors or executive officers or any other related person had or will have a direct or indirect material interest,
excluding, among other things, compensation arrangements with respect to employment and Board of Directors membership. Our audit
committee could approve a related-party transaction if it determines that the transaction is in our best interests. Our directors
are required to disclose to this committee or the full Board of Directors any potential conflict of interest, or personal interest
in a transaction that our Board of Directors is considering. Our executive officers are required to disclose any related-party
transaction to the audit committee. We also poll our directors on an annual basis with respect to related-party transactions and
their service as an officer or director of other entities. Any director involved in a related-party transaction that is being
reviewed or approved must recuse himself or herself from participation in any related deliberation or decision. Whenever possible,
the transaction should be approved in advance and if not approved in advance, must be submitted for ratification as promptly as
practical.
Director
Independence
Our
board of directors has determined that each of Ron Bentsur, Erick Lucera, Yoori Lee, William Forbes and Robert F. Carey is independent
within the meaning of Rule 5605(a)(2) of the NASDAQ Listing Rules and the rules and regulations promulgated by the SEC. In making
its independence determinations, the board of directors sought to identify and analyze all of the facts and circumstances related
to any relationship between a director, his immediate family and our company and our affiliates and did not rely on categorical
standards other than those contained in the NASDAQ rule referenced above.
Purchases
of Our Securities
On
June 3, 2019, Steven Lisi purchased 58,252 shares of our common stock at a purchase price of $5.15 per share, or $300,000. On
December 12, 2019, Mr. Lisi purchased 190,437 shares of our common stock at a purchase price of $3.66 per share.
SELLING
STOCKHOLDERS
The
following table sets forth the name of each selling stockholder and the number of shares of common stock that each selling stockholder
may offer pursuant to this prospectus. Except as otherwise indicated, we believe that each of the selling stockholders listed
below has sole voting and investment power with respect to such shares, subject to community property laws, where applicable.
Unless otherwise noted, the address of each stockholder is c/o Beyond Air, Inc., 825 East Gate Boulevard, Suite 320, Garden City,
NY 11530.
Except
as noted in the table below or elsewhere in this prospectus, none of the selling stockholders has had a material relationship
with us other than as a stockholder at any time within the past three years or has ever been one of our or our affiliates’
officers or directors. Each of the selling stockholders has acquired its shares of our common stock to be resold hereunder in
the ordinary course of business and, at the time of acquisition, none of the selling stockholders was a party to any agreement
or understanding, directly or indirectly, with any person to distribute the shares of our common stock to be resold by such selling
stockholder under this registration statement.
Because
a selling stockholder may sell all, some or none of the shares of common stock it holds, and because the offering contemplated
by this prospectus is not underwritten, no estimate can be given as to the number of shares of common stock that will be held
by a selling stockholder upon termination of the offering. The information set forth in the following table regarding the beneficial
ownership after resale of shares is based upon the hypothetical assumption that the selling stockholders will sell all of the
shares of common stock owned by it and covered by this prospectus.
In
accordance with the rules and regulations of the SEC, in computing the number of shares of common stock (as applicable) beneficially
owned by a person and the percentage ownership of that person, shares issuable through the exercise of any option, warrant or
right, through conversion of any security held by that person that are currently exercisable or that are exercisable within 60
days are included. These shares are not, however, deemed outstanding for the purpose of computing the percentage ownership of
any other person.
The
share numbers in the second column of the table below do not reflect the Ownership Cap. See “Security Ownership of Certain
Beneficial Owners and Management”.
Shareholder
|
|
Shares
Owned
Prior
to the Offering
|
|
|
Number
of
Shares
Offered
|
|
|
Shares
Owned
After
the Offering
(1)
|
|
|
Percentage
|
|
Ali Ardakani
|
|
|
28,420
|
|
|
|
8,332
|
(2)
|
|
|
20,088
|
|
|
|
*
|
|
Allianz Biotechnologie
|
|
|
560,723
|
|
|
|
333,334
|
(2)
|
|
|
227,389
|
|
|
|
1.61
|
%
|
Amir Avniel
|
|
|
557,876
|
|
|
|
43,334
|
(2)
|
|
|
514,542
|
|
|
|
3.64
|
%
|
ANR Investment Company
|
|
|
5,542
|
|
|
|
5,542
|
(2)
|
|
|
-
|
|
|
|
|
|
Ari Raved
|
|
|
430,064
|
|
|
|
116,666
|
(2)
|
|
|
313,398
|
|
|
|
2.24
|
%
|
B.F.Y Invest
|
|
|
8,332
|
|
|
|
8,332
|
(2)
|
|
|
-
|
|
|
|
|
|
BTG Investments LLC
|
|
|
33,334
|
|
|
|
33,334
|
(2)
|
|
|
-
|
|
|
|
|
|
David Grossman
|
|
|
3,332
|
|
|
|
3,332
|
(2)
|
|
|
-
|
|
|
|
|
|
DBM Investing House
|
|
|
16,600
|
|
|
|
16,600
|
(2)
|
|
|
-
|
|
|
|
|
|
Deerfield Partners
L.P.
|
|
|
833,334
|
|
|
|
833,334
|
(2)
|
|
|
-
|
|
|
|
|
|
Dov Shafir
|
|
|
58,943
|
|
|
|
11,110
|
(2)
|
|
|
47,833
|
|
|
|
*
|
|
Ein Tal
|
|
|
5,554
|
|
|
|
5,554
|
(2)
|
|
|
-
|
|
|
|
|
|
Empery Asset Master,
Ltd.
|
|
|
72,804
|
|
|
|
72,804
|
(2)
|
|
|
-
|
|
|
|
|
|
Empery Tax Efficient
II, LP
|
|
|
93,864
|
|
|
|
93,864
|
(2)
|
|
|
-
|
|
|
|
|
|
Enrique Derzavich
|
|
|
66,666
|
|
|
|
66,666
|
(2)
|
|
|
-
|
|
|
|
|
|
First Fire Global Opportunities
Fund LLC
|
|
|
33,334
|
|
|
|
33,334
|
(2)
|
|
|
-
|
|
|
|
|
|
HFR HE Sphera Global
Healthcare Master Trust
|
|
|
11,332
|
|
|
|
11,332
|
(2)
|
|
|
-
|
|
|
|
|
|
HMLK
|
|
|
11,096
|
|
|
|
11,096
|
(2)
|
|
|
-
|
|
|
|
|
|
Hudson Bay Master Fund
Ltd.
|
|
|
83,334
|
|
|
|
83,334
|
(2)
|
|
|
-
|
|
|
|
|
|
Intracoastal Capital
LLC
|
|
|
16,666
|
|
|
|
16,666
|
(2)
|
|
|
-
|
|
|
|
|
|
Kingdon Associates
|
|
|
118,604
|
|
|
|
118,604
|
(2)
|
|
|
-
|
|
|
|
|
|
Kingsbrook Opportunities
Master Fund LP
|
|
|
16,666
|
|
|
|
16,666
|
(2)
|
|
|
-
|
|
|
|
|
|
M. Kingdon Offshore
Master Fund L.P.
|
|
|
214,730
|
|
|
|
214,730
|
(2)
|
|
|
-
|
|
|
|
|
|
Mor Research
|
|
|
381,845
|
|
|
|
16,666
|
(2)
|
|
|
365,179
|
|
|
|
2.58
|
%
|
Orcom Strategies Ltd.
|
|
|
16,666
|
|
|
|
16,666
|
(2)
|
|
|
-
|
|
|
|
|
|
Pulmonox Technologies
Corporation
|
|
|
380,002
|
|
|
|
380,002
|
(2)
|
|
|
-
|
|
|
|
|
|
Ron BenTsur
|
|
|
333,499
|
|
|
|
50,000
|
(2)
|
|
|
283,499
|
|
|
|
2.01
|
%
|
Ronen Kantor
|
|
|
10,000
|
|
|
|
10,000
|
(2)
|
|
|
-
|
|
|
|
|
|
Rosario underwriting
Services (A.S) Ltd.
|
|
|
83,332
|
|
|
|
83,332
|
(2)
|
|
|
-
|
|
|
|
|
|
Ruth Gorenstein
|
|
|
13,334
|
|
|
|
13,334
|
(2)
|
|
|
-
|
|
|
|
|
|
Sagit Shiran
|
|
|
66,666
|
|
|
|
66,666
|
(2)
|
|
|
-
|
|
|
|
|
|
Shay Teitelbaum
|
|
|
66,666
|
|
|
|
66,666
|
(2)
|
|
|
-
|
|
|
|
|
|
Sphere Global Healthcare
Master Fund
|
|
|
322,000
|
|
|
|
322,000
|
(2)
|
|
|
-
|
|
|
|
|
|
Steven Lisi
|
|
|
919,097
|
|
|
|
83,334
|
(2)
|
|
|
835,763
|
|
|
|
5.91
|
%
|
Traistman Radzievsky
Fundansia Ltd.
|
|
|
133,334
|
|
|
|
133,334
|
(2)
|
|
|
-
|
|
|
|
|
|
Yossi Av-Gay- G.N.E.
Biotechnologies
|
|
|
3,332
|
|
|
|
3,332
|
(2)
|
|
|
-
|
|
|
|
|
|
Alous Luis
Praxair & Sandra Praxmerer JTWROS
|
|
|
10,000
|
|
|
|
10,000
|
(3)
|
|
|
-
|
|
|
|
|
|
Ashok Suppiah
|
|
|
16,666
|
|
|
|
16,666
|
(3)
|
|
|
-
|
|
|
|
|
|
Ayman Baki
|
|
|
6,666
|
|
|
|
6,666
|
(3)
|
|
|
-
|
|
|
|
|
|
Bruce D. Singleton
|
|
|
14,000
|
|
|
|
14,000
|
(3)
|
|
|
-
|
|
|
|
|
|
David Levine
|
|
|
16,666
|
|
|
|
16,666
|
(3)
|
|
|
-
|
|
|
|
|
|
James W. Lees
|
|
|
16,666
|
|
|
|
16,666
|
(3)
|
|
|
-
|
|
|
|
|
|
Jan J. Laskowski &
Sofia M. Laskowski JTWROS
|
|
|
10,000
|
|
|
|
10,000
|
(3)
|
|
|
-
|
|
|
|
|
|
John Molter
|
|
|
8,332
|
|
|
|
8,332
|
(3)
|
|
|
-
|
|
|
|
|
|
Michael Turner
|
|
|
8,332
|
|
|
|
8,332
|
(3)
|
|
|
-
|
|
|
|
|
|
Robert Dunn & Judy
Dunn JTWROS
|
|
|
16,666
|
|
|
|
16,666
|
(3)
|
|
|
-
|
|
|
|
|
|
Robert N. Blank
|
|
|
8,332
|
|
|
|
8,332
|
(3)
|
|
|
-
|
|
|
|
|
|
Ronald A. Soicher
|
|
|
17,000
|
|
|
|
17,000
|
(3)
|
|
|
-
|
|
|
|
|
|
Ronald J. Woodward
|
|
|
5,000
|
|
|
|
5,000
|
(3)
|
|
|
-
|
|
|
|
|
|
Stephen Park &
Tracy Park JTWOS
|
|
|
8,332
|
|
|
|
8,332
|
(3)
|
|
|
-
|
|
|
|
|
|
Sterne Agee & Leach
Inc C/f Brian Smith R/O IRA
|
|
|
16,666
|
|
|
|
16,666
|
(3)
|
|
|
-
|
|
|
|
|
|
Sterne Agee & Leach
Inc C/F John Sommer IRA
|
|
|
25,000
|
|
|
|
25,000
|
(3)
|
|
|
-
|
|
|
|
|
|
Volkhard Bregulla
|
|
|
8,332
|
|
|
|
8,332
|
(3)
|
|
|
-
|
|
|
|
|
|
W Wade Brawley Revocable
Trust
|
|
|
8,332
|
|
|
|
8,332
|
(3)
|
|
|
-
|
|
|
|
|
|
Charles Marlio
|
|
|
535,273
|
|
|
|
150,273
|
(4)
|
|
|
385,000
|
|
|
|
2.72
|
%
|
Jacques Marlio
|
|
|
211,612
|
|
|
|
136,612
|
(4)
|
|
|
75,000
|
|
|
|
*
|
|
Susan Marlio
|
|
|
145,628
|
|
|
|
95,628
|
(4)
|
|
|
50,000
|
|
|
|
*
|
|
Jordi Arresse Castane
|
|
|
68,306
|
|
|
|
68,306
|
(4)
|
|
|
-
|
|
|
|
|
|
Victor Arrese
|
|
|
68,306
|
|
|
|
68,306
|
(4)
|
|
|
-
|
|
|
|
|
|
Donald Wright
|
|
|
13,661
|
|
|
|
13,661
|
(4)
|
|
|
-
|
|
|
|
|
|
*
less than 1%
(1)
Based upon 14,137,675 common stock outstanding at January 22, 2020
(2)
January 2017 and February 2017 warrant
(3)
March 2017 warrant
(4)
December 2019 private placement
Description
of the Merger and the Private Placements
The
Merger
On
December 29, 2016, we entered into an Agreement and Plan of Merger, which, as amended, we refer to as the Merger Agreement, together
with Red Maple Ltd., or Merger Sub, a wholly owned subsidiary of KokiCare, Inc., and Beyond Air Ltd. (f/k/a AIT Ltd.). The Merger
Agreement provided for (i) the merger of Merger Sub with and into Beyond Air Ltd. (f/k/a AIT Ltd.) pursuant to the laws of the
State of Israel, referred to as the Israeli Merger, and (ii) the conversion of the ordinary shares and other outstanding securities
of Beyond Air Ltd. (f/k/a AIT Ltd.) into the right to receive shares and other applicable securities of KokiCare, Inc., with Beyond
Air Ltd. (f/k/a AIT Ltd.) surviving as our wholly owned subsidiary, which we refer to as the Merger. The Israeli Merger became
effective on December 29, 2016 and the Merger closed on January 13, 2017.
Immediately
prior to the Merger, Beyond Air Ltd. (f/k/a AIT Ltd.) consummated a private placement pursuant to which it issued to investors
an aggregate of 1,701,616 of its ordinary shares, together with warrants to purchase an aggregate of 3,403,232 ordinary shares,
for gross proceeds of approximately $10,210,000. In connection with the Merger, we assumed Beyond Air Ltd. (f/k/a AIT Ltd.)’s
obligations under the purchase agreements with respect to such private placement, including the registration rights contained
therein. In connection with the closing of the Merger, all outstanding ordinary shares, warrants and options of Beyond Air Ltd.
(f/k/a AIT Ltd.) were converted into shares of our common stock, warrants for our common stock and options for our common stock,
respectively, at a ratio of 1:1.
The
2017 Private Placement
On
March 31, 2017 we consummated a private placement in which we issued and sold an aggregate of 110,494 units, each composed of
one share of our common stock and a five-year warrant to purchase two shares of common stock at an initial exercise price of $6.90
per share. We issued and sold the units to certain investors at a purchase price of $6.00 per unit, for which we received approximately
$663,000 of gross proceeds.
December
2019 Private Placement
On
December 10, 2019, the Company and certain existing U.S. and foreign investors entered into common stock purchase agreements for
the issue and sale of an aggregate of 532,786 unregistered shares of common stock at $3.66 per share. The private placement closed
on December 12, 2019.
DESCRIPTION
OF SECURITIES
General
The
following describes the material terms of the capital stock of the Company. The following description does not purport to be complete
and is subject to, and qualified in its entirety by reference to, the Company’s Amended and Restated Certificate of Incorporation
and Bylaws. All prospective investors are urged to read our Amended and Restated Certificate of Incorporation and Bylaws carefully
and in their entirety.
Authorized
Capital Stock; Issued and Outstanding Capital Stock
We
are authorized to issue up to 100,000,000 shares of our common stock, par value $0.0001 per share, of which 14,137,675
shares are issued and outstanding as of January 22, 2020. Additionally, we are authorized to issue up to 10,000,000 shares
of preferred stock, par value $0.0001 per share, of which no shares are issued and outstanding.
Common
Stock
The
holders of our common stock are entitled to one vote per share on all matters submitted to vote of our stockholders, including
the election of directors. Holders of our common stock are not entitled to cumulate their votes for the election of directors.
Except as otherwise required by law, or as otherwise fixed by resolution or resolutions of our Board of Directors with respect
to one or more series of our preferred stock, the entire voting power and all voting rights is vested exclusively in our common
stock.
Holders
of our common stock are not entitled to receive dividends except if declared by our Board of Directors and are not be entitled
to a liquidation preference in respect of their shares of common stock. Upon liquidation, dissolution or winding up of our company,
the holders of our common stock would be entitled to receive pro rata all assets remaining for distribution to stockholders after
the payment of all of our liabilities and of all preferential amounts to which any series of our preferred stock may be entitled.
Holders
of our common stock have no preemptive or subscription rights, and have no rights to convert their common stock into any other
securities. The common stock is not subject to call or redemption.
Preferred
Stock
Our
Amended and Restated Certificate of Incorporation authorizes our Board of Directors to fix or alter the dividend rights, dividend
rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or
prices, and dissolution preferences or any wholly unissued series of our preferred stock, and the number of shares constituting
any such series and the designation thereof, or any of them.
Our
Amended and Restated Certificate of Incorporation also provides that our Board of Directors is expressly authorized to increase
or decrease (but not below the number of shares of such series of preferred stock then outstanding) the number of shares of any
series of preferred stock subsequent to the issue of shares of that series.
We
will fix the rights, preferences, privileges and restrictions of the preferred stock of each series in the certificate of designation
relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will
incorporate by reference from a current report on Form 8-K that we file with the Commission, the form of any certificate of designation
that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred
stock. This description will include any or all of the following, as required:
|
●
|
the
title and stated value;
|
|
●
|
the
number of shares we are offering;
|
|
●
|
the
liquidation preference per share;
|
|
●
|
the
purchase price;
|
|
●
|
the
dividend rate, period and payment date and method of calculation for dividends;
|
|
●
|
whether
dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
|
|
●
|
any
contractual limitations on our ability to declare, set aside or pay any dividends;
|
|
●
|
the
procedures for any auction and remarketing, if any;
|
|
●
|
the
provisions for a sinking fund, if any;
|
|
●
|
the
provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and
repurchase rights;
|
|
●
|
any
listing of the preferred stock on any securities exchange or market;
|
|
●
|
whether
the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be
calculated, and the conversion period;
|
|
●
|
whether
the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be
calculated, and the conversion period;
|
|
●
|
voting
rights, if any, of the preferred stock;
|
|
●
|
preemptive
rights, if any;
|
|
●
|
restrictions
on transfer, sale or other assignment, if any;
|
|
●
|
whether
interests in the preferred stock will be represented by depositary shares;
|
|
●
|
a
discussion of any material or special United States federal income tax considerations applicable to the preferred stock;
|
|
●
|
the
relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind
up our affairs;
|
|
●
|
any
limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred
stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and
|
|
●
|
any
other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.
|
Our
board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect
the voting power or other rights of the holders of our common stock. Preferred stock could be issued quickly with terms designed
to delay or prevent a change in control of our Company or make removal of management more difficult. Additionally, the issuance
of preferred stock could have the effect of decreasing the market price of our common stock.
Warrants
2017
Warrants
In
January and February 2017, the Company issued 1,701,616 Units which resulted in the issuance of 1,701,616 shares of common stock
and 3,403,232 warrants to purchase common stock at $6.90 per share which expires in five years. In March 2017, the Company issued
110,494 Units, each of which comprised one share of common stock and two warrants to acquire shares of common stock at an exercise
price of $6.90 per share which expires in five years. In addition, the placement agent received 11,050 warrants with an exercise price of $6.90 per share
which expires in five years This comprises the “2017 Warrants”. Each of the foregoing 2017
Warrants has an adjusted exercise price of $3.66 per share of common stock and a five-year term. During 2017, in connection with
a license agreement, the Company issued to Pulmonox a warrant to purchase 208,333 shares of common stock with an exercise price
of $4.80 per share, which warrant expires in January 2024. The total warrants outstanding at December 31, 2017 was 3,843,603.
Subject
to certain exceptions, if we issue or sell, or are deemed to have issued or sold, any common stock for a consideration per share,
referred to as the New Issuance Price, less than a price equal to the exercise price of the 2017 Warrants then in effect immediately
prior to such issuance or sale, then immediately after such issuance or sale the exercise price of such 2017 Warrants then in
effect would be reduced to the New Issuance Price. If any sale or issuance, or deemed issuance, is for no consideration, then
the New Issuance Price is deemed to be $0.01 per share and the number of shares of common stock for which such 2017 Warrant is
exercisable would be increased to the number of shares determined by multiplying the exercise price in effect immediately prior
to such adjustment by the number of shares of common stock issuable upon exercise of the warrant immediately prior to such adjustment
and dividing the product thereof by the exercise price resulting from such adjustment.
2018
Warrants
On
February 16, 2018, we consummated an offering (the “February 2018 Offering”) in which we issued and sold an aggregate
of 4,599,604 warrants (the “February 2018 Warrants”), comprised of 2,299,802 warrants (the “Tranche A Warrants”)
to purchase one share of common stock at an exercise price of $4.25 per share, exercisable within three days from the issue date
of the Tranche A Warrants and an equal amount of warrants (the “Tranche B Warrants”) to purchase one share of common
stock at an exercise price of $4.25 per share, exercisable within three years from the issue date of the Tranche B Warrants. Immediately
following the consummation of the February 2018 Offering, each shareholder exercised the full amount of their Tranche A Warrants,
resulting in gross proceeds to us from the sale of the February 2018 Warrants for $0.01 per underlying warrant share, together
with the exercise price of the Tranche A Warrants, of approximately $9,820,000.
If
at any time a registration statement covering the resale of the shares of common stock issuable upon exercise of any of the 2017
Warrants or 2018 Warrants is not currently effective and available for the resale of all such shares, then the holders of such
warrants may exercise all or any part of their respective warrants in a “cashless” or “net-issue” exercise.
Furthermore, the warrants contain anti-dilution provisions in the case of a subdivision or combination of our shares of common
stock, stock dividends, any reclassification of common stock, and corporate events such as a reorganization, consolidation, merger,
or sale of all or substantially all of our assets.
A
summary of the Company’s outstanding warrants as of December 31, 2019 are as follows and are converted on a one for one
basis to shares of common stock:
Warrant
Holders
|
|
Number
Of Warrants
|
|
|
Exercise
Price
|
|
|
Date
Of Expiration
|
|
|
January
2017 offering - investors
|
|
|
1,701,616
|
|
|
$
|
3.66
|
|
|
|
January
2022
|
(a)
|
January
2017 offering - investors
|
|
|
1,701,616
|
|
|
$
|
3.66
|
|
|
|
February
2022
|
(a)
|
March
2017 offering - investors
|
|
|
220,988
|
|
|
$
|
3.66
|
|
|
|
March
2021
|
(a)
|
March
2017 offering - placement agent
|
|
|
11,050
|
|
|
$
|
3.66
|
|
|
|
March
2021
|
(a)
|
February
2018 offering - investors
|
|
|
2,299,802
|
|
|
$
|
4.25
|
|
|
|
March
2022
|
|
Third-party
|
|
|
208,333
|
|
|
$
|
4.80
|
|
|
|
January
2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
6,143,405
|
|
|
|
|
|
|
|
|
|
(a)
|
These
warrants have down round protection.
|
Indemnification
of Officers and Directors
Incorporated
in the State of Delaware, the Company is subject to the Delaware General Corporation Law (the “DGCL”). Section 145
of the DGCL empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other
than an action by or in the right of such corporation) by reason of the fact that such person is or was a director, officer, employee
or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent
of another corporation or enterprise. A corporation may, in advance of the final action of any civil, criminal, administrative
or investigative action, suit or proceeding, pay the expenses (including attorneys’ fees) incurred by any officer, director,
employee or agent in defending such action, provided that the director or officer undertakes to repay such amount if it shall
ultimately be determined that he or she is not entitled to be indemnified by the corporation. A corporation may indemnify such
person against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by such person in connection with such action, suit or proceeding if he or she acted in good faith and in a manner he
or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal
action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
A
Delaware corporation may indemnify officers and directors in an action by or in the right of the corporation to procure a judgment
in its favor under the same conditions, except that no indemnification is permitted without judicial approval if the officer or
director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in
the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys’
fees) which he or she actually and reasonably incurred in connection therewith. The indemnification provided is not deemed to
be exclusive of any other rights to which an officer or director may be entitled under any corporation’s by-law, agreement,
vote or otherwise.
Our
Amended and Restated Certificate of Incorporation provides that we shall indemnify our directors, officers and agents (and any
other persons to which applicable law permits the Company to provide indemnification) whether serving us or at our request, any
other entity, to the full extent required or permitted by the DGCL, including the advancement of expenses under the procedures
and to the full extent permitted by law.
Our
Amended and Restated By-laws (“Bylaws”) provide that, we shall indemnify our directors and executive officers (“executive
officers” shall have the meaning defined in Rule 3b-7 promulgated under the 1934 Act) to the extent not prohibited by the
DGCL or any other applicable law; provided, however, that we may modify the extent of such indemnification by individual contracts
with our directors and executive officers; and, provided, further, that we shall not be required to indemnify any director or
executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification
is expressly required to be made by law, (ii) the proceeding was authorized by the Board of Directors of the corporation, (iii)
such indemnification is provided by us, in our sole discretion, pursuant to the powers vested in the Company under the DGCL or
any other applicable law or (iv) such indemnification is required to be made under section 44(d) of the Bylaws.
We
have power to indemnify our other officers, employees and other agents as set forth in the DGCL or any other applicable law. The
Board of Directors shall have the power to delegate the determination of whether indemnification shall be given to any such person
except executive officers to such officers or other persons as the Board of Directors shall determine.
Anti-Takeover
Effects and Exclusive Form Provisions of our Charter Documents and Delaware Law
Delaware
Law
We
are subject to the provisions of Section 203 of the General Corporation Law of the State of Delaware. Under Section 203, we would
generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years
following the time that such stockholder became an interested stockholder unless:
|
●
|
prior
to this time, our Board of Directors approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder;
|
|
●
|
upon
consummation of the transaction that resulted in the stockholder becoming an interested
stockholder, the interested stockholder owned at least 85% of our voting stock outstanding
at the time the transaction commenced, subject to certain exceptions; or
|
|
●
|
at
or subsequent to such time, the business combination is approved by our Board of Directors
and authorized at an annual or special meeting of our stockholders, and not by written
consent, by the affirmative vote of at least two-thirds of the outstanding voting stock
that is not owned by the interested stockholder.
|
Under
Section 203, a “business combination” includes:
|
●
|
any
merger or consolidation involving the Company and the interested stockholder;
|
|
●
|
any
transaction with the interested stockholder involving any sale, lease, exchange, mortgage,
pledge, transfer or other disposition of assets of the Company
having
a market value of 10% or more of either the consolidated assets of the Company or the market value of all of the Company’s
outstanding stock
(whether
in one transaction or in a series of transactions);
|
|
●
|
any
transaction that results in the issuance or transfer by the Company of any stock of the Company to the interested stockholder,
subject to limited exceptions;
|
|
●
|
any
transaction involving the Company that has the effect of increasing the proportionate
share of the stock of any class or series of the Company beneficially owned
by
the interested stockholder; or
|
|
●
|
any
receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits
provided by or through the Company.
|
In
general, Section 203 defines an “interested stockholder” as an entity or person beneficially owning 15% or more of
the outstanding voting stock of a corporation and any entity or person affiliated with or controlling or controlled by such entity
or person.
Amended
and Restated Certificate of Incorporation and By-Law Provisions
Our
Amended and Restated Certificate of Incorporation and Bylaws may delay or discourage transactions involving an actual or potential
change of control of our company or change in our Board of Directors, including transactions in which our stockholders might otherwise
receive a premium for their shares of our common stock, or transactions that our stockholders might otherwise deem to be in their
best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our Amended
and Restated Certificate of Incorporation and Bylaws and applicable Delaware law:
|
●
|
permit
our Board of Directors to issue up to 10,000,000 shares of preferred stock, with any
rights, preferences and privileges as they may designate (including
dividend
rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions),
redemption price or prices, and
dissolution
preferences);
|
|
|
|
|
●
|
provide
that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by a vote of
a majority of directors then in office;
|
|
|
|
|
●
|
do
not provide for cumulative voting rights (therefore allowing the holders of a majority
of the shares of common stock entitled to vote in any election of directors to
elect
all of the directors standing for election, if they should so choose);
|
|
|
|
|
●
|
provide
that, unless with otherwise consent to an alternative forum, the Court of Chancery of the State of Delaware is the sole and
exclusive forum for: (A) any derivative action or proceeding brought on behalf of us; (B) any action asserting a claim of
breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (C) any action
asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, our Amended and Restated
Certificate of Incorporation or our Bylaws; or (D) any action asserting a claim against us governed by the internal affairs
doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company shall
be deemed to have notice of and to have consented to the foregoing exclusive forum.
|
Other
than the provision with respect to the issuance of preferred stock, the amendment of which would require approval by holders of
at least a majority of the voting power of all of the then outstanding shares of capital stock of the Company entitled to vote
generally in the election of directors, voting together as a single class, any amendment to the other provisions described above
requires the vote of holders of at least 66% (2/3) of the voting power of all of the then outstanding shares of capital stock
of the Company entitled to vote generally in the election of directors, voting together as a single class.
PLAN
OF DISTRIBUTION
The
common stock offered by this prospectus is being offered by the selling stockholders. The common stock may be sold or distributed
from time to time by the selling stockholders directly to one or more purchasers or through brokers, dealers, or underwriters
who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices,
at negotiated prices, or at fixed prices, which may be changed. The sale of the Common Stock offered by this prospectus may be
effected in one or more of the following methods:
|
●
|
ordinary
brokers’ transactions;
|
|
●
|
transactions
involving cross or block trades;
|
|
●
|
through
brokers, dealers, or underwriters who may act solely as agents;
|
|
●
|
in
other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected
through agents;
|
|
●
|
in
privately negotiated transactions; or
|
|
●
|
any
combination of the foregoing.
|
The
selling stockholders may also sell shares of common stock under Rule 144 promulgated under the Securities Act, if available, rather
than under this prospectus. In addition, the selling stockholders may transfer the shares of common stock by other means not described
in this prospectus.
Brokers,
dealers, underwriters, or agents participating in the distribution of the shares as agents may receive compensation in the form
of commissions, discounts, or concessions from the selling stockholders and/or purchasers of the common stock for whom the broker-dealers
may act as agent.
The
selling stockholders may be deemed to be “underwriters” within the meaning of the Securities Act.
Neither
we nor the selling stockholders can presently estimate the amount of compensation that any agent will receive. We know of no existing
arrangements between the selling stockholders, any other stockholders, broker, dealer, underwriter, or agent relating to the sale
or distribution of the shares offered by this prospectus. At the time a particular offer of shares is made, a prospectus supplement,
if required, will be distributed that will set forth the names of any agents, underwriters, or dealers and any compensation from
the selling stockholders, and any other required information.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling
persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the
Securities Act and is therefore, unenforceable.
We
may suspend the sale of shares by the selling stockholders pursuant to this prospectus for certain periods of time for certain
reasons, including if the prospectus is required to be supplemented or amended to include additional material information.
LEGAL
MATTERS
The
validity of the shares of common stock offered by this prospectus will be passed upon for us by Sichenzia Ross Ference LLP, New
York, New York.
EXPERTS
The
consolidated financial statements of Beyond Air, Inc. and subsidiaries as of March 31, 2018 and December 31, 2017, for the transition
period ended March 31, 2018, and for the fiscal year ended December 31, 2017, contained in this prospectus have been included
in reliance upon the report of Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global, predecessor independent
registered public accounting firm, and upon the authority of said firm as experts in accounting and auditing.
The
consolidated financial statements of Beyond Air, Inc. and subsidiaries as of and for the year ended March 31, 2019 contained in
this prospectus have been included in reliance upon the report of Friedman LLP, independent registered public accounting firm,
and upon the authority of said firm as experts in accounting and auditing.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the common stock offered
by this prospectus. This prospectus is a part of the registration statement and does not contain all of the information set forth
in the registration statement and its exhibits and schedules, portions of which have been omitted as permitted by the rules and
regulations of the SEC. For further information about us and our common stock, you should refer to the registration statement
and its exhibits and schedules. Statements contained in this prospectus about the contents of any contract or any other document
filed as an exhibit are not complete and in each instance we refer you to the copy of the contract or other document filed as
an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. The agreements
and other documents filed as exhibits to this registration statement are not intended to provide factual information or other
disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them
for that purpose. In particular, any representations and warranties made by the registrant in these agreements or other documents
were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs
as of the date they were made or at any other time.
Our
registration statement on Form S-1 of which this prospectus is a part is available to the public on the SEC’s website at
http://www.sec.gov. You may also read and copy, at SEC prescribed rates, any document we file with the SEC, including the registration
statement (and its exhibits) of which this prospectus is a part, at the SEC’s Public Reference Room located at 100 F Street,
N.E., Washington D.C. 20549. You can call the SEC at 1-800-SEC- 0330 to obtain information on the operation of the Public Reference
Room.
We
are subject to the information and reporting requirements under the Securities Exchange Act of 1934 and, in accordance with this
law, file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and
other information are available for inspection and copying at the SEC’s public reference facilities and the website of the
SEC referred to above. Those filings will also be available to the public on, or accessible through, our website under the heading
“Investor Relations” at www.beyondair.net/investors. You may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a
part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only.
CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS
INDEX
BEYOND
AIR, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
|
September
30, 2019
|
|
|
March
31, 2019
|
|
|
|
(Unaudited)
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
1,895,389
|
|
|
$
|
1,340,203
|
|
Restricted cash
|
|
|
459,234
|
|
|
|
16,934
|
|
Marketable securities
|
|
|
7,485,819
|
|
|
|
6,542,667
|
|
Right-of-use lease
assets
|
|
|
58,267
|
|
|
|
-
|
|
Other
current assets and prepaid expenses
|
|
|
414,033
|
|
|
|
788,409
|
|
Total current assets
|
|
|
10,312,742
|
|
|
|
8,688,213
|
|
Licensed right to
use technology
|
|
|
431,801
|
|
|
|
495,000
|
|
Right-of-use lease
assets
|
|
|
169,760
|
|
|
|
-
|
|
Property
and equipment, net
|
|
|
228,789
|
|
|
|
244,872
|
|
TOTAL ASSETS
|
|
$
|
11,143,092
|
|
|
$
|
9,428,085
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’
EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
2,104,323
|
|
|
$
|
1,164,672
|
|
Accrued expenses
|
|
|
2,068,246
|
|
|
|
1,567,638
|
|
Deferred revenue
|
|
|
990,223
|
|
|
|
2,263,294
|
|
Stock to be issued
to a vendor
|
|
|
138,000
|
|
|
|
144,000
|
|
Operating lease
liability
|
|
|
65,092
|
|
|
|
-
|
|
Loan
payable
|
|
|
88,582
|
|
|
|
263,604
|
|
Total current liabilities
|
|
|
5,454,466
|
|
|
|
5,403,208
|
|
|
|
|
|
|
|
|
|
|
Long-term liabilities
|
|
|
|
|
|
|
|
|
Operating lease
liability
|
|
|
169,005
|
|
|
|
-
|
|
Total liabilities
|
|
|
5,623,471
|
|
|
|
5,403,208
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity
|
|
|
|
|
|
|
|
|
Preferred Stock, $0.0001 par value
per share: 10,000,000 shares authorized, 0 shares issued and outstanding
|
|
|
-
|
|
|
|
-
|
|
Common Stock, $0.0001 par value per
share: 100,000,000 shares authorized,10,746,780 and 8,714,815 shares issued and outstanding as of September 30, 2019 and March
31, 2019, respectively
|
|
|
1,075
|
|
|
|
871
|
|
Treasury stock
|
|
|
(25,000
|
)
|
|
|
(25,000
|
)
|
Additional paid-in
capital
|
|
|
53,466,679
|
|
|
|
41,693,578
|
|
Accumulated
deficit
|
|
|
(47,923,133
|
)
|
|
|
(37,644,572
|
)
|
Total
shareholders’ equity
|
|
|
5,519,621
|
|
|
|
4,024,877
|
|
TOTAL
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
|
$
|
11,143,092
|
|
|
$
|
9,428,085
|
|
The
accompanying notes are an integral part of these condensed consolidated financial statements.
BEYOND
AIR, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
|
|
For
the Three Months Ended
|
|
|
For
the Six Month Ended
|
|
|
|
September
30,
|
|
|
September
30,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
License
revenues
|
|
$
|
645,602
|
|
|
$
|
-
|
|
|
$
|
1,273,071
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
(2,849,990
|
)
|
|
|
(647,866
|
)
|
|
|
(5,173,503
|
)
|
|
|
(1,711,011
|
)
|
General
and administrative
|
|
|
(2,064,872
|
)
|
|
|
(1,765,489
|
)
|
|
|
(4,247,430
|
)
|
|
|
(2,458,494
|
)
|
Operating expenses
|
|
|
(4,914,862
|
)
|
|
|
(2,413,355
|
)
|
|
|
(9,420,933
|
)
|
|
|
(4,169,505
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(4,269,260
|
)
|
|
|
(2,413,355
|
)
|
|
|
(8,147,862
|
)
|
|
|
(4,169,505
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Realized and unrealized gain (loss)
from marketable securities
|
|
|
142,806
|
|
|
|
2,805
|
|
|
|
(2,164,513
|
)
|
|
|
8,208
|
|
Dividend income
|
|
|
30,691
|
|
|
|
31,085
|
|
|
|
34,067
|
|
|
|
63,986
|
|
Foreign exchange loss
|
|
|
(1,977
|
)
|
|
|
(4,167
|
)
|
|
|
(253
|
)
|
|
|
(966
|
)
|
Other expenses
|
|
|
-
|
|
|
|
(5,587
|
)
|
|
|
-
|
|
|
|
(9,289
|
)
|
Total other income
(loss)
|
|
|
171,520
|
|
|
|
24,136
|
|
|
|
(2,130,699
|
)
|
|
|
61,939
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(4,097,740
|
)
|
|
$
|
(2,389,219
|
)
|
|
$
|
(10,278,561
|
)
|
|
$
|
(4,107,566
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net basis and
diluted loss per share
|
|
$
|
(0.38
|
)
|
|
$
|
(0.28
|
)
|
|
$
|
(1.03
|
)
|
|
$
|
(0.49
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of shares of common stock used in computing basic and diluted net loss per share
|
|
|
10,699,370
|
|
|
|
8,440,457
|
|
|
|
9,935,444
|
|
|
|
8,420,281
|
|
The
accompanying notes are an integral part of these condensed consolidated financial statements.
BEYOND
AIR, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2019 (UNAUDITED)
|
|
Common
Stock
|
|
|
Treasury
|
|
|
Additional
Paid-in
|
|
|
Accumulated
|
|
|
Total
Shareholders’
|
|
|
|
Number
|
|
|
Amount
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Equity
|
|
Balance as of April 1, 2019
|
|
|
8,714,815
|
|
|
$
|
871
|
|
|
$
|
(25,000
|
)
|
|
$
|
41,693,578
|
|
|
$
|
(37,644,572
|
)
|
|
$
|
4,024,877
|
|
At the market stock issuance of common
stock, net,
|
|
|
250,000
|
|
|
|
25
|
|
|
|
-
|
|
|
|
1,173,785
|
|
|
|
-
|
|
|
|
1,173,810
|
|
Issuance of common stock upon exercise
of options
|
|
|
32,122
|
|
|
|
3
|
|
|
|
-
|
|
|
|
83,854
|
|
|
|
-
|
|
|
|
83,857
|
|
Issuance of common stock pursuant to
a private placement, net of offering cost
|
|
|
1,583,743
|
|
|
|
159
|
|
|
|
-
|
|
|
|
7,839,336
|
|
|
|
-
|
|
|
|
7,839,495
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
919,037
|
|
|
|
|
|
|
|
919,037
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(6,180,821
|
)
|
|
|
(6,180,821
|
)
|
Balance as of June 30, 2019
|
|
|
10,580,680
|
|
|
$
|
1,058
|
|
|
$
|
(25,000
|
)
|
|
$
|
51,709,590
|
|
|
$
|
(43,825,393
|
)
|
|
$
|
7,860,255
|
|
|
|
Common
Stock
|
|
|
Treasury
|
|
|
Additional
Paid-in
|
|
|
Accumulated
|
|
|
Total
Shareholders’
|
|
|
|
Number
|
|
|
Amount
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Equity
|
|
Balance as of July l, 2019
|
|
|
10,580,680
|
|
|
$
|
1,058
|
|
|
$
|
(25,000
|
)
|
|
$
|
51,709,590
|
|
|
$
|
(43,825,393
|
)
|
|
$
|
7,860,255
|
|
At the market stock issuance of common stock,
net
|
|
|
160,000
|
|
|
|
16
|
|
|
|
-
|
|
|
|
808,168
|
|
|
|
-
|
|
|
|
808,184
|
|
Issuance of common stock upon exercise of options
|
|
|
6,100
|
|
|
|
1
|
|
|
|
-
|
|
|
|
25,924
|
|
|
|
-
|
|
|
|
25,925
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
922,997
|
|
|
|
|
|
|
|
922,997
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(4,097,740
|
)
|
|
|
(4,097,740
|
)
|
Balance as of
September 30, 2019
|
|
|
10,746,780
|
|
|
$
|
1,075
|
|
|
$
|
(25,000
|
)
|
|
$
|
53,466,679
|
|
|
$
|
(47,923,133
|
)
|
|
$
|
5,519,621
|
|
The
accompanying notes are an integral part of these condensed consolidated financial statements.
BEYOND
AIR, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR
THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2018 (UNAUDITED)
|
|
Common
Stock
|
|
|
Treasury
|
|
|
Additional
Paid-in
|
|
|
Accumulated
|
|
|
Total
Shareholders’
|
|
|
|
Number
|
|
|
Amount
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Equity
|
|
Balance as of April 1, 2018
|
|
|
8,397,056
|
|
|
$
|
840
|
|
|
$
|
(25,000
|
)
|
|
$
|
32,141,110
|
|
|
$
|
(30,572,750
|
)
|
|
$
|
1,544,200
|
|
Adjustment due to the adoption of ASU-2017-11)
(A)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,194,292
|
|
|
|
(516,358
|
)
|
|
|
5,677,934
|
|
Issuance of common stock upon exercise
of options
|
|
|
9,601
|
|
|
|
1
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
-
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,000
|
|
|
|
|
|
|
|
80,000
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,718,347
|
)
|
|
|
(1,718,347
|
)
|
Balance as of June 30, 2018
|
|
|
8,406,657
|
|
|
$
|
841
|
|
|
$
|
(25,000
|
)
|
|
$
|
38,415,401
|
|
|
$
|
(32,807,455
|
)
|
|
$
|
5,583,787
|
|
(A)
|
The
Company elected to adopt Accounting Standards Update 2017-11 retrospective to outstanding financial instruments with down
round feature by means of cumulative-effect adjustment to the beginning additional paid-in capital of $6,194,292 and accumulated
deficit of $(516,358) as of April 1, 2018. This ASU affects all entities that issue financial instruments (for example, warrants
or convertible instruments) that include down round features.
|
|
|
Common
Stock
|
|
|
Treasury
|
|
|
Additional
Paid-in
|
|
|
Accumulated
|
|
|
Total
Shareholders’
|
|
|
|
Number
|
|
|
Amount
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Equity
|
|
Balance as of July 1, 2018
|
|
|
8,406,657
|
|
|
$
|
841
|
|
|
$
|
(25,000
|
)
|
|
$
|
38,415,401
|
|
|
$
|
(32,807,455
|
)
|
|
$
|
5,583,787
|
|
At the market stock issuance of common stock,
net
|
|
|
117,000
|
|
|
|
11
|
|
|
|
|
|
|
|
(18,511
|
)
|
|
|
|
|
|
|
(18,500
|
)
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
842,010
|
|
|
|
|
|
|
|
842,010
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,402,519
|
)
|
|
|
(2,392,024
|
)
|
Balance as of
September 30, 2018
|
|
|
8,523,657
|
|
|
$
|
852
|
|
|
$
|
(25,000
|
)
|
|
$
|
39,238,900
|
|
|
$
|
(35,209,974
|
)
|
|
$
|
4,004,778
|
|
The
accompanying notes are an integral part of these condensed consolidated financial statements.
BEYOND
AIR, INC. AND ITS SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
|
|
For
the Six Months Ended
September
30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Cash flows
from operating activities
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(10,278,561
|
)
|
|
$
|
(4,107,566
|
)
|
Adjustments to reconcile
net loss to net cash used in operating activities
|
|
|
|
|
|
|
|
|
Depreciation and
amortization of property and equipment
|
|
|
33,819
|
|
|
|
30,591
|
|
Amortization of
intangible asset
|
|
|
63,199
|
|
|
|
-
|
|
Amortization right-
of-use lease assets
|
|
|
30,578
|
|
|
|
-
|
|
Stock-based compensation
|
|
|
1,836,034
|
|
|
|
922,010
|
|
Realized and unrealized
loss (gain) from marketable securities
|
|
|
2,164,513
|
|
|
|
(11,013
|
)
|
Changes in:
|
|
|
|
|
|
|
|
|
Other current assets
and prepaid expenses
|
|
|
374,374
|
|
|
|
(66,168
|
)
|
Accounts payable
|
|
|
939,651
|
|
|
|
20,367
|
|
Accrued expenses
|
|
|
500,610
|
|
|
|
(895,252
|
)
|
Lease payments
|
|
|
(24,508
|
)
|
|
|
-
|
|
Deferred
revenue
|
|
|
(1,273,071
|
)
|
|
|
-
|
|
Net cash used
in operating activities
|
|
|
(5,633,362
|
)
|
|
|
(4,107,031
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows
from investing activities
|
|
|
|
|
|
|
|
|
Investment in marketable
securities
|
|
|
(11,856,706
|
)
|
|
|
(60,887
|
)
|
Proceeds from redemption
of marketable securities
|
|
|
8,749,041
|
|
|
|
3,816,000
|
|
Purchase
of property and equipment
|
|
|
(17,736
|
)
|
|
|
(36,487
|
)
|
Net cash (used
in) provided by investing activities
|
|
|
(3,125,401
|
)
|
|
|
3,718,626
|
|
|
|
|
|
|
|
|
|
|
Cash flows
from financing activities
|
|
|
|
|
|
|
|
|
Issuance of common
stock in private placement, net of offering cost
|
|
|
7,839,495
|
|
|
|
-
|
|
Issuance of common
stock related to at the market offerings, net
of offering costs
|
|
|
1,981,994
|
|
|
|
(18,500
|
)
|
Payment of loan
|
|
|
(175,022
|
)
|
|
|
-
|
|
Proceeds
from the exercise of stock options
|
|
|
109,782
|
|
|
|
-
|
|
Net cash provided
by (used in) financing activities
|
|
|
9,756,249
|
|
|
|
(18,500
|
)
|
|
|
|
|
|
|
|
|
|
Increase (decrease) in cash, cash equivalents
and restricted cash
|
|
|
997,486
|
|
|
|
(406,905
|
)
|
Cash, cash equivalents
and restricted cash at beginning of period
|
|
|
1,357,137
|
|
|
|
739,234
|
|
Cash, cash equivalents
and restricted cash at end of period
|
|
$
|
2,354,623
|
|
|
$
|
332,329
|
|
Supplemental disclosure of non-investing
activities
|
|
|
|
|
|
|
|
|
Right-of-use assets
|
|
$
|
258,605
|
|
|
$
|
-
|
|
Operating lease liability
|
|
$
|
266,570
|
|
|
$
|
-
|
|
Supplemental disclosure of cash flow
items:
|
|
|
|
|
|
|
|
|
Interest paid
|
|
$
|
3,082
|
|
|
$
|
-
|
|
The
accompanying notes are an integral part of these condensed consolidated financial statements.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
1 ORGANIZATION AND BUSINESS
Beyond
Air, Inc. (“Beyond Air” or the “Company”) was incorporated on April 24, 2015 as KokiCare, Inc. under the
laws of the State of Delaware. On January 9, 2017, the name of the Company was changed to AIT Therapeutics, Inc. The Company filed
an Amendment to its Certificate of Incorporation to change its name from AIT Therapeutics, Inc. to Beyond Air, Inc., effective
June 26, 2019.
Advanced
Inhalation Therapies Ltd. was incorporated in Israel on May 1, 2011 and is a wholly-owned subsidiary of the Company. On August
29, 2014 Advanced Inhalation Therapies Ltd, established a subsidiary, Advanced Inhalation Therapies Inc. On July 4, 2019, Advanced
Inhalation Therapies Ltd.’s name was changed to Beyond Air, Ltd. (“BA Ltd.)”.
In
December 2016, the Company consummated a reverse merger with KokiCare, Inc. Under reverse recapitalization accounting, BA Ltd.
was considered the acquirer for accounting and financial reporting purposes. Consequently, the unaudited condensed consolidated
financial statements of the Company reflect the operations of the acquirer for accounting purposes together with a deemed issuance
of shares, equivalent to the shares held by the former stockholders of the legal acquirer and a recapitalization of the equity
of the accounting acquirer. These unaudited condensed consolidated financial statements include the accounts of the Company since
the effective date of the reverse capitalization and the accounts of BA Ltd. since inception.
The
Company is an emerging medical device company that is developing a Nitric Oxide (“NO”) delivery system that generates
NO from ambient air. Since its inception, the Company has devoted substantially all of its
efforts to business planning and research and development.
Liquidity
Risks and Uncertainties
As
shown in the accompanying financial statements, the Company has incurred cash used in operating activities of $5,633,362 for the
six months ended September 30, 2019 and has accumulated losses of $47.9 million. The Company has cash, cash equivalents and marketable
securities of $9.4 million as of September 30, 2019. Included in marketable securities are common shares of Circassia Pharmaceuticals
plc of $1.9 million, see Note 3 and 9. Based upon the Company’s current business plan, and expected cash utilization, the
Company estimates that it will have enough cash, including the proceeds from the sale of all its marketable securities, to operate
its business for at least one year from the filing of the Company’s September 30, 2019 10-Q.
The
Company’s future capital needs and the adequacy of its available funds will depend on many factors, including the cost of
clinical studies and other actions needed to obtain regulatory approval of our medical devices in development. The Company will
be required to raise additional funds through sale of equity or debt securities or through strategic collaboration and/or licensing
agreements, to fund operations and continue our clinical trials until the Company is able to generate enough product or royalty
revenues, if any. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed
could have a material adverse effect on our growth plans, our results of operations and our financial condition.
On
July 2, 2019, the SEC declared effective the Company’s Form S-3 shelf registration statement which allows the Company to
sell up to $100 million of equity securities.
In
addition, the Company has a $20 million purchase agreement (“Purchase Agreement”) and a registration rights agreement
with Lincoln Park Capital Fund, LLC (“LPC”), providing for the issuance of up to $20 million of the Company’s
common stock through August 2021 at the Company’s discretion, see Note 5.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation
The
unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles
in the United States (“US GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly,
they do not include all of the information and footnotes required to be presented for complete financial statements. The accompanying
unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring items) which
are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. The accompanying
unaudited condensed consolidated Balance Sheet as of March 31, 2019 has been derived from the audited consolidated financial statements
included in our Annual Report on Form 10-K for the year ended March 31, 2019. The unaudited condensed consolidated financial statements
and related disclosures have been prepared with the assumption that users of the interim financial information have read or have
access to the audited consolidated financial statements and the related notes thereto included in the Annual Report on Form 10-K
for the year ended March 31,2019 which was filed with the United States Securities and Exchange Commission, (“SEC”),
on June 28, 2019.
Principles
of Consolidation
These
unaudited condensed consolidated financial statements include the accounts of the Company and the accounts of BA Ltd. All intercompany
balances and transactions have been eliminated in the accompanying financial statements.
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those
estimates. The Company’s significant estimates are accrual of expenses under consulting and licensing agreements, stock-based
compensation, assumptions associated with revenue recognition, and the determination of deferred tax attributes and the valuation
allowance thereon.
Other
Risks and Uncertainties
The
Company is subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence
on key personnel, protection of proprietary technology, compliance with government regulations, product liability, uncertainty
of market acceptance of products and the potential need to obtain additional financing. The Company is dependent on third party
suppliers, in some cases single-source suppliers.
There
can be no assurance that the Company’s products will be accepted in the marketplace, nor can there be any assurance that
any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or
that such products will be successfully marketed, if at all.
The
Company’s products require approval or clearance from the U.S. Food and Drug Administration prior to commencing commercial
sales in the United States. The Company is expected to file a Premarketing (PMA) Approval application before the end of its fiscal
year end on March 31, 2020 for its first product. There can be no assurance that the Company’s products will receive all
of the required approvals or clearances. Approvals or clearances are also required in foreign jurisdictions in which the Company
may license or sell its products. If the Company is denied such approvals or clearances or such approvals or clearances are delayed,
it may have a material adverse impact on the Company’s results of operations, financial position and liquidity.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
Concentrations
The
Company’s license revenue was from two milestone payments from one customer. The Company is seeking additional Partners
outside of the United States and China.
The
Company relies on two vendors to manufacture its delivery system. The Company is reliant on the vendors for commercial manufacturing
of our LungFit™ generator and delivery systems and nitrogen dioxide filters for both clinical studies and commercial supply,
if regulatory approval is received.
Financial
Instruments
Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents
and marketable securities. The Company maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts
in major banks in Israel and the U.S., the balances of which, at times, may exceed federally insured limits.
The
Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign
hedging arrangements.
Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months
or less at acquisition.
Restricted
Cash
As
of September 30, 2019, restricted cash includes $442,000 of cash that is designated for a contract manufacturer. This cash is
expected be used for parts that require a long lead time. Collateral for vehicle leases are invested in bank deposit accounts
which is restricted and as of September 30, 2019 was $17,234 and as of March 31,2019 was $16,934.
The
following table is the reconciliation of the recently adopted accounting standard that modifies certain aspects of the recognition,
measurement, presentation and disclosure of financial instruments as shown on the Company’s unaudited condensed consolidated
statements of cash flows:
|
|
September
30, 2019
|
|
|
March
31, 2019
|
|
Cash and cash equivalents
|
|
$
|
1,895,389
|
|
|
$
|
1,340,203
|
|
Restricted cash
|
|
|
459,234
|
|
|
|
16,934
|
|
Cash and cash
equivalents and restricted cash
|
|
$
|
2,354,623
|
|
|
$
|
1,357,137
|
|
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
Revenue
The
Company recognizes revenue when we transfer promised goods or services to customers in an amount that reflects the consideration
to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with
customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s)
in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in
the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess
the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those
that are performance obligations.
The
Company must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above
and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction
price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract
for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other
variable consideration, except for royalties, should be included in the transaction price. The transaction price is allocated
to each performance obligation on an estimated stand-alone selling price basis, for which the Company recognizes revenue as or
when the performance obligations under the contract are satisfied, see, Note 9.
Where
a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under
the terms of a license arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying
performance obligation is satisfied.
Segment
reporting
Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, we
have viewed our operations and managed our business as one segment.
Income
Taxes
The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change
is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established
when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to
realize the benefit, or that future deductibility is uncertain. As of September 30, 2019, and March 31, 2019, the Company recorded
a valuation allowance to the full extent of our net deferred tax assets since the likelihood of realization of the benefit does
not meet the more likely than not threshold.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
The
Company files a U.S. Federal, various state, and International income tax returns. Uncertain tax positions are reviewed on an
ongoing basis and are adjusted in light of changing facts and circumstances. Such adjustment is reflected in the tax provision
when appropriate. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in income
taxes in the statements of operations and comprehensive loss. The Company has a liability in accrued expenses of $154,300 for
uncertain tax positions as of September 30, 2019 and March 31, 2019. Tax returns that are open for examination for Beyond Air
since to 2015 and for BA Ltd since 2013.
Foreign
Exchange Transactions
BA
Ltd. operations are in Israel and Beyond Air’s operations are in the United States. The Company’s management believes
that the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to continue
to operate in the foreseeable future. Thus, the functional and reporting currency of the Company is the U.S. dollar. The Company’s
transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances
have been re-measured to U.S. dollars in accordance with the Accounting Standards Board Codification Topic 830, “Foreign
Currency Matters”.
Stock-Based
Compensation
The
Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date
fair value of the award. Fair value for restricted stock awards is valued using the closing price of the Company’s stock
on the date of grant. That cost is recognized over the period during which an employee is required to provide service in exchange
for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes
option pricing model adjusted for the unique characteristics of those instruments. The risk-free interest rate assumptions were
based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield
was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends
in the foreseeable future. The Company does not have enough history to establish volatility based upon its own stock trading.
Therefore, the expected volatility was based similar publicly traded peer companies. The Company routinely reviews its calculation
of volatility based on, the Company’s life cycle, its peer group, and other factors.
The
Company uses the simplified method for share-based compensation to estimate the expected term. Compensation expense for options
and warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity
instruments issued, whichever is more reliably measured, and is recognized over the service period. The expense was previously
adjusted to fair value at the end of each reporting period until such awards vested, and the fair value of such instruments, as
adjusted, was expensed over the related vesting period. Adjustments to fair value at each reporting date resulted in income or
expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. In June 2018, the
FASB issued ASU No. 2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting, which amends
the existing accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring
and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity
awards is fixed on the grant date. We adopted this ASU the fourth quarter of fiscal 2019, and as a result, the fair value of all
non-employee awards became fixed at the start of the fourth quarter.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
Investment
in Marketable Securities
Investments
in equity marketable securities classified available-for-sale are carried at fair value with the changes in unrealized gains and
losses recognized in the Company’s results in operations. Realized gains and (losses) from the sale of marketable securities
are recognized in the statement of operations using the specific identification method on a trade date basis. Additionally,
we assess our marketable debt securities for potential other-than-temporary impairment. If the cost of an investment exceeds its
fair value, we evaluate, among other factors, the magnitude and duration of the decline in fair value.
Property
and Equipment
Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization is
calculated using the straight-line method over the estimated useful life of the assets as follows:
Computers
equipment
|
Three
years
|
Furniture
and fixtures
|
Seven
years
|
Clinical
and medical equipment
|
Fifteen
years
|
Leasehold
improvements
|
Shorter
of term of lease or estimated useful life of the asset
|
Licensed
Right to Use Technology
Licensed
right to use technology is an intangible asset resulting from the NitricGen transaction, see Note 11. The intangible asset was
valued based upon the fair value of the options issued to NitricGen and the cash paid for this transaction. The license contains
two future milestone additional payments aggregating $1,800,000. The intangible asset is being amortized on a straight-line method
over its estimated useful life of thirteen years.
Impairment
of Long-Lived Assets
The
Company assess the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate
that the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:
●
|
significant
underperformance relative to expected historical or projected future operating results,
|
|
|
●
|
significant
changes in the manner of our use of the acquired assets or the strategy for our overall business,
|
|
|
●
|
significant
negative regulatory or economic trends, and
|
|
|
●
|
significant
technological changes, which would render equipment and manufacturing processes obsolete.
|
Recoverability
of assets that will continue to be used in our operations is measured by comparing the carrying value to the future net undiscounted
cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues,
driven by market growth rates, and estimated future costs. There were no events during the reporting periods that were deemed
to be a triggering event that would require an impairment assessment.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
Net
Loss Per Share
Basic
net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders
by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share is computed by
dividing net income (loss) for the period by the weighted average number of shares of common stock and potentially dilutive common
stock outstanding during the period. The dilutive effect of outstanding options, warrants, and other stock-based compensation
awards is reflected in diluted net income (loss) per share by application of the treasury stock method. The calculation of diluted
net income (loss) per share excludes all anti-dilutive common shares. For periods in which the Company has reported net losses,
diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common
stockholders, because such common shares are not assumed to have been issued if their effect is anti-dilutive, see Note 8.
Recently
Adopted Accounting Pronouncements
On
April 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which
generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use assets on the
balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing
arrangements. The Company early adopted the new guidance using the modified retrospective transition approach and practical expedients
to all leases existing at the date of initial application and not restating comparative periods, see Note 11.
Operating
lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the
expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued
rent. The interest rate implicit in our leases is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease
payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized
the remaining lease term of its leases in determining the appropriate incremental borrowing rates. The weighted average discount
rate and remaining term on lease obligation is approximately 8.3% and 3.7 years. Operating lease expense is recognized on a straight-line
basis over the lease term and is included in general and administrative expenses. Amortization expense for finance (capital) leases
is recognized on a straight-line basis over the lease term and is included in general and administrative expenses and research
and development expenses, while interest expense for finance leases is recognized using the effective interest method.
As
of the April 1, 2019, the adoption date, the Company has identified three operating lease arrangements. The adoption of ASC 842
resulted in the recognition of operating lease liabilities and right-of-use assets of approximately of $266,600 and $258,600,
respectively. The adoption of the standard did not have a material effect on the Company’s unaudited condensed consolidated
statements of operation and comprehensive loss or unaudited condensed consolidated statements of cash flows.
Recent
Accounting Pronouncements Not Yet Adopted
There
have been no recent accounting pronouncements or changes in accounting standard during the three and six months ended September
30, 2019, as compared to the recent accounting standards described in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2019, that are of significance or potential significance to the Company.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
3 FAIR VALUE MEASUREMENT
The
Company’s financial instruments primarily include cash, cash equivalents, restricted cash, marketable securities and accounts
payable. Due to the short-term nature of cash, cash equivalents and accounts payable, the carrying amounts of these assets and
liabilities approximate their fair value. Fair value is defined as the price that would be received to sell an asset or paid to
transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting
guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair
value. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active
markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:
|
Level
1 -
|
quoted
prices in active markets for identical assets or liabilities;
|
|
|
|
|
Level
2 -
|
inputs
other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar
assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets
or liabilities; or
|
|
|
|
|
Level
3 -
|
unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
|
|
|
As
of September 30, 2019
|
|
|
|
Level
1
|
|
|
Level
2
|
|
|
Level
3
|
|
|
Total
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketable equity securities
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Circassia Pharmaceuticals
plc, see Note 9
|
|
$
|
1,890,748
|
|
|
|
|
|
|
|
|
|
|
$
|
1,890,748
|
|
Mutual funds:
short-term fixed income
|
|
|
5,595,071
|
|
|
|
|
|
|
|
|
|
|
|
5,595,071
|
|
|
|
$
|
7,485,819
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
7,485,819
|
|
|
|
As
of March 31, 2019
|
|
|
|
Level
1
|
|
|
Level
2
|
|
|
Level
3
|
|
|
Total
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketable equity securities
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Circassia Pharmaceuticals
plc, see Note 9
|
|
$
|
5,649,486
|
|
|
|
|
|
|
|
|
|
|
$
|
5,649,486
|
|
Mutual funds:
short-term fixed income
|
|
|
893,181
|
|
|
|
|
|
|
|
|
|
|
|
893,181
|
|
|
|
$
|
6,452,667
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
6,542,667
|
|
Net
gains and (losses) recognized during the three and six months ended September 30, 2019 from marketable equity securities were
$142,806 and $(2,164,513) respectively. Net unrealized gains for the three and six months ended September 30, 2018 were $2,805
and $8,208, respectively Unrealized net losses recognized during the three and six months ended September 30, 2019 from marketable
equity securities held were $62,635 and $(1,467,409), respectively.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
4 PROPERTY AND EQUIPMENT
Property
and equipment consist of the following as of September 30, 2019 and March 31, 2019, respectively:
|
|
September
30, 2019
|
|
|
March
31, 2019
|
|
|
|
|
|
|
|
|
Clinical and medical equipment
|
|
$
|
357,795
|
|
|
$
|
357,795
|
|
Computer equipment
|
|
|
50,476
|
|
|
|
42,782
|
|
Furniture and fixtures
|
|
|
51,506
|
|
|
|
41,464
|
|
Leasehold improvements
|
|
|
5,336
|
|
|
|
5,336
|
|
|
|
|
465,113
|
|
|
|
447,377
|
|
Accumulated depreciation
and amortization
|
|
|
(236,324
|
)
|
|
|
(202,505
|
)
|
|
|
$
|
228,789
|
|
|
$
|
244,872
|
|
Depreciation
and amortization expense related to fixed assets for the three and six months ended September 30, 2019 and September 30, 2018
was $15,917, $16,775, $33,819 and $30,591 respectively.
NOTE
5 SHAREHOLDER’S EQUITY
In
August 2018, the Company entered into a Stock Purchase Agreement with Lincoln Park (“LPC”) Corporation for $20 million
(the Purchase Agreement). The Company may sell and issue LPC and LPC is obligated to purchase up to $20 million in value of shares
of common stock from time to time over three years. The Company may direct LPC, at its sole discretion, and subject to certain
conditions, to purchase up to 10,000 to 30,000 shares of common stock on any business day, provided that at least one business
day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided,
however that LPC cannot make any single purchase that exceeds $750,000. The purchase price of shares of common stock related to
the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the
Stock Purchase Agreement. For the six months ended September 30, 2019, the Company received proceeds of $1,981,994 from the sale
of 410,000 shares of the Company’s stock or an average price per share of $4.83. There is $16,673,821 remaining under the
Purchase Agreement as of September 30, 2019.
On
July 2, 2019, the SEC declared effective, the Company’s Form S-3 shelf registration statement which allows the Company to
sell up to $100 million of equity securities.
On
June 3, 2019, the Company entered into a Stock Purchase Agreement with investors for the issuance of 1,583,743 registered shares
of common stock. The Company raised net proceeds was $7,839,494 and sold it through the Company’s S-3. The Company’s
CEO participated in this offering by investing $300,000 and receiving 58,253 shares of common stock at $5.15 per share. In addition,
LPC invested $500,000 and received 100,000 shares of common stock at $5.00 per share. This investment was not part of the Stock
Purchase Agreement.
Stock
to be Issued to a Vendor
As
of March 31, 2019, the Company was obligated to issue 30,000 shares to a vendor for services related to investor relations. The
Company recorded stock-based compensation of $144,000 for the shares to be issued, or $4.80 per share, the fair market value.
The Company recorded this obligation as a liability for shares to be issued. For the three months and six months ended September
30, 2019, the Company recorded stock-based compensation of $(28,500) and $ (6,000), respectively, which was due the change in
the fair market value of the stock to be issued. The fair market value of the liability as of September 30, 2019 was $138,000.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
5 SHAREHOLDER’S EQUITY (continued)
Issuance
of Restricted Shares
On
December 26, 2018, the Board of directors approved the issuance of 304,000 and 36,000 shares of restricted stock to the board
of directors, officers, employees and consultants to be granted on December 31, 2018 and January 1, 2019, respectively. Fair value
for restricted stock awards is valued using the closing price of the Company’s stock on the date of grant. Restricted stock
vests annually over five years. During the three and six months ended September 30, 2019, 5,000 shares of restricted stock were
forfeited. The Company recorded stock-based compensation expense of $219,269 and $348,279 for the three and six months ended September
30, 2019 associated with these grants.
Stock
Option Plan
The
Company has an amended and restated Equity Incentive Option Plan (the “2013 Plan”), that grants stock options, restricted
stock units and restricted shares to officers, directors, employees, and non-employees for shares of the Company’s stock.
The options vesting terms are generally between two to four years and expire up to ten years after the grant date. On December
26, 2018 and February 13, 2019, the Board of Directors authorized the increase of an additional 600,000 and 1,000,000 shares to
a total of 3,100,000 shares for issuance under the 2013 Plan, respectively. As of September 30, 2019, there are 288,707 options
available for future grants.
A
summary of the Company’s options for the six months ended September 30, 2019, is as follows:
|
|
Number
Of
Options
|
|
|
Weighted
Average
Exercise
Price
- Options
|
|
|
Weighted
Average
Remaining
Contractual
Life-Options
|
|
|
Aggregate
Intrinsic
Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding as of
April 1, 2019
|
|
|
2,375,812
|
|
|
$
|
4.32
|
|
|
|
9.2
|
|
|
$
|
523,820
|
|
Granted
|
|
|
30,000
|
|
|
|
4.92
|
|
|
|
|
|
|
|
-
|
|
Exercised
|
|
|
(38,222
|
)
|
|
|
2.87
|
|
|
|
|
|
|
|
(81,051
|
)
|
Forfeited
|
|
|
(25,643
|
)
|
|
|
4.87
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding as
of September 30, 2019
|
|
|
2,341,947
|
|
|
$
|
4.52
|
|
|
|
8.7
|
|
|
$
|
442,769
|
|
Exercisable as
of September, 30, 2019
|
|
|
824,699
|
|
|
$
|
4.37
|
|
|
|
7.9
|
|
|
$
|
246,834
|
|
As
of September 30, 2019, the Company has unrecognized stock-based compensation expense of approximately $2,570,361 related to unvested
stock options and is expected to be expensed over the weighted average remaining service period of 1.7 years. The weighted average
fair value of options granted was $3.49 per share during the six months ended September 30, 2019. The following were utilized
on the date of grant:
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
5 SHAREHOLDER’S EQUITY (continued)
|
|
Three
Months September 30, 2019
|
|
|
Three
Months September 30, 2018
|
|
|
Six
Months September 30, 2019
|
|
|
Six
Months September 30, 2018
|
|
Risk -free interest rate
|
|
|
1.4% - 2.3
|
%
|
|
|
2.5-3.1
|
%
|
|
|
1.4% -2.3
|
%
|
|
|
2.5-3.1
|
%
|
Expected volatility
|
|
|
82.3- 83.4
|
%
|
|
|
80.7-81.2
|
%
|
|
|
82.3 – 83.4
|
%
|
|
|
80.7-81.2
|
%
|
Dividend yield
|
|
|
0
|
%
|
|
|
0
|
|
|
|
0
|
%
|
|
|
0
|
%
|
Expected terms (in years)
|
|
|
6.25
|
|
|
|
5-9.9
|
|
|
|
6.25
|
|
|
|
5-9.9
|
|
The
following summarizes the components of stock-based compensation expense for the three and six three months ended September 30,
2019 and September 30, 2018, respectively
|
|
Three
Months Ended
|
|
|
Six
Months Ended
|
|
|
|
September
30,
|
|
|
September
30,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
$
|
183,766
|
|
|
$
|
26,766
|
|
|
$
|
333,688
|
|
|
$
|
96,193
|
|
General and administrative
|
|
|
739,231
|
|
|
|
815,244
|
|
|
|
1,508,346
|
|
|
|
825,817
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based
compensation expense
|
|
$
|
922,997
|
|
|
$
|
842,010
|
|
|
$
|
1,842,034
|
|
|
$
|
922,010
|
|
Warrants
A
summary of the Company’s outstanding warrants as of September 30, 2019 are as follows:
Warrant
Holders
|
|
Number
Of Warrants
|
|
|
Exercise
Price
|
|
|
Date
Of
Expiration
|
|
January 2017 offering - investors
|
|
|
1,701,616
|
|
|
$
|
4.25
|
|
|
|
January
2022
|
(a)
|
January 2017 offering - investors
|
|
|
1,701,616
|
|
|
$
|
4.25
|
|
|
|
February
2022
|
(a)
|
March 2017 offering - investors
|
|
|
220,988
|
|
|
$
|
4.25
|
|
|
|
March
2022
|
(a)
|
March 2017 offering - placement agent
|
|
|
11,050
|
|
|
$
|
4.25
|
|
|
|
March
2022
|
(a)
|
February 2018 offering - investors
|
|
|
2,299,802
|
|
|
$
|
4.25
|
|
|
|
February
2021
|
|
Pulmonox license
agreement
|
|
|
208,333
|
|
|
$
|
4.80
|
|
|
|
January
2024
|
|
Total
|
|
|
6,143,405
|
|
|
|
|
|
|
|
|
|
|
(a)
|
These
warrants have down round protection.
|
There
were no warrants exercised during any periods presented.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
6 CURRENT ASSETS AND PREPAID EXPENSES
A
summary of current assets and prepaid expenses as of September 30, 2019 and March 31, 2019 is as follows:
|
|
September
30, 2019
|
|
|
March
31, 2019
|
|
Research and development
|
|
$
|
55,578
|
|
|
$
|
324,063
|
|
Insurance
|
|
|
110,742
|
|
|
|
297,945
|
|
Other
|
|
|
247,713
|
|
|
|
166,401
|
|
|
|
$
|
414,033
|
|
|
$
|
788,409
|
|
NOTE
7 ACCRUED EXPENSES
A
summary of the accrued expenses as of September 30, 2019 and March 31, 2019 is as follows:
|
|
September
30, 2019
|
|
|
March
31, 2019
|
|
Research and development
|
|
$
|
785,428
|
|
|
$
|
103,320
|
|
Professional fees
|
|
|
767,000
|
|
|
|
1,030,127
|
|
Income taxes payable
|
|
|
154,300
|
|
|
|
154,300
|
|
Employee salaries and benefits
|
|
|
223,201
|
|
|
|
183,271
|
|
Other
|
|
|
138,316
|
|
|
|
96,620
|
|
Total
|
|
$
|
2,068,245
|
|
|
$
|
1,567,638
|
|
NOTE
8 BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE
The
following potentially dilutive securities were not included in the calculation of diluted net loss per share attributable to common
stockholders because their effect would have been anti-dilutive for the three and six months ended September 30:
|
|
2019
|
|
|
2018
|
|
Common stock warrants
|
|
|
6,143,405
|
|
|
|
6,143,405
|
|
Common stock options
|
|
|
2,353,115
|
|
|
|
1,394,972
|
|
Restricted shares
|
|
|
335,000
|
|
|
|
-
|
|
Total
|
|
|
8,831,520
|
|
|
|
7,538,377
|
|
NOTE
9 LICENSE AGREEMENT
On
January 23, 2019, the Company entered into an agreement for commercial rights (“the License Agreement”) with Circassia
Pharmaceuticals plc, (located in the United Kingdom) for persistent pulmonary hypertension of the newborn (PPHN) and future related
indications at concentrations of < 80 ppm in the hospital setting in the United States and China. The Company may receive
payments up to $32.55 million in up front and regulatory milestones, of which $31.5 million is associated with the U.S. market.
All such payments are payable in cash or ordinary shares of Circassia Pharmaceuticals plc, at the discretion of Circassia Pharmaceuticals,
Inc., with payments in cash discounted by approximately 5%. Royalties are payable only in cash.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
9 LICENSE AGREEMENT (continued)
This
contract was evaluated under ASC 606, which was adopted by the Company during fiscal 2019. Based upon the evaluation, it was determined
that the contract consists of five performance obligations, as follows:
●
|
Performance
Obligation 1: non-exclusive transfer of functional intellectual property rights to Circassia, which includes:
|
|
o
|
the
consummation of the License, Development, and Commercialization Agreement, which included significant pre-agreement negotiation,
product specification, and
|
|
|
|
|
o
|
the
successful completion of the pre-submission meeting with the FDA. At this meeting the FDA reinforced their assessment of LungFit™
PH as a medical device and the requirements for approval.
|
●
|
Performance
Obligation 2: ongoing support associated with the PMA submission and regulatory approval by the FDA. This also includes development
activities including manufacturing readiness process ahead of the approval.
|
|
|
●
|
Performance
Obligation 3: launch of the approved product in the field in the USA upon FDA regulatory approval
|
|
|
●
|
Performance
obligation 4: FDA approval of the product in the field for use in cardiac surgery
|
|
|
●
|
Performance
obligation 5: regulatory approval in China for marketing and sale of the product in China for any indication
|
In
consideration of the rights and licenses granted to Circassia by the Company, Circassia shall pay the Company the following five
milestone amounts in US dollars or Circassia shares:
|
●
|
$7.35
million upon signing or 12,300,971 ordinary shares of Circassia Pharmaceuticals plc;
|
|
|
|
|
●
|
$3.15
million payable within five (5) business days following the successful completion of a Food and Drug Administration (the “FDA”)
pre-submission meeting or 5,271,844 ordinary shares of Circassia Pharmaceuticals plc;
|
|
|
|
|
●
|
$12.6
million payable on the sooner of ninety (90) days post FDA approval of the Product or the launch of the Product in the United
States,
|
|
|
|
|
●
|
$8.4
million payable within five (5) business days following the approval by the FDA of the Product in certain hospital and clinic
settings for use in cardiac surgery; and
|
|
|
|
|
●
|
$1.05
million payable within five (5) business days following approval by the FDA equivalent in China for marketing and sale of
the Product.
|
In
addition, Circassia shall pay the Company the following royalty amounts until expiration of all of the applicable patents:
|
●
|
A
one-time 5% royalty on the first cumulative $50 million in gross profit in the United States;
|
|
|
|
|
●
|
A
one-time 5% royalty on the first cumulative $20 million in gross profit in China;
|
Thereafter,
running royalty amounts of 15% of annual gross profit (United States & China combined) up to and including $100 million and
20% of annual gross profit (United States & China combined) exceeding $100 million.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
9 LICENSE AGREEMENT (continued)
Following
expiration of the patents, Circassia shall pay the Company a 14% royalty on annual gross profits up to and including $100 million
and a 19% royalty on annual gross profits exceeding $100 million.
Due
to the consideration constraints associated with milestones 3, 4, and 5, only the amounts associated with milestone 1 and 2 have
been allocated. During the three months ended March 31, 2019, the Company met the first two milestones under the license agreement
and received 17,572,815 ordinary shares valued at $9,987,295. This consideration was allocated to the first two performance obligations.
one being the transfer of the intellectual property to Circassia, which was recognized at a point in time and was valued at $7,116,232
and the other being the ongoing support associated with the PMA submission and regulatory approval by the FDA, which was valued
at $2,871,063 and recorded as deferred revenue to be recognized over a period of time from the commencement of the agreement to
when management expects to submit the PMA. For the three and six months ended September 30, 2019, $645,602 and $1,273,071, respectively
of such revenue associated with this second performance obligation has been recognized. As of September 30, 2019, and March 31,
2019, deferred revenue was $990,223 and $2,263,294, respectively.
NOTE
10 LOAN PAYABLE
In
January 2019, and in connection with the Company’s insurance policy, a loan of $292,500 was used to finance part of the
premium. There are ten monthly payments of $29,687 and the interest rate is 3.3% per annum. The balance as of September 30, 2019
and March 31, 2019 was $88,582 and $263,604, respectively.
NOTE
11 COMMITMENTS AND CONTINGENCIES
License
Agreements
On
October 22, 2013, the Company entered into a patent license agreement with CareFusion, pursuant to which Beyond Air agreed to
pay to the third party a non-refundable upfront fee of $150,000 and is obligated to pay 5% royalties of any licensed product net
sales, but at least $50,000 per annum through the term of the agreement and the advance is credited against future royalties payments.
As of September 30, 2019, the Company did not pay any royalties since the Company did not have any revenues from this license.
The term of the agreement extends through the life of applicable patents and may be terminated by either party with 60 days’
prior written notice in the event of a breach of the agreement, and may be terminated unilaterally by CareFusion with 30 days’
prior written notice in the event that we do not meet certain milestones.
In
August 2015, BA Ltd entered into an Option Agreement (the “Option Agreement”) with Pulmonox whereby BA Ltd acquired
the Option to purchase certain intellectual property assets and rights (the “Option”) on September 7, 2016 for $25,000.
On January 13, 2017, the Company exercised the Option and paid $500,000. The Company becomes obligated to make certain one-time
development and sales milestone payments to Pulmonox, commencing with the date on which we receive regulatory approval for the
commercial sale of the first product candidate qualifying under the agreement. These milestone payments are capped at a total
of $87 million across three separate and distinct indications that fall under the agreement, with the majority of them, approximately
$83 million, being sales related based on cumulative sales milestones for each of the three products.
On
January 31, 2018 the Company entered into an agreement (“Agreement”) with NitricGen, Inc. (“NitricGen”)
acquire a global, exclusive, transferable license and associated assets including intellectual property, know-how, trade secrets
and confidential information from NitricGen related to LungFit™. The Company acquired the licensing right to use the technology
and agreed to pay NitricGen a total of $2,000,000 in future payments based upon achieving certain milestones, as defined in the
Agreement, and royalties on sales LungFit™. The Company paid NitricGen $100,000 upon the execution agreement, $100,000 upon
achieving the next milestone and issued 100,000 options to purchase the Company’s stock valued at $295,000 upon executing
the agreement. The remaining future milestone payments are $1,800,000 of which $1,500,000 in six months after the first
approval of LungFit™ by the FDA or EMEA.
Employment
Agreements
Certain officer agreements contain a change of control
provision for payment of severance arrangements.
BEYOND
AIR, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NOTE
11 COMMITMENTS AND CONTINGENCIES (continued)
Operating
Leases
In
March 2018, the Company entered into an operating lease for office space in Madison, Wisconsin. The lease commenced in March 2018,
with the Company providing a security deposit of $1,728, which is recorded as restricted cash in the unaudited condensed consolidated
balance sheets. The lease agreement expires in April 2021, at which point the Company has the option to renew the lease for one
additional five-year term. The renewal period was not included the lease term for purposes of determining the lease liability
or right-of-use asset.
In
May 2018, the Company entered into an operating lease for office space in Garden City, New York. The lease commenced in July 2018,
with the Company providing a security deposit of $9,771, which is recorded as restricted cash in the unaudited consolidated balance
sheets. The lease agreement expires in June 2023, at which point the Company has the option to renew the lease for one additional
three-year term. The renewal period was not included the lease term for purposes of determining the lease liability or right-of-use
asset.
The
Company has other operating lease agreements with commitments of less than one year or that are not significant. The Company elected
the practical expedient option and as such these lease payments are expensed as incurred.
Other Information For The Six Months
Ended September 30, 2019
|
|
|
|
Cash paid for amounts included in the
measurement of lease liabilities:
|
|
|
|
|
Cash paid
|
|
$
|
40,799
|
|
Right-of-use assets obtained in exchange
for new operating lease liabilities:
|
|
|
-
|
|
Weighted-average remaining lease term
— operating leases
|
|
|
3.5
years
|
|
Weighted-average discount rate —
operating leases
|
|
|
8.3
|
%
|
Maturity
of Lease Liabilities
|
|
Six
months ended
September
30,
|
|
|
|
Operating
Leases
|
|
Remainder of 2020
|
|
$
|
65,092
|
|
2021
|
|
|
58,741
|
|
2022
|
|
|
64,826
|
|
2023
|
|
|
64,693
|
|
2024
|
|
|
15,868
|
|
Total lease payments
|
|
|
269,220
|
|
Less: interest
|
|
|
(35,123
|
)
|
Present value
of lease liabilities
|
|
$
|
234,097
|
|
Litigation
Contingencies
On
March 16, 2018, Empery Asset Master, Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (collectively, “Empery”),
filed a complaint in the Supreme Court of the State of New York, relating to the notice of adjustment of both the exercise price
of and the number of warrant shares issuable under warrants issued to Empery in January 2017. The Empery Suit alleges that, as
a result of certain circumstances in connection with the February 2018 Offering, the January 2017 Warrants issued to Empery provide
for adjustments to both the exercise price of the warrants and the number of warrant shares issuable upon such exercise. Empery
seeks monetary damages and declaratory relief under theories of breach of contract or contract reformation predicated on mutual
mistake. The Company continues to vigorously defend all claims. The Company believes they met the contractual requirements of
the contract and properly adjusted the applicable warrants in accordance with the protection features.
Discovery
remains ongoing in the litigation and it is not possible to determine or assess the probability of any particular outcome.
BEYOND
AIR, INC. AND ITS SUBSDIARIES
CONSOLIDATED
FINANCIAL STATEMENTS
AS
OF MARCH 31, 2019
INDEX
-
- - - - - - - - - - - - -
Report
of Independent Registered Public Accounting Firm
To
the Shareholders and Board of Directors of Beyond Air, Inc. (formerly: AIT Therapeutics, Inc.)
Opinion
on the Financial Statements
We
have audited the accompanying consolidated balance sheets of Beyond Air, Inc. (formerly: AIT Therapeutics, Inc.) and its subsidiaries
(the Company) as of March 31, 2018 and December 31, 2017, the related consolidated statements of comprehensive loss, changes in
shareholders’ equity (deficiency) and cash flows for the period from January 1, 2018 to March 31, 2018, and of the fiscal
year in the period ended December 31, 2017, and the related notes (collectively referred to as the “consolidated financial
statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company at March 31, 2018 and December 31, 2017, and the results of its operations and its cash flows for the
period from January 1, 2018 to March 31, 2018, and of the fiscal year in the period ended December 31, 2017, in conformity with
U.S. generally accepted accounting principles.
Basis
for Opinion
These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on
the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.
/s/
KOST FORER GABBAY &
KASIERER
|
|
A
Member of EY Global
|
|
We
have served as the Company’s auditor since 2014.
June
15, 2018
Tel-Aviv,
Israel
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and
Stockholders
of Beyond Air, Inc. (formerly: AIT Therapeutics, Inc.) and Subsidiaries
Opinion
on the Financial Statements
We
have audited the accompanying consolidated balance sheet of Beyond Air, Inc. (formerly: AIT Therapeutics, Inc.) and Subsidiaries
(the “Company”) as of March 31, 2019, and the related consolidated statements of operations and comprehensive loss,
stockholders’ equity (deficiency), and cash flows for the year ended March 31, 2019, and the related notes (collectively
referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of March 31, 2019, and the results of its operations and its cash flows for
the year ended March 31, 2019, in conformity with accounting principles generally accepted in the United States of America.
Basis
for Opinion
These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on
the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.
We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but
not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.
Accordingly, we express no such opinion.
Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audit provides a reasonable basis for our opinion.
/s/
Friedman LLP
|
|
|
|
We
have served as the Company’s auditor since 2019.
|
|
|
|
East
Hanover, New Jersey
|
|
June
27, 2019
|
|
BEYOND
AIR, INC. AND SUBSIDIARIES
CONSOLIDATED
BALANCE SHEETS
|
|
March
31, 2019
|
|
|
March
31, 2018
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
1,340,203
|
|
|
$
|
732,542
|
|
Restricted
cash
|
|
|
16,934
|
|
|
|
5,692
|
|
Marketable
securities
|
|
|
6,542,667
|
|
|
|
8,304,392
|
|
Other
current assets and prepaid expenses
|
|
|
788,409
|
|
|
|
59,249
|
|
Total
current assets
|
|
|
8,688,213
|
|
|
|
9,101,875
|
|
Licensing
right to use technology
|
|
|
495,000
|
|
|
|
-
|
|
Property
and equipment, net
|
|
|
244,872
|
|
|
|
253,184
|
|
TOTAL
ASSETS
|
|
$
|
9,428,085
|
|
|
$
|
9,355,059
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND SHAREHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
1,164,672
|
|
|
$
|
842,039
|
|
Accrued
expenses
|
|
|
1,533,102
|
|
|
|
1,257,762
|
|
Deferred
revenue
|
|
|
2,263,294
|
|
|
|
-
|
|
Stock
to be issued to a vendor
|
|
|
144,000
|
|
|
|
-
|
|
Loans
from related parties and others
|
|
|
34,536
|
|
|
|
33,124
|
|
Loan
payable
|
|
|
263,604
|
|
|
|
-
|
|
Total
current liabilities
|
|
|
5,403,208
|
|
|
|
2,132,925
|
|
|
|
|
|
|
|
|
|
|
Liabilities
related to warrants
|
|
|
-
|
|
|
|
5,677,934
|
|
Total
long-term liabilities
|
|
|
-
|
|
|
|
5,677,934
|
|
|
|
|
|
|
|
|
|
|
Commitments
and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders’
equity
|
|
|
|
|
|
|
|
|
Preferred
Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding
|
|
|
-
|
|
|
|
-
|
|
Common
Stock, $0.0001 par value per share: 100,000,000 shares authorized, 8,714,815 and 8,397,056 shares issued and outstanding as
of March 31, 2019 and March 31, 2018, respectively
|
|
|
871
|
|
|
|
840
|
|
Treasury
stock
|
|
|
(25,000
|
)
|
|
|
(25,000
|
)
|
Additional
paid-in capital
|
|
|
41,693,578
|
|
|
|
32,141,110
|
|
Accumulated
deficit
|
|
|
(37,644,572
|
)
|
|
|
(30,569,764
|
)
|
Accumulated
other comprehensive loss
|
|
|
-
|
|
|
|
(2,986
|
)
|
Total
shareholders’ equity
|
|
|
4,024,877
|
|
|
|
1,544,200
|
|
TOTAL
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
|
$
|
9,428,085
|
|
|
$
|
9,355,059
|
|
The
accompanying notes are an integral part of these consolidated financial statements
BEYOND
AIR, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
|
|
Year
Ended
March
31, 2019
|
|
|
Three
Months Ended
March
31, 2018
|
|
|
Year
Ended December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
License
revenue
|
|
$
|
7,724,001
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
(3,929,558
|
)
|
|
|
(1,637,387
|
)
|
|
|
(4,438,264
|
)
|
General
and administrative
|
|
|
(6,852,988
|
)
|
|
|
(803,069
|
)
|
|
|
(6,629,344
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(3,058,545
|
)
|
|
|
(2,440,456
|
)
|
|
|
(11,067,608
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
in fair value of warrant liabilities
|
|
|
-
|
|
|
|
3,493,664
|
|
|
|
(5,411,551
|
)
|
Realized
and unrealized loss on available for sale marketable securities
|
|
|
(3,581,193
|
)
|
|
|
|
|
|
|
|
|
Dividend
income
|
|
|
85,242
|
|
|
|
-
|
|
|
|
-
|
|
Amortization
of beneficial conversion feature and debt issuance costs related to convertible note
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,031,360
|
)
|
Issuance
cost related to warrants to investors and placement agent
|
|
|
-
|
|
|
|
-
|
|
|
|
(457,250
|
)
|
Imputed
interest with respect to convertible notes
|
|
|
|
|
|
|
|
|
|
|
(14,878
|
)
|
Amortization
of debt issuance cost
|
|
|
|
|
|
|
|
|
|
|
(14,273
|
)
|
Foreign
exchange loss
|
|
|
(920
|
)
|
|
|
(5,521
|
)
|
|
|
-
|
|
Issuance
of common stock to finder fee upon the conversion of convertible notes
|
|
|
|
|
|
|
|
|
|
|
(18,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
expenses
|
|
|
(3,034
|
)
|
|
|
-
|
|
|
|
(29,426
|
)
|
Total
other income (loss)
|
|
|
(3,499,905
|
)
|
|
|
3,488,143
|
|
|
|
(6,976,738
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision
for income taxes
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
(loss) income
|
|
$
|
(6,558,450
|
)
|
|
$
|
1,047,687
|
|
|
$
|
(18,044,346
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized
income (loss) on marketable securities
|
|
|
|
|
|
|
(5,135
|
)
|
|
|
2,149
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
other comprehensive (loss) income
|
|
$
|
(6,558,450
|
)
|
|
$
|
1,042,552
|
|
|
$
|
(18,042,197
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
(loss) income (loss) per share - basic
|
|
$
|
(0.77
|
)
|
|
$
|
0.15
|
|
|
$
|
(3.01
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
(loss) income per share – diluted
|
|
$
|
(0.77
|
)
|
|
$
|
0.14
|
|
|
$
|
(3.01
|
)
|
Weighted
average number of common shares outstanding – basic
|
|
|
8,498,525
|
|
|
|
7,196,048
|
|
|
|
6,002,052
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of common shares outstanding - diluted
|
|
|
8,498,525
|
|
|
|
7,250,194
|
|
|
|
6,002,052
|
|
The
accompanying notes are an integral part of these consolidated financial statements
BEYOND
AIR, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIENCEY)
FOR
THE FROM JANUARY 1, 2017 TO MARCH 31, 2019
|
|
Common
Stock
|
|
|
Treasury
|
|
|
Additional
Paid-in
|
|
|
Accumulated
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Total
Shareholders’
|
|
|
|
Number
|
|
|
Amount
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Income
(loss)
|
|
|
Equity (Deficiency)
|
|
Balance
January 1, 2017
|
|
|
2,207,450
|
|
|
$
|
221
|
|
|
$
|
-
|
|
|
$
|
8,873,110
|
|
|
$
|
(13,573,105
|
)
|
|
$
|
-
|
|
|
$
|
(4,699,774
|
)
|
Stock
issued with respect to merger of Beyond Air
|
|
|
103,200
|
|
|
|
10
|
|
|
|
|
|
|
|
(295,000
|
)
|
|
|
|
|
|
|
|
|
|
|
(294,990
|
)
|
Purchase
of treasury stock
|
|
|
(90,000
|
)
|
|
|
(9
|
)
|
|
|
(25,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(25,009
|
)
|
Stock-based
compensation- employees and non-employees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
537,000
|
|
|
|
|
|
|
|
|
|
|
|
537,000
|
|
Stock-based
compensation related to restricted stock issuance of shares to members of board of directors
|
|
|
856,909
|
|
|
|
86
|
|
|
|
|
|
|
|
2,521,000
|
|
|
|
|
|
|
|
|
|
|
|
2,521,086
|
|
Cancellation
of restricted stock granted to a member of the board of directors
|
|
|
(246,312
|
)
|
|
|
(25
|
)
|
|
|
|
|
|
|
844,000
|
|
|
|
|
|
|
|
|
|
|
|
843,975
|
|
Issuance
of warrants to service provider
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
480,000
|
|
|
|
|
|
|
|
|
|
|
|
480,000
|
|
Stock-based
compensation related to restricted stock issuance of shares to members of board of directors
|
|
|
3,927
|
|
|
|
1
|
|
|
|
|
|
|
|
4,000
|
|
|
|
|
|
|
|
|
|
|
|
4,001
|
|
Issuance
of common stock, net of issuance costs
|
|
|
1,812,110
|
|
|
|
181
|
|
|
|
|
|
|
|
6,322,000
|
|
|
|
|
|
|
|
|
|
|
|
6,322,181
|
|
Conversion
of convertible notes into common stock upon merger
|
|
|
1,397,068
|
|
|
|
140
|
|
|
|
|
|
|
|
3,973,000
|
|
|
|
|
|
|
|
|
|
|
|
3,973,140
|
|
Issuance
of stock upon exercise of stock options
|
|
|
52,902
|
|
|
|
5
|
|
|
|
|
|
|
|
1,000
|
|
|
|
|
|
|
|
|
|
|
|
1,005
|
|
Net
unrealized gains on available-for-sale investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,149
|
|
|
|
2,149
|
|
Net
loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(18,044,346
|
)
|
|
|
|
|
|
|
(18,044,346
|
)
|
Balance December
31, 2017
|
|
|
6,097,254
|
|
|
|
610
|
|
|
|
(25,000
|
)
|
|
|
23,260,110
|
|
|
|
(31,617,451
|
)
|
|
|
2,149
|
|
|
|
(8,379,582
|
)
|
Stock-based
compensation – employees and non-employees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130,000
|
|
|
|
|
|
|
|
|
|
|
|
130,000
|
|
Stock-based
compensation related to restricted stock issuance of shares to members of board of directors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,000
|
|
|
|
|
|
|
|
|
|
|
|
17,000
|
|
Issuance
of common stock, net of issuance costs
|
|
|
2,299,802
|
|
|
|
230
|
|
|
|
|
|
|
|
8,734,000
|
|
|
|
|
|
|
|
|
|
|
|
8,734,230
|
|
Net
unrealized loss on available-for-sale-investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5,135
|
)
|
|
|
(5,135
|
)
|
Net
income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,047,687
|
|
|
|
|
|
|
|
1,047,687
|
|
Balance
as of March 31, 2018
|
|
|
8,397,056
|
|
|
$
|
840
|
|
|
$
|
(25,000
|
)
|
|
$
|
32,141,110
|
|
|
$
|
(30,569,764
|
)
|
|
$
|
(2,986
|
)
|
|
$
|
1,544,200
|
|
The
accompanying notes are an integral part of these consolidated financial statements
BEYOND
AIR, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIENCY)
FOR
THE FROM JANUARY 1, 2017 TO MARCH 31, 2019
|
|
Common
Stock
|
|
|
Treasury
|
|
|
Additional
Paid-in
|
|
|
Accumulated
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Total
Shareholders’
|
|
|
|
Number
|
|
|
Amount
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Income
(loss)
|
|
|
Equity (Deficiency)
|
|
Balance
as of April 1, 2018
|
|
|
8,397,056
|
|
|
$
|
840
|
|
|
$
|
(25,000
|
)
|
|
$
|
32,141,110
|
|
|
$
|
(30,569,764
|
)
|
|
$
|
(2,986
|
)
|
|
$
|
1,544,200
|
|
Adjustment
due to the adoption of ASU- 2017-11 (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,194,292
|
|
|
|
(516,358
|
)
|
|
|
|
|
|
|
5,677,934
|
|
At
the market stock sales, net
|
|
|
297,000
|
|
|
|
29
|
|
|
|
-
|
|
|
|
799,156
|
|
|
|
-
|
|
|
|
-
|
|
|
|
799,185
|
|
Issuance
of common stock upon the exercise of stock options
|
|
|
20,759
|
|
|
|
2
|
|
|
|
-
|
|
|
|
8,699
|
|
|
|
-
|
|
|
|
-
|
|
|
|
8,701
|
|
Stock-based
compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,550,321
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,550,321
|
|
Adjustment
due to adoption of ASU 2016-01 (Note 2)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,986
|
|
|
|
2,986
|
|
Net
loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(6,558,450
|
)
|
|
|
|
|
|
|
(6,558,450
|
)
|
Balance
as of March 31, 2019
|
|
|
8,714,815
|
|
|
$
|
871
|
|
|
$
|
(25,000
|
)
|
|
$
|
41,693,578
|
|
|
$
|
(37,644,572
|
)
|
|
$
|
0
|
|
|
$
|
4,024,877
|
|
|
(1)
|
The
Company elected to adopt Accounting Standards Update 2017-11 retrospective to outstanding financial instruments with down
round feature by means of cumulative-effect adjustment to the beginning additional paid-in capital of $6,194,292 and accumulated
deficit of $(516,358) as of April 1, 2018. This ASU affects all entities that issue
financial instruments (for example, warrants or convertible instruments) that include down round features.
|
The
accompanying notes are an integral part of these consolidated financial statements
BEYOND
AIR, INC. AND ITS SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|
For
The Year
Ended
March
31, 2019
|
|
|
For
The Three
Months
Ended
March
31, 2018
|
|
|
For
The Year Ended
December
31, 2017
|
|
Cash
flows from operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
(loss) income
|
|
$
|
(6,558,450
|
)
|
|
$
|
1,047,687
|
|
|
$
|
(18,044,346
|
)
|
Adjustments
to reconcile net (loss) income to net cash used in operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
64,787
|
|
|
|
14,603
|
|
|
|
38,137
|
|
Stock-based
compensation
|
|
|
2,399,321
|
|
|
|
146,429
|
|
|
|
4,384,844
|
|
Unrealized
loss on marketable securities to available for sale marketable securities
|
|
|
3,498,883
|
|
|
|
|
|
|
|
|
|
Change
in fair value of warrant liabilities
|
|
|
|
|
|
|
(3,493,664
|
)
|
|
|
5,412,341
|
|
Change
of management’s assessment of prior year research and development to licensing right to use technology
|
|
|
(200,000
|
)
|
|
|
|
|
|
|
|
|
Adoption
of ASU 2016-01
|
|
|
2,986
|
|
|
|
|
|
|
|
|
|
Amortization
of beneficial conversion feature and debt discount related to convertible notes upon merger
|
|
|
-
|
|
|
|
-
|
|
|
|
1,045,633
|
|
Issuance
cost related to warrants liability
|
|
|
-
|
|
|
|
-
|
|
|
|
457,250
|
|
Imputed
interest on convertible notes and others
|
|
|
-
|
|
|
|
-
|
|
|
|
33,097
|
|
Issuance
of common stock to finder upon the conversion of convertible notes
|
|
|
-
|
|
|
|
-
|
|
|
|
18,000
|
|
Changes
in:
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
current assets and prepaid expenses
|
|
|
(729,159
|
)
|
|
|
49,567
|
|
|
|
(31,252
|
)
|
Accounts
payable
|
|
|
322,633
|
|
|
|
173,347
|
|
|
|
141,583
|
|
Accrued
expenses
|
|
|
276,757
|
|
|
|
312,495
|
|
|
|
(573,624
|
)
|
Deferred
revenue
|
|
|
2,263,294
|
|
|
|
-
|
|
|
|
-
|
|
Net
cash provided by (used) in operating activities
|
|
|
1,341,052
|
|
|
|
(1,749,536
|
)
|
|
|
(7,118,337
|
)
|
Cash
flows from investing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase
price paid for the merger
|
|
|
|
|
|
|
|
|
|
|
(294,862
|
)
|
Investment
in available for sale marketable securities
|
|
|
(12,222,774
|
)
|
|
|
(9,403,543
|
)
|
|
|
(2,000,000
|
)
|
Proceeds
from redemption of marketable securities
|
|
|
10,485,610
|
|
|
|
1,700,050
|
|
|
|
1,396,143
|
|
Purchase
of property and equipment
|
|
|
(56,475
|
)
|
|
|
(1,000
|
)
|
|
|
(244,461
|
)
|
Net
cash provided by (used in) investing activities
|
|
|
(1,793,639
|
)
|
|
|
(7,704,493
|
)
|
|
|
(1,143,180
|
)
|
Cash
flows (used in) from financing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds
from the issuance of units consisting of common stock and warrants, net of offering cost
|
|
|
-
|
|
|
|
-
|
|
|
|
9,888,335
|
|
Purchase
of treasury stock
|
|
|
-
|
|
|
|
-
|
|
|
|
(25,000
|
)
|
Maturity
of loan and interest from related parties and others
|
|
|
-
|
|
|
|
|
|
|
|
(418,000
|
)
|
Proceeds
from issuance of convertible notes, net of issuance cost
|
|
|
|
|
|
|
8,984,917
|
|
|
|
|
|
Issuance
of common stock, net of offering cost
|
|
|
799,185
|
|
|
|
-
|
|
|
|
-
|
|
Proceeds
from loan
|
|
|
292,250
|
|
|
|
|
|
|
|
|
|
Payment
of loans
|
|
|
(28,646
|
)
|
|
|
-
|
|
|
|
(41,828
|
)
|
Proceeds
from loan from related parties and others
|
|
|
|
|
|
|
-
|
|
|
|
56,957
|
|
Cash
received for the exercise of stock options
|
|
|
8,701
|
|
|
|
|
|
|
|
1,199
|
|
Net
cash provided by financing activities
|
|
|
1,071,490
|
|
|
|
8,984,917
|
|
|
|
9,461,663
|
|
Increase
(decrease) in cash, cash equivalents and restricted cash
|
|
|
618,903
|
|
|
|
(469,112
|
)
|
|
|
1,200,346
|
|
Cash,
cash equivalents and restricted cash at beginning of period
|
|
|
738,234
|
|
|
|
1,207,346
|
|
|
|
7,201
|
|
Cash,
cash equivalents and restricted cash at end of period
|
|
$
|
1,357,137
|
|
|
$
|
738,234
|
|
|
$
|
1,207,346
|
|
Supplemental
disclosure of non-cash investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion
of convertible notes to common stock
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
3,955,000
|
|
Issuance
cost related to warrants
|
|
$
|
-
|
|
|
$
|
250,000
|
|
|
$
|
-
|
|
Fair
market value of options issued to NitricGen for the licensing right to use technology
|
|
$
|
295,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Fair
market value of stock to be issued to vendor
|
|
$
|
144,000
|
|
|
$
|
-
|
|
|
$
|
-
|
|
The
accompanying notes are an integral part of these consolidated financial statements
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 ORGANIZATION AND BUSINESS
Beyond
Air, Inc. (“Beyond Air” or the “Company”) was incorporated on April 24, 2015 as KokiCare, Inc. under the
laws of the State of Delaware. On January 9, 2017, the name of the Company was changed to AIT Therapeutics, Inc. On June 25, 2019,
the Company filed an Amendment to its Certificate of Incorporation to change its name from AIT Therapeutics, Inc. to Beyond Air,
Inc., effective June 26, 2019.
Advanced
Inhalation Therapies (AIT) Ltd. (“AIT”) was incorporated in Israel on May 1, 2011 and is a wholly-owned subsidiary
of the Company. On August 29, 2014, AIT established a wholly-owned subsidiary, Advanced Inhalation Therapies (AIT) Inc. (“Inc.”),
a Delaware corporation. Its principal business activity is to provide executive management and administrative support functions
to AIT.
In
December 2016, the Company consummated a reverse merger with KokiCare, Inc. and it was accounted as a reverse recapitalization
which is outside the scope of Accounting Standards Codification “ASC” 805, “Business Combinations”. Under
reverse capitalization accounting, AIT was considered the acquirer for accounting and financial reporting purposes and acquired
the assets and assumed the liabilities of the Company. Assets acquired and liabilities assumed are reported at their historical
amounts. Consequently, the consolidated financial statements of the Company reflect the operations of the acquirer for accounting
purposes together with a deemed issuance of shares, equivalent to the shares held by the former stockholders of the legal acquirer
and a recapitalization of the equity of the accounting acquirer. These consolidated financial statements include the accounts
of the Company since the effective date of the reverse capitalization and the accounts of AIT since inception.
The
Company is an emerging medical device company that is developing a Nitric Oxide (“NO”) delivery system that generates
NO from ambient air. Since its inception, the Company has devoted substantially all of its
efforts to business planning, research and development.
Liquidity
Risks and Uncertainty
As
shown in the accompanying financial statements, the Company has incurred cash provided from operating cash flows of $1,341,052
for the year March 31, 2019 and has accumulated losses of $37,644,572 since inception through March 31, 2019. The Company has
cash equivalents and marketable securities of $7,899,804 as of March 31, 2019. Included in marketable securities are shares of
Circassia Pharmaceuticals plc (Circassia) of $5.6 million (Note 9). Based upon the Company’s current business plan and expected
cash burn rate, including net proceeds received from the sales of common stock through the financial statement filing date (Note
13) and excluding any proceeds from the sale of Circassia stock, the Company estimates that it has enough cash to operate its
business into the third calendar quarter of 2020.
The
Company’s future capital needs and the adequacy of its available funds will depend on many factors, including the cost of
clinical studies and other actions needed to obtain regulatory approval of our medical devices in development. The Company will
be required to raise additional funds through sale of equity or debt securities or through strategic collaboration and/or licensing
agreements, to fund operations and continue our clinical trials until the Company is able to generate enough product or royalty
revenues, if any. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed
could have a material adverse effect on our growth plans, our results of operations and our financial condition.
On
June 3, 2019, the Company entered into a Stock Purchase Agreements with investors for the issuance of 1,583,743 unregistered shares
of common stock. The Company raised gross proceeds of $7,960,635, see Note 13.
In
addition, the Company has a $20 million purchase agreement and a registration rights agreement with Lincoln Park Capital Fund,
LLC (“LPC”), providing for the issuance of up to $20 million of the Company’s common stock over 36 months at
the Company’s discretion (Note 5). Subsequent to March 31, 2019, the Company issued and sold to LPC 250,000 shares of common
stock for proceeds of $1,173,810 at an average price of $4.70 per share. There is $17,482,005 remaining on the Purchase Agreement.
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES
Principles
of Consolidation
These
consolidated financial statements include the accounts of the Company and the accounts of AIT. All intercompany balances and transactions
have been eliminated in the accompanying financial statements.
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those
estimates. The Company’s significant estimates are accrual of expenses under consulting and licensing agreements, stock-based
compensation, warrant liabilities valuation for fiscal years to March 31, 2019, assumptions associated with revenue recognition,
and the determination of deferred tax attributes and the valuation allowance thereon.
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
Other
Risks and Uncertainties
The
Company is subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence
on key personnel, protection of proprietary technology, compliance with government regulations, product liability, uncertainty
of market acceptance of products and the potential need to obtain additional financing. The Company is dependent on third party
suppliers, in some cases single-source suppliers.
There
can be no assurance that the Company’s products will continue to be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics,
or that such products will be successfully marketed, if at all.
The
Company’s product requires approval or clearance from the U.S. Food and Drug Administration prior to commencing commercial
sales in the United States. The Company will be filing a Premarketing (PMA) Approval application during the third calendar quarter
of 2019.There can be no assurance that the Company’s products will receive all of the required approvals or clearances.
Approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its products. If the
Company is denied such approvals or clearances or such approvals or clearances are delayed, it may have a material adverse impact
on the Company’s results of operations, financial position and liquidity.
Concentrations
The
Company’s license revenue was from two milestone payments from one customer. The Company is seeking additional Partners
outside of the United States and China.
We
are heavily dependent on the Aeronox system, which is a portable titration and monitoring system that delivers nitric oxide gas
and measures nitric oxide and nitro dioxide gas concentrations in parts per million (ppm). The company that manufactures it is
International Biomedical, located in Texas. If International Biomedical decides not to continue to support the Aeronox system
(for example, selling parts and providing repair services for the device), then we might not be able to conduct our U.S. trial.
This system is not manufactured specifically for us, and we have no agreement with International Biomedical for the continued
manufacture or support of this Aeronox system. Additionally, the Aeronox system is not currently approved for use in the U.S.
above 80 ppm concentration required by our proprietary NO formulations, and we currently engage a third-party contractor to modify
the Aeronox system in order for it to monitor our NO formulations above 80 ppm. Unless the Aeronox system obtains such approval,
of which we have no current expectation, we would be required to seek an alternative delivery system in order to conduct a clinical
trial of our formulation within the U.S.
The
Company relies on two vendors to manufacture its delivery system. The Company is reliant on the vendors for commercial manufacturing
of our delivery systems for both clinical studies and commercial supply, if regulatory approval is received.
Financial
Instruments
Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents
and marketable securities. The Company maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts
in major banks in Israel and the U.S., the balances of which, at times, may exceed federally insured limits.
The
Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign
hedging arrangements.
Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months
or less at acquisition. Restricted cash is collateral for vehicle leases and invested in bank deposit accounts.
The
following table is the reconciliation of the recently adopted new accounting standard that modifies certain aspects of the recognition,
measurement, presentation and disclosure of financial instruments as shown on the Company’s consolidated statement of cash
flows:
|
|
For
The
Year Ended
March 31, 2019
|
|
|
For
The
Three Months
March 31, 2018
|
|
|
For
The
Year Ended
December 31, 2017
|
|
Cash
and cash equivalents
|
|
$
|
1,340,203
|
|
|
$
|
732,542
|
|
|
$
|
1,201,654
|
|
Restricted
cash
|
|
|
16,934
|
|
|
|
5,692
|
|
|
|
5,692
|
|
Cash
and cash equivalents and restricted cash
|
|
$
|
1,357,137
|
|
|
$
|
738,234
|
|
|
$
|
1,207,346
|
|
Research
and Development
Research
and development expenses are charged to the statement of operations and comprehensive loss as incurred. Research and development
expenses include salaries, costs incurred by outside laboratories, manufacturer’s, consultants, accredited facilities in
connection with clinical trials and preclinical studies and stock based-compensation.
Foreign
Exchange Transactions
AIT’s
operations are in Israel and Beyond Air’s operations are in the United States. The Company’s management believes that
the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate
in the foreseeable future. Thus, the functional and reporting currency of the Company is the U.S. dollar. The Company’s
transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances
have been re-measured to U.S. dollars in accordance with the Accounting Standards Board Codification Topic 830, “Foreign
Currency Matter”.
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
Stock-Based
Compensation
The
Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date
fair value of the award. Fair value for restricted stock awards is valued using the closing price of the Company’s stock
on the date of grant. That cost is recognized over the period during which an employee is required to provide service in exchange
for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes
option pricing model adjusted for the unique characteristics of those instruments. The risk-free interest rate assumptions were
based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield
was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends
in the foreseeable future. The Company does not have enough history to establish volatility based upon its own stock trading.
Therefore, the expected volatility was based similar publicly traded peer companies. The Company routinely reviews its calculation
of volatility changes in future volatility, the Company’s life cycle, its peer group, and other factors. The Company uses
the simplified method for share-based compensation to estimate the expected term Compensation expense for options and warrants
granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments
issued, whichever is more reliably measured, and is recognized over the service period. The expense was previously adjusted to
fair value at the end of each reporting period until such awards vested, and the fair value of such instruments, as adjusted,
was expensed over the related vesting period. Adjustments to fair value at each reporting date resulted in income or expense,
depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. In June 2018, the FASB issued
ASU No. 2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting, which amends the existing
accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying
nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed
on the grant date. We adopted this ASU the fourth quarter of fiscal 2019, and as a result, the fair value of all non-employee
awards became fixed at the start of the fourth quarter.
Investment
in Marketable Securities
Investments
in marketable securities classified available for sale are carried at fair value with the changes in unrealized gains and losses
recognized in the Company’s results in income or (loss). Realized gains and (loss) from the sale of marketable securities
are recognized in the statement of operations. using the specific identification method on a trade date basis. Additionally,
we assess our marketable equity securities for potential other-than-temporary impairment. The Company employ a methodology that
considers available evidence in evaluating potential other-than-temporary impairment of our marketable equity securities classified
as available-for-sale. If the cost of an investment exceeds its fair value, we evaluate, among other factors, the magnitude and
duration of the decline in fair value. We also evaluate the financial health of and business outlook for the issuer, the performance
of the underlying assets for interests in securitized assets, and, for securities classified as available-for-sale, our intent
and ability to hold the investment.
Property
and Equipment
Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization is
calculated using the straight-line method over the estimated useful life of the assets as follows:
Computers
equipment
|
Three
years
|
Furniture
and fixtures
|
Seven
years
|
Clinical
and medical equipment
|
Fifteen
years
|
Leasehold
improvements
|
Shorter
of term of lease or estimated useful life of the asset
|
Licensing
Right to Use Technology
Licensing
right to use technology is an intangible asset resulting from the NitricGen transaction. The intangible asset was valued based
upon the fair value of the options issued to NitricGen and the cash paid for this transaction. The Company reversed a prior period
expense of $200,000 and recorded a licensing right to use asset related to acquired technology. This adjustment was due to the
Company’s re-assessment of the acquired technology and the conclusion that it has alternative future use. The license contains
two milestone payments aggregating $1,800,000.
Impairment
of Long-Lived Assets
The
Company assess the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate
that the carrying value may not be recoverable. The Company’s impairment review process is based upon an estimate of future
undiscounted cash flow. Factors we consider that could trigger an impairment review include the following:
●
|
significant
underperformance relative to expected historical or projected future operating results,
|
|
|
●
|
significant
changes in the manner of our use of the acquired assets or the strategy for our overall business,
|
|
|
●
|
significant
negative industry or economic trends, and
|
|
|
●
|
significant
technological changes, which would render equipment and manufacturing processes obsolete.
|
Recoverability
of assets that will continue to be used in our operations is measured by comparing the carrying value to the future net undiscounted
cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues,
driven by market growth rates, and estimated future costs.
Revenue
Recognition
During
the year ended March 31, 2019, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts
with Customers (Topic 606) (“Topic 606”) using the modified retrospective method which consisted of applying and recognizing
the cumulative effect of Topic 606 at the date of initial application. Topic 606 supersedes the revenue recognition requirements
in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition (“Topic 605”). There was no
impact on adoption to the Company’s consolidated financial statements related to the adoption of ASC 606 since there was
no revenue at such time.
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
The
Company recognizes revenue when we transfer promised goods or services to customers in an amount that reflects the consideration
to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with
customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s)
in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in
the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess
the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those
that are performance obligations.
The
Company must use significant judgment to determine: a) the number of performance obligations based on the determination under
step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b)
the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified
in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones
or other variable consideration, except for royalties, should be included in the transaction price. The transaction price is allocated
to each performance obligation on an estimated stand-alone selling price basis, for which the Company recognizes revenue as or
when the performance obligations under the contract are satisfied, see (Note 9) for the performance obligations.
Where
a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under
the terms of a license arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying
performance obligation is satisfied.
Segment
reporting
Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, we
have viewed our operations and managed our business as one segment.
Income
Taxes
The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change
is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established
when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to
realize the benefit, or that future deductibility is uncertain. As of March 31, 2019, and March 31, 2018, the Company recorded
a valuation allowance to the full extent of our net deferred tax assets since the likelihood of realization of the benefit does
not meet the more likely than not threshold.
The
Company files a U.S. Federal, various state, and International income tax returns. Uncertain tax positions are reviewed on an
ongoing basis and are adjusted in light of changing facts and circumstances. Such adjustment is reflected in the tax provision
when appropriate. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in income
taxes in the statements of operations and comprehensive loss. The Company has recorded a liability in accrued expenses of $154,300
and $154,300 for uncertain tax positions as of March 31, 2019 and 2018, respectively. Tax returns that are open for examination
for Beyond Air since to 2015 and for AIT is from 2013 to 2017.
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
Net
Income (Loss) Per Share
Basic
net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to
common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per
share is computed by dividing net income (loss) for the period by the weighted average number of shares of common stock and potentially
dilutive common stock outstanding during the period. The dilutive effect of outstanding options, warrants, restricted stock and
stock-based compensation awards is reflected in diluted net income (loss) per share by application of the treasury stock method.
The calculation of diluted net income (loss) per share excludes all anti-dilutive common shares. For periods in which the Company
has reported net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share
attributable to common stockholders, because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.
Recently
Issued and Adopted Accounting Standards
In
January 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-01,
Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The
main objective of this update is to enhance the reporting model for financial instruments to provide users of financial statements
with more decision-useful information. The new guidance addresses certain aspects of recognition, measurement, presentation, and
disclosure of financial instruments. The Company adopted this standard during the fourth quarter of fiscal year ended March 31,
2019 which resulted in $3,498,833 being expensed to the statement of operations as opposed to being recorded as a component of
accumulated other comprehensive income (loss).
In
January 2017, the Financial Accounting Standards Board (“FASB”) FASB released Accounting Standards Update “ASU”
2017-01, Business Combinations: Clarifying the Definition of a Business, which clarifies the definition of a business with the
objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or
disposals of assets or businesses. The amendments in this ASU should be applied prospectively and are effective for fiscal years
beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. No disclosures
are required at transition. The Company adopted this standard during the third quarter December 31, 2018 and this standard did
not have a material impact on the Company’s consolidated financial statements.
In
May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718):
Scope of Modification Accounting. This standard provides clarity and reduces both (1) diversity in practice and (2) cost and complexity
when applying the guidance in Topic 718, Compensation-Stock Compensation, to a change to the terms or conditions of a share-based
payment award. The Company adopted the standard commencing January 1, 2019. The impact of the adoption had no effect to the Company’s
consolidated financial statement
In
July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and
Derivatives and Hedging (Topic 815) Accounting for Certain Financial Instruments with Down Round Features. This ASU affects all
entities that issue financial instruments (for example, warrants or convertible instruments) that include down round features.
This ASU relates to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments
that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260.
The Company elected to adopt Update ASU 2017-11during the third quarter of 2018, retrospective to outstanding financial instruments
with down round feature by means of cumulative-effect adjustment by increasing beginning additional paid-in capital by $6,194,292
and decreasing accumulated deficit by $516,358 as of April 1, 2018.
In
November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (ASU 2016-18), which requires
companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents
when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The Company adopted
the standard commencing January 1, 2018. The impact of the adoption was immaterial to the
Company’s consolidated financial statements.
During
the year ended March 31, 2019, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts
with Customers (Topic 606) (“Topic 606”) using the modified retrospective method which consisted of applying and recognizing
the cumulative effect of Topic 606 at the date of initial application. Topic 606 supersedes the revenue recognition requirements
in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition (“Topic 605”). There was no
impact on adoption to the Company’s consolidated financial statements related to the adoption of ASC 606 since there was
no revenue at such time.
In
June 2018, the FASB issued ASU No. 2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting,
which amends the existing accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance
on measuring and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee
equity awards is fixed on the grant date. This ASU becomes effective for fiscal years beginning after December 15, 2018 and early
adoption is permitted but no earlier than an entity’s adoption date of Topic 606. Entities will apply the ASU by recognizing
a cumulative-effect adjustment to retained earnings as of the beginning of the annual period of adoption. The Company adopted
this standard during the fourth quarter for fiscal year March 31, 2019, and as a result of such adoption, the fair value of the
unvested non-employee stock options became fixed as of the date of adoption.
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)
Recently
Issued and not Adopted Accounting Standards
In
February 2016, the Financial Accounting Standards Board, or FASB issued ASU No. 2016-02, Leases. ASU 2016-2 sets out the principles
for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors).
The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on
the principle of whether or not the lease effectively finances a purchase by the lessee. This classification will determine whether
lease expense is recognized based on an effective interest method (finance lease) or on a straight-line basis over the term of
the lease (operating lease). A lessee is also required to record a right-of-use asset and a lease liability for all leases with
a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted
for similar to existing guidance for operating leases today. ASU 2016-2 supersedes the existing guidance on accounting for leases
in “Leases (Topic 840).” Subsequent to ASU 2016-02, the FASB has issued ASU No. 2018-01 (“ASU 2018-01”)
Leases (Topic 842): Land Easement Practical Expedient for Transition which clarifies the application of lease easements and eases
adoption efforts for some land easements. The provisions of ASU 2016-2 are effective for fiscal years, and interim reporting periods
within those fiscal years, beginning after December 15, 2018. In July 2018, the FASB issued ASU No. 2018-10 and No. 2018-11, Leases
(ASC 842). ASU 2018-10 provides narrow amendments that clarify how to apply certain aspects of the guidance in ASU 2016-02. ASU
2018-11 provides entities with an option of an additional transition method, by allowing entities to initially apply the new leases
standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the
period of adoption, if necessary. The Company elected the available practical expedients on adoption. In preparation for
adoption of the standard, the Company implemented internal controls to enable the preparation of financial information. The standard
will have a material impact on our consolidated balance sheets, but will not have a material impact on our consolidated statements
of operations. The most significant impact will be the recognition of right of use assets and lease liabilities for operating
leases, while our accounting for capital leases remains substantially unchanged. The Company has evaluated the effect of the impact
of the adoption of this standard and has determined the adoption will result in the recognition of additional right of use assets
and lease liabilities of approximately $360,000 for operating leases.
In
June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326), to introduce a new impairment
model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses (“ECL”).
Under the new model, an entity is required to estimate ECL on available-for-sale (AFS) debt securities only when the fair value
is below the amortized cost of the asset and is no longer based on an impairment being “other-than-temporary”. The
new model also requires the impairment calculation on an individual security level and requires an entity use present value of
cash flows when estimating the ECL. The credit-related losses are required to be recognized through earnings and non-credit related
losses are reported in other comprehensive income. In April 2019, the FASB further clarified the scope of the credit losses standard
and addressed issues related to accrued interest receivable balances, recoveries, variable interest rates and prepayment. The
ASU will be effective for public entities in fiscal years beginning after December 15, 2019 (fiscal 2021 for the Company), including
interim periods within those fiscal years. The new guidance will require modified retrospective application to all outstanding
instruments, with a cumulative effect adjustment recorded to opening retained earnings as of the beginning of the first period
in which the guidance becomes effective. The Company does not believe the adoption of this new guidance will have a material impact
on its consolidated financial statements.
In
August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, “Disclosure Update and Simplification,”
amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the
amendments expanded the disclosure requirements on the analysis of stockholders’ equity for interim financial statements.
Under the amendments, an analysis of changes in each caption of stockholders’ equity presented in the balance sheet must
be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending
balance of each period for which a statement of comprehensive income is required to be filed. This final rule is effective on
November 5, 2018. The Company is evaluating the impact of this guidance on its financial statements. The Company implemented this
release as of April 1, 2019 and it did not have an effect on the Company’s consolidated financial statements.
In
August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820):
Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement”, which adds disclosure requirements
to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.
The guidance is effective for the Company’s interim and annual reporting periods beginning with the Company’s fiscal
year ended March 31, 2021, and early adoption is permitted. The Company is evaluating the impact of this accounting standard update
on the Company’s consolidated financial statements.
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
3 FAIR VALUE MEASUREMENT
The
Company’s financial instruments primarily include cash, cash equivalents, restricted cash, marketable securities and accounts
payable. Due to the short-term nature of cash and accounts payable, the carrying amounts of these assets and liabilities approximate
their fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an
exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a
three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value. A fair value
hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical
assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:
|
Level
1 -
|
quoted
prices in active markets for identical assets or liabilities;
|
|
|
|
|
Level
2 -
|
inputs
other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar
assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets
or liabilities; or
|
|
|
|
|
Level
3 -
|
unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
|
The
Company accounted for the warrants issued to accredited shareholders included, among others, down round protective provisions
as a non-current liability according to provisions of ASC 815. The Company had measured the warrants at fair value in each reporting
period until they are exercised or expired, with changes in the fair value being recognized in the Company’s statements
of operations and comprehensive loss. Under ASC 820, the warrants and option liability are classified as Level 3, cash, cash equivalents,
restricted cash and marketable securities invested in mutual funds are classified as Level 1. The Company considered its investment
in Circassia Pharmaceuticals, Inc. as Level 3 and based upon its evaluation, a discount of 4.76% was taken to the quoted market
value. This was based upon the Company ability its current cash position, the size the number of shares it owns at March 31, 2019,
the trading volume in the stock, and other factors. There has been no transfer between any levels during the year. During the
three and nine months ended December 31, 2018, the Company adopted ASU 2017-11 retrospectively to outstanding financial instruments
with a down round feature by means of cumulative-effect adjustment. The balance as of April 1, 2018 for additional paid-in capital
was increased by $6,194,292 and accumulated deficit was decreased by $516,358 and therefore are classified in stockholders; equity.
|
|
As
of March 31, 2019
|
|
|
|
Level
1
|
|
|
Level
2
|
|
|
Level
3
|
|
|
Total
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketable
securities -
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
Circassia
Pharmaceuticals plc (Note 9)
|
|
$
|
-
|
|
|
|
|
|
|
|
5,649,486
|
|
|
|
5,649,486
|
|
Mutual
funds
|
|
|
893,181
|
|
|
|
-
|
|
|
|
-
|
|
|
|
893,181
|
|
|
|
$
|
893,181
|
|
|
$
|
-
|
|
|
$
|
5,649,486
|
|
|
$
|
6,542,667
|
|
|
|
As
of March 31, 2018
|
|
|
|
Level
1
|
|
|
Level
2
|
|
|
Level
3
|
|
|
Total
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Mutual
funds
|
|
$
|
8,304,392
|
|
|
|
-
|
|
|
|
-
|
|
|
|
8,304,392
|
|
|
|
As
of March 31, 2018
|
|
|
|
Level
1
|
|
|
Level
2
|
|
|
Level
3
|
|
|
Total
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
related to warrants
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
5,677,934
|
|
|
$
|
5,677,934
|
|
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
4 PROPERTY AND EQUIPMENT
Property
and equipment consist of the following as of March 31, 2019 and 2018, respectively:
|
|
As
of
|
|
|
As
of
|
|
|
|
March
31, 2019
|
|
|
March
31, 2018
|
|
|
|
|
|
|
|
|
Clinical
and medical equipment
|
|
$
|
357,795
|
|
|
$
|
357,795
|
|
Computer
equipment
|
|
|
42,782
|
|
|
|
28,727
|
|
Furniture
and fixtures
|
|
|
41,464
|
|
|
|
1,889
|
|
Leasehold
improvements
|
|
|
5,336
|
|
|
|
2,491
|
|
|
|
|
447,377
|
|
|
|
390,902
|
|
Accumulated
depreciation and amortization
|
|
|
(202,505
|
)
|
|
|
(137,718
|
)
|
|
|
$
|
244,872
|
|
|
$
|
253,184
|
|
Depreciation
and amortization expense for the year ended March 31, 2019, for the three months ended March 31, 2018 and for the year ended December
31, 2017 was $64,787, $14,603 and $38,137, respectively
NOTE
5 SHAREHOLDER’S EQUITY
Common
Stock
In
December 2016, AIT entered into a Securities Purchase and Registration Rights Agreement (the “SPA”) pursuant to which
AIT agreed to issue and sell purchased units in the minimum aggregate amount of $10,000,000 and up to a maximum aggregate amount
of $25,000,000. Each purchased unit (each a “Unit”) comprised one common stock, and two warrant to purchase one share
of common stock per warrant. The exercise price for each warrant is $6.90 per share and are eligible to be exercised on a cashless
basis in the sole discretion of the holder. The warrants expire in five years from the date of issuance. The warrants have anti-dilution
price protection features including under certain circumstances the adjustment of the exercise price of the warrants and number
of warrant shares.
In
addition, based on the terms of the SPA, because the issuance of Units by AIT, together with issuances of Units by the Company
following the Merger, failed to raise aggregate gross proceeds of at least $15,000,000 the Company issued each investor the same
warrants. The Company issued 1,701,616 Units which resulted in the issuance of 1,701,616 shares of common stock and 3,403,232
warrants to purchase common stock. For the year ended December 31, 2017, the Company recorded a warrant liability of $3,760,000,
and a non-cash expense for the change in the fair market value of the warrant liabilities of $2,978,000 was recognized. In
addition, based on the terms of the SPA, because the issuance of Units, together with issuances of Units by the Company following
the Merger, failed to raise aggregate gross proceeds of at least $15 million, the Company adjusted the number of warrants
and issued an additional 1,701,616 warrants to the investors. Consequently, the Company recorded in 2017 additional
finance expenses amounting to $2,434,000. During the third quarter of 2019, the Company adopted ASU 2017-11 retrospectively
to outstanding financial instruments with a down round feature by means of cumulative-effect adjustment, see (Note 2). There will
be no future changes for recording the change in warrant liabilities due to the adoption of ASU-2017-11 by means of cumulative-effect
adjustment, see (Note 2). As a result of the adoption, down round features became excluded in determining whether the instrument
was indexed to the Company’s own stock. Accordingly, the previously recorded derivative liability and changes in its fair
value were reversed as of the beginning of the fiscal year, and there will be no future changes for recording the change in warrant
liabilities.
The
note holders elected to convert the carrying value of the convertible notes including accrued interest into converted 1,397,098
shares of common stock at the time of the reverse merger based upon the quoted market value. Following the conversion, the holder
no longer had any right or claims under the note agreements. AIT accounted for this amendment to the note agreement as a modification
according to ASC 470-50 “Modification and Extinguishments”. The Company received $3,342,000 from the note holders
of which $892,000 were from related parties. The Company recognized a discount from the beneficial conversion feature and it was
amortized over the life of the note. In addition, debt issuance costs were amortized immediately.
On
January 13, 2017, the principal and accrued interest on all of the outstanding convertible notes, amounting to $3,955,140 were
converted into 1,390,595 shares of common stock. In addition, the Company issued 6,473 shares of common stocks as a finders’
fee upon the conversion of the convertible notes. This resulted in the Company recording for the year ended December 31, 2017
in other expenses $18,000, for the finder’s fees.
In
March 2017, the Company raised net proceeds of $663,000 through the issuance of an aggregate of 110,494 purchased units, each
of which comprised one share of common stock and two warrants to acquire shares of common Stock at an exercise price of $6.90
per share. Direct and incremental costs related to this investment round amounted to $199,000. In addition, the Company incurred
additional costs amounted to $15,000 with respect to warrants that the Company is obligated to issue to the placement agent. These
costs were allocated between the common stock and the warrants. The warrants have anti-dilution price protection features including
under certain circumstances the adjustment of the exercise price of the warrants and number of warrant shares.
During
the three and nine months ended December 31, 2018, the Company adopted ASU 2017-11 retrospectively to outstanding financial instruments
with a down round feature by means of cumulative-effect adjustment, see (Note). There will be no future changes for recording
the change in warrant liabilities due to the adoption of ASU-2017-11.
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
5 SHAREHOLDER’S EQUITY (continued)
On
February 16, 2018, the Company entered into a Securities Purchase Agreement with several accredited shareholders. The Company
issued warrants to purchase 4,599,604 shares of its common stock, par value $0.0001 per share at a purchase price of $0.01 per
underlying warrant share. The warrants are comprised of an aggregate of (i) 2,299,802 Tranche A Warrants to purchase shares of
common stock at an exercise price of $4.25 per share exercisable within three days from the issue date of the Tranche A Warrants
and (ii) an equal amount of Tranche B Warrants to purchase shares of common stock at an exercise price of $4.25 per share for
the Tranche B Warrant, exercisable within three years from the issue date of the warrants. In connection with the February 2018
stock offering, the Company’s Board of Directors approved the issuance of warrants to purchase common stock with an exercise
price of $4.25 per share. Immediately following the closing, all the shareholders in this offering exercised the full amount of
their Tranche A Warrants resulting in net proceeds of $9,820,000.
In
February 2018, the Board of Directors repriced outstanding options to purchase common stock issued in 2017 to $4.25 per share.
The Company accounted for the change in exercise price as a modification pursuant to ASC 718. Accordingly, the modification was
valued at $59,507 and is being recorded over the remaining vesting period for the options based upon the incremental fair value
of the modified award and the fair value of the original award on the modification date. On August
10, 2018, the Company entered into a $20 million Purchase Agreement (commonly known as At The Market Offering, or ATM) with LPC.
Pursuant to the terms of the Purchase Agreement, the Company may sell and issue LPC and LPC is obligated to purchase up to $20
million in value of shares of common stock from time to time over three years. The Company also entered into a registration rights
agreement with LPC whereby the Company agreed to file a registration statement with the SEC and the shares of the Company’s
common stock that may be issued to LPC under the terms of the Purchase Agreement. The Company may direct LPC, at its sole discretion,
and subject to certain conditions, to purchase up to 10,000 shares of common stock on any business day, provided that at least
one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances
provided, however that LPC cannot make any single purchase that exceeds $750,000. The purchase price of shares of common stock
related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described
in the Purchase Agreement. The Company filed a registration statement with the SEC and it was accepted on October 12, 2018.
From
the execution of the Purchase Agreement on August 10, 2018 to March 31, 2019, the Company issued and sold to LPC 297,000 shares
of common stock at an average price of $4.53 per shares for net proceeds of $1,344,185 at an average price per share of $4.43
and incurred offering costs of $545,000 that was charged to additional paid in capital. Net proceeds for these transactions were
$799,185. Subsequent to March 31, 2019, through June 18, 2019, the Company issued and sold to LPC 250,000 shares of common stock
for proceeds of $1,173,810 at an average price of $4.70 per share. There is $17,482,005 remaining on the Purchase Agreement.
Stock
to be Issued to a Vendor
During
the year ended March 31, 2019, the Company is obligated to issue 30,000 shares to a vendor for services related to investor relations.
The Company recorded stock-based compensation of $144,000 for the shares to be issued, or $4.80 per share, at fair market value.
The Company recorded this obligation as a liability for shares to be issued.
Issuance
of Restricted Shares
On
January 13, 2017, the Company issued 492,624 restricted stock to one of the directors of the Company, of which 246,312 vested
in July 2017. During 2017, 246,312 restricted stock were cancelled. During the year ended 2017, the Company recorded general and
administrative expenses of approximately $1,961,000 in connection with the above grant, out of which $844,000 were recorded with
respect to the restricted cancellation. No related expenses were recorded for the year ended March 31, 2019 and for the three
months ended March 31, 2018.
On
December 26, 2018, the Board of directors approved the issuance of 304,000 and 36,000 restricted stock to the board of directors,
officers, employees and consultants to be granted on December 31, 2018 and January 1, 2019, respectively. The restricted stock
vests annually over five years. The Company recorded stock-based compensation expense of $147,719 for the year ended March 31,
2019.
BEYOND
AIR, INC. ITS SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
5 SHAREHOLDERS’ EQUITY (continued)
Stock
Option Plan
The
Company has an amended and restated Equity Incentive Option Plan (the “2013 Plan”), that grants stock options, restricted
stock units and restricted shares to officers, directors, employees, and non-employees for shares of the Company’s stock.
The options vesting terms are generally between two to four years and expire up to ten years after the grant date. On August 2,
2018, the Board of Directors authorized the increase of an additional 1,033,324 shares to a total of 1,500,000 shares for issuance
under the 2013 Plan. On December 26, 2018 and February 13, 2019, the Board of Directors authorized the increase of an additional
600,000 and 1,000,000 shares to a total of 3,100,000 shares for issuance under the 2013 Plan, respectively. As of March 31,2019,
there are 310,525 options are available for future grants.
A
summary of the Company’s options for the year ended March 31, 2019 is as follows:
|
|
Number
Of
Options
|
|
|
Weighted
Average
Exercise
Price
- Options
|
|
|
Weighted
Average
Remaining
Contractual
Life- Options
|
|
|
Aggregate
Intrinsic
Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options
outstanding as of April 1, 2018
|
|
|
510,904
|
|
|
$
|
4.32
|
|
|
|
9.0
|
|
|
$
|
625,626
|
|
Granted
|
|
|
1,919,000
|
|
|
|
4.54
|
|
|
|
|
|
|
|
237,463
|
|
Exercised
|
|
|
(20,759
|
)
|
|
|
0.42
|
|
|
|
|
|
|
|
(90,033
|
)
|
Forfeited
|
|
|
(33,333
|
)
|
|
|
4.25
|
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
as of March 31, 2019
|
|
|
2,375,812
|
|
|
$
|
4.48
|
|
|
|
9.2
|
|
|
$
|
773,056
|
|
Exercisable
as of March 31, 2019
|
|
|
806,397
|
|
|
$
|
4.33
|
|
|
|
8.0
|
|
|
$
|
426,510
|
|
BEYOND
AIR, INC. ITS SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
5 SHAREHOLDERS’ EQUITY (continued)
As
of March 31, 2019, the Company has unrecognized stock-based compensation expense of approximately $4,299,400 related to unvested
stock options and is expected to be expensed over the weighted average remaining service period of 2.3 years. The weighted average
fair value of options granted during the year ended March 31, 2019, three months ended March 31, 2018 and year ended December
31, 2017 was approximately $3.11 per share, $1.88 and $1.66 per share, respectively, on the date of grant using the Black-Scholes
option pricing model with the following assumption:
|
|
March
31, 2019
|
|
|
March
31, 2018
|
|
|
December
31, 2017
|
|
Risk
-free interest rate
|
|
|
2.5%
- 3.2
|
%
|
|
|
2.4%
- 2.6
|
%
|
|
|
2.1%
- 3.5
|
%
|
Expected
volatility
|
|
|
80.7%
- 84.5
|
%
|
|
|
84.5
|
%
|
|
|
75.0
|
%
|
Dividend
yield
|
|
|
0
|
%
|
|
|
0
|
%
|
|
|
0
|
%
|
Expected
terms (in years)
|
|
|
5-9-10
|
|
|
|
3.5-5.8
|
|
|
|
5.5-6.0
|
|
During
the year ended March 31, 2019, the Company granted 340,000 restricted stock awards of which, 133,000 restricted stock awards were
to officers. The fair market value of the restricted shares for stock-based expense is equal to the closing pricing of the Company’s
stock at the date of grant. Stock based compensation for the year ended March 31, 2019 was $147,719. The shares vest and is expected
to be issued annually over five years.
The
following summarizes the components of stock-based compensation expense which includes common stock, stock options, warrants and
restricted stock in the consolidated statements of operations and comprehensive loss for the year ended March 31, 2019, three
months ended March 31, 2018 and year ended December 31, 2017, respectively
Stock-based
Compensation
|
|
Year
Ended
March 31, 2019
|
|
|
Three
Months Ended
March
31, 2018
|
|
|
Year
Ended December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
$
|
572,918
|
|
|
$
|
49,875
|
|
|
$
|
618,482
|
|
General
and administrative
|
|
|
1,977,403
|
|
|
|
96,554
|
|
|
|
3,766,362
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
stock-based compensation expense
|
|
$
|
2,550,321
|
|
|
$
|
146,429
|
|
|
$
|
4,384,844
|
|
Warrants
A
summary of the Company’s outstanding warrants as of March 31, 2019 are as follows:
Warrant
Holders
|
|
Number
Of Warrants
|
|
|
Exercise
Price
|
|
|
Date
Of
Expiration
|
|
January
2017 offering - investors
|
|
|
1,701,616
|
|
|
$
|
4.25
|
|
|
|
January
2022
|
(a)
|
January 2017
offering - investors
|
|
|
1,701,616
|
|
|
$
|
4.25
|
|
|
|
February
2022
|
(a)
|
March 2017
offering - investors
|
|
|
220,988
|
|
|
$
|
4.25
|
|
|
|
March
2021
|
(a)
|
March
2017 offering - placement agent
|
|
|
11,050
|
|
|
$
|
4.25
|
|
|
|
March
2021
|
(a)
|
March 2018
offering - investors
|
|
|
2,299,802
|
|
|
$
|
4.25
|
|
|
|
March
2022
|
|
Third-party
license agreement
|
|
|
208,333
|
|
|
$
|
4.80
|
|
|
|
January
2024
|
|
Total
|
|
|
6,143,405
|
|
|
|
|
|
|
|
|
(b)
|
|
(a)
|
These
warrants have down round protection.
|
|
|
|
|
(b)
|
In
August 2015, AIT entered into an Option Agreement (the “Option Agreement”) with a third party whereby AIT acquired
the Option to purchase certain intellectual property assets and rights (the “Option”) on September 7, 2016 for
$25,000. Upon exercise of the Option, we became obligated to make certain one-time development and sales milestone payments
to Pulmonox, commencing with the date on which we receive regulatory approval for the commercial sale of the first product
candidate qualifying under the agreement. These milestone payments are almost entirely sales related and are capped at a total
of $87 million across three separate and distinct indications that fall under the agreement. AIT exercised the Option
in January 2017 and paid an exercise price of $500,000. AIT issued to the third party a warrant (the “Third Party Warrant”)
to purchase up to 178,570 ordinary shares of AIT at an exercise price of $4.80 for each share. This warrant was exchanged
for a warrant to acquire the same number of shares of the Company’s common stock upon consummation of the merger. The
shares exchange was at 1:1 ratio. The Company recorded stock-based compensation expense of $479,700 to research and development
based upon the fair value using the Black-Scholes option pricing model. On May 10, 2018, the Company issued to the third-party
additional warrants to purchase up to 29,763 shares of the Company at an exercise price of $4.80 per share for each share
of common stock. The Company recorded stock-based compensation expense of $55,900 to research and development based upon the
fair value using the Black-Scholes option pricing model.
|
There
were no warrants exercised during the year ended March 31, 2019, three months ended March 31, 2018 or for the year ended December
31, 2017.
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
6 CURRENT ASSETS AND PREPAID EXPENSES
A
summary of current assets and prepaid expenses as of March 31, 2019 and March 31, 2018 is as follows:
|
|
As
of
March
31, 2019
|
|
|
As
of
March 31, 2018
|
|
Research
and development
|
|
$
|
324,063
|
|
|
$
|
-
|
|
Insurance
|
|
|
297,945
|
|
|
|
-
|
|
Other
|
|
|
166,401
|
|
|
|
59,249
|
|
|
|
$
|
788,409
|
|
|
$
|
59,249
|
|
NOTE
7 ACCRUED EXPENSES
A
summary of the accrued expenses as of March 31, 2019 and March 31, 2018 is as follows:
|
|
As
of
March
31, 2019
|
|
|
As
of
March 31, 2018
|
|
Vendors
– research and development
|
|
$
|
103,320
|
|
|
$
|
497,577
|
|
Professional
fees
|
|
|
780,127
|
|
|
|
492,250
|
|
Income
taxes payable
|
|
|
154,300
|
|
|
|
154,300
|
|
Employee
salaries and benefits
|
|
|
183,271
|
|
|
|
104,110
|
|
Other
|
|
|
62,084
|
|
|
|
9,525
|
|
Total
|
|
$
|
1,283,102
|
|
|
$
|
1,257,762
|
|
BEYOND
AIR, INC. ITS SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
8 BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE
The
following potentially dilutive securities were not included in the calculation of diluted net income (loss) per share attributable
to common stockholders because their effect would have been anti-dilutive for the periods presented:
|
|
Year
Ended
March
31, 2019
|
|
|
Three
Months Ended
March
31, 2018
|
|
|
Year
Ended
December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock warrants
|
|
|
6,143,405
|
|
|
|
6,089,259
|
|
|
|
3,843,603
|
|
Common
stock options
|
|
|
2,375,812
|
|
|
|
510,904
|
|
|
|
548,183
|
|
Restricted
shares
|
|
|
340,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
8,859,217
|
|
|
|
6,660,163
|
|
|
|
4,391,786
|
|
NOTE
9 LICENSE AGREEMENT
On
January 23, 2019, the Company entered into an agreement for commercial rights (“the License Agreement”) with Circassia
Pharmaceuticals plc, (located in the United Kingdom) for persistent pulmonary hypertension of the newborn (PPHN) and future related
indications at concentrations of < 80 ppm in the hospital setting in the United States and China. This License Agreement
covers The Company may receive payments up to $32.5 million in up front and regulatory milestones, of which $31.5 million is associated
with the U.S. market. All such payments are payable in cash or ordinary shares of Circassia Pharmaceuticals plc, at the discretion
of Circassia Pharmaceuticals, Inc., with payments in cash discounted by approximately 5%. Royalties are payable in cash.
This
contract was evaluated under ASC 606, which was adopted by the Company during 2019. Based upon the evaluation, it was determined
that the contract consists of five performance obligations, as follows:
●
|
Performance
Obligation 1: transfer of functional intellectual property rights to Circassia, which includes:
|
|
o
|
the
consummation of the License, Development, and Commercialization Agreement, which included significant pre-agreement negotiation,
product specification, and
|
|
|
|
|
o
|
the
successful completion of the pre-submission meeting with the FDA. At this meeting the FDA reinforced their assessment of AirNOvent
as a medical device and aligned with the Beyond Air pathway to approval, notably confirming that Beyond Air did not need to
conduct clinical trials to be approved.
|
●
|
Performance
Obligation 2: ongoing support associated with the PMA submission and regulatory approval by the FDA. This also includes development
activities including manufacturing readiness process ahead of the approval.
|
|
|
●
|
Performance
Obligation 3: launch of the approved product in the field in the USA upon FDA regulatory approval
|
|
|
●
|
Performance
obligation 4: FDA approval of the product in the field for use in cardiac surgery
|
|
|
●
|
Performance
obligation 5: regulatory approval in China for marketing and sale of the product in China for any indication
|
In
consideration of the rights and licenses granted to Circassia by the Company, Circassia shall pay the Company the following milestone
amounts in US dollars or Circassia shares (with Circassia shares being priced at a 5% discount):
|
●
|
$7.35
million upon signing;
|
|
|
|
|
●
|
$3.15
million payable within five (5) business days following the successful completion of a Food and Drug Administration (the “FDA”)
pre-submission meeting or 5,271,844 ordinary shares of Circassia Pharmaceuticals plc;
|
|
|
|
|
●
|
$12.6
million payable on the sooner of ninety (90) days post FDA approval of the Product or the launch of the Product in the United
States,
|
|
|
|
|
●
|
$8.4
million payable within five (5) business days following the approval by the FDA of the Product in certain hospital and clinic
settings for use in cardiac surgery; and
|
|
|
|
|
●
|
$1.05
million payable within five (5) business days following approval by the FDA equivalent in China for marketing and sale of
the Product.
|
In
addition, Circassia shall pay the Company the following royalty amounts until expiration of all of the applicable patents:
|
●
|
A
one-time 5% royalty on the first cumulative $50 million in gross profit in the United States;
|
|
|
|
|
●
|
A
one-time 5% royalty on the first cumulative $20 million in gross profit in China;
|
|
|
|
|
●
|
Thereafter,
running royalty amounts of 15% of annual gross profit (United States & China combined) up to and including $100 million
and 20% of annual gross profit (United States & China combined) exceeding $100 million.
|
Following
expiration of the patents, Circassia shall pay the Company a 14% royalty on annual gross profits up to and including $100 million
and a 19% royalty on annual gross profits exceeding $100 million.
Due
to the consideration constraints associated with milestones 3, 4, and 5, only the amounts associated with milestone 1 and 2 have
been allocated. During the fourth quarter 2019, the Company met the first two milestones under the license agreement and received
17,572,815 ordinary shares valued at $9,987,295. This consideration was allocated to the first two performance obligations. one
being the transfer of the intellectual property to Circassia, which was recognized at a point in time and was valued at $7,116,232
and the other being the ongoing support associated with the PMA submission and regulatory approval by the FDA, which was valued
at $2,871,063 and recorded as deferred revenue to be recognized over a period of time from the commencement of the agreement to
when management expects to submit the PMA. Through March 31, 2019, approximately $607,769 of such deferred revenue associated
with this second performance obligation has been recognized.
NOTE
10 LOAN PAYABLE
In
January 2019, connection with the Company’s insurance policy, a loan of $292,500 was used to finance part of the premium.
There are ten monthly payments of $29,687 and the interest rate is 3.3% per annum.
BEYOND
AIR, INC. ITS SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
11 INCOME TAXES
The
Company’s foreign subsidiary is in Israel and subject to a corporate tax rate as follow: 2019 and 2019 – 23%, 2017
- 24%. December 2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic
Policy for the 2017 and 2018 Budget Years), which reduces the corporate income tax rate to 24% (instead of 25%) effective from
January 1, 2017 and to 23% effective from January 1, 2018. As of March 31, 2019, there is approximately a net operating loss carry
forward of $12,340,000 which offset taxable income for an indefinite period of time.
As
of March 31, 2019, the Company has available approximately $5,719,000 of unused NOL carryforwards for federal tax purposes
of which $688,000 is subject to Section 382 limitation. Net operating loss carryforwards of approximately $1,375,000, which were
generated prior to March 2018 expire through 2037. The net operating loss of approximately $4,343,000 can be carried forward indefinitely.
The Company also has state net operating losses in the amount of approximately $2,644,000 expiring during the years 2035 to 2039.
The
Company is subject to the NOL utilization provisions of Section 382 of the Code. The effect of an ownership change would
be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount
of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company’s capital
during a specified period prior to the change, and the federal published interest rate.
The
components of net (loss) income before the provision for income taxes are as follows:
|
|
For
the Year Ended
March 31, 2019
|
|
|
For
the Three Months
March 31, 2018
|
|
|
For
the Year Ended
December 31, 2017
|
|
Domestic
|
|
$
|
(4,475,659
|
)
|
|
$
|
2,935,850
|
|
|
$
|
(7,469,198
|
)
|
Foreign
|
|
|
(2,082,791
|
)
|
|
|
(1,888,163
|
)
|
|
|
(10,575,148
|
)
|
Total
|
|
$
|
(6,558,450
|
)
|
|
$
|
1,047,687
|
|
|
$
|
(18,044,346
|
)
|
There
is no provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation
allowance against its net deferred tax assets. The valuation allowance increased by approximately $3,013,000 during the year ended
March 31, 2019
The
tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows:
|
|
As
of March 31, 2019
|
|
|
As
of March 31, 2018
|
|
Net
operating loss carry forward
|
|
$
|
4,201,000
|
|
|
$
|
2,909,000
|
|
Research
and development tax credits
|
|
|
243,000
|
|
|
|
|
|
Other
|
|
|
120,000
|
|
|
|
|
|
Reserves
and allowances - foreign
|
|
|
6,000
|
|
|
|
10,000
|
|
Stock-based
compensation
|
|
|
608,000
|
|
|
|
|
|
Unrealized
loss on available for sale investment
|
|
|
966,000
|
|
|
|
|
|
Research
and development - foreign
|
|
|
550,000
|
|
|
|
762,000
|
|
Net
deferred tax
|
|
|
6,694,000
|
|
|
|
3,681,000
|
|
Valuation
allowance
|
|
|
(6,694,000
|
)
|
|
|
(3,681,000
|
)
|
Net
deferred tax asset
|
|
$
|
-
|
|
|
$
|
-
|
|
A
reconciliation of the statutory U.S. Federal rate to the Company’s effective tax rate is as follows for the year ended March
31, 2019.
Federal
income tax at statutory rate
|
|
|
(21.00
|
)%
|
State
income tax, net of federal benefit
|
|
|
(6.62
|
)
|
Permanent
items
|
|
|
0.00
|
|
Change
in valuation allowance
|
|
|
36.10
|
|
Research
and development tax credits
|
|
|
(3.71
|
)
|
Other
|
|
|
(4.77
|
)
|
Effective
income tax expense rate
|
|
|
0
|
%
|
For
the three months ended March 31, 2019 and for the year ended December 31, 2017, the main reconciling item between the effective
tax rate is the recognition of valuation allowances in respect to deferred taxes related to accumulated operating net operating
losses carried forward due to the uncertainty of the realization of such deferred taxes.
A
reconciliation of the of unrecognized tax benefits related to uncertain tax positions for the year ended March 31, 2019, three
months ended March 31, 2018 and for the year ended December 31, 2017 is as follows:
|
|
Year
ended
March
31,2019
|
|
|
Three
Months Ended
March 31, 2018
|
|
|
Year
ended December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at beginning of period
|
|
$
|
154,300
|
|
|
$
|
154,300
|
|
|
$
|
154,300
|
|
Additions
for current year’s tax position
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at the end of period
|
|
$
|
154,300
|
|
|
$
|
154,300
|
|
|
$
|
154,300
|
|
Tax
years 2015 through 2019 remain open to examination by federal and state tax jurisdictions. The Company files tax returns in Israel
for which tax years 2013 through 2019 remain open.
NOTE
12 COMMITMENTS AND CONTINGENCIES
On
October 22, 2013, The Company entered into a patent license agreement with a third party, pursuant to which AIT agreed to pay
to the third party a non-refundable upfront fee of $150,000 and is obligated to pay 5% royalties of any licensed product net sales,
but at least $50,000 per annum through the term of the agreement and the advance is credited against future royalties payments.
As of March 31, 2019, the Company did not pay any royalties since the Company did not have any revenues from this license. The
term of the agreement extends through the life of applicable patents and may be terminated by either party with 60 days’
prior written notice in the event of a breach of the agreement, and may be terminated unilaterally by CareFusion with 30 days’
prior written notice in the event that we do not meet certain milestones.
BEYOND
AIR, INC. ITS SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
12 COMMITMENTS AND CONTINGENCIES (continued)
In
August 2015, AIT entered into an Option Agreement (the “Option Agreement”) with a third party whereby AIT acquired
the Option to purchase certain intellectual property assets and rights (the “Option”) on September 7, 2016 for $25,000.
On January 13, 2017, the Company exercised the Option and paid $500,000. The Company became obligated to make certain one-time
development and sales milestone payments to Pulmonox, commencing with the date on which we receive regulatory approval for the
commercial sale of the first product candidate qualifying under the agreement. These milestone payments are capped at a total
of $87 million across three separate and distinct indications that fall under the agreement, with the majority of them, approximately
$83 million, being sales related based on cumulative sales milestones for each of the three products. AIT issued to the third
party a warrant (the “Third Party Warrant”) to purchase up to 178,570 ordinary shares of AIT at an exercise price
of $4.80 for each share. This warrant was exchanged for a warrant to acquire the same number of shares of the Company’s
common stock upon consummation of the merger. The shares exchange was at 1:1 ratio. The Company recorded stock-based compensation
expense of $479,700 to research and development based upon the fair value using the Black-Scholes option pricing model. On May
10, 2018, the Company issued to the third-party additional warrants to purchase up to 29,763 shares of the Company at an exercise
price of $4.80 per share for each share of common stock. The Company recorded stock-based compensation expense of $55,900 to research
and development based upon the fair value using the Black-Scholes option pricing model. The warrants expire in January 2024.
On
January 31, 2018 the Company entered into an agreement (“Agreement”) with NitricGen, Inc. (“NitricGen”)
acquire a global, exclusive, transferable license and associated assets including intellectual property, know-how, trade secrets
and confidential information from NitricGen related to NO delivery systems (“Delivery System”). The Company acquired
the licensing right to use the technology and agreed to pay NitricGen a total of $2,000,000 in future payments based upon achieving
certain milestones, as defined in the Agreement, and royalties on sales of the Delivery System. The Company paid NitricGen $100,000
upon the execution agreement, $100,000 upon achieving the next milestone and has an obligation to issue 100,000 options to purchase
the Company’s stock upon executing the agreement. The remaining future milestone payments are $1,800,000 of which
$1,500,000 in six months after the first approval of the eNOGenorator by the FDA or EMEA. The term of the options is five year
and has an exercise price of $6.90 per share. The Company issued 100,000 options to purchase common stock. The Company recorded
stock-based compensation of $295,000 which was the fair market value of the options Black-Scholes option pricing model. The Company
used a volatility rate of 79.9%, risk-free interest rate of 2.5%, an expected term of five years and a dividend rate of 0%. The
Company recorded the milestone payments and the fair market value of the options as a licensing right to use the technology which
is an intangible asset, aggregating $495,000. The Company reversed a prior period expense of $200,000 and recorded a licensing
right to use asset related to acquired technology. This adjustment was due to the Company’s re-assessment of the acquired
technology and the conclusion that it has alternative future uses.
The
Company entered into two office lease agreements, which expire on April 2021 and June 2023. Future minimum commitments for each
of the fiscal years ending March 31, are as follows:
Year
Ended
March 31,
|
|
Operating
Leases
|
|
2020
|
|
$
|
129,100
|
|
2021
|
|
|
90,100
|
|
2022
|
|
|
65,400
|
|
2023
|
|
|
64,700
|
|
2024
|
|
|
16,300
|
|
|
|
|
|
|
Total
|
|
$
|
365,600
|
|
Rent
expense for the year ended March 31, 2019, for the three months ended March 31, 2018 and for the year ended December 31, 2018
was $115,276, $25,059 and $73,013, respectively.
Litigation
Contingencies
On
March 16, 2018, Empery Asset Master, Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (collectively, “Empery”),
filed a complaint in the Supreme Court of the State of New York, relating to the notice of adjustment of both the exercise price
of and the number of warrant shares issuable under warrants issued to Empery in January 2017. The Empery Suit alleges that, as
a result of certain circumstances in connection with the February 2018 Offering, the January 2017 Warrants issued to Empery provide
for adjustments to both the exercise price of the warrants and the number of warrant shares issuable upon such exercise. Empery
seeks monetary damages and declaratory relief under theories of breach of contract or contract reformation predicated on mutual
mistake. The Company intends to vigorously defend all claims. The
Company believes they met the contractual requirements of the contract and properly adjusted the applicable warrants in accordance
with the protection features.
Given
the early stage of the litigation, it is not possible to determine or assess the probability of any particular outcome.
In
connection with the Licensing agreement signed with Circassia Pharmaceuticals plc, the Company is obligated to pay an investment
banker, $250,000, if a future milestone is reached. The Company has accrued this obligation since it is probable that the event
will occur.
Certain
officer agreements contain a change of control provision for payment of severance arrangements.
BEYOND
AIR, INC. ITS SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
13 SUBSEQUENT EVENTS
From
April 1, 2019 through June 18, 2019, the Company issued and sold 250,000 shares of common stock for proceeds of $1,173,810 at
an average price of $4.70 per share to LPC, see (Note 5).
On
June 3, 2019, the Company entered into a Stock Purchase Agreements with investors for the issuance of 1,583,743 unregistered shares
of common stock. The Company raised gross proceeds of $7,960,635.
On
June 25, 2019, the Company filed an amendment to its Amended and Restated Certificate of Incorporated whereby the Company changed
its name to Beyond Air, Inc., effective June 26, 2019.
BEYOND
AIR, INC. AND ITS SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
14 TRANSITION PERIOD COMPARATIVE DATA
STATEMENTS
OF CONSOLIDATED OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
|
|
Year
Ended
March 2018
|
|
|
Three
Months Ended
March 31, 2017
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
Research
and development expenses
|
|
$
|
(4,636,287
|
)
|
|
$
|
(1,438,704
|
)
|
General
and administrative expenses
|
|
|
(5,306,884
|
)
|
|
|
(2,127,813
|
)
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(9,943,171
|
)
|
|
|
(3,566,517
|
)
|
|
|
|
|
|
|
|
|
|
Other
Income (Loss)
|
|
|
|
|
|
|
|
|
Change
in fair value of warrant liabilities
|
|
|
(794,093
|
)
|
|
|
(1,123,814
|
)
|
Amortization
of beneficial conversion feature and debt issuance costs related to convertible debt
|
|
|
-
|
|
|
|
(1,031,360
|
)
|
Amortization
of debt issuance costs
|
|
|
|
|
|
|
(14,273
|
)
|
Issuance
of additional warrants granted to investors
|
|
|
|
|
|
|
(17,899
|
)
|
Imputed
interest expense respect to convertible notes
|
|
|
|
|
|
|
(14,878
|
)
|
Imputed
interest income (expense) with respect to loans from related parties and others and loan from bank
|
|
|
3,495
|
|
|
|
(13,286
|
)
|
Issuance
costs related to warrants granted
|
|
|
|
|
|
|
(457,366
|
)
|
Foreign
exchange gain (loss)
|
|
|
21,524
|
|
|
|
(38,064
|
)
|
Other
expense
|
|
|
(3,610
|
)
|
|
|
(2,779
|
)
|
Total
other income (loss)
|
|
|
(772,684
|
)
|
|
|
(2,713,719
|
)
|
|
|
|
|
|
|
|
|
|
Net
loss and other comprehensive loss
|
|
$
|
(10,715,855
|
)
|
|
$
|
(6,280,236
|
)
|
|
|
|
|
|
|
|
|
|
Net
basic and diluted loss per share of common stock
|
|
$
|
(1.68
|
)
|
|
$
|
(1.12
|
)
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares used in computing net basic loss per share of common stock
|
|
|
6,391,218
|
|
|
|
5,617,762
|
|
BEYOND
AIR, INC. AND ITS SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
14 TRANSITION PERIOD COMPARATIVE DATA
STATEMENTS
OF CONSOLIDATED CASHFLOWS (UNAUDITED)
|
|
Year
Ended
March 31, 2018
|
|
|
Three
Months Ended March 31, 2017
|
|
Cash
flows from operating activities
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(10,715,855
|
)
|
|
$
|
(6,280,236
|
)
|
Adjustments
to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
46,535
|
|
|
|
6,205
|
|
Stock-based
compensation
|
|
|
574,395
|
|
|
|
1,877,442
|
|
Adoption
of ASU 2016-01
|
|
|
(2,986
|
)
|
|
|
|
|
Changes
in fair value of warrant liabilities
|
|
|
793,956
|
|
|
|
1,123,814
|
|
Amortization
of beneficial conversion feature and debt issuance costs related to coverable notes
|
|
|
-
|
|
|
|
1,045,633
|
|
Issuance
costs related to warrant liability
|
|
|
-
|
|
|
|
457,366
|
|
Issuance
of common stock to finder upon the conversion of convertible notes
|
|
|
-
|
|
|
|
18,545
|
|
Imputed
interest on convertible notes, loans from related parties and others
|
|
|
3,721
|
|
|
|
30,164
|
|
Change
in:
|
|
|
|
|
|
|
|
|
Other
current assets and prepaid expenses
|
|
|
117,163
|
|
|
|
(101,677
|
)
|
Accounts
payables
|
|
|
293,768
|
|
|
|
20,079
|
|
Accrued
expenses
|
|
|
196,853
|
|
|
|
(409,728
|
)
|
Net
cash used in operating activities
|
|
|
(8,692,450
|
)
|
|
|
(2,212,393
|
)
|
|
|
|
|
|
|
|
|
|
Cash
flows from investing activities
|
|
|
|
|
|
|
|
|
Investment
in available for sale marketable securities
|
|
|
(8,304,392
|
)
|
|
|
-
|
|
Purchase
price paid upon reverse merger
|
|
|
-
|
|
|
|
(294,862
|
)
|
Purchase
of property and equipment
|
|
|
(219,595
|
)
|
|
|
(25,206
|
)
|
Net
cash used in investing activities
|
|
|
(8,523,987
|
)
|
|
|
(320,068
|
)
|
|
|
|
|
|
|
|
|
|
Cash
flows from financing activities
|
|
|
|
|
|
|
|
|
Proceeds
from issuance of units consisting of common stock and warrants, net of issuance costs
|
|
|
10,813,767
|
|
|
|
9,889,035
|
|
Proceeds
from loans from related parties and others
|
|
|
-
|
|
|
|
56,957
|
|
Maturity
of loans and interest from related parties and others
|
|
|
-
|
|
|
|
(241,000
|
)
|
Purchase
of treasury stock
|
|
|
-
|
|
|
|
(25,000
|
)
|
Repayment
of bank loans
|
|
|
-
|
|
|
|
(13,828
|
)
|
Net
cash provided by financing activities
|
|
|
10,813,767
|
|
|
|
9,666,164
|
|
|
|
|
|
|
|
|
|
|
(Decrease)
increase in cash, cash equivalents and restricted cash
|
|
|
(6,402,670
|
)
|
|
|
7,133,103
|
|
Cash,
cash equivalents and restricted cash at beginning of period
|
|
|
7,140,904
|
|
|
|
7,201
|
|
Cash,
cash equivalents and restricted cash at end of period
|
|
$
|
738,234
|
|
|
$
|
7,140,904
|
|
|
|
|
|
|
|
|
|
|
Supplemental
disclosure of non-cash investing activities:
|
|
|
|
|
|
|
|
|
Conversion
of convertible notes to common stock
|
|
$
|
-
|
|
|
$
|
3,995,000
|
|
Issuance
of convertible notes to common stock
|
|
$
|
250,000
|
|
|
$
|
-
|
|
BEYOND
AIR, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
15 RELATED PARITES
For
the year ended December 31, 2017, the Company had the following related party transactions.
|
1)
|
On
February 10, 2014, AIT signed a loan agreement with one of its stockholders for a total amount of $22,000. The loan bears
an interest of 4% per annum.
|
|
|
|
|
2)
|
In
2016 and 2017, AIT entered into loan agreement with existing stockholders pursuant to which AIT received the amounts of $340,000
and $57,000 (the “Stockholder Loans”), respectively, which bears an interest rate of 16% per annum and shall be
fully repaid in 12 months from the date each was funded. In the event of full payment of the stockholder loans at any time
within 90 days of the funding, a minimum interest rate of 4% of the stockholder loans shall be paid along with the principal.
|
|
|
|
|
3)
|
For
the year ended December 31, 2017, the Company recorded expenses regarding all aforesaid
loans in the amount of approximately $13,000.
|
|
|
|
|
4)
|
On
January 13, 2017, upon the closing of the reverse merger, the holdings of certain of
the above stockholders were diluted, and they are no longer considered related parties
as of December 31, 2017.
|
|
|
|
|
5)
|
In
previous years, the Company entered into consultancy agreements with certain stockholders.
|
|
|
|
|
6)
|
Commencing
December 2013, AIT issued the convertible notes for which aggregate consideration of
$892,000 was received from
related parties. The convertible notes bore an interest rate of 8% per annum compounded
annually. Upon the closing of the merger, all of the outstanding
convertible Notes were converted into 1,397,068 shares of common stock.
|
4,157,006 SHARES
Common
Stock
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From Apr 2023 to Apr 2024